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Major depressive disorder (MDD) is a common psychiatric disorder and a 
leading cause of disability worldwide. Such illness is the result of a complex 
interplay between genetic susceptibility and environmental risk factors. 
Adverse life events are experienced before the onset of depressive episodes 
in most patients, with robust evidence for the role of stressful life events 
(SLE) as a main trigger of depressive symptoms. However, not all individuals 
develop depression after episodes of stress. Thus, an individual’s sensitivity 
to stress is an important predictor of stress response that may mediate the 
association between stress and depression. A deeper understanding of the 
genetic mechanisms underlying stress-sensitivity and stress response is, 
therefore, crucial to a better understanding of MDD and thus to improve 
treatments for both depressive symptoms and other stress-related conditions.  
This PhD thesis uses empirical data from white Caucasian population-based 
samples. By incorporating in new hypothesis-free genome-wide association 
studies and polygenic approaches quantitative measures of recent SLE and 
neuroticism---a personality trait though to mediate or moderate the effects of 
adversity on depression risk---, this PhD thesis identifies the genetic 
influences to a proxy for sensitivity to environmental stress and genotype-by-
environment interaction (GxE) effects underlying depressive symptoms.  
Following an introductory chapter, chapter 2 conceptualizes a proxy for our 
sensitivity to negative outcomes by modelling the interaction between genetic 
variants and MDD status on neuroticism score through a genome-wide 
interaction study. This chapter seeks to identify genetic variants contributing 
to a potential endophenotype mediating the associations between stress and 
depression, and examines whether genetic effects on such proxy for stress 
sensitivity partially explains the genetic contributions to liability not 
attributable to additive main effects. The strongest signals came from genetic 
variants associated with the glucocorticoid receptor function. Therefore, 
iv 
Chapter 3 assesses the enrichment of the genetic contributions to liability of 
MDD within three glucocorticoid-related gene sets: one gene set reflecting 
“up-stream” cortisol signalling genes and two gene sets reflecting “down-
stream” cortisol response genes. Chapter 4 empirically tests and assesses 
the diathesis-stress theory for depression; using polygenic risk scores 
weighted by the additive effects of MDD derived from the Psychiatric Genetic 
Consortium MDD genome-wide association study and self-reported 
measures on recent SLE. This chapter provides evidence for the presence of 
GxE effects between stress and common genetic variants on risk of 
depressive symptoms. The empirical support for this theory validates other 
GxE approaches applying a genome-wide approach to investigate the 
causative effect of stress in the development of depressive symptoms. Thus, 
chapter 5 presents findings from genome-wide by environment interaction 
studies in two cohorts that seek to identify common variants displaying an 
increased risk of liability to depressive symptoms in response to SLE. 
Whether inclusion of GxE effects improves the prediction of liability to MDD 
over that explained by genetic additive main effects alone is also tested. 
Furthermore, two potential forms of gene-environment interplay (i.e. GxE and 
gene-environment correlation) and their biological interpretation are 
extensively discussed. Stress contributes to many human conditions. 
Therefore, the GxE effects are also used to predict other stress-related 
physical and mental conditions. This chapter reports evidence of a potential 
shared aetiology between depression and other traits, such as schizotypal 
personality or heart disease, due to genetic mechanism underlying the 
effects of SLE. Finally, chapter 6 brings back the diathesis-stress model 
investigated in chapter 4. This chapter incorporates into the diathesis 
framework the genetics effects for stress sensitivity and stress response 
estimated in chapters 2 and chapter 5, respectively, and assess their 
relevance to the diathesis-stress theory. Genetic differences between women 
and men in stress response underlying the aetiology of depression are also 
discussed. 
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Genetics plays a significant role in the effects of stress. The findings 
presented in this thesis emphasize the relevance of genetic effects for stress 
sensitivity and stress response in depression and health in general. Overall, 
this thesis presents a range of original studies in order to advance our 
understanding of the genetic response to stress, comprehensively discussing 
the limitations and pitfalls of this research area, and provides a basis for 




Depression is a common mental disorder that impacts on individuals, families 
and society.  Genetic and environmental factors combine to increase the risk 
of suffering from depression. Indeed, before developing symptoms, most 
patients are affected by adverse or stressful environments. However, not all 
individuals that are exposed to adverse circumstances get depressed, 
suggesting differences in vulnerability to stress. One can think about this 
sensitivity towards the effects of stress as a behavioural or personality trait 
that mediates the association between stress and depression. Hence, 
several genes may influence such trait. A genetic component is behind the 
differences in how people respond to the effects of stress. Some genes 
modulate the effects of negative environments incrementing the risk of 
illness. This is known as gene-by-environment interaction effect. In this PhD 
thesis, the theory that genetic variation and stressful life events combine to 
increase the liability to depression is investigated. Multiple methods are 
explored in order to identify the nature of the genetic variants underlying both 
sensitivity and response to the effects of stress, as well as their importance in 
predicting depressive symptoms, in white European population. Genetic 
response to stress plays a key role on the onset and development of 
depression. Identifying genetic mechanisms underpinning the causative 
effects of stress may help to advance our understanding, not only of 
depression, but also of other disease of which stress is a main trigger, and 
thus, improve current treatments. This PhD thesis encompasses several 
original studies on this area of research seeking along the entire genome 
those genes contributing to the responses to environmental stress, 
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DNA Deoxyribonucleic acid 
DSLE Dependent stressful life events 
DSM-IV The Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition 
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xiv 
GxE gene-environment interaction; also genotype-by-environment 
interaction 
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ICD International Classification of Diseases 
ISLE  Independent stressful life events 
LD linkage disequilibrium 
MDD major depressive disorder 
MDE  major depressive episode 
OMIM  Online Mendelian Inheritance in Man 
PGC  Psychiatric Genomics Consortium 
PHQ Patient Health Questionnaire 
PRS polygenic risk score 
PRSD polygenic risk score weighted by depression score effects 
PRSjoint polygenic risk score weighted by joint effects (i.e. combined 
additive and GxE effects) 
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PRSMDD polygenic risk score weighted by MDD effects derived from 
PGC 
PRSN polygenic risk score weighted by neuroticism effects 
PRSSS polygenic risk score weighted by stress-sensitivity effects 
PRSxE polygenic risk score by environment interaction 
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s.e. Standard error 
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 1 
Chapter 1 Background 
 
1.1 Introduction to major depressive disorder 
 
Major depressive disorder (MDD; OMIM 608516), sometimes called major 
depression, clinical depression or unipolar depression, is a common 
psychiatric condition that debilitates and affects patient’s mental health. In 
2017, the World Health Organization ranked depression as the single largest 
contributor to global disability1. This, included the associated suffering to both 
patients and relatives, the deteriorated function and quality of life2, medical 
morbidities3,4, the potential mortality5,6, and the global economic impact of the 
illness7,8, and identifies depression (and mental health in general) as a 
public-health priority problem that must be faced and cannot be ignored. 
MDD is a complex disorder with an aetiology resulting from multiple (often 
common and low-penetrance) susceptibility loci in combination with many 
environmental risk factors that may act and interact at multiple levels (i.e. 
genetic, physiological, psychological, social, cultural)9,10. It is well recognised 
that both genetic and environmental risk factors play a critical role in the 
development of MDD, and mental illness in general10-14. To fully understand 
the aetiological mechanisms underlying MDD we must integrate insights from 
multiple approaches and address the aetiology of MDD from different 
explanatory perspectives. This includes not only the study of genetic and 
environmental risk factors, but the integration of their interplay15. Therefore, 
investigating genetic responses and gene-environment interactions (GxE) 
between susceptibility loci and environmental risk factors, as in this thesis, is 
part of approaches aiming to provide insights into the aetiology of MDD. 
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1.1.1 Clinical features of major depressive disorders: 
symptoms and diagnosis 
According to The Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition, text revision (DSM-IV-TR)16, the manual most widely used by 
mental health professionals for diagnosing clinical MDD based on symptoms 
criteria, MDD is defined by a single or recurrent major depressive episode 
(MDE) without a history of manic, hypomanic, or mixed episodes. The 
essential feature of a MDE is the appearance of either depressed mood or 
anhedonia (or both) in nearly all tasks and situations during the day, nearly 
every day, and over a period of at least two consecutive weeks. In children 
and adolescents, however, such mood may be exhibited as irritability rather 
than low or empty mood. In addition, to be diagnosed with a MDE, the 
affected patient must present nearly every day at least four (or three if the 
patient presents both depressed mood and anhedonia) of seven additional 
symptoms drawn from a list (see Table 1.1). All these symptoms must either 
be newly exhibited or must be clearly exacerbated compared with the 
patient’s pre-episode condition. They cannot be included if they are better 
account for by bereavement, or due to the direct psychological effect of a 
medical illness or substance abuse such as illegal drugs, alcohol or 
medication. The overall symptomatological panel must coexist with clinically 
significant distress or impairment in daily functioning (i.e. personal, familial, 
social, occupational or others) to the patient. Depending on the number of 
episodes, MDD can be classified as single episode or recurrent MDD if there 
are at least two MDE manifested over a lifetime. Recurrent episodes must be 
separated by a period of two consecutive months without meeting criteria for 
a MDE to be considered as an independent episode. MDD includes a broad 
range of illness, from mild to moderate or severe depression, depending on 
the number and severity of MDE. The precise criteria according to DSM-IV 






Five  (or more) of  the  following symptoms have been present during  the same 2‐
week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Note: Do 



















7. Feelings  of worthlessness  or  excessive  or  inappropriate  guilt  (which may  be




9. Recurrent  thoughts  of  death  (not  just  fear  of  dying),  recurrent  suicidal
ideation without  a  specific  plan,  or  a  suicide  attempt  or  a  specific  plan  for
committing suicide
B. The symptoms do not meet criteria for a Mixed Episode





In DSM-IV, MDD is classified into the category “depressive disorders” along 
with dysthymia, a chronic and persistent mild depressive disorder (less 
intense and more persistent than MDD), and depressive disorder not 
otherwise specified. Depressive disorders are characterised by an 
overwhelming feeling of sadness, empty or irritable mood, and loss of interest 
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or pleasure in usual activities severe and persistent enough to interfere on 
daily functions, often accompanied by feelings of guilt, low self-esteem, 
tiredness, sleep or appetite disrupted patterns and cognitive impairment. 
Briefly, dysthymia consists of a milder but more persistent type of depressive 
disorder than MDD. It is defined by the presence of depressed mood nearly 
all day, for more days than not, during a period of at least two years (1 year 
for children or adolescents), along with two (or more) symptoms from a list 
including: diminished appetite or overeating; insomnia or hypersomnia; 
fatigue or low energy; reduced self-esteem; poor concentration or 
indecisiveness; and feelings of hopelessness. During the two year time 
period, the patient must never be without the manifested symptoms for more 
than two months at a time. Depressive disorder not otherwise specified 
(called “unspecified depressive disorder” in DSM-V17) encompasses any 
depressive disorder that fail to meet criteria for any other depressive disorder 
as, for example, in those patients that meet fewer than the required five 
symptoms for a diagnosis of MDD for two or more weeks. At the same time, 
in DSM-IV, depressive disorders are classified along with bipolar disorders 
into the diagnostic term “mood disorders”. Depressive disorders are 
distinguished from bipolar disorder by the lack of an episode of mania or 
hypomania. Unlike DSM-IV, DSM-V classifies “depressive disorders” into a 
unique section adding, along with MDD and dysthymia, new depressive 
disorders classified by specific symptoms criteria (i.e. disruptive mood 
dysregulation disorder, other specified depressive disorder and unspecified 
depressive disorder), as well as by aetiology (i.e. premenstrual dysphoric 
disorder, substance/medication-induced depressive disorder, or depressive 
disorder due to another medical condition). 
As we can see, the diagnosis of MDD is not easy or straightforward, and 
indeed, protocols and criteria vary across countries. Other widely used 
diagnostic tools such as The International Classification of Diseases (ICD)18 
maintained by the World Health Organization, are also applied to diagnose 
MDD and mental disorders in general. Completely opposite 
symptomatological panels (e.g. psychomotor retardation, weight gain and 
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hypersomnia; psychomotor agitation, weigh loss and insomnia) can result in 
the same “diagnosis of MDD” for patients who may need different 
treatments19. In fact, there are at least 227 possible combinations to meet 
DSM-IV (or DSM-V) criteria for MDE, many more if one takes into account 
subcategories of each symptom (i.e. severity, persistence, recurrence)20. 
Indeed, the current diagnosis of MDD may be too broad, resulting in 
significant clinical heterogeneity. Therefore, MDD cannot be seen as a 
clinical homogeneous entity, an issue widely discussed and investigated 
nowadays21. The range of symptoms I have just described with varying 
degrees of severity from severe to milder forms of MDE lying along a 
continuum, often accompanied by a range of comorbidities, suggest to some 
extent the existence of a depressive disorder spectrum of which the 
boundary with other depressive and mood disorders is confused22. Moreover, 
evidence suggests that psychiatric disorders lie on a continuous and broad 
spectrum of overlapping mental illness where the causal genetic influences 
transcend clinical diagnostic boundaries defined by DSM-IV/V and ICD-10. 
Consequently, there is a growing debate about moving from a symptoms-
based nosology towards an aetiology-based nosology for psychiatric 
disorders, including MDD23.  
MDD is a treatable condition, although often it goes unreported and 
untreated. Symptoms can respond to pharmacotherapy or psychotherapy, 
with greater effectiveness when a combined treatment is applied24. However, 
the effectiveness of antidepressant treatments is imprecise. Almost all 
treatments are entirely symptomatic-based and focus on treating the 
symptoms rather than the aetiology. Indeed, recent studies suggest that 
taking antidepressants alone is ineffective in up to 40% of patients25. 
Whereas some suggest that the benefits appear to be greater the more 
severe the MDE is (i.e. treatment may be effective against chronic and 
severe depression, but probably fail on treating mild depressive 
episodes)26,27, others disagree and suggest that effectiveness is not 
dependent on severity28. Either way, the adequacy and quality of 
antidepressant treatments need to improve29. Improved preventions and 
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more effective treatments targeting and treating the underlying 
pathophysiological cause, rather than focussing on relieving the symptoms 
perceived, are required. Therefore, insights derived from this thesis may 
provide better understanding of the aetiology of MDD, which eventually 
permit the application of better treatments and targeted provision of 
prevention strategies, at least, in a subtype of MDD patients. 
1.1.2 Epidemiology and cost of major depressive disorder 
Recently, the World Health Organization has estimated the number of people 
living with depressive disorders as 322 million1, 3.5% more than estimates 
from 201530. The number of individuals suffering depressive disorders is 
likely to keep increasing in the near future, with many people not only 
suffering from depression but also from other stress-related conditions 
simultaneously such as anxiety disorders, thus becoming the leading cause 
of disability worldwide, particularly in countries with low and middle income31.  
MDD is the commonest psychiatric illness worldwide, with lifetime prevalence 
estimated to be about 14%; although it varies widely across populations, 
countries and with socioeconomic status: from 1% in Czech Republic to 
16.9% in US, with a 12-month prevalence ranging from 0.3% to 10%, 
respectively9. Overall, the global point prevalence of MDD has been 
estimated at 4.7% (4.4–5.0%)32, with its highest point in older adulthood. 
Studies looking at prevalence of MDE estimated the average 12-month 
prevalence at 3.2% in patients without associated comorbidities, but it 
increased to 23% in patients with chronic comorbidities4. In general, the 
prevalence seems to be higher in high-income countries, although no 
difference is found in 12-month prevalence estimates, which may reflect 
higher persistence of MDE in low- and middle-income countries. Prevalence 
is also higher in people living in conflict areas33. However, this wide variability 
is likely due, in part, to a combination of factors linked to the epidemiological 
survey design (e.g. diagnostic criteria used, measurement applied, and 
sample selection among others)32.  
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MDD can affect people of all ages, including preschool-aged children with 
minimum age of onset manifesting as early as 3 years34. However, the 
average age of onset is between 25-34 years33,35. Patients with earlier age of 
onset often show more severe symptoms and experience more lifetime 
episodes, among other features (e.g. higher levels of neuroticism, anxiety, 
paranoid or compulsive behaviours), than patients with later onset36-38. Early-
onset is associated with increased social and occupational impairment, poor 
life quality, decreased self-esteem, greater suicidal ideations, more suicide 
attempts, and greater medical and psychiatric comorbidity, which overall 
results in greater health impact39; as well as increased risk in first-degree 
relatives and higher heritability.40-42 The global distribution of age of onset of 
first MDE suggest heterogeneity by age of onset in MDD, showing plausible 
earlier-childhood-onset and late-adult-onset subtypes43,44. The former, has 
greater genetic overlap with more severe psychiatric disorders such as 
bipolar disorder and schizophrenia45, as well as higher co-morbidity with 
personality disorders; whereas late-adult-onset is characterized by higher 
prevalence of preceding stressful life events (SLE)46. 
Gender-specific differences between women and men are also present in 
many aspects of the disorder, from manifestation of symptoms and course of 
illness to treatment response47,48. Women show a prevalence of MDD around 
2-fold times greater than men, they are at higher risk (approximately 1.5- 2-
fold increased risk compared to men), often report more symptoms, and have
different coping skills (e.g. whereas women tend to cope through verbal and
emotional strategies, men tend to cope by doing sport and consuming
alcohol)49-54. In addition, MDD is associated with pregnancy55. MDD with
postpartum onset (postpartum or postnatal depression; according to DSM-IV
symptoms must appear in the first 4-6 weeks) is estimated to affect 10-15%
of women56,57, although it is not limited to mothers and also affects fathers58.
Psychiatric comorbid disorders are common in patients with depressive 
disorders3,59,60. Most patients with MDD suffer comorbid disorders such as 
anxiety disorders59,61,62, substance use disorders59,63 and other depressive 
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disorders such as dysthymia64. For example, reports show that around 59% 
of individuals with lifetime MDD will suffer at least one episode of anxiety 
disorder (mostly generalised anxiety disorder or panic disorder), and 24% to 
30% of cases will co-occur with substance use and impulse control disorders, 
respectively59. However, the list of possible psychiatric comorbidities is large, 
including (but not exclusive to): other anxiety disorders (i.e. agoraphobia, 
social phobia, obsessive-compulsive disorder, post-traumatic stress 
disorder), alcohol dependence, psychotic disorders, antisocial personality, 
insomnia and eating disorders3,65. Comorbidity is also frequent with somatic 
diseases and conditions such as cardiovascular diseases66, diabetes,67 
chronic pain68 and inflamation69. Co-occurring conditions may contribute as 
risk factor to each other (e.g. MDD can both be triggered by inflammatory 
mechanisms, as well as trigger inflammatory processes69-71), which offers an 
opportunity to use those risk factors to stratify MDD based on associated risk 
factors, and at same time, underpin the pathophysiological mechanism 
underlying specific subtypes of MDD. It has been proposed that inflammation 
resulting from the hyperactivity of the hypothalamus-pituitary-adrenal (HPA) 
axis, as response to stressful stimulus, and adult depression may be part of 
the same pathophysiological process72. However, the directional relationship 
between co-occurring conditions is unknown. It may be that somatic illness 
causes chronic and intense pain and stress that trigger an MDE, and 
maintain it over time, or that the biological mechanisms underlying the 
somatic condition eventually cause such MDE (e.g. endocrine diseases such 
as Cushing or Addison syndromes where a dysfunction in stress-response 
mechanisms, or the decreased levels of dopamine in Parkinson’s disease73, 
may eventually lead to depressive symptoms), or both. Therefore, if 
comorbidities are untreated, the cost of MDD may increase in both direct and 





1.2 The aetiology of major depressive disorder 
 
There are still many questions about the aetiology of MDD that remain 
unresolved. It is well known that both genetic and environmental factors play 
a key role in the development of psychiatric disorders. More than 30 years 
ago, Kendler and Eaves already argued in their article Models for the joint 
effect of genotype and environment on liability to psychiatric illness74 
published in 1986 about the importance of both genetic and environmental 
influences, and the relevance of investigating how both come together to fully 
understand the aetiology of most psychiatric disorders, including MDD. 
“It is our conviction that a complete understanding of the etiology of most psychiatric 
disorders will require an understanding of the relevant genetic risk factors, the relevant 
environmental risk factors, and the ways in which these two risk factors interact. Such 
understanding will only arise from research in which the important environmental variables 
are measured in a genetically informative design. Such research will require a synthesis of 
research traditions within psychiatry that have often been at odds with one another in the 
past. This interaction between the research tradition that has focused on the genetic etiology 
of psychiatric illness and that which has emphasized environmental causation will 
undoubtedly be to the benefit of both.” (Kendler and Eaves, 1986)74. 
However, few decades later, how exactly environmental factors such as 
psychological stress interact on the molecular level with our genome in order 
to shape risk, and resilience to, MDD, which genetic mechanisms are 
involved in such interactions, or why under the same environmental pressure 
some people develop depressive symptoms while others do not, are just 
some of the questions about MDD that still remain elusive and psychiatric 
research should solve.  
1.2.1 Epidemiological risk factors 
While the aetiology of MDD is undoubtedly influenced by genetic factors, as I 
further discuss in the following section 1.2.2, there are many other factors 
(e.g. physical, psychological or environmental) that also increase liability to 
MDD. Family history of psychiatric disorders, as well as factors within the 
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family environment (e.g. parental depression, disturbed parent-child 
relationship, changes of family structure, violence or neglect), can contribute 
to depressive disorders, mostly in adolescence75-78. Factors related to an 
individual’s physical or mental health (e.g. chronic pain, sleep disorders, 
fatigue or history of previous MDE) also increase the risk of depressive 
disorders. As said in the previous section, there are many comorbid disorders 
associated with MDD, so that physical and mental illnesses (e.g. anxiety, 
hormonal disorders, Parkinson’s disease, cancer, stroke and heart attack, 
among others) can increase such risk. Several psychological and cognitive 
factors that alter judgment and perception (e.g. distorted perception of life 
experience and others’ views, chronic low self-esteem, pessimism or 
incapacity to recognize personal accomplishment) also add greater liability to 
depressive disorders78. Similarly predisposing personality traits such as high 
neuroticism, borderline or avoidant personality disorders increase risk79,80. 
Some of these traits can be at same time conceptualized as endophenotypes 
for MDD, as discussed in further detail in section 1.4. These risk factors, 
including issues caused by substance abuse or misuse, being in a low 
socioeconomic status, preterm birth and low birth weight, among others81, 
are influenced by their environment.  
Twin studies indicate an environmental component to MDD82. Risk factors 
confirmed as individual-specific environmental risk factors for MDD include: 
little or no social support and a wide range of adverse and SLE such as 
childhood abuse or maltreatment, being exposed to traumatic events, 
premature parental loss, the loss of a loved one, relationship break-up, 
divorce, sexual abuse, financial difficulties, social issues, poverty and 
unemployment75,78,79,83-90. It has been determined that 63% of the variance in 
liability to MDD could be accounted by “environmental” influences specific to 
an individual (i.e. individual-specific non-genetic factors) that are not shared 
within families91. However, this estimate could be inflated due to 
measurement error at the expense of shared environmental or additive 
genetic influences91.  
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1.2.1.1 Environmental stress 
Most individual-specific environmental risk factors produce some amount of 
psychological stress to the individual who suffers them. By psychological 
stress, I refer to a state characterized by strong negative emotions evoking 
distress (e.g. anxiety, rage, fear, anger, etc.) and usually accompanied by 
physiological changes derived from environmental adversity (e.g. SLE, or 
childhood trauma). The role of stressful environments and the physiology of 
stress response systems (e.g. the HPA the axis) have been always closely 
related to MDD, often categorized within stress-related disorders92. SLE play 
an important role in the aetiology of MDD. SLE are consistently associated 
with many aspects of the illness, from the onset of MDE to remission and 
relapse, as well as the severity of each episode and the number of 
depressive symptoms manifested in both adults and adolescents84,90,93-95. For 
example, individuals reporting a SLE have been estimated to have odds ratio 
of 5.64 for the onset of MDD during the month following the event93. 
However, the final individual’s measure of SLE applied in research must be 
interpreted with caution as its construction, which most of times is done 
through self-reported questionnaires, may be genetically influenced (e.g. 
through genetic control of exposure to stressful environments or genetic 
control of how the events are reported) and therefore, not representative of 
pure random environmental effect (i.e. self-reporting bias). Self-reported SLE, 
as well as how we perceive the associated stress, have been shown to be 
moderately heritable96-98. One approach to address this limitation is to divide 
SLE into those likely to be influenced by genetic contributions and those 
likely to be random or out of individual control99,100. Thus, two categories for 
SLE have been proposed: dependent SLE and independent SLE. Such 
categorization is based on whether experiencing the event could be the 
response to our own behaviour and symptoms (likely driven by genetic 
influences), in which case we could be playing and active role in experiencing 
such dependent SLE; or not, so the independent SLE experienced is out of 
our control and not genetically influenced99. However, it is possible that some 
genetic variation implicated in MDD may increase exposure (or reporting) to 
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stressful environments (both dependent and independent)101,102. Thus, 
individuals with higher risk for MDD may expose themselves into riskier and 
more stressful environments, or may have greater vulnerability to their 
depressive effects103. At same time, whereas dependent SLE have been 
proved to have a causal effect on liability to MDD104, individuals with 
diagnosis of depressive disorders also report more dependent SLE105-107.  
Heritability of reported number of SLE has been estimated from twin studies 
at between 20 to 40%108,109, with an average heritability estimated from 6 
studies of 28%97. Heritability estimates are higher for dependent life events 
(43-45%; similar to those for depressive disorders) than for independent life 
events (7-18%)109-111. Couple and familial environments tend to have a higher 
influence on independent life events110. A recent study, of which I am co-
author, showed that SLE are positively associated with MDD, both for self-
reported dependent and independent SLE, with relative risk of MDD for those 
experiencing any SLE of 1.44, and rising up to 1.91 when reporting 4 SLE, 
compared to non-exposed individuals98. Such association was already shown 
decades ago using the equivalent terms “personal” and “network” SLE, 
instead of dependent and independent SLE102. More recently, SNP-based 
heritability (ℎ  of self-reported SLE, the variation on self-reported SLE 
attributed to common genetic variance, has been estimated at between 8-
29%112,113. In a sample of more than 2,500 unrelated European individuals 
enriched by MDD cases ℎ  was estimated at 29% (s.e. 0.16)112, and in a 
sample of 7,179 African American women ℎ  was estimated at 8% (s.e. 
0.04). The latter also provided evidence of a strong genetic correlation (rg = 
0.95, p = 0.01) between the number of SLE reported and MDD113. Thus, 
highlighting the overlap of genetic variation contributing to both MDD and 
self-reported SLE. The differences in heritability estimates may be 
consequence of differences in genetic architecture, measures applied or 




Important for the rationale of this thesis, the effect of SLE on MDD may be 
mediated by genetics or gene-by-environment interactions (GxE)11,114. Twin 
studies have suggested a genetic contribution to sensitivity to the 
depressogenic effects of SLE on liability to depression79,103,115. It has been 
shown that the effect of SLE on those with a depressed co-twin was greater 
in monozygotic twins than in dizygotic twins116. Therefore, the incorporation 
of knowledge about environmental stress into molecular approaches should 
improve the ability to predict MDD. This is a main aim of this thesis. From 
now on, as environmental stress I refer to stress caused by environmental 
and psychosocial events with a psychological stress component, excluding 
other forms of environmental stress. 
 
1.2.2 Genetic susceptibility factors: from the origins to the 
present 
The first evidence that genetics may contribute towards the development of 
MDD, categorized into “manic-depressive illness” at that time, was in the 
1920s117. Since then, many different approaches have been employed to 
investigate the role of genetic risk factors on susceptibility to MDD, from 
family and twin studies to more recent molecular analyses such as linkage 
and association approaches, which nowadays take advantage of whole 
genome sequencing technologies, in order to localize and identify such 
genetic risk factors.  
1.2.2.1 Family and twin studies: MDD as heritable disorder 
In the early decades of the twentieth century, studies suggested that what we 
know nowadays as MDD results from genetic influences. It was seen that 
depressive symptoms aggregate within families, seeding the idea that 
depressive disorders may be heritable118. Many years later, using the 
highest-quality family studies, a meta-analysis estimated that first-degree 
relatives of patients with MDD have an increased odds ratio of 2.84 of 
developing the illness119, with similar estimates of 2.26 in a recent study120. 
However, families tend to share environments (as well as genetics). 
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Therefore, family studies alone cannot differentiate shared environmental 
influences from purely genetic influences. To get robust evidence of a genetic 
contribution on liability, twin studies were performed comparing depression 
concordance rates between monozygotic twin (identical) and dizygotic twin 
(non-identical) pairs119,121, strengthening prior evidence and highlighting the 
existence of genetic factors underlying the aetiology of MDD.  Finally, by 
meta-analysing primary twin studies, additive heritability (h2; also called 
narrow-sense heritability)122, which captures only the proportion of trait 
variation due to additive genetic effects, was estimated to range between 31-
42% for MDD119. Meanwhile, others addressed the apparently sex specific 
effect, showing that MDD is substantially more heritable in women (40-42%) 
than men (29-30%), although most of the genetic risk seemed to be shared 
between sexes with the genetic correlation estimated at 0.50-0.65121,123,124. 
1.2.2.2 Molecular genetic studies: MDD and its genetic complexity 
Heritability alone does not provide information about the genetic architecture 
of MDD, its complexity or its mode of action. Once it was shown that genetic 
features play a role in the aetiology of MDD, genetic studies including linkage 
and association studies were performed to map and identify genetic risk 
factors. Linkage studies attempted to identify the chromosome regions 
containing genetic risk factors and map the chromosomal location of the 
susceptibility loci involved based on the co-inheritance within families of such 
loci. The advantage of this kind of study was its ability to detect genetic 
influences without any prior knowledge of the pathophysiology of the illness 
under assessment. However, the first linkage studies in the 70s and 80s 
found no significant results, mainly due to the high polygenicity and low effect 
of the genetic variants contributing to liability to MDD (linkage studies are 
more appropriate to Mendelian disorders)125-127. Nevertheless, since 2003 
when the first three genome-wide linkage analyses of MDD were performed, 
several genome-wide linkage analyses have reported statistically significant 
findings across various regions. However, they showed inconsistent results 
between them and reported different chromosomic regions126,128-134. 
Probably, the most robust evidence of a susceptibility loci linked to MDD was 
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found in two independent studies133,134 showing a linkage to the 
chromosomal region 3p25-26, which contains among many others, a gene 
known to encode a protein for the metabotropic glutamate receptor 7 
(GRM7). 
Association approaches are generally classified in two main categories: 
candidate gene studies and, more recently, genome-wide association studies 
(GWAS). They are designed to test whether specific alleles are more 
common among patients with illness than among healthy individuals in a 
case-control design (e.g. MDD patients versus healthy controls), or whether 
such alleles are associated with variation on a quantitative trait (e.g. number 
of depressive symptoms). As the allelic spectrum underlying MDD is so 
broad13,135,136, association approaches assess genetic variants on three 
major classes: common variants, including single-nucleotide polymorphisms 
(SNPs) with allele frequencies ≥1-5%, generally with allelic odds ratio < 1.2; 
rare variants, including SNPs with allele frequencies <1% with effect sizes 
ranging from small to large effect sizes; and structural variants, including 
copy number variants, insertion/deletions and translocations. From now on, 
all association studies will refer to studies using common variants unless 
specified. 
1.2.2.2.1 Candidate gene studies in depression 
Association studies of common variants were first limited to candidate gene 
studies. Candidate gene studies are based on prior evidence about the 
biological function of a gene, or relatively small number of genes, in the 
liability to MDD. These studies were based on prior insight on the 
pathophysiological mechanisms underlying MDD, or on regions thought to be 
involved with depression. Therefore, candidate gene studies were largely 
limited to testing polymorphisms from genes with a potential role on biological 
systems targeted by antidepressants (e.g. neurotransmitter, neuroendocrine 
or neuropeptide systems). Hence, many genetic variants in many candidate 
genes have been tested for association with susceptibility to MDD. A meta-
analyses of candidate gene studies reported some evidence of several genes 
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associated with MDD in pathways including: serotonergic and dopaminergic 
systems, calcium signalling, neuroplasticity, cell binding, drug metabolism, 
developmental processes, cardiovascular functioning, cellular stress 
response, and other cellular regulatory pathways, within others137. However, 
most of the findings from candidate gene studies were not replicable. Given 
that our knowledge of the biology underlying MDD was (and still is) poor, the 
low effect sizes expected of common variants and the relatively small sample 
sizes used, the probability that any gene tested was detected as relevant was 
low, as result of underpowered studies, with a high likelihood of false-positive 
hits. These facts limit this type of strategy and are reflected in the number of 
non-replicated findings13,138-140.  
1.2.2.2.2 Genome-Wide Association Studies (GWAS) 
Unlike hypothesis-driven candidate gene studies, GWAS allow scanning of 
variants along the whole genome to seek common risk variants linked to 
liability of MDD in a hypothesis-free approach without any a priori knowledge 
required about the underlying biology or regions involved141. This is possible 
due to the development of DNA technologies able to genotype hundreds of 
thousands of SNPs across the genome at an affordable cost (below $100 per 
sample). Due to linkage disequilibrium (LD; a non-random association of 
alleles), alleles from many nearby SNPs between recombination hotspots co-
segregate in blocks (or haplotypes). Alleles from the same haplotype are 
non-randomly associated and co-inherited together. Thus, nearby SNPs are 
strongly correlated, allowing representative SNPs (called tag SNPs) to be 
informative for most of the other SNPs within the same haplotype. This high 
correlation across SNPs allows genotype arrays to cover most common 
genetic variation in a specific genomic region by genotyping a subset of its 
informative tag SNPs. This strategy attempts to cover most of an individual’s 
genome-wide genetic variation just by genotyping a preselected subset of its 
total number of SNPs. In a GWAS, such large number of SNPs generates a 
large number of hypotheses and statistical comparisons to be tested. To 
control for false discoveries, and thus consider a SNP as genome-wide 
significant, a conventional type 1 error threshold is applied at p-value < 5 x 
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10-8. This approximates to a Bonferroni correction p-value = 0.05 divided by 
the estimated effective number of independent statistical tests (i.e. 1 million 
tests)142.  
The first GWAS of MDD dates back to 2009, when the genomes from 1,738 
individuals diagnosed with MDD were compared against the genomes from 
1,802 healthy controls143. Since then, many GWAS have been performed. 
Most of them lead by the Psychiatric Genomics Consortium (PGC)144, 
founded after it became obvious that larger sample sizes were required to 
gain enough power to detect common risk variants of small effect. Therefore, 
PGC obtained larger sample sizes by combining samples from around the 
world (i.e. impossible to reach by a single research group). Nevertheless, and 
unlike other psychiatric traits such schizophrenia145, the success of such 
GWAS and meta-analyses in identifying statistically significant genome-wide 
SNPs associated with MDD was initially poor13,146. In 2013, the PGC 
published an MDD mega-analysis involving 9,240 MDD cases and 9,159 
controls. However, this study failed to identify robust and replicable findings, 
concluding that common loci accounting for 0.5% or more of the phenotypic 
variance could be rejected with 90% power at that sample size147. Hence, 
they focused on obtaining larger sample sizes. Later, GWAS meta-analysis 
of depressive symptoms involving more than 34,500 individuals from 17 
independent samples collected by the CHARGE Consortium failed to report 
any genome-wide significant loci, concluding that only sample sizes larger 
than 50,000 individuals would have enough power to detect common variants 
associated with depressive symptoms148. It was not until 2015 that the first 
genome-wide significant findings on MDD were published. In fact, the first 
study to report genome-wide significant findings was not conducted by the 
PGC, but by the CONVERGE Consortium. Following a different strategy, 
CONVERGE used low-coverage whole-genome sequencing and focused on 
reducing the phenotypic and ancestral heterogeneity. CONVERGE 
conducted a GWAS with only 5,303 selected Han Chinese women with a 
severe subtype of recurrent MDD (and 5,337 screened controls). As a result, 
they identified and replicated in an independent Chinese sample the first two 
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loci to reach genome-wide significance149. However, the associated loci may 
have population specific effects, as the genetic variants identified (in 
chromosome 10 near SIRT1 and in LHPP genes) are much less common in 
European populations. These loci were not identified in larger meta-analysis 
conducted by PGC in European samples150,151. A year later, another meta-
analysis of depressive symptoms, now involving 161,460 individuals, 
identified two further new replicable findings152. In addition, a study using 
self-reported MDD, based on self-reported diagnosis or treatment for 
depression, on 75,607 “affected” individuals and 231,747 “unaffected” 
controls identified 15 associated loci, some of which were implicated in 
GWAS of related psychiatric illnesses153. Later, a meta-analysis conducted 
by PGC involving 130,664 individuals diagnosed with MDD and 330,470 
controls identified 44 loci at genome-wide significance (containing almost 600 
SNPs meeting statistical genome-wide significance), of which 6 loci were 
shared with schizophrenia150. Finally, the largest and most recent meta-
analysis to date based on 246,363 cases and 561,190 controls detected 102 
independent common variants (87 of which replicated in a further 
independent sample of 474,574 cases and 1,032,579 controls), 269 genes, 
and 15 gene-sets associated with depression151. Despite of the success from 
the CONVERGE study using a refined and apparently less heterogeneous 
subset in detrimental of sample size, maximizing the number of individuals 
involved is likely to provide better insights, at least on the currently available 
sample sizes154.  
Together, these studies reflect how difficult has been to identify causal loci 
for MDD and how essential it is to collect larger sample sizes. As for most 
human complex traits155,156, the polygenic architecture of MDD involves many 
genetic loci of small effect. However, the low success in identifying genome-
wide significant loci compared to other psychiatric disorders such as 
schizophrenia, which required 3-5 times less affected cases in order to detect 
similar number of significant findings, is due to many factors resulting in a 
lack of power157. For example, MDD is substantially more prevalent and less 
heritable than schizophrenia (prevalence < 1%, H2: 65-85%), so assuming 
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that both disorders share similar number of common causal variants, their 
effect sizes on MDD must be smaller and therefore more difficult to detect. In 
addition, MDD is likely to be more genetically heterogeneous (i.e. due to 
misdiagnosis, or individuals sharing the same diagnosis or symptoms due to 
different genetic aetiologies), what substantially reduce the power to detect 
any association158,159. Hopefully, a combination of different strategies, 
incorporating new DNA sequencing technologies (i.e. whole- and exome-
genome sequencing), will provide, in a near future, insights on the effects of 
the full spectrum of genetic variation, including rare and copy-number 





1.3 Exploiting GWAS statistics summary data 
 
Although, until recently, there has been poor success in identifying single risk 
variants for MDD or depressive symptoms, GWAS summary statistics can be 
used in combination with bioinformatics tools to perform downstream 
analyses and thus gain further insights on the genetic aetiology underlying 
MDD. For example, association signals from each single marker summarized 
from GWAS data, even if not significant, can be aggregated and translated 
into sets of scores, genes, systems or networks in order to examine genetic 
effects beyond the association of a single locus. Next, I present some of the 
most relevant bioinformatics tools applied in this thesis with some findings on 
depression. 
1.3.1 Pathway and gene-set analyses 
The signals detected in GWAS can be aggregated into functionally related 
gene sets that aggregate in specific biological networks, or into ontologically 
related genes that share specific features or attributes (e.g. biological 
process, molecular function or cellular component). Looking at the 
enrichment of the aggregated signal in these sets of genes, gene-set 
analysis can provide insights about pathways and networks underlying 
biological mechanisms, functions and components involved in the 
pathogenesis of MDD. Several pathway analyses have implicated pathways 
and networks likely to be involved in the underlying biological mechanisms of 
MDD including: protein phosphatase type 2A regulatory activity, cell and cell-
cell junction organization, apical junction assembly, regulation of histone 
modification160, neurotransmitter and neuronal systems, immune system, 
inflammatory response161, negative regulation of transcription and nucleic 
acid metabolism162, among many others150,151. Furthermore, many of the 
pathways identified have been also implicated in other psychiatric disorders 
suggesting a shared aetiology across psychiatric disorders163,164. 
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1.3.2 Polygenic risk scores 
Another powerful tool that benefits from GWAS data is the construction of 
polygenic risk scores (PRS; also called genomic scores or polygenic profile 
scores). PRS are individual single measures of common genetic risk burden 
for a specific trait or condition derived from GWAS summary statistics. PRS 
aggregate the number of risk alleles (i.e. unweighted PRS) for many genetic 
variants that exceed a selected p-value threshold (e.g. p-value < 1 x 10-5 or 
p-value < 0.05). The relative contribution of each allele (i.e. their effect sizes:
odds ratios or betas) derived from the GWAS can be used to weight these
risk alleles. Thus, weighted PRS aggregate the number of risk alleles
weighted by their effect sizes. Whereas unweighted PRS assume that all risk
alleles have the same effect and therefore contribute equally to develop the
disorder, weighted PRS take into account the importance and contribution of
each allele. Therefore, PRS takes into account the aggregated genetic risk
from a large number of common risk variants that given the lack of power do
not reach genome-wide significance. From now on, I will always refer to
weighted PRS when citing PRS.
PRS have potential research, medical and clinical applications as predictors 
of MDD or as predictors of other diseases, conditions (e.g. prognosis, 
severity of symptoms or treatment response) and cross-disorder effects of 
common risk variants, providing insights on the genetic correlation and 
overlap of the disorder165-167. PRS have shown that liability to MDD, and the 
number of depressive symptoms, is increased in carriers of high burden of 
common risk variants associated with MDD83,147,150,168,169. To date, the largest 
GWAS for MDD have identified common variants that account for up to 1.2 - 
1.9% of the variance in liability to clinical MDD150,151. However, the accuracy 
and the amount of variance predicted by PRS is dependent on the number of 
variants aggregated, the phenotypic diagnose used and, specially, the 
sample size of the discovery sample (i.e. the sample where the GWAS 
summary statistics were generated)170. Therefore, it is expected that PRS 
prediction explanatory power will increase with larger sample sizes167,170. 
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1.3.3 SNP-based heritability and genetic correlation 
SNP-based heritability ( ℎ ) and genetic correlation (rg) are important 
population parameters that can be estimated using either individual-level 
genotype data or only GWAS summary statistics without requiring of 
individual’s raw genotype data. ℎ  is the variance in liability due to common 
additive genetic variation (i.e. narrow-sense heritability; ℎ ) attributable to the 
common risk variants used in a GWAS171,172. Therefore, ℎ  is often seen as 
a lower bound for the total ℎ . rg is the additive genetic effect shared between 
MDD and other traits and diseases. Statistically, it is estimated as the 
covariance between two traits captured by all SNPs scaled by the square 
root of the product of the genetic variance for each trait. In this thesis, I use 
two methods to estimate both parameters: linkage disequilibrium (LD) score 
regression173,174, which only requires GWAS summary statistics, and 
genomic restricted maximum likelihood (GREML), implemented in the GCTA 
software, that uses individual-level genotype data to construct a genomic 
relationship matrix175-177. LD score regression uses data on LD correlations 
between SNPs extracted from a reference panel of the ancestry population 
under study in order to calculate an LD score for each SNP as the sum of its 
LD correlations with other SNPs. Under polygenic architecture, SNPs with 
high LD are more likely to tag a causal SNP and therefore expected to have 
higher test statistics than SNPs with lower LD. With a single-trait LD score 
regression, the ℎ  explained by all common variants, used to infer the LD 
structure, can be estimated as a function of the regression coefficient of all 
SNP association test statistics on their LD scores173,178. Thus, LD score 
regression can estimate variance/covariance components by regressing 
association test statistics of the SNPs detected in GWAS on their estimated 
LD scores. Cross-trait LD score regression exploits the relationship expected 
between two traits in order to estimate the genetic covariance required to 
calculate rg173,174. Conversely, GCTA exploits genomic relationship matrix 
constructed based on common genetic variants using individual-level 
genotype data from unrelated individuals in order to estimate similarities 
between cases and controls and thus, to estimate genetic variance and 
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covariance structures171,175-177. The genomic relationship matrix captures the 
genetic relatedness between individuals and is the key component in the 
GREML method179,180. It uses a linear mixed model to compare pairwise 
similarities between case pairs and control pairs to case-control pairs in order 
to estimate genetic variation and to detect the aggregated effects of common 
variants affecting both traits. While LD score regression is much less 
computational demanding in terms of memory and time than the GREML 
approach, LD score regression is less accurate and report larger standard 
errors for the variance components estimated174,181. Therefore, if possible, it 
is recommended to apply the GREML approach rather than LD score 
regression. LD score regression assumes that discovery samples of GWAS 
are drawn from the same reference population used to estimate the LD 
structure. However, differences in LD structure between samples (genetic 
heterogeneity) can be present and, consequently, bias LD score regression 
estimations181. 
The lifetime risk (or prevalence) in a population is required to estimate ℎ  
on the liability scale. The most recent estimates of ℎ  on the liability scale 
suggested that common variants account for 8.7 - 8.9% of the heritability 
(s.e. 0.004 and 0.003; using a prevalence of 15% and 0.3%, 
respectively150,151); showing enrichment of ℎ  particularly at highly 
conserved regions in mammals, and at intronic and H3K4me1 regions across 
the genome implicated in regulatory activity150,151. Enrichment was not 
detected in exons, suggesting that common exonic variants may not have a 
large role in the aetiology of MDD. A previous study from PGC comparing 
ℎ  estimates on the liability scale across psychiatric disorders, including 
MDD (9,041cases and 9,381 controls), estimated MDD ℎ  at 0.21 (s.e. 
0.021; 15% prevalence), similar to ℎ  estimates between 15-30% in the 
other psychiatric disorders182. SNP-based coheritabilities between MDD and 
other psychiatric disorders were estimated at 0.47 (s.e. 0.06) with bipolar 
disorder, 0.43 (s.e. 0.06) with schizophrenia, and 0.32 (s.e. 0.07) with 
attention-deficit hyperactivity disorder. However, no significant SNP-based 
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coheritability between MDD and autism spectrum was detected. Therefore, 
these study provided evidence of genetic contributions and a partial shared 
genetic overlap, reflecting pleiotropy, between psychiatric disorders182. 
Another study, performed on 25,571 participants from UK Biobank, estimated 
ℎ  for moderate and severe recurrent MDD at 0.195 (s.e. 0.03)183. 
Surprisingly, ℎ  of single MDE was estimated as 0, also on males and 
females, respectively183. It must be note that all the estimates from this study 
were adjusted by a variable reflecting negative experiences in the previous 2 
years, which suggests that environmental factors are the major cause of 
single MDE.  
There is a strong genetic correlation (rg = 0.85) between clinical MDD 
diagnosed by clinicians and self-reported definitions of depression184. A study 
estimating rg between depression and 23 other phenotypes using LD score 
regression and GWAS summary statistics reported significant rg of MDD with 
height (rg = -0.13; s.e. 0.05, p = 0.01), triglyceride levels (rg = 0.18; s.e. 0.08, 
p = 0.03), and other psychiatric disorders: bipolar disorder (rg = 0.48; s.e. 
0.11, p = 6.5 x 10-6) and schizophrenia (rg = 0.51; s.e. 0.07, p = 1.32 x 10-
11)174. This finding supported the rg estimated between MDD and other major
psychiatric disorders in a former study using raw genotype data in GCTA182.
This former study estimated significant rg between MDD and other psychiatric
disorders:  bipolar disorder (rg = 0.47; s.e. 0.06, p = 1.5 x 10-14),
schizophrenia (rg = 0.43; s.e. 0.06, p = 6.0 x 10-15), and attention-deficit
hyperactivity disorder (rg = 0.32; s.e. 0.07, p = 6.8 x 10-6)182. Recently, the
best-powered analyses of rg between MDD and other traits estimated
significant rg with a wide range of psychiatric disorders, medical diseases and
human traits150,151. Among all psychiatric disorders tested, rg was significantly
positive thus providing more evidence that the aetiology of MDD overlaps
substantially with other psychiatric disorders. Therefore, it reinforces what is
well establish nowadays, that some specific common variants are associated
with a wide range of psychiatric and stress-related disorders92,166 and confer
vulnerability towards a wide range of physical and mental conditions23.
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1.4 The endophenotype concept 
 
The link between genetic contributions and the final clinical symptoms of 
MDD is largely unknown. A strategy used in psychiatric research to identify 
causal mechanisms between the genetic aetiology and the final clinical 
manifestation is the use of endophenotypes. “Endophenotype” is a term used 
for biological or psychological entities (some times called “internal 
phenotypes”) that may lie between the causal genetic factors and the 
eventual symptoms of the disease185. It builds on the assumption that some 
entities are aetiologically less complex than others. To be considered an 
endophenotype, such entity or biomarker must fulfil a range of criteria: it must 
be heritable, associated with the illness in the population, be largely state-
independent (i.e. it manifests in the individual regardless of being the illness 
active or not), both endophenotype and illness must co-segregate together 
within families, and it must be found at higher relative risk in unaffected family 
members than in general population185. Therefore, endophenotypes are 
measurable biomarkers phenotypically associated and genetically correlated 
with liability to disease due to, at least in part, shared underlying genetic 
influences185,186.  Overall, the initial hope was that endophenotypes would be 
less genetically complex (i.e. involving fewer genetic variants) and more 
closely related to the underlying aetiology than the clinical symptoms or 
phenotype of interest. Consequently, endophenotypes should improve the 
power to detect genetic influences on liability to psychiatric diseases, and the 
aetiology of endophenotypes should be easier to understand. Maybe 
occupying an intermediate position, endophenotypes would be linked to the 
causal pathway between genetic determinants and the final diagnosable 
symptoms of disorders, with larger genetic effect sizes, and being potentially 
closer to the genetic variability level. Nevertheless, even if the 
endophenotype as a concept is easier to understand or define than the 
phenotype under study (e.g. cerebral cortex thickness vs. intelligence), their 
aetiology has not been proven to be less complex. Indeed, evidence 
suggests that the assumptions behind the concept and its benefits are not 
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met187. Hence, the challenges faced in the study of psychiatric disorders due 
to their aetiological complexity arise as well on the study of the aetiology of 
endophenotypes, thus raising more questions.  
A wide variety of endophenotypes have been proposed for MDD (e.g. 
learning and memory impairments; reduced reward functioning; increased 
stress-sensitivity; REM sleep abnormalities; functional and structural brain 
abnormalities; dysfunctions in serotonergic, catecholaminergic, HPA axis, 
and corticotropin-releasing hormone systems; and intracellular signal 
transduction measures)188. However, their true credentials as endophenotype 
were often not assessed or are unmet (e.g. there is little or no evidence of 
co-segregation within families of depression for most of the putative 
endophenotypes listed above). However, in 2012, Glahn et al. developed an 
empirically-derived metric called Endophenotype Ranking Value (ERV) to 
rank and select optimal endophenotypes for mental illness based on 
heritability estimates of both the endophenotype, the disorder of interest, and 
their shared genetic correlation189. They applied the ERV to recurrent MDD in 
a large set of putative behavioural/neurocognitive endophenotypes and 
reported as the top-ranked endophenotypes a score to measure severity of 
depressive symptoms called Beck Depression Inventory190 and the score 
assessing neuroticism derived from the Eysenck Personality Questionnaire 
(EPQ)191. More recently, a review of selected candidate endophenotypes for 
depression reported moderate to strong evidence that neuroticism is a true 
endophenotype of depression192. The criteria was also met for morning 
cortisol, cortisol awakening response, and frontal asymmetry of cortical 
electrical activity; although they lacked evidence of heritability and familial co-
segregation with depression, probably due to the lack of family and twin 
studies with such a focus192.   
1.4.1 Depressive symptoms 
Measures of depressive symptoms show substantial heritability estimates, 
ranging from 15% to 50%148,152,193,194. As endpohenotypes, scores based on 
depressive symptoms should improve the likelihood of identifying genetic 
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factors contributing to MDD189. MDD results from combinations of numbers 
and levels of severity of depressive symptoms; MDD status and depressive 
symptoms are highly associated and share mostly the same aetiology. MDD 
shows a genetic correlation with measures of depressive symptoms up to rg = 
0.98150. Similar risk factors are consistently associated across different types 
of depression, from brief episodes to recurrent manifestations, including 
subthreshold depressive disorders195. Both clinical diagnoses of MDD and 
depression diagnose defined based on self-reported symptoms are 
genetically strongly correlated (rg = 0.85)184. These definitions of MDD status 
show estimates of genetic correlation with measures of depressive symptoms 
around rg = 0.8184. There is a high genetic correlation between depressive 
symptoms and well-being, and between depressive symptoms and 
neuroticism152. However, there are several instruments to assess the severity 
and number of depressive symptoms, with high sensitivity to detect cases of 
MDD196, including, among others, the Beck Depression Inventory190 sated 
above to define a top candidate endophenotype of MDD, or the General 
Health Questionnaire197 further and extensively discussed in chapter 4 and 
chapter 5.  
1.4.2 Neuroticism 
Neuroticism is one of the most promising candidate endophenotypes of 
MDD198; and a key component in chapter 2 and chapter 3 to derive a proxy 
for sensitivity to stress. It is a personality trait characterized by emotional 
instability with predisposition to experience and report negative emotions 
often accompanied by low self-esteem and feelings of negative affect (e.g 
depressive, anxious or guilty feelings)199 defined as a tendency to cope 
poorly with stress and to experience feelings of sadness, anxiety, anger, 
irritability, self-consciousness, worry, hostility and vulnerability200. The most 
common strategy to construct a measurable entity for an individual’s level of 
neuroticism is through the use of a self-reported questionnaire. In this thesis, 
the neuroticism scores applied were assessed using 12-item questions from 
the “neuroticism-stability” domain of the EPQ, that has a reliability greater 
than 0.8191,201. A score on a range of 0-12 reflecting a neuroticism level is 
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constructed by adding up the number of “Yes” responses from the self-
reported EPQ revised short-form. The 12-item questionnaire is provided in 
Table 1.2.  
Neuroticism scores are able to consistently distinguish depressed and non-
depressed individuals, although only at the group level202. Consistent with the 
criteria required to be considered an endophenotype, neuroticism is highly 
heritable, with heritability estimates up to 54% (being greater for women than 
men)189,203-207. Broad-sense heritability based on the meta-analysis of six 
cohorts was estimated at 48% with strong evidence of non-additive genetic 
influences204. Up to 15% of the phenotypic variance in neuroticism has been 
attributed to a non-additive genetic component205. There is no consistent 
evidence for a shared environmental component, suggesting that neuroticism 
is influenced by genetic (i.e. additive and non-additive) and unshared 
environmental factors205,207,208. Narrow-sense heritability (ℎ ) estimates range 
from 22 to 43%189,203. A twin study estimated that 55% of the genetic 
variance in depression was shared with neuroticism209. There is evidence 
that high neuroticism and depressive disorders co-segregate within 
families210 and are strongly correlated at the phenotypic and genetic 
level198,211,212, with estimates of rg at 0.7 and 0.74 in MDD and recurrent 
MDD, respectively150,151,189. Neuroticism levels are higher in depressed 
patients compared to non-depressed individuals202,213,214, and there is 
evidence that neuroticism levels differ in individuals with depression during 
the depressive state and before or after symptoms manifest215. In addition, a 
Mendelian randomisation approach has reported a putative causal effect of 
neuroticism on depression, and also a putative causal effect of depression on 
neuroticism151. Neuroticism shows a substantial stable component across 
lifespan216. However, some studies report evidence for change as well as 
stability throughout our lifetimes217-220. Whereas the stable component of 
neuroticism is strongly determined by genetics, change in neuroticism score 
is attributed to the effects of unshared environment217. Persistent change in 
neuroticism score has been shown in response to life events, including 
SLE218-220. Therefore, neuroticism has been used as a measure of stress-
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sensitivity221. There is evidence that neuroticism score mediates or interacts 
with the effects of adverse life events on risk of depression79,222,223. 
Individuals with higher neuroticism levels show higher risk of depression as 















Personality traits may influence how individuals experience and self-report 
SLE. For example, neuroticism is correlated with greater reporting of SLE, 
with a more severe perception of the corresponding impact among 
individuals with high levels of neuroticism223,224. Therefore, it is possible that 
neuroticism increases both sensitivity to and/or reporting of SLE amongst 
individuals with depression. Neuroticism has been positively associated with 




1.5 Gene-environment interplay: theoretical models 
There is clear evidence that MDD is influenced by both genetics and 
environmental stress14. However, how both components interplay is complex 
and poorly understood. There are multiple theoretical models proposed in the 
literature to explain how genetics and the environment interact and how GxE 
affects liability to MDD. Next, I present the most relevant models for this 
thesis: the first theoretical models presented in 1986 for the joint effects of 
genes and environments on liability to psychiatric illness by Kendler and 
Eaves74, the diathesis-stress model225, and the differential susceptibility 
model226,227. 
1.5.1 Models from Kendler & Eaves, 1986  
Kendler and Eaves were convinced, more than 3 decades ago now, that the 
aetiology of psychiatric disorders, including MDD, involves the interaction 
between the effects of an individual’s genes and the environment74. As 
previously shown at the beginning of section 1.2., Kendler and Eaves argued 
that to entirely understand the cause, or set of causes, of such disorders 
requires the comprehension of both the relevant genetic risk factors, the 
relevant environmental risk factors and the ways in which they interact. 
Therefore, they proposed three basic theoretical models to conceptualize 
fundamentally different forms in which genetics and environmental risk 
factors may jointly influence liability to psychiatric disorders. Representative 
illustrations of each model are shown in Figure 1.1.  
1st model: additive effects of genotype and environment. This model 
conceptualizes the additive contribution of genetic and environmental risk 
factors to liability. It has been the base of most epidemiological research 
carried on MDD since then. This model, seen as the simplest one, considers 
genetics and environmental factors as completely independent entities; 
therefore, the final risk of MDD would be the mere additive combination of 
their corresponding completely independent effects (Figure 1.1; left). 
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2nd model: genetic control of sensitivity to the environment. This model is 
based on the idea that genes (or genomic features) may control sensitivity to 
environmental effects, although it can also be conceptualized as the 
environmental control of gene expression. In other words, one entity (i.e. 
genetic or environmental) alters the protective or risky influence of the other. 
Under this assumption, not only environmental stressors but also their 
corresponding genetic responses play a key role on the pathogenesis of 
MDD. This is the fundamental premise behind theories such as the diathesis-
stress theory or the differential susceptibility perspective (explained below), 
studies of GxE, and this thesis in general (Figure 1.1; centre).  
3rd model: genetic control of exposure to environment. This model suggests 
that there are genetic influences on how we expose ourselves to certain 
environments, so genes may alter the probability of being involved in adverse 
situations and stressful environments. This genetic control may act through 
personality and behaviour. It is known that certain genes influence certain 
behaviours and personality traits (e.g. neuroticism and extraversion). These 
traits are associated with higher exposure to risk-predisposing environments, 
thus, acting as mediators between genes and the environment97 (Figure 1.1; 
right). As shown later in section 1.6.2, this is a case of active gene-
environment correlation (rGE), but not GxE. To better understand the nature 
of the causal relationship between genes and the environment some studies 
focus on exploring the heritability of the environmental exposure, which is 
measured through self-reported questionnaires96,109. 
However, and as Kendler and Eaves already highlighted, the effect of the 
genetics-environment interplay on liability to MDD cannot be entirely 
explained by one of these three “basic” models, but likely by more complex 
combinations of all them74. For example, the “fan-shaped” GxE detailed later 
in section 1.6.1 result from combining the effects conceptualized in the 1st 




Figure  1.1  Theoretical  models  on  liability  to  psychiatric  illness  from  Kendler  & 
Eaves,  1986. 1st model  represents  the  liability  to  illness  as a  function of  genotype 
and  environment with  additive  effects  of  both  the  genotype  and  the  environment 
(independent  from  each  other).  2nd  model  represents  the  liability  to  illness  as  a 
function  of  genotype  and  environment  with  genetic  control  of  sensitivity  to  the 
environment  (alternatively,  environmental  control  of  gene  expression).  3rd  model 




1.5.2 The diathesis-stress model 
Perhaps, the leading theoretical framework, and most widely investigated in 
GxE research, to explain the development of MDD is the diathesis-stress 
model. It goes back to 1960s, when it was first introduced in order to explain 
the development of schizophrenia228.  The core basis of this theory is that 
genetic factors (i.e. an individual’s inherent features) and environmental 
adversity (e.g. psychological stress) increase the liability to illness both 
independently and in combination; but it is only when combined that a liability 
threshold is reached and consequently the symptoms and illness manifest. 
Therefore, the predisposing effects of such adversity or stress would trigger 
the manifestation of symptoms only when combined with an inherent 
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vulnerability. Diathesis refers to this inherent vulnerability as a genetic 
vulnerability, predisposition or risk. In genetically predisposed individuals, 
their vulnerability to develop and manifest the disease will be increased when 
exposed to the effects of such environmental adversity, but it would not be 
enough to trigger the disorder in the absence of such environmental 
influences. On the other hand, individuals exposed to the same 
environmental exposure that do not develop the disease, either because they 
do not have this inherent diathesis or because they are under the influences 
of other protective factors, are resilient225,228. However, this model has 
received criticism for adopting a perspective where only the negative 
influences of the environment have an effect on liability and thus omitting the 
protective influences from positive environmental factors226. The diathesis-
stress model is illustrated in red in Figure 1.2.  
1.5.3 The differential susceptibility model 
A more recent alternative theoretical framework is proposed by the 
differential susceptibility theory, so-called because instead of adopting a 
perspective of genetic vulnerability as the diathesis-stress theory, it adopts a 
perspective of a genetic susceptibility to the effects of both negative and 
positive environmental influences226,227 (the differential susceptibility model is 
represented in Figure 1.2).  In accordance with this theory, individuals who 
are more genetically susceptible to environmental influences would be more 
vulnerable to the negative effects of environmental adversity and 
consequently be at higher risk of developing MDD. However, these same 
individuals would also get higher benefits and higher protective effects from 
positive environmental influences (e.g. parenting or social support). Hence, 
the differential susceptibility theory supports genetic plasticity, as the 
presence of “plasticity alleles” that are more susceptible to both beneficial 
and detrimental effects from environmental influences, rather than “risk 
alleles”229,230. Recently, an individual’s genetic response to positive 
environmental influences has also been conceptualize into a specific 
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theoretical framework called vantage sensitivity231, in which only the positive 
influences of the environment have an effect on liability (see represented the 
vantage sensitivity model in blue in Figure 1.2). The benefits of such positive 
influences and protective effects on liability would vary as a function of their 
inherent features (e.g. genetic variants) and would be relevant for clinical 
intervention and treatment response232.  
As we see, the differential susceptibility theory takes into account the full 
spectrum of environmental influences from negative to positive exposures. 
Whereas the diathesis-stress theoretical framework would fit the differential-
susceptibility theory when you only consider negative environmental 
exposures, the vantage sensitivity theoretical framework would fit the 
differential susceptibility theory when you only consider positive 
environmental exposures (Figure 1.2). The direct test of either the vantage 
sensitivity model or the differential susceptibility model for liability to MDD 
would require high-quality measures of positive environmental exposures. 
Unfortunately, such data is limited in most population-based cohorts that 
have genetic data available, much more than measures of negative 
environmental exposures.  Ideally, in the case of testing the differential 
susceptibility model, such measures must capture the full spectrum of 









sensitivity  theory  and  the  differential  susceptibility  theory.  In  red,  under  the 
diathesis‐stress model,  individuals with high diathesis or vulnerability to  illness are 
at higher risk of psychiatric  illness when they are exposed to adverse and negative 
environments  than  resilient  individuals  with  low  diathesis.  Conversely,  under  the 
vantage  sensitivity  model  in  blue,  individuals  with  high  susceptibility  to  the 
environment exposed to positive environments are at lower risk of psychiatric illness 
and  more  resilient  than  vulnerable  individuals  with  low  susceptibility.  Under  the 
differential susceptibility model in black, plastic individuals with high susceptibility to 
the environment will  be more malleable and at higher  risk  to psychiatric  illness  in 
negative  environments  but  at  lower  risk  in  positive  environments  than  individuals 
with low susceptibility to environmental influences. 
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1.6 Research on gene-by-environment interactions 
If genes and the environment interact, gaining a good understanding of either 
genetic or environmental effects requires studying them in tandem. Research 
on GxE can help to detect new genetic effects associated with depression 
and to identify some of the underlying biological pathways involved233,234. In 
addition, the presence of a substantial GxE effect may, at least in part, help 
to explain some of the negative findings of main effects found in the 
literature. For example, as GWAS do not take into account environmental 
effects, those genetic variants that predispose to MDD under negative 
environments (i.e. that have a GxE effect) may be enriched in healthy 
individuals selected into control samples (some of which may did not develop 
symptoms because were exposed to neutral of positive environments). Thus, 
the power to detect association between these variants and MDD in a GWAS 
is dependent on the distribution of positive-negative environments between 
and within case-control samples. Therefore, the power to detect such 
variants in a GWAS would be maximised if we take into account 
environmental influences.  
1.6.1 Gene-environment interaction (GxE) 
Genetic variation can influence and modify the response to, and the effect of, 
environmental risk factors. Interpreted in another way, the effect of a genetic 
variant can be altered by an environmental exposure. This relationship is 
known as gene-by-environment interaction (GxE)74,235. In regard to this 
thesis, GxE can be defined as genetic differences in susceptibility to the 
effects of SLE, or stress causing differences to the genetic vulnerability.  
There are two main types of GxE: the fan-shaped interaction and the 
crossover interaction236. Both types are illustrated in Figure 1.3. The fan-
shaped interaction is the underlying GxE in depression hypothesized by the 
diathesis-stress theory. Under such interaction, the risk of depression 
depends on both the genotype and the environment with a genetic control of 
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mean liability to illness and sensitivity to the exposure. Note that this mode of 
interaction is a combination of the 1st and 2nd basic models from Kendler and 
Eaves. The fan-shaped interaction is the type of interaction assumed in most 
studies of stress and depression, and includes the known main effects of 
genetics and stress. Therefore, in accordance with a fan-shaped interaction, 
under stress, genetically vulnerable individuals are at higher risk of 
developing depressive symptoms than resilient individuals. However, in the 
absence of stress, such risk is not significantly different among individuals. 
The fan-shaped is the type of interaction underpinning the difference in 
estimates of heritability by environmental context detected in twin studies237-
239. Conversely, the crossover interaction supports the Differential 
Susceptibility model and the concept of genetic plasticity rather than 
vulnerability. Therefore, in accordance with a crossover interaction, 
individuals that are more prone to develop symptoms under stressful and 
adverse environments will be as well more resilient under positive and 
favourable environments230. This type of interactions is consistent with 
evolutionary developmental theories that support that such variability in 
environmental response would be beneficial under selection pressure; and 
related to the theory of biological sensitivity to context240. It has been 
reported that children genetically prone to be highly reactive to stress display 
significantly higher rates of morbidity under stressful environments but 
significantly lower rates under supportive environments241,242. Unlike fan-
shaped interactions, crossover interactions do not assume a main effect of 
genetics and environment, as they could, theoretically, have equal 
distributions between levels of exposure (see bottom right plot in Figure 1.3). 
However, this specific type of crossover interaction, if existent, must be 
rare236.  Crossover interactions require less power to be detected than fan-
shaped interactions, however, in practice they are difficult to distinguish from 
each other. As the crossover point of the interaction can vary along the 
exposure spectrum, both fan-shaped and crossover interactions can be 




Figure 1.3 Types of  gene‐by‐environment  interactions. Fan‐shaped  (top  row) and 






were  equal  (right).  Note  that  if  we  expand  the  environmental  spectrum  (if  we 
expand the lines) at some point we would see a crossover point and thus, such fan‐
shaped  interaction  would  become  a  crossover  interaction.  Similar,  if  we  only 
consider  positive  or  negative  influence  from  the  environment  in  a  crossover 
interaction  with  crossover  point  in  neutral  environment,  we  would  detect  a  fan‐
shaped interaction. Plots adapted from Dick 2011236. 
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1.6.2 Gene-environment correlation 
Not all forms of gene-environment interplay are considered GxE235. As shown 
previously by the 3rd model from Kendler & Eaves, exposure to specific 
environmental conditions can partly depend on an individual’s genotype, so 
instead to be influenced by an independent and random environment, it may 
be driven by genetic control (e.g. through specific behaviours or personality 
traits such as neuroticism)74,108. This relationship is known as gene-
environment correlation243. Gene-environment correlation can be categorizes 
as: passive, active and evocative. Passive gene-environment correlation 
occurs when an individual is exposed to environments established by their 
parents genetically influenced behaviour. Active gene-environment 
correlation occurs when an individual is exposed to environments selected by 
its own genetically influenced traits. For example, the gene-environment 
interplay seen in the 3rd model proposed by Kendler & Eaves of genetic 
control of exposure to environment is an example of active gene-environment 
correlation, but it is not a case of GxE. Finally, evocative gene-environment 
correlation occurs when an individual is exposed to environments or 
environmental responses from others that are evoked by his/her genetically 
influenced behaviour. As Kendler and Eaves suggested, genes may partially 
act by altering the environment to which individuals are exposed. This is also 
known as “nature via nurture”, and is an example of how genes can influence 
the final outcome via environmental exposure. However, this does not mean 
that the effect of such environment is moderated by the genotype, nor the 
effect of the genotype itself moderated by the environmental exposure. We 
must remember that correlation does not imply causation and distinguish a 
pure GxE from gene-environment correlation. Below, I show two similar 
cases to further exemplify the difference between GxE and gene-
environment correlation. 
Case of GxE: 
Imagine that living in poverty is a risk factor for depressive symptoms. 
Imagine that if carriers of allele “X” at a polymorphic locus live in poverty at 
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young ages, they are at a higher risk of suffering depressive symptoms in 
adulthood. However, if carriers of allele “X” do not live in poverty, they are 
resilient to developing depressive symptoms. Whilst, non-carriers of allele “X” 
at such locus tend to be resilient regardless of whether they lived in poverty 
at young age or not. This is a case of a GxE between allele “X” and living in 
poverty at young age on odds of suffering depressive symptoms in 
adulthood. This is a case where the effect of the environment is moderated 
by the genotype, or the environment moderates the effect of the genotype. 
Case of gene-environment correlation: 
However, now imagine that the odds of suffering depressive symptoms as a 
result of exposure to negative environments are the same for a group of 
people, but carriers of allele “Z” at a polymorphic locus behave in a way that 
contributes to be exposed to “negative” environments (e.g. poverty) at young 
ages at a higher rate than non-carriers of allele “Z”. Then, due to have been 
exposed to “negative” environments at a young age, carriers of allele “Z” 
have a higher rate of depressive symptoms in adulthood. This is a case of 
gene-environment correlation. Allele “Z” does not modulate the effects of 
living in poverty on odds of suffering depressive symptoms. 
 
1.6.3 Statistical framework to test GxE 
GxE studies, from primary GxE studies on candidate genes to the recently 
emerging genome-wide by environment interaction studies (GWEIS), test 
whether the joint effect of both genetic contributions and environmental risk 
factors is significantly different from the additive product of their individual 
effects. The statistical method to test for GxE effects differs from that used to 
test main additive effects in standard GWAS, which consist of a regression 
model (e.g. logistic or linear) that test whether the effect of a genotype (𝛽 ) 
differs significantly from 0 (note that such test under a logistic model with 
absence of covariates would be roughly equivalent to an allele counting chi-
square test in a case-control sample): 
41
𝑦   𝛽 𝛽 𝐺  𝜖  
The statistical method to test GxE effects in GxE studies consist of a similar 
regression model (e.g. logistic or linear) that additively fits the direct main 
effects of both the genotype and the environmental exposure plus the 
product of both terms (the interaction effect). The basic equation to study 
GxE is as follows: 
𝑦   𝛽 𝛽 𝐺 𝛽 𝐸 𝛽 𝐺 𝑥𝐸  𝜖  
In such an equation, we have 𝑦  representing the phenotype under study 
(e.g. MDD status or depressive symptoms) as a function of the effects (𝛽) 
from an individual’s genotype or genetic variable (𝐺 ; e.g. allele, genotype or 
genetic score such as PRS), the environmental variable (𝐸 ; e.g. number of 
SLE reported in the last 6 months), the interaction between both factors 
(𝐺 𝑥𝐸 ) and an error term 𝜖 , which may include the effect of control variables 
(covariates) such as sex, age or others related to the sample under study. To 
assess whether there is a substantial GxE effect ( 𝛽 ), the following 
hypothesis is tested: 
𝐻 : 𝛽 0 𝑣𝑠.  𝐻 : 𝛽 0 
Thus, if 𝛽 0, it means that the interaction between “genetics” (𝐺 ) and the 
environment (𝐸 ) significantly contribute on the output. Therefore, if MDD 
status were the output, it would mean that there is a significant GxE effect 
underlying the aetiology of MDD.  
An alternative test is to jointly assess the contribution of the genotype and the 
GxE together233,244. This is called a joint test and assesses the combined 
main additive 𝐺  and 𝐺 𝑥𝐸  effect on the output. It compares the model above 
to study GxE against a null model where both 𝛽  and 𝛽  equal 0. Therefore, 
to test the significance of a joint effect, the following hypothesis is tested: 
𝐻 : 𝛽 𝛽 0 𝑣𝑠.  𝐻 : 𝛽 𝛽 0 
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This can be conceptualized as the total genetic effect (𝛽 𝛽 ). 
1.6.4 GxE studies: transition from classical approaches and 
candidate genes to whole-genome studies 
Early evidence for the presence of non-additive genetic effects on depressive 
disorders were found in studies based on structural models using twin, 
pedigree or adoption data, without requiring genetic data245. These studies 
used the relatedness between individuals to estimate a proxy of the genetic 
risk expected for each individual. Combining this latent measure of genetic 
influence with the environmental context derived from the data structure, 
these studies provided a range of ways to infer potential GxE in depression. 
They compared how genetic and environmental influences change across 
groups with different risk proxies, suggesting that the association between 
environmental stress and depression was partially mediated by familiar 
contributions including both genetics and shared environment93,103,116,246-248. 
1.6.4.1 Candidate gene-by-environment interaction studies 
Initial implementations of genetic data to investigate GxE effects were 
candidate gene studies. In early 2002, Caspi et al. reported that maltreated 
children carrying a functional polymorphism associated with higher activity of 
the neurotransmitter-metabolizing enzyme monoamine oxidase A (MAOA 
gene) were less likely to develop antisocial disorders249. The hypothesis-
driven strategy implemented was typical of the majority of following GxE 
studies on liability to depression. Probably the most influential and 
controversial GxE study on depression, performed by Caspi et al. in 2003, 
studied a serotonin transporter gene (SLC6A4; also known as 5-HTT gene) 
as candidate gene. They reported that the likelihood of have suffered a MDE, 
depressive symptoms or attempted suicide in the past year was higher in 
carriers of one or two copies of the short allele from a functional 
polymorphism on a promoter region linked to the 5-HTT gene (5-HTTLPR) 
than for homozygous carriers for the long allele250. This was a result of a 
dose-response interaction between 5-HTTLPR and the number of SLE 
reported over the preceding 5 years, and supported the hypothesis that 
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genetic variation can modulate an individual’s sensitivity to environmental 
stress. Similar findings were reported when childhood maltreatment was 
considered as the environmental exposure. However, the robustness of 
these findings is still debated92,251-254. In fact, there are a large number of 
candidate gene GxE studies (more than fifty just attempting replication of 
Caspi’s findings) reporting results of which is not clear how robust and 
replicable they are. Many other candidate gene studies have been performed 
with other polymorphisms from a restricted set of hypothesis-driven 
candidate genes, based on previous empirical evidence about the link 
between their biological functions and some environmental influences, e.g. 
SLC6A4, FKBP5, CRHR1, COMT, CNR1, BDNF or MAPK14255-260. These 
have mostly focused on the monoaminergic systems (e.g. serotoninergic, 
dopaminergic) or stress-response pathways linked to the HPA axis. 
Nevertheless, robust findings have been absent and the results are in doubt 
due to their lack of power254. Two meta-analyses concluded, a few years 
after Caspi’s findings, that there was no evidence of a significant GxE effect 
between the 5-HTTLPR polymorphism and SLE in depression in any sex or 
at population level251,252. However, Caspi et al. came back with a later review 
emphasizing that evidence for GxE effects come from a wide range of 
studies including observational studies in humans and non-human primates, 
studies of 5-HTT mutations in rodents and from experimental neuroscience 
studies261. The presence of such GxE effect was later support by a larger 
meta-analysis253. Nevertheless, a recent collaborative meta-analysis based 
on 31 studies including 38,802 individuals from European ancestry concluded 
that there was no evidence of a significant GxE, but that if such interaction 
exist, its effect must be modest and only detectable in specific scenarios262. 
Therefore, more than 15 years later, the debate about whether GxE between 
the serotonin transporter genotype and environmental stress increase liability 
to depression or not still remains open, highlighting how complex is the study 
of GxE effects.  
44 
1.6.4.2 Genome-wide GxE studies 
Genome-wide GxE studies may follow different study designs (e.g. case-
only, two-phase case–control or counter-matched designs)263,264. In 2014, the 
first genome-wide GxE study in psychiatric disorders was conducted in 
schizophrenia265. It tested a final set of 29,082 SNPs displaying nominal 
association with maternal load of cytomegalovirus infection with maternal 
load of cytomegalovirus infection as the “environmental” exposure. Although 
it did not achieve the accepted genome-wide significance threshold from 
standard genome-wide studies (p = 5 x 10-8) and it was not replicated, they 
reported a significant GxE (p = 7.3 x 10-7; Bonferroni significance p = 1.72 x 
10-6) in CTNNA3, a gene previously unknown in schizophrenia265. If such
association were replicated266, this study would provide evidence for the
importance of including environmental risk factors in genetic studies in order
to identify genetic risk variants. In regards to liability to MDD, only a very few
genome-wide GxE studies have been performed to date113,267-270. Recently,
few studies have applied similar approaches to pre-select candidate
polymorphism before testing for GxE effects on MDD. In 2017, Van der
Auwera et al. selected 27 candidate genes and 268 SNPs previously
associated with either MDD or GxE effects in MDD and tested for GxE effects
using case-control and case-only designs in a PGC sample of 3,944
individuals of European ancestry270. No genome-wide significant finding was
reported. Finally, Coleman et al. recently used over 73,000 participants from
UK Biobank and a set of 1,652 imputed SNPs nominally associated (p < 1 x
10-4) in GWAS of depression and/or trauma exposure in order to investigate
GxE effects in MDD status using a binary variable of overall self-reported
trauma in childhood and adulthood269. They reported evidence of GxE with
trauma exposure in 78 SNPs (p < 3 x 10-5).
Recently, a new strategy has emerged to investigate GxE at the genome-
wide scale, the performance of genome-wide by environment interaction 
studies (GWEIS; sometimes called gene-environment-wide interaction 
studies)263,271. Paradoxically, nowadays this kind of strategy is more limited 
by lack of high-quality assessment of environmental factors, and the 
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existence of such data on “environmental” measures in general, than by 
availability and quality of genomic data. GWEIS refer to genome-wide GxE 
studies with epidemiological cohort and case–control designs that 
independently test genotyped SNPs along the genome without requiring any 
prior knowledge about the underlying biology of MDD. GWEIS can also test 
associations with the combined additive and GxE effects (i.e. the joint effect; 
further details in section 1.6.3)233,244. In 2016, Dunn et al. conducted the first 
and largest GWEIS of depressive symptoms to date in two samples of 
women from minority populations: 7,179 African American and 3,138 
Hispanic/Latinas women113. They reported a significant GxE in the African 
American sample 14kb from CEP350 (p = 4.10 x 10-10), but this interaction 
was not replicated in independent samples of either African American or 
Hispanic/Latinas women. That same year, two other GWEIS on depressive 
symptoms in the Japanese population were published. Otowa et al. reported 
a significant GxE 8kb upstream of RGS10 (p = 4.5 x 10-8) in a cohort of 320 
Japanese267. However, the veracity of such finding is very low due to its lack 
of power, which themselves reported as 2% in order to detect significant 
interactions accounting for at least 1% of the variance in such small sample 
size. Ikeda et al. conducted the other GWEIS in a sample of 1,112 Japanese 
individuals (91% women) using a robust joint test268. This robust joint test 
combines the effect of the GxE with the main SNP additive effect into a joint 
effect that may help to identify locus associated with MDD272. Using a 
measure of SLE, they reported a single significant association with such joint 
effect (p = 8.2 x 10-9) between depressive state and a variant downstream of 
BMP2, a gene with no direct relationship with mood disorder susceptibility but 
with neurotrophic effects and enriched in neurons. Nevertheless, they did not 
test the interaction effect alone. Noteworthy, the robust joint test implemented 
on this GWEIS adjusts by a systematic and spurious genome-wide inflation 
that occurs on most GxE studies due to heteroscedasticity in the data. 
Heteroscedasticity is a statistical phenomenon that arises when the variance 
of the trait under study (e.g. depressive symptoms) is not homogeneous 
across each level of the environmental exposure (e.g. number of reported 
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SLE). Therefore, this phenomenon must be taken into account in GWEIS. 
Ikeda et al. conducted such GWEIS applying an R plugin for PLINK273 
developed by Almli et al.272.  
1.6.4.3 Polygenic risk scores to test GxE effects 
A rising alternative to investigate GxE effects locus by locus is to use PRS 
weighted by genetic factors associated with the phenotype of interest and 
test their interaction with an environmental variable (i.e. PRSxE)274. PRS 
explain more phenotypic variance and have much greater explanatory power 
than individual SNPs. In addition, by aggregating all weightings from 
genome-wide data into a single score there is only a single genetic 
independent variable to be tested and thus, it reduces the multiple testing. 
This new approach has been applied to investigate GxE effects on MDD with 
childhood trauma83,86,275 and adult SLE86,169,276. However, initial results 
contradict. In 2014, Peyrot et al. conducted a study in European individuals 
involving 1,645 MDD cases and 340 screened controls83 using PRS weighted 
by main additive effects of MDD derived from a PGC genome-wide meta-
analysis147. They reported that individuals with high genetic vulnerability were 
at higher risk of developing MDD when they had been exposed to childhood 
trauma, and that the risk increased with increasing severity of the events. In a 
similar approach, and using the same GWAS summary data, in a US 
population-based sample of 8,761 older adults, Musliner et al. reported no 
significant interaction between PRS and recent SLE on current depressive 
symptoms276. They therefore concluded that there was no evidence of SLE 
modulating polygenic risk. Later, a replication study from Mullins et al. 
assessed the interaction of the same PRS in a UK sample involving 1,605 
individuals with MDD and 1,064 controls86. In this case, they assessed PRS 
interaction with both childhood trauma and adult SLE reporting similar 
findings to the previous studies of Peyrot et al. and Musliner et al. but with 
controversial interpretations for the modulating effects of childhood trauma 
(i.e. opposing interaction effect). As in Musliner et al., they found no 
significant interaction between PRS and adult SLE, but significant interaction 
between PRS and childhood trauma, suggesting that only very severe events 
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such as childhood trauma modulated the risk effect, or that only the effect of 
very severe events such as childhood trauma is modulated by genetic 
variation. Furthermore, contrary to the conclusions of Peyrot et al., individuals 
who suffer moderate to severe childhood trauma were found to be at higher 
risk of MDD when they had lower genetic risk of MDD. Conversely to both 
studies, a recent meta-analysis conducted by Peyrot et al., which included 
both studies investigating childhood trauma as exposure along with several 
other cohorts contributing to the PGC and involved 3,024 MDD cases and 
2,741 controls, reported no significant interaction between PRS (weighted by 
a substantially larger discovery sample of ~110,000 individuals) and 
childhood trauma. Therefore, concluding that previous evidence from Peyrot 
et al. and Mullins et al. were no longer significant when using a PRS 
weighted by a larger discovery sample and thus, they should be interpreted 
as chance findings. Although further research is required, the most recent 
evidence suggests that genetics does not modulate the negative effect of 
childhood trauma on odds of suffering depression in adulthood.  
Conversely, Colodro-Conde et al. recently tested the interaction between 
PRS and adult SLE (i.e. two kinds of SLE, so-called personal and network 
SLE), as well as the interaction with social support (i.e. a measure of positive 
environment), in a sample of 5,221 individuals from 3,083 Australian families 
following a diathesis-stress framework169. Unlike the previous studies 
described, they used a genomic relationship matrix and a linear mix model 
implemented in GCTA to estimate the variance in depression explained by 
the PRSxE while taking into account the independent effects of PRS and 
environment scores. They used PRS weighted by the most recent genome-
wide meta-analysis conducted by PGC at that time (N=159,601) and more 
extensive and informative measures of SLE. In contrast to the previous 
Musliner et al. and Mullins et al. studies, they reported a significant 
interaction between PRS and SLE on liability to depression, using personal 
SLE and mainly driven by effects in women. Thus, concluding that there is an 
extra risk on liability to depression in individuals that combine high genetic 
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risk of MDD and high number of reported SLE. They found no significant 
interaction with network SLE or social support.  
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1.7 Thesis summary and aims 
 
The aim of this thesis is to advance our understanding of the genetic 
responses to environmental stress underlying MDD. Herein, I present 
findings from a range of new genome-wide studies and polygenic 
approaches, using data from Caucasian populations of United Kingdom 
ancestry, in order to investigate the complex interplay between genetic 
factors and environmental stress in the aetiology of depression. 
In chapter 2 and chapter 3 I explore the genetic basis of a proxy for 
sensitivity to stress without direct measures of environmental stress but 
exploiting the relationship between stress, neuroticism and depression. In 
chapter 2, such proxy for sensitivity to stress is operationalized through a 
genome-wide interaction study, and chapter 3 explores the enrichment of 
genetic factors contributing to risk of MDD and stress sensitivity within the 
HPA axis and glucocorticoid pathways. In chapter 4, chapter 5 and chapter 
6 I incorporate self-reported quantitative measures of recent SLE to 
investigate the genetic response to SLE in depression. Chapter 4 empirically 
tests the diathesis-stress model for depression, using PRS weighted by the 
additive effects of MDD derived from the PGC MDD GWAS and SLE 
measures, in order to validate previous findings supporting the diathesis-
stress theory. Chapter 5 presents the results from GWEIS conducted in two 
cohorts that seek to identify common variants with GxE effect on depression 
in response to SLE. Finally, chapter 6 incorporates the weightings for 
genetic stress sensitivity and stress response derived from chapters 2 and 
chapter 5 into a new assessment of the diathesis-stress model for 
depression following the diathesis-stress framework implemented in chapter 
4. Finally, in chapter 7 I discuss my findings, some limitations and pitfalls of 





Chapters 2, chapter 4 and chapter 5 have been accepted for publication to 
peer-reviewed journals. As of January 2019, chapter 2 has been published 
in PLOS ONE (attached into the Appendix A.4), and both chapter 4 and 
chapter 5 have been published in Translational Psychiatry (attached into the 
Appendix C.3 and the Appendix D.7, respectively). Chapter 6 is going to be 
submitted to PLOS Genetics. All the studies presented in this thesis are my 
own work based on my research conducted during the 4 years of my PhD 
program in Computational Biology. 
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Chapter 2 Genome-wide interaction study of a 
proxy for stress-sensitivity and its 
prediction of major depressive 
disorder 
Well-powered GxE studies require having a large sample with both genetic 
and environmental data available from the same individuals. However, data 
on key environmental exposures such as SLE or childhood maltreatment is 
missing or limited by a lack of high quality in most population-based cohorts 
with genetic data available. The quality of measures on environmental stress 
tends to decline in relation to sample size and even fewer prospective studies 
exist with this data available. However, several population-based cohorts with 
genetic data have measures on neuroticism levels. In this chapter, I exploit 
the relationship between environmental stress, neuroticism and MDD to 
derive a proxy for stress sensitivity without requiring direct measures of SLE.  
This chapter is presented as it has been published in PLOS ONE, which 
explains the use of “we” within the chapter. I confirm that the work presented 
(i.e. investigation, conceptualization, data curation, formal analysis, plot 
generation and writing) is my own work under guidance from my supervisor 
Dr. Pippa Thomson. She provided the original idea and the initial draft of the 
introduction. Co-authors contributed with the collection, access and 
preliminary curation of some raw data and/or providing critical revisions. I 
performed all the analyses myself. The published article and Supplementary 
Material can be found in Appendix A. 
Publication: 
Arnau-Soler, A. et al. Genome-wide interaction study of a proxy for stress-





Individual response to stress is correlated with neuroticism and is an 
important predictor of both neuroticism and the onset of major depressive 
disorder (MDD). Identification of the genetics underpinning individual 
differences in response to negative events (stress-sensitivity) may improve 
our understanding of the molecular pathways involved, and its association 
with stress-related illnesses. We sought to generate a proxy for stress-
sensitivity through modelling the interaction between SNP allele and MDD 
status on neuroticism score in order to identify genetic variants that 
contribute to the higher neuroticism seen in individuals with a lifetime 
diagnosis of depression compared to unaffected individuals. Meta-analysis of 
genome-wide interaction studies (GWIS) in UK Biobank (N = 23,092) and 
Generation Scotland: Scottish Family Health Study (N = 7,155) identified no 
genome-wide significance SNP interactions. However, gene-based tests 
identified a genome-wide significant gene, ZNF366, a negative regulator of 
glucocorticoid receptor function implicated in alcohol dependence (p = 1.48 x 
10-7; Bonferroni-corrected significance threshold p < 2.79 x 10-6). Using
summary statistics from the stress-sensitivity term of the GWIS, SNP
heritability for stress-sensitivity was estimated at 5.0%. In models fitting
polygenic risk scores of both MDD and neuroticism derived from independent
GWAS, we show that polygenic risk scores derived from the UK Biobank
stress-sensitivity GWIS significantly improved the prediction of MDD in
Generation Scotland. This study may improve interpretation of larger
genome-wide association studies of MDD and other stress-related illnesses,








Stressful life events are known to increase liability to mental illness and 
disease-related traits277 including neuroticism218-220, major depressive 
disorder (MDD)79,84,85, autoimmune diseases278 and some cancers279,280. A 
greater understanding of the causal mechanism by which negative events 
affect disease risk or outcome may be beneficial in identifying individuals for 
targeted support. However, it has been proposed that sensitivity to stress 
may be an important predictor of response to stress188,281. In particular, the 
effect on an individual may result more from the perceived stress than the 
event itself, and may be dependent on individual differences in stress-
sensitivity282-287. Studies of 5-HTT and twin studies suggest that stress-
sensitivity may, at least in part, be heritable261,288-290. Despite a complex 
interaction between MDD, neuroticism and stress, multivariate structural 
equation models have confirmed a genetic effect on perceived stress, 
overlapping that on MDD or neuroticism, but with a specific genetic 
component288. The inter-relatedness of these traits may offer an approach to 
identify the genetic variation that affects an individual’s stress-sensitivity, and 
improve genetic prediction of an individual’s liability to negative outcomes. By 
modelling the interaction between SNP allele and MDD status on neuroticism 
score through genome-wide interaction studies (GWIS), we sought to 
investigate the genetics of stress-sensitivity. 
The personality trait neuroticism is moderately heritable (30–50% estimates 
from twin studies)189,203,204,291, is higher in individuals with depression 
compared to controls213,214 and is known to have shared genetic aetiology 
with depression292-295. Neuroticism is strongly correlated with measures of 
sensitivity to punishment but not reward296, positively correlated with 
perceived personal relevance of a stressor297,298 and has been used 
previously as a proxy measure of stress-sensitivity221. Neuroticism is thought 
to mediate or interact with the effects of adverse life events on risk of 
depression79,222. It has a substantial stable component299, however, there is 
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evidence for change, as well as stability, across the life span217-220. Individual 
differences in neuroticism are enduringly influenced by both genetic and 
environmental factors300. Whereas the stable component of neuroticism is 
strongly determined by genetics, change in neuroticism score is attributed to 
the effects of unshared environment217. Persistent change in neuroticism 
score has been shown in response to life events218-220. Negative life events 
lead to small persistent increases in neuroticism over time220. However, 
recent stressful life events (β = 0.14 95%CI 0.13 - 0.15, p < 0.001) have a 
stronger effect than distant stressful life events suggesting a reduction of 
effect over time220. Long-lasting increases in neuroticism associated with 
distant negative life events are mediated by depression218.  
Major depressive disorder (MDD) is a complex disorder influenced by both 
genetic contributions and environmental risk factors, with heritability 
estimates from twin and family studies of between 31-42%119,150. Confirmed 
environmental risk factors for MDD include maternal infections, childhood 
maltreatment and negative life events79,81,83-85. However, few genetic studies 
have such information and even fewer prospective studies exist. 
Incorporation of stressful life events has been shown to improve the ability to 
predict MDD86,169 and, although stress is an environmental risk factor, it may 
have an independent genetic contribution to risk of depression97,103,114,115,169. 
These studies suggest that a genetic variable derived from the difference in 
neuroticism levels seen in individuals with MDD compared to controls may 
allow us to identify genetic loci important for stress-sensitivity. We sought to 
identify the genetic underpinnings of individual’s sensitivity to stress response 
(stress-sensitivity) by identifying variants that contribute to the higher 
neuroticism levels seen in individuals with a lifetime diagnosis of MDD. 
Further, polygenic risk scores (PRS) derived from this stress-sensitivity 
variable may improve prediction of MDD over that based on MDD or 
neuroticism PRS alone. 
Using unrelated individuals from two large population-based samples, UK 
Biobank (UKB; N = 23,092) and Generation Scotland: Scottish Family Health 
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Study (GS:SFHS; N = 7,155), we sought to identify genes involved in stress-
sensitivity by performing GWIS for the interaction between MDD status and 
SNP allele on neuroticism score. We identified a gene significantly 
associated with stress-sensitivity and show that a PRS derived from the 
interaction term of the GWIS, significantly predicts liability to depression 





2.3 Materials and methods 
 
2.3.1 UK Biobank (UKB) Participants  
UKB is a major national health resource that aims to improve the prevention, 
diagnosis and treatment of a wide range of illnesses. It recruited more than 
500,000 participants aged from middle to older age who visited 22 
assessment centres across the UK between 2006 and 2010. Data were 
collected on background and lifestyle, cognitive and physical assessments, 
sociodemographic factors and medical history. The scientific rationale, study 
design, ethical approval, survey methods, and limitations are reported 
elsewhere301,302. UKB received ethical approval from the NHS National 
Research Ethics Service North West (Research Ethics Committee Reference 
Number: 11/NW/0382). All participants provided informed consent. The 
present study was conducted on genome-wide genotyping data available 
from the initial release of UKB data (released 2015). Details of sample 
processing specific to UKB project are available at 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155583 and the Axiom array 
at 
http://media.affymetrix.com/support/downloads/manuals/axiom_2_assay_aut
o_workflow_user_guide.pdf. UKB genotyping and the stringent QC protocol 
applied to UKB data before it was released can be found at 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580. SNPs genotyped on 
GS:SFHS were extracted from the imputed UKB genotype data303 (imputed 
by UKB using a merged panel of the UK10K haplotype reference panel and 
the 1000 Genomes Phase 3 reference panel) with quality > 0.9 was hard-
called using PLINK v1.9273. Individuals were removed based on UKB 
genomic analysis exclusion (UKB Data Dictionary item #22010), non-white 
British ancestry (#22006: genetic ethnic grouping; from those individuals who 
self-identified as British, principal component analysis was used to remove 
outliers), high genotype missingness (#22005), genetic relatedness (#22012; 





QC failure in UK BiLEVE study (#22050 and #22051: UK BiLEVE Affymetrix 
and UK BiLEVE genotype quality controls for samples) and gender mismatch 
(#22001: genetic sex). Further, from the initial release of UKB data and using 
PLINK pi-hat < 0.05, individuals who were also participants of GS:SFHS and 
their relatives were excluded to remove any overlap of individuals between 
discovery and target samples. A dataset of 109,283 individuals with 557,813 
SNPs remained for further analysis, aged 40-79 (57,328 female, 51,954 
male; mean age = 57.1 years, s.d. = 7.99), of which 109,282 had data 
available for neuroticism score and 23,092 had data available on MDD status 
(ncases = 7,834, ncontrols = 15,258, nfemale = 11,510, nmale = 11,582; mean age = 
57.7 years, s.d. = 8.04). Thus, the final dataset comprised 23,092 unrelated 
individuals.  
2.3.2 Generation Scotland Scottish Family Health Study 
(GS:SFHS) Participants 
GS:SFHS is a family-based genetic epidemiology study which includes 
23,960 participants from ~ 7,000 Scottish family groups collected by a cross-
disciplinary collaboration of Scottish medical schools and the National Health 
Service (NHS) from February 2006 to March 2011. Participants were 
interviewed and clinically assessed for a wide range of health-related traits 
(including high-fidelity phenotyping for Major Depressive Disorder and related 
endophenotypes), environmental covariates and linked to routine health 
records304,305. All components of GS:SFHS obtained ethical approval from 
the Tayside Committee on Medical Research Ethics on behalf of the NHS 
(Research Ethics Committee Reference Number: 05/S1401/89) and 
participants provided written consent. The protocol for recruitment is 
described in detail in previous publications124,306. GS:SFHS genotyping and 
quality control is detailed elsewhere307. Briefly, individuals with more than 2% 
missing genotypes and sex discrepancies were removed, as well as 
population outliers. SNPs with genotype missingness > 2%, minor allele 
frequency < 1% and a Hardy-Weinberg Equilibrium test p < 1 x 10−6 were 
exclude. Finally, individuals were removed based on relatedness (pi-hat < 
0.05), maximizing retention of case individuals, using PLINK v1.9273. 
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Genome-wide SNP data for further analysis comprised 7,233 unrelated 
individuals genotyped for 560,698 SNPs (nfemale = 3,476, nmale = 3,757), aged 
18-92 (mean age = 50.4 years, s.d. = 12.06) of which: 7,190 had clinical data
on MDD; 7,196 individuals had data on neuroticism; and 7,155 had data on
both neuroticism and MDD.
2.3.3 Phenotype assessment 
2.3.3.1 Neuroticism score (EPQN) 
Participants in both UKB and GS:SFHS cohorts were assessed for 
neuroticism using 12 questions from the Eysenck Personality Questionnaire-
Revised Short Form’s Neuroticism Scale (EPQN)198,308-310. Neuroticism can 
be scored by adding up the number of “Yes” responses on EPQN. This short 
scale has a reliability of more than 0.8201. EPQN distributions were found to 
be sufficiently “normal” after assessment for skewness and kurtosis to be 
analysed using linear regression (both coefficients were between -1 and 1). 
2.3.3.2 MDD diagnoses 
In UKB, the MDD phenotype was derived following the definitions from Smith 
et al.310 Current and previous depressive symptoms were assessed by items 
relating to the lifetime experience of minor and major depression308, items 
from the Patient Health Questionnaire311 and items on help-seeking for 
mental health310. Using a touchscreen questionnaire, participants were 
defined as probable cases if they i) answered “Yes” to the question “Ever 
depressed for a whole week” (UKB field: 4598), plus at least 2 weeks 
duration (UKB field: 4609), or ii) did report having seen a GP or psychiatrist 
for nerves, anxiety, tension or depression (UKB fields: 2090 and 2010) and 
reported symptoms (UKB field: 4631) with at least 2 weeks duration (UKB 
field: 5375). In our unrelated sample, 7,834 participants were diagnosed with 
MDD (with single, moderate or recurrent episodes) and 15,258 were controls 
(N = 23,092). 
In GS:SFHS, participants took in-person clinical visits where they were 
screened for a history of psychiatric and emotional disorders (i.e., psychiatric, 





trained researchers using the Structured Clinical Interview for DSM-IV Non-
Patient Version (SCID)312, which is internationally validated to identify 
episodes of depression. Those participants that were positive in the initial 
screening continue through clinical interview and were administered the 
mood sections of the SCID. The SCID elicited the presence or absence of a 
lifetime history of MDD, age of onset and number of episodes. Participants 
fulfilling the criteria for at least one major depressive episode within the last 
month were defined as current MDD cases. Participants who were screened 
positive for Bipolar I Disorder were excluded.  Those participants who were 
negative during the initial screening or did not fulfilled criteria for MDD were 
assigned as controls. Further details regarding the diagnostic assessment 
are reported elsewhere124,305. All interviewers were trained for the 
administration of the SCID. Inter-rater reliability for the presence or absence 
of a lifetime diagnosis of major depressive disorder was good (Kappa = 0.86, 
p < 0.001, 95%CI 0.7 to 1.0). In our unrelated GWIS sample (N = 7,155), 
2,010 had a lifetime diagnosis of MDD and 5,145 were controls. 
2.3.4 Statistical Methods 
2.3.4.1 GWIS and derivation of a genetic stress-sensitivity effect 
The effect size of an stress-sensitivity effect 𝛽  was derived by performing 
a GWIS for the effect of the MDD status and SNP allele on EPQN 
(dependent variable) in both UKB and GS:SFHS cohorts using PLINK 1.90 
(PLINK-command --gxe; fitting MDD diagnosis as a binary “group” effect)273. 
PLINK-command --gxe estimates the difference in allelic association with a 
quantitative trait (EPQN) between two groups (MDD cases vs. controls) 
producing effect estimates on each group and a test of significance for the 
interaction between SNP allele and MDD status. The interaction p value 
reflects the difference between the regression coefficient of the allelic effect 
in a linear model for EPQN in MDD cases (𝛽 ) and the same regression 
coefficient in a linear model for EPQN in controls (𝛽 ). The stress-sensitivity 
interaction effect was defined as the difference in allele effect between MDD 
cases and control groups. 
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Considering one SNP, the effect it confers to EPQN can be modelled by 
MDD status (control = 0, MDD case = 1) as follows: 
𝑀𝐷𝐷 0;  𝐸𝑃𝑄𝑁 𝛽 𝛽 𝑆𝑁𝑃 𝛽 𝐶𝑂𝑉 𝜀
𝑀𝐷𝐷 1;  𝐸𝑃𝑄𝑁 𝛽 𝛽 𝑆𝑁𝑃 𝛽 𝐶𝑂𝑉 𝜀  
This is equivalent to modelling the effect on MDD cases as follows: 
𝑀𝐷𝐷 0;  𝐸𝑃𝑄𝑁 𝛽 𝛽 𝑆𝑁𝑃 𝛽 𝐶𝑂𝑉 𝜀
𝑀𝐷𝐷 1;  𝐸𝑃𝑄𝑁 𝛽 𝛽 𝑆𝑁𝑃 𝛽 𝛽 𝑆𝑁𝑃 𝛽 𝐶𝑂𝑉 𝜀
 
Or, it can be modelled as a whole as: 
𝐸𝑃𝑄𝑁 𝛽 𝛽 𝑀𝐷𝐷 𝛽 𝑆𝑁𝑃 𝛽 𝛽 𝑆𝑁𝑃 ∗ 𝑀𝐷𝐷 𝛽 𝐶𝑂𝑉 𝛽 𝐶𝑂𝑉
∗ 𝑀𝐷𝐷 𝜀 
Where COV stands for covariates, 𝛽  stands for 𝛽 𝛽 , and 𝛽  stands for 
𝛽 𝛽 . 
Thus, the interaction effect (𝛽 ) can be estimated as the difference in allelic 
effect on EPQN between MDD cases (𝛽 ) and controls (𝛽 ) as follows, 
𝛽 𝛽 𝛽
𝛽  is therefore defined as the effect size reflecting the genetic stress-
sensitivity effect on MDD cases compared to controls (Appendix A: 
Supplementary Figure 1). 
2.3.4.2 Stress-sensitivity GWIS, main additive effect GWASs, meta-
analysis and gene-set analysis. 
For GWIS and subsequent analyses, sample specific covariates were applied 
as follows: UKB. All phenotypes were adjusted for centre, array and batch as 
random effects prior to analyses. Analyses were adjusted for age, sex and 15 
informative principal components (PCs; UKB Data Dictionary items 
#22009.01 to #22009.15) as fixed effects to take account of possible 
population stratification. GS:SFHS. All the analyses were adjusted for age, 





GWAS for MDD and neuroticism, using logistic and linear models of additive 
allelic effects respectively, were conducted on the same sample sets for 
comparison and generation of matched PRS using PRSice-2313. 
Results from the GWIS of UKB and GS:SFHS were combined in a sample 
size weighted meta-analysis performed using METAL314. While the use of 
standard error weighting is more common, the different diagnostic scheme 
and MDD prevalence between the two cohorts (GS:SFHS; 12.2%, UKB: 
25.8%)124,310 may indicate systematic differences in the measurement of 
MDD. Generalized gene-based analysis of the meta-analysis was performed 
using MAGMA315 implemented through FUMA316 (http://fuma.ctglab.nl). 
Briefly, SNP summary statistics were mapped to 17,931 protein-coding 
genes. Individual SNP p values from a gene were combined into a gene test-
statistic using a SNP-wise model and a known approximation of the sampling 
distribution used to obtain a gene-based p value. Genome-wide significance 
was defined at p = 0.05/17,931 = 2.79 x 10-6. 
2.3.4.3 LD Score regression 
The summary statistics from the meta-analysis were used to examine the 
genetic overlap between the polygenic architecture of stress-sensitivity, MDD 
and neuroticism. LD score regression was used to derive the genetic 
correlations (rG) between these traits173,174 using meta-analysed GWAS and 
GWIS summary statistics. SNP-based heritability was also estimated using 
LD score regression, using the summary statistics from single-SNP analyses. 
2.3.4.4 Pathway, functional and gene expression analyses 
Lead SNPs, independently associated with the phenotype, were identified 
using PLINK 1.90 by clumping (p threshold < 2 x 10-5; LD r2 > 0.1; physical 
kb threshold = 500kb; 1000 Genomes Project Phase 1 CEU, GBR, TSI 
genotype data), and analysed using DEPICT317. Further detail is given in 
Appendix A.1. 
Genes associated with lead SNPs were investigated for evidence of: 
phenotypic association in the NCBI dbGaP database of genotypes and 
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phenotypes318 (https://www.ncbi.nlm.nih.gov/gap/phegeni), regulatory DNA 
elements in normal cell lines and association with expression quantitative 
trait loci (eQTLs) using the RegulomeDB database319 
(http://www.regulomedb.org) and the Genotype-Tissue Expression (GTEx) 
Portal320 (http://www.gtexportal.org).  
2.3.4.5 Polygenic profiling 
PRS were produced using PRSice-2313, permuted 10,000 times and 
standardized to a mean of 0 and a standard deviation of 1. Using GWIS 
summary statistics, we created PRS for stress-sensitivity (PRSSS) by 
weighting the sum of the reference alleles in an individual by the stress-
sensitivity effect 𝛽 . Additional PRS were generated weighting by MDD 
main additive effects (PRSD) and neuroticism main additive effects (PRSN) 
using GWAS summary statistics from GS:SFHS or UKB. In addition, PRSD 
and PRSN were also generated using summary statistics from the most 
recent Psychiatric Genetic Consortium (PGC) MDD meta-analysis150 
(excluding GS:SFHS, and UKB individuals when required; N = 155,866 & 
138,884) and the Genetics of Personality Consortium (GPC) neuroticism 
meta-analysis204,321 (N = 63,661). Generalized linear models were 
implemented in R 3.1.3322. The direct effect of PRSSS (model 1), PRSD 
(model 2) and PRSN (model 3) on MDD risk were assessed in independent 
logistic regression models on GS:SFHS (target cohort) using GWAS and 
GWIS statistics from UKB (the largest cohort) as the discovery sample to 
weight PRS. Multiple regression models fitting both PRSD and PRSN (model 
4) and fitting each of them separately with PRSSS (models 5 and 6) were also
calculated. Finally, full additive multiple regression models fitting PRS
weighted by all three effects (full model) was assessed using both PRSSS,
PRSD and PRSN at their best-fit in independent models. Further, results were
also assessed using PRSD and PRSN weighted by PGC2 MDD150 and GPC
neuroticism321 summary statistics. Further detail is given in Appendix A.2. All
models were adjusted by sex, age and 20 PCs. A null model was estimated
from the direct effects of all covariates on MDD. 10,000 permutations were
used to assess significance of each PRS. The predictive improvement of
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combining the effects of multiple PRS over a single PRS alone was tested for 
significance using the likelihood-ratio test. 
Cross-validation was performed using UKB as target sample and GS:SFHS 
as discovery sample. Additional analyses using PRSD and PRSN weighted by 
PGC2 MDD150 and GPC neuroticism321 summary statistics were also tested. 
MDD status on UKB was adjusted by centre, array and genotyping batch as 
random effects and scaled (between 0 and 1) prior to analysis, giving a 
quasi-binomial distribution of MDD status on UKB. Models implemented on 
UKB (quasi-binomial regression) were adjusted by sex, age and 15 PCs. 
Nagelkerke’s R2 coefficients were estimated to quantify the proportion of 
MDD liability explained at the observed scale by each model and converted 
into R2 coefficients at the liability scale (prevalence: 12.2% in GS:SFHS124 
and 25.8% in UKB310) using Hong Lee’s transformation172 available from 
GEAR: GEnetic Analysis Repository323.  
2.3.4.6 Using stress-sensitivity to stratify depression 
GS:SFHS MDD cases (ncases = 2,016; nfemale = 1,345, nmale = 671) have data 
available on MDD course (single or recurrent), age of onset (n = 1,964) and 
episode count (n = 2,016), as well as on neuroticism (n = 2,010). In addition, 
a subset were evaluated by Mood Disorder Questionnaire324 (MDQ; n = 
1,022) and Schizotypal Personality Questionnaire325 (SPQ; n = 1,093). The 
reduced sample number of MDQ and SPQ reflects the later addition of these 
questionnaires to the study and does not reflect a particular subgroup of 
GS:SFHS. 
Difference in PRSSS and PRSD between MDD cases and controls on 
GS:SFHS were tested using a Student’s two sample t-test (two tailed). Cases 
of MDD on GS:SFHS with data available on each trait analyzed were 
stratified by quintiles based on PRSSS and PRSD (5 x 5 groups). Post hoc, the 
effects on each trait of quintiles based on PRSSS and its interaction effect with 
quintiles based on PRSD were assessed using linear regression models 
adjusting by sex and age in an attempt to identify a characteristic subtype of 
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MDD patients with differential stress-sensitivity levels. The same analysis 
was reproduced using PRSs as continuous variables. 
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2.4 Results 
We confirmed the elevated neuroticism score in MDD cases in our samples. 
Individuals with a diagnosis of MDD had significantly higher EPQN scores 
compared to healthy controls (all p < 1.9. x 10-279) in both GS:SFHS 
(meancontrols = 3.16; meancases = 6.42) and UKB (meancontrols = 2.79; meancases 
= 5.64). Neuroticism levels differ significantly between males and females. To 
control for this and any age/polygenic effects, which may account for 
differences in the prevalence of MDD, we created a matched set of cases 
and controls. The difference in neuroticism levels between cases and 
controls remained significant after matching the controls for PGC PRSD, sex 
and age. (GS:SFHS: meancontrols = 3.51; UKB: meancontrols = 2.97; all p < 2.7 x 
10-158; Appendix A: Supplementary Table 1).
2.4.1.1 Meta-analysis of stress-sensitivity in UKB and GS:SFHS 
No SNPs were associated with stress-sensitivity at the genome-wide 
significant threshold (p < 5 x 10-8, Figure 2.1). However, 14 SNPs from 8 loci 
achieved suggestive p value (p < 1 x 10-5) ranging between p = 8.9 x 10-6 - 
5.1 x 10-7 (Meta-analysis: Table 2.1; UKB and GS:SFHS: Appendix A: 
Supplementary Table 2 and Supplementary Table 3; Meta-analysis QQ-plot 
with λ: Appendix A: Supplementary Figure 2; UKB and GS:SFHS QQ-plots: 
Appendix A: Supplementary Figure 3). Traits with prior evidence of 
association with the nearest genes to the 8 lead SNPs were identified using 
dbGap and are shown in Appendix A: Supplementary Table 4. Comparison 
between the SNP association profile along the genome between stress-
sensitivity GWIS and MDD GWAS meta-analyses is shown in Miami plots 
filtering for the most significant stress-sensitivity or MDD SNPs (p < 0.001; 
Meta-analysis: Figure 2.2; UKB and GS:SFHS: Appendix A: Supplementary 
Figure 4). No SNP with a p-value < 0.01 had a corresponding p-value in the 
alternate trait, suggesting that different variants contribute to depression and 
stress-sensitivity. Gene-based test identified ZNF366 as the only gene 
achieving genome-wide significance (p = 1.48 x 10-7; Bonferroni-corrected 
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significance threshold p < 2.79 x 10-6; Appendix A: Supplementary Table 5 
and Supplementary Figure 5). Using summary statistics from meta-analysis 
GWIS results, stress-sensitivity SNP-based heritability was estimated from 
LD score regression at 5.0% (h2 = 0.0499, s.e. = 0.017, p = 1.67 x 10-3). 
Conversely, the SNP-based heritability for MDD and neuroticism were 
estimated at 9.6% (h2 = 0.0962, s.e. = 0.0179, p = 3.87 x 10-8) and 10.1% (h2 
= 0.1006, s.e. = 0.0076, p = 3.47 x 10-40) respectively, using summary 
statistics from the meta-analysed GWAS of UKB and GS:SFHS. 
LD score regression was performed to obtain genetic correlations between 
stress-sensitivity, MDD and neuroticism. As previously shown, there was a 
significant genetic correlation between MDD and neuroticism (rG = 0.637, s.e. 
= 0.0704, p = 1.39 x 10-19). However, we found no evidence for a genetic 
correlation between stress-sensitivity and MDD (rG = -0.099, s.e. = 0.182, p 
= 0.585) or between stress-sensitivity and neuroticism (rG = 0.114, s.e. = 
0.107, p = 0.285).  
2.4.1.2 Pathway enrichment, functional annotation and gene 
expression analyses 
Lead SNPs from the GWIS meta-analysis were investigated using DEPICT. 
No gene showed statistically significant links to stress-sensitivity at a DEPICT 
false discovery rate (FDR) < 0.05. No significant result was found for either 
gene set analysis or tissue enrichment analysis at FDR < 0.05. Evidence of 
regulatory elements on normal cell lines/tissues was identified for 5 of the 12 
lead SNPs (i.e. rs3762096, rs10987199, rs2221540, rs246565, rs319924). 
Two lead SNPs were associated with eQTLs: rs319924 (an intronic SNP in 
EYS) and rs9509508 (an intronic SNP in LATS2) and potentially regulate 







Figure  2.1  Manhattan  plots  showing  stress‐sensitivity  associations.  Manhattan 
plots  of  the GWIS  from  (A) UKB,  (B) GS:SFHS  and  (C)  sample  size weighted meta‐
analysis of UKB and GS:SFHS. The x‐axis is chromosomal position and y‐axis is the p‐
value  (‐log10  p‐value)  of  association  with  stress‐sensitivity  effect.  Suggestive 









=  1  x  10‐3:  (A)  filtering  for  stress‐sensitivity  p‐values  (•),  (B)  filtering  for  MDD  p‐
values  (×).  The  x‐axis  is  chromosomal  position  and  y‐axis  is  the  p‐value  (‐log10 p‐
value) of association with stress‐sensitivity (up; red dots) and MDD p‐value (down; 
blue  crosses).  Dot  line:  genome‐wide  suggestive  threshold  (p  =  1  x  10‐5)  at  the 
filtered effect; dashed lines: p = 0.01 and 0.05 at unfiltered effect. 
Table 2.1 Top 25 SNPs from meta‐analysis of GWIS 
Rank  CHR  SNP  BP  A1  Z‐score  Effecta  pb   p (EPQN) c  p (MDD) d  GENE  POSITIONe 
1  6  rs319924  64487247  A  5.024  ++  5.05x10‐7  0.376  0.637  EYS  Intronic 
2  5  rs246565  71809247  A  ‐4.684  ‐‐  2.82x10‐6  0.248  0.589  ZNF366  5998bp 5' 
3  10  rs2265265  24854876  A  4.604  ++  4.15x10‐6  0.035  0.084  KIAA1217 / ARHGAP21  18104bp 3' / 17662bp 3' 
4  6  rs1057530  64427095  A  ‐4.556  ‐‐  5.21x10‐6  0.636  0.840  PHF3/EYS  1677bp 3' / 2781bp 3' 
5  16  rs7199110  78790765  A  ‐4.553  ‐‐  5.29x10‐6  0.661  0.741  WWOX  Intronic 
6  6  rs10485358  64386060  A  ‐4.546  ‐‐  5.46x10‐6  0.390  0.902  PHF3  Intronic 
7  12  rs10778077  101193988  A  4.54  ++  5.62x10‐6  0.614  0.430  ANO4  Intronic 
8  5  rs13358894  71803446  A  4.527  ++  5.99x10‐6  0.257  0.651  ZNF366  197bp 5' 
9  10  rs2256220  24856314  A  ‐4.524  ‐‐  6.06x10‐6  0.134  0.129  KIAA1217 / ARHGAP21  19542bp 3' / 16224bp 3' 
10  10  rs3762096  98136250  A  ‐4.521  ‐‐  6.15x10‐6  0.437  0.149  TLL2  Intronic 
11  11  rs2221540  132716369  A  ‐4.492  ‐‐  7.05x10‐6  0.468  0.364  OPCML  Intronic 
12  5  rs10043659  71781839  A  4.483  ++  7.37x10‐6  0.339  0.808  ZNF366  Intronic 
13  12  rs10778078  101195088  A  ‐4.45  ‐‐  8.58x10‐6  0.599  0.456  ANO4  Intronic 
14  9  rs10987199  128968987  A  ‐4.442  ‐‐  8.91x10‐6  0.199  0.026  LOC101929116  63416bp 3' 
15  5  rs10042132  71789021  A  ‐4.416  ‐‐  1.01x10‐5  0.418  0.538  ZNF366  Intronic 
16  11  rs10894606  132671611  A  ‐4.404  ‐‐  1.06x10‐5  0.438  0.587  OPCML  Intronic 
17  12  rs7295089  2440464  A  4.372  ++  1.23x10‐5  0.266  0.212  CACNA1C  Intronic 
18  5  rs9293292  71696942  A  ‐4.351  ‐‐  1.36x10‐5  0.126  0.731  PTCD2/ZNF366  41762bp 3' / 42292bp 3' 
19  15  rs3097437  27872136  A  4.346  ++  1.38x10‐5  0.970  0.226  GABRG3  93762bp 3' 
20  9  rs1999377  11919732  A  4.344  ++  1.40x10‐5  0.436  0.064  ‐  Intragenic 
21  5  rs6862221  71754962  A  4.342  ++  1.41x10‐5  0.543  0.823  ZNF366  Intronic 
22  5  rs9293289  71683885  A  ‐4.323  ‐‐  1.54x10‐5  0.395  0.510  PTCD2/ZNF366  28705bp 3' / 55349bp 3' 
23  11  rs4575282  132719646  A  ‐4.313  ‐‐  1.61x10‐5  0.598  0.514  OPCML  Intronic 
24  9  rs2417008  128970219  A  ‐4.3  ‐‐  1.71x10‐5  0.208  0.026  LOC101929116  62184bp 3' 






2.4.1.3 Polygenic risk scores for stress-sensitivity predict MDD 
liability 
PRS were used to investigate whether common variants affecting stress-
sensitivity predict MDD risk. We generated PRS (PRSSS) for stress-sensitivity 
based on the summary statistics from the GWIS. After 10,000 permutations, 
PRSSS significantly predicted MDD risk in GS:SFHS using weights from the 
larger UKB summary data (Empirical-p = 0.04; p = 5.2 x 10-3; β = 0.078, s.e. 
= 0.028; best-fit p threshold = 0.005; Appendix A: Supplementary Table 6). 
On the liability scale, the MDD variance explained in GS:SFHS by PRSSS 
was modest (R2 = 0.195%). This was less than predicted by PRS weighted 
by the genetic main effects of MDD or neuroticism (PRSD: R2 = 0.368%; 
PRSN: R2 = 0.459%; Table 2.2 and Appendix A: Supplementary Table 6). 
However, this association was not cross-validated in UKB using summary 
data from the smaller GS:SFHS GWIS (Empirical-p = 0.68; p = 0.23; β = 
0.004, s.e. = 0.003; best-fit p threshold = 0.005; PRSSS R2 = 0.013%; 
Appendix A: Supplementary Table 6), likely due to lack of power as a result 
of the small discovery sample size. PRSD (R2 = 0.204%) and PRSN (R2 = 
0.166%) derived from GS:SFHS significantly predicted MDD in UKB (Table 
2.2 and Appendix A: Supplementary Table 6). 
Due to the known genetic correlations between MDD, neuroticism and 
stressful life events288, models jointly fitting the effects of multiple PRS were 
analysed. Multiple regression analyses in GS:SFHS showed that, compared 
to PRSD effects alone, the stress-sensitivity effect derived from the UKB 
GWIS effects significantly explains an additional 0.195% (a predictive 
improvement of 53.1%, p = 5.1 x 10-3; PRSD: β = 0.112, s.e. = 0.029; PRSSS : 
β = 0.078, s.e. = 0.028). The inclusion of PRSSS in the full model, where 
PRSSS was fitted along with both PRSD and PRSN weighted by GWAS 
summary statistics derived from UKB remained significant; explaining an 
additional 0.172% (a predictive improvement of 24.6%, p = 8.5 x 10-3; PRSD: 
β = 0.093, s.e. = 0.029; PRSN: β = 0.107, s.e. = 0.030; PRSSS: β = 0.073, s.e. 
= 0.028). In models fitting PRSD and PRSN, the variances explained were 
non-additive, demonstrating the partial overlap between MDD risk prediction 
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from PRSD and PRSN main additive effects. This is consistent with the known 
genetic correlation between these two traits. An overlap was not seen 
between the variance explained by PRSSS effect and the variance explained 
by PRSD and/or PRSN. Multiple regression analyses fitting PRSD and PRSN 
derived from worldwide consortiums (Figure 2.3) showed that the increased 
sample size from GWAS used to derive PRSD resulted in an increment of 
MDD variance explained in GS:SFHS by PRSD (from 0.368% to 1.378%). 
However, there was no change in the proportion of the variance explained by 
the PRSSS in the full model (PRSSS p = 3.5 x 10-3). These results suggest that 
PRSSS explains a proportion of MDD risk not accounted for by PRSD or PRSN 
at current sample sizes. However, these findings were not cross-validated in 
UKB using PRSSS derived from GS:SFHS GWIS, likely due to lack of power 
as a result of the small discovery sample size (Appendix A: Supplementary 
Figure 6).  
2.4.1.4 Using stress-sensitivity to stratify MDD in GS:SFHS 
MDD cases show significantly higher PRSSS (p = 2 x 10-3) and PRSD (p = 1.8 
x 10-4) than controls. Association between MDD-related traits and stress-
sensitivity risk quintiles was assessed on MDD cases in order to identify a 
subgroup of MDD patients, perhaps defining a characteristic aetiological 
subtype of MDD. However, stratification analysis failed, and no quintile based 
on PRSSS nor its interaction with quintiles based on PRSD showed 
statistically significant effects on any trait analyzed. Individuals with high 
PRSSS were not significantly different from other cases for sex, MDD course, 
age of onset or episode count, nor neuroticism, mood disorder or schizotypal 
personality scores (p > 0.05; Appendix A: Supplementary Table 7). Results 




Weighted effect  Best fit threshold  # SNPs  R2 (%)d R2 (%)e  p  Empirical‐p 
Stress‐sensitivity  0.005  1,626  0.141  0.195  5.2x10‐3  0.0399 
MDDa  0.1  22,771  0.265  0.368  1.3x10‐4  0.0015 
EPQNb  0.4  65,276  0.330  0.459  1.8x10‐5  0.0002 
MDDa + EPQNb  ‐  ‐  0.503  0.699  8.0x10‐7 ‐
joint modelsc  ‐  ‐  0.627  0.871  1.2x10‐7 ‐
PGC2 & GPC predicting on GS:SFHS 
PGC2 MDDa  1  92,248  0.993  1.378  1.4x10‐13  ≤0.0001 
GPC EPQNb  0.01  3,521  0.108  0.149  0.014  0.1038 
PGC2 MDD + GPC EPQNb  ‐  ‐  1.052  1.461  1.7x10‐13 ‐
joint modelsc  ‐  ‐  1.203  1.671  1.6x10‐14 ‐
GS:SFHS predicting on UKB 
Weighted effect  Best fit threshold  # SNPs  R2 (%)a R2 (%)b  p  Empirical‐p 
Stress‐sensitivity  0.005  1,526  0.008  0.013  0.231  0.6841 
MDDa  0.03  7,725  0.130  0.204  1.6x10‐6  ≤0.0001 
EPQNb  0.05  12,296  0.106  0.166  1.6x10‐5  0.0005 
MDDa + EPQNb  ‐  ‐  0.197  0.309  2.8x10‐8 ‐
joint modelsc  ‐  ‐  0.206  0.322  6.6x10‐8 ‐
PGC2 & GPC predicting on UKB 
PGC2 MDDa  0.5  64,113  0.919  1.440  3.4x10‐37  <0.0001 
GPC EPQNb  0.03  8,761  0.066  0.104  6.5x10‐4  0.006 
PGC2 MDDa + GPC EPQNb  ‐  ‐  0.950  1.488  2.9x10‐37 ‐





Figure  2.3  MDD  is  best  predicted  using  multiple  PRS.  MDD  risk  explained  (R2 










The existence of genetic variants affecting an individual’s risk of depression 
in response to stress has been predicted previously103,115,169 and is consistent 
with the departure from a simple additive genetic model seen in twin-studies 
of recurrent depressive disorder82. Through international research efforts 
such as the PGC and UK Biobank, there are ever-increasing sample sizes 
available for understanding the genetics of MDD. These resources are 
beginning, and will continue to, identify genome-wide significant loci149,150,153. 
However, the lack of environmental data and/or their reliability, makes the 
study of genetic individual’s response to their negative effects, and their 
contribution to the onset of MDD and other stress-related disorders, difficult. 
As a way to address this limitation, we generated a proxy for stress-
sensitivity through modelling the interaction between SNP allele and MDD 
status on neuroticism score in a GWIS approach. Thus, we sought to identify 
the genetic underpinnings of individual’s sensitivity to stress response 
(stress-sensitivity) through those variants that contribute to higher 
neuroticism levels only in individuals with a lifetime diagnosis of MDD but not 
in healthy controls.  
We performed a GWIS to identify loci showing differential effects on 
neuroticism scores in individuals with and without MDD (so called stress-
sensitivity proxy). No SNPs reached genome-wide significance, but 14 SNPs 
from 8 loci reached suggestive significance levels (see Appendix A: 
Supplementary Table 4 for prior evidence of associated phenotypes). 
Enrichment analysis showed no evidence for enrichment of specific pathways 
or tissues. The top two loci, PTP4A1-PHF3-EYS and ZNF366 have been 
previously associated with alcohol dependence326-330, alcohol intake (dbGaP: 
phs000342) and glucocorticoid receptor function331-333. The most significant 
SNP in this study, rs319924, is an intronic variant in EYS that is a potential 
eQTL for LGSN320, a gene previously associated with male-specific 
depression334. This is of particular interest given previous studies linking 
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alcohol consumption, stress and the risk of depression335-340. However, 
findings should be interpreted with caution, as these loci did not reach 
genome-wide significance at current sample size. Evidence of an eQTL effect 
was predicted for a lead SNP in LATS2, a positive regulator of histone 
methyltransferase activity341 a process important in anxiety-related 
behaviours342. The prior association of the top two loci in this study with 
alcohol related-phenotypes suggests that genes involved in the sensitivity to 
stress may mediate the effects of stress on alcohol consumption. Some 
PHF3 paralogs have been shown to be linked with depression and modulate 
stress response343,344.  
Gene-based analysis identified a genome-wide significant association 
between ZNF366 and stress-sensitivity. ZNF366 (also known as DC-
SCRIPT) is a corepressor of transcription found in nuclear receptor 
complexes including the glucocorticoid receptor. ZNF366 represses 
glucocorticoid receptor-mediated transcription in monocyte-derived dendritic 
cells331; and may act through histone deacetylases to modulate immune 
response332. There is evidence from a large-scale mRNA display study that 
PHF3, in the region underlying the most significant peak in the single SNP 
analysis, may also interact, directly or indirectly, with the glucocorticoid 
receptor (IntAct database 333) but this has not been confirmed. These results 
reinforce the hypothesis that our proxy for stress-sensitivity truly reflects the 
genetic architecture of sensitivity to respond to stress. 
We estimated a significant lower bound on common SNP-based heritability 
for stress-sensitivity of 5%. Whilst the known genetic overlap between MDD 
and neuroticism was detectable, the lack of genetic correlation with stress-
sensitivity, reinforced by results from multiple regression analyses, indicated 
a lack of significant overlap in the genetics factors underpinning stress-
sensitivity and MDD or neuroticism. This analysis may be limited by our 
sample size, although using the largest available meta-analyses of MDD and 
neuroticism150,321 did not decrease the proportion of liability explained by the 
PRSSS. We note, that as such meta-analyses increase in size it is likely, as 
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with the effects of smoking in schizophrenia345,346, that the indirect genetic 
effects of the environment on the risk of depression will be detected by 
GWAS. However, through studies such as ours, or similar, the mechanism 
for the effect of the risk alleles may be clarified. 
Further, we show that such genetic information in stress-sensitivity could 
significantly improve the proportion of liability to MDD predicted by PRS 
based only on additive genetic effects on MDD identified by large GWAS. 
The summary results from the GWIS were used to derive a PRS reflecting 
the genetic difference in stress-sensitivity. This variable significantly 
predicted liability to MDD in GS:SFHS (p = 5.2 x 10-3, Empirical-p = 0.04 after 
10,000 permutations), although this finding could not be replicated in UKB 
(Empirical-p = 0.68), likely due to lack of power. This is consistent with the 
expectation that the larger the discovery sample (i.e. UKB), the greater the 
accuracy of the weighting and the more predictive the PRS170. Multiple 
regression models in GS:SFHS suggest that inclusion of PRS weighted by 
stress-sensitivity significantly improves MDD prediction over use of either 
MDD and/or neuroticism weighted PRS alone (improvement in full model p = 
8.5 x 10-3). However, we were unable to identify a subgroup of MDD cases 
with higher PRSSS. The polygenic interaction approach used in our study 
may, therefore, improve the interpretation of both positive and negative 
findings from GWAS studies (i.e. pathways and mechanisms involved, lack of 
replication, or negative findings in variants mediating environmental effects). 
Added to paralleling recent developments in GWAS analyses, it may 
maximize our power to detect gene-by-environment effects in this 
heterogeneous disorder. 
Future studies will be required to further investigate the effects of adverse life 
events in individuals with high or low polygenic risk scores for stress-
sensitivity. However, the methodology presented allows addressing the 
genetic response to negative outcomes via proxy in the absence of 
prospective environmental data.  
78 
Here we identify an independent set of risk variants for an individual’s 
response to negative outcomes and show that incorporating information 
across many loci provides clear and replicable evidence for a genetic effect 
of stress-sensitivity on MDD risk; identifying a potential genetic link with 
alcohol intake. These results require further study, but may inform treatment 
of comorbid alcohol dependency and depression. 
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Chapter 3 Enrichment of genetic variation 
conferring MDD risk in 
glucocorticoid-related genesets: 
partitioning risk based on main 
additive contributions to MDD, 
neuroticism and the proxy for 
stress-sensitivity 
3.1 Introduction 
In chapter 2, the strongest signals for the proxy of stress-sensitivity coming 
from genetic variants associated with the glucocorticoid receptor function (e.g. 
ZNF366 and the PTP4A1-PHF3-EYS locus). Thus, within this chapter, I aim to 
investigate the enrichment of genetic contributions to risk of MDD within sets 
of genes related to the glucocorticoid signalling and stress response 
pathways.  
In response to acute periods of psychological stress, a cascade of adaptive 
physiological changes occurs through the hypothalamic-pituitary-adrenal 
(HPA) axis involving the brain, the pituitary gland and the adrenal glands347. 
This is a complex neuroendocrine pathway responsible for the regulation and 
eventually release of glucocorticoid hormones, cortisol in humans, from the 
adrenal cortex to the bloodstream. The relationship between psychological 
stress, HPA axis function and major depressive disorder (MDD) has been 
widely studied but the mechanisms underlying this linkage remain 
unclear72,348,349. In response to stress, glucocorticoid hormones regulate the 
HPA axis activation through negative feedback, acting in multiple target 
tissues including the brain where they effect the structure and plasticity of 
neurons350,351. While the signalling cascade is activated, non-essential 
functions such as controlling metabolism or immune response are inhibited to 
prioritize the most essential ones, such as behavioural arousal and 
cardiovascular activity349,352, partially explaining why chronic stress during 
long times of period is such a problem for health. For example, cortisol 
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reduces histamine and proinflammatory cytokine secretion resulting in anti-
inflammatory effects353. Conversely, resistance to glucocorticoid hormones is 
reflected in hyperactivity of the HPA axis that can activate the immune system 
and inflammatory processes, a characteristic feature of depression354. 
Hyperactivity of the HPA axis and inflammatory process in adult depression 
as response to stress may be part of the same pathophysiological process72. 
Elevated cortisol also cause insulin resistance, which may explain why 
conditions such Type II diabetes and metabolic syndrome present higher 
prevalence in recurrent depression355. Therefore, psychosocial stress could 
induce strong effects on the HPA axis. Stress-induced HPA axis dysfunction 
is associated with depressive symptoms and is frequently found in individuals 
with MDD356-359. Permanent changes in the HPA axis caused by early-life 
stress have been demonstrated360,361 and could be a major trigger for the 
development of depressive disorders in those individuals with genetic 
vulnerability. Such dysregulation of the HPA axis also contributes to craving, 
alcohol dependence, damage in the brain’s reward system, and their 
associated problematic behaviours362. The association seen in chapter 2 
between the top 2 loci detected in the genome-wide interaction study (GWIS) 
of a proxy for stress-sensitivity and alcohol related conditions suggested that 
genes involved in sensitivity to stress may mediate the association between 
stress and alcohol consumption. In line, the interplay between a dysregulation 
of the HPA axis and exposure to stress has been reported to also increase 
the risk of developing alcohol-related disorders362,363. 
Such proxy for stress-sensitivity modeled in chapter 2 was estimated from the 
MDD-dependent increment in neuroticism score seen in individuals with MDD
compared to healthy controls. Although neuroticism is report to be, at
population level, a stable trait strongly determined by genetics, there is
evidence that individuals experience changes in neuroticism throughout their
lives217-220,299.  Such change is attributed to the effects of environmental
factors217-220, however, genetic factors may moderate the association between
stress and such increment in neuroticism.  Increments of neuroticism
sustained over time have been associated with stressful life events220.
Genetic contributions to the MDD-depended change in neuroticism, here so-
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called stress-sensitivity, may differ from the strong genetic contributions to the 
stable component of neuroticism.  
 At the molecular level, glucocorticoids diffuse across cell membranes and 
bind cytoplasmic glucocorticoid receptors, which are then translocated into the 
nucleus. In the nucleus these receptors bind to specific glucocorticoid 
receptor binding sites acting as transcription factors through specific 
glucocorticoid response elements within the promoter regions of 
glucocorticoid-regulated genes, which consist of a short DNA sequence that 
mediates the effect of glucocorticoids on gene expression364,365. Such 
glucocorticoid response elements are found in many genes and can both 
activate or inhibit (i.e. negative glucocorticoid response elements) gene 
expression364-366. The glucocorticoid receptor binding sites have been 
characterized in humans and mouse in previous studies, mainly in blood, 
using protein-binding microarrays that combine Chromatin 
ImmunoPrecipitation with next generation sequencing (i.e. ChipSeq 
techniques), using dexamethasone as an analog of glucocorticoid 
hormones367-369. Polman et al.368 compared the degree of overlap of 
glucocorticoid receptor binding sites in neuronal PC12 cells from rat with 
glucocorticoid receptor binding sites identified in human lung carcinoma 
(A549) in Reddy et al.367, and in mouse adipocytes (3T3-L1) from a third 
study369. The majority of glucocorticoid receptor binding sites identified in 
PC12 cells (87%) appeared unique to neuronal PC12 cells. Only 7% of them 
were shared with A549 cells and 11% with 3T3-L1 cells, with only 4% of 
glucocorticoid receptor binding sites overlapping across all three cell types. 
This low degree of overlap in glucocorticoid binding sites across cell types 
concurred with other ChIP-Seq studies370.  
Sensitivity to long-term effects of psychological stress in the development of 
MDD may be modulated by genetic variability. Genes associated with the 
correct functioning of the HPA axis such as CRHR1, FKBP5 and NR3C2371-374 
have been reported to moderate the effects of stress in depression and 
amygdala function375,376. Arloth et al.377 suggested that genetic differences in 
the activation of gene expression induced by glucocorticoid receptors might 
mediate MDD risk by altering a network of co-expressed stress-sensitive 
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genes that are responsive to glucocorticoids in the brain. The glucocorticoid 
stress response pathway may be crucial for susceptibility to MDD, or 
susceptibility to environmental stress leading to depression. I hypothesize that 
there will be a significant enrichment in SNPs associated with the proxy for 
stress-sensitivity in the glucocorticoid stress response pathway. 
In this chapter, I use gene ontologies to select genes ontologically related with 
the HPA axis to define a geneset representative of “up-stream” glucocorticoid 
signalling.  I used freely available data on glucocorticoid receptor binding 
sites367,368 to define two sets of genes representative of “down-stream” 
glucocorticoid response including genes selected as candidate glucocorticoid-
regulated targets through activation of glucocorticoid response elements (i.e. 
genes of which transcription profile is likely to be modulated by glucocorticoid 
receptors) in two different cell types: human lung epithelial carcinoma367 and 
pheochromoytoma of the rat adrenal medulla368.  
The aim of this chapter is to investigate the contribution of genetic variation to 
risk to MDD from genetic variation in glucocorticoid-related genes. I assess 
whether the genetic contributions to both MDD, neuroticism and sensitivity to 
stress that increase the risk to liability are significantly more clustered in the 
three glucocorticoid-related genesets than expected by random chance. 
Enrichment of common variants conferring risk of MDD in the “down-stream” 
sets of glucocorticoid response genes was present, including an enrichment 
of contributions from stress-sensitivity to MDD when additive main effects of 
MDD and neuroticism are taken into account. The results suggest that 
characterizing genes modulated by glucocorticoid receptors on neuronal cell 
lines may benefit the assessment of the link between glucocorticoid receptor-
mediated gene expression and risk of depression. 
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3.2 Materials and methods 
 
3.2.1 Cohorts’ profiles 
This study uses genotype data from Generation Scotland (GS) and UK 
Biobank (UKB) from unrelated individuals previously described in chapter 2.  
Further details about study ethics, cohort descriptions and phenotype 
assessment are described previously. MDD status and the Eysenck 
Personality Questionnaire-Revised Short Form’s Neuroticism Scale were 
available in both UKB and GS cohorts. Briefly, dataset used from UKB 
contains genome-wide genotyping data available on 109,282 unrelated 
individuals (KING-estimated kinship coefficient < 0.0442) aged 40-79 with 
neuroticism data available, of which 23,092 had MDD data after the quality 
control process. Dataset from GS includes genome-wide genotyping data on 
7,233 unrelated individuals (pi-hat < 0.05) aged 18-92 of which: 7,190 had 
clinical data on MDD; 7,196 individuals had data on neuroticism; and 7,155 
had data on both neuroticism and MDD, after the quality control process. See 
chapter 2 for further details (e.g. genotyping, imputation and quality 
control)378. 
3.2.2 Glucocorticoid-related genesets design 
Three genesets were defined targeting the glucocorticoid stress response 
pathway. The list of genes forming each geneset can be found in Appendix 
B: Supplementary Table 1. All gene are selected using the following criteria: 
known genes, as well as genes of unknown function with identifiers: LOC# (# 
= 6 digits number), KIAA@ (@ = 4 digits) and homo sapiens chromosome “x” 
open reading frame “y” (Cxorfy); long non-coding RNA and long intergenic 
non-coding RNA genes with identifiers AC# and LINC#. All other classes of 
gene elements or identifiers were excluded from the geneset design. All gene 
products were obtained from GENCODE (UCSC Genome Browser: 
http://genome.ucsc.edu) assembly Dec. 2013 (GRCh38/hg38) but gene 
coordinates were remapped to assembly Feb. 2009 (GRCh37/hg19) using the 
Batch Coordinate Conversion (liftOver) tool from UCSC Genome Browser to 
match the GS genotype data. HGNC symbols are used to define the genes, 
with -50 kb upstream and +50 kb downstream used to define the gene 
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boundaries when extracting SNPs from the genotype data (since LD blocks 
are likely to be contained within these intervals) using python scripts of own 
design. The list of genes without SNP data in GS is presented in Appendix B: 
Supplementary Table 2. Human orthologous search and ID conversions were 
carried out using Ensembl379 and BioMart380 when required. To assess each 
geneset design, I investigated gene ontology terms enriched in each geneset 
in comparison to the full list of genes in the human genome (GRCh37/hg19; p-
value threshold = 1 x 10-5) using Gorilla381; gene ontology terms divided in 
biological processes, molecular functions and cellular components. Revigo382 
was used to visualize summary results. In geneset 3, the p-value threshold 
was increased to 1 x 10-4 to see the most enriched ontologies for molecular 
functions. Hypergemoetric test was applied to test whether the degree of 
overlap between gensets was significantly higher than expected by chance. 
3.2.2.1 Geneset 1: genes ontologically related with HPA axis 
Geneset 1 contains genes ontologically-related to the glucocorticoid 
signalling. These were extracted from the web application AmiGO383 from the 
Gene Ontology (GO) website using as key words: glucocorticoid, 
mineralocorticoid, cortisol, CRH (corticotropin-releasing hormone), CRF 
(corticotropin-releasing factor), ACTH (adrenocorticotropic hormone) and 
POMC (proopiomelanocortin). All gene products non-human genes were 
converted to human orthologous genes. There is no SNP data for 8 of those 
genes in GS (Appendix B: Supplementary Table 2). This geneset contains 
348 genes (7 from chromosome X). 
3.2.2.2 Geneset 2: genes overlapping a glucocorticoid receptor binding 
sequence or within 50Kb from an A549 cell line (human lung 
epithelial carcinoma) 
Geneset 2 represents all genes overlapping a genomic binding site of 
glucocorticoid receptor, or the closest gene to that sequence within 50 kb 
(when there is no overlap) from an immortalized A549 cell line derived from 
human lung epithelial carcinoma (from a 58-year-old Caucasian male). The 
genomic binding sites for glucocorticoid receptor were previously defined by 
Reddy et al.367 using Chromatin ImmunoPrecipitation combined with next 
generation sequencing (ChIP-Seq) followed by next-generation DNA 
sequencing to measure glucocorticoid receptor binding in response to 100nM 
85 
of dexamethasone, a synthetic glucocorticoid used primarily in the treatment 
of inflammatory disorders. Data manipulation and gene extraction was carried 
out using BEDtools384 and Galaxy server (http://galaxyproject.org/). This 
geneset contains 5,936 genes (163 from chromosome X). 
3.2.2.3  Geneset 3: genes overlapping a glucocorticoid receptor binding 
sequence or within 50Kb from a PC12 cell line 
(pheochromoytoma of the rat adrenal medulla).  
Geneset 3 contains human orthologous genes overlapping a genomic binding 
site of glucocorticoid receptor, or the closest gene in a range of 50 kb when 
there is no-overlap, from a PC12 cell line (cultured and differentiated into a 
neuronal phenotype for ten days) derived from a pheochromocytoma of the 
rat adrenal medulla using ChIP-seq. Human orthologous genes were obtained 
from the list of rat genes that met these requirements from a previous study 
by Polman et al.368. Approximately one third (31%) of all significant genomic 
binding sites were located within a gene. Human orthologous search from rat 
genes and ID conversions were carried out using Ensembl and BioMart. This 
geneset contains 633 genes (13 from chromosome X). 
3.2.3 Polygenic profiling 
Polygenic risk scores (PRS) were produced using PRSice313 and 
standardized to mean of 0 and standard deviation of 1. PRS were weighted 
using GWAS and GWIS summary statistics for MDD, neuroticism, and stress-
sensitivity conducted in UKB and GS and previously used to assess MDD risk 
at genome-wide level (discovery sample size: UKB GWAS of MDD = 23,092; 
UKB GWAS of neuroticism = 109,282; UKB GWIS of stress-sensitivity = 
23,092; GS GWAS of MDD = 7,190; GS GWAS of neuroticism = 7,196; and 
GS GWIS of stress-sensitivity = 7,155). Further details about GWAS and 
GWIS were reported in chapter 2. First, we clumped all SNPs present in both 
the discovery and target samples (GS and UKB) to obtain a set of 
independent SNPs in approximate linkage equilibrium (r2 < 0.1, within a 
250kb window). From the clumped SNPs, which are used at the genome-wide 
level prediction, a subset was selected (see “Glucocorticoid-related genesets 
design” above) for each of the glucocorticoid-related genesets. Thus, each 
geneset only contains as predictors independent SNPs from the genome-wide 
prediction, making each geneset prediction proportional to its contribution to 
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the genome-wide set, if the genome-wide MDD risk was polygenic and 
randomly distributed along the genome. The number of SNPs selected for 
each dataset and its contribution to the genome-wide set are shown in Table 
3.1. Finally, three sets of PRS were generated for each dataset in each cohort 
(GS and UKB) using the summary results generated in the previous chapter 
2: the genetic effects of MDD derived from GWAS of MDD (PRSMDD), the 
genetic effects of neuroticism derived from GWAS of neuroticism (PRSN), and 
the genetic effects of stress-sensitivity derived from GWIS (PRSSS). 
Table 3.1 Density of independent SNPs in each data set 
Set  Genome‐wide  Geneset 1  Geneset 2  Geneset 3 
Target sample  UK Biobank 
Number of SNP  98,556  2,266  39,032  5,640 
Genome‐wide representation  100 (%)  2.30 (%)  39.60 (%)  5.72 (%) 
Target sample  Generation Scotland 
Number of SNP  97,678  2,245  38,623  5,596 
Genome‐wide representation  100 (%)  2.30 (%)  39.54 (%)  5.73 (%) 
All  SNPs  are  independent  in  approximate  linkage  equilibrium  (r2  <  0.1,  within  a  250kb 
window). Genome‐wide  representation  is  the  ratio  between  the number of  SNPs  in  a  set 
and the total number of genome‐wide SNPs.  
3.2.4 PRS prediction of MDD risk 
Using UKB (the largest cohort) summary statistics as the discovery sample to 
weight PRS and logistic regression models, we estimated the variance of 
MDD risk explained by both PRSD (model 1), PRSN (model 2) and PRSSS 
(model 3) independently in GS at genome-wide level. Then, models fitting 
additively both PRSD and PRSN (model 4), and all three PRS together (model 
5) were tested. A null model was also estimated from the direct effects of all
covariates on MDD (null model). All models were adjusted by sex, age and 20
PCs.
model 1:  𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
model 2: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
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model 3: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
model 4: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
model 5: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
null model: 𝑀𝐷𝐷 ~ 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
 All predictions and models were repeated and implemented partitioning by 
genesets. Likelihood ratio tests were used to assess: (i) the significance of 
each PRS (models 1, 2 and 3 against null model), (ii) the significance of the 
full risk model (model 5 against null model) and (iii) the significance of PRSSS 
effect on the residual variance of MDD after considering the effects of PRSD 
and PRSSN (model 5 against model 4). Nagelkerke’s R2 coefficients were 
estimated to quantify the proportion of MDD liability explained at the observed 
scale. Generalized linear models were implemented in R 3.1.3322. Cross-
validation was conducted in UKB (target sample) using GS as the discovery 
sample. In UK Biobank, MDD was adjusted for centre, array and batch as 
random effects and the residuals scaled and used for prediction. This resulted 
in a quasi-binomial distribution of MDD status in UKB. Thus, quasi-binomial 
regressions were implemented. PRS predictive models were adjusted for age, 
sex and 15 principal components (PCs; UKB Data Dictionary items #22009.01 
to #22009.15).  
3.2.5 Enrichment of MDD risk 
The expected amount of MDD risk variance that is explained by each geneset 
was estimated as that expected if genome-wide MDD risk is polygenic and 
homogeneously distributed along the genome using the genome-wide 
estimations of MDD risk reported in chapter 2. The ratio between the 
observed MDD risk explained by each genetic contribution and that expected 
was used as indicator of enrichment in each geneset. To assess significance 
of MDD risk enrichment on each geneset, we derived a null predictive 
distribution by permuting 1,000 times MDD phenotype from models 1, 2 and 
3. From each permutation and for each set of PRS, PRS at the best p-
threshold predicting the permuted phenotype were selected and combined
into models 4 and 5 respectively to predict real MDD status. P-values from
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likelihood ratio test applied at each permutation testing models 1, 2 and 3 
against null model, (ii) model 5 against null model, and (iii) model 5 against 
model 4 were used to create an empirical cumulative distribution function to 
adjust the observed p-values. The significance threshold of empirical p-values 
was fixed at α = 0.05. 
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3.3 Results 
3.3.1 Genesets overlap 
Top enriched gene ontology terms in predefined genesets compared to the 
full list of genes in the human genome are shown in Tables 3.2, 3.3 and 3.4. 
Visualization of summary results is shown in Appendix B: Supplementary 1-
9. 
The degree of overlap of genes across genesets was low (Figure 3.1), but 
significantly higher than expected by chance in comparison with a genomic 
background of 26,292 genes (Human Genome version 19; overlap genesets 
1-2: p-value = 6.13 x 10-17, geneset 1-3: p-value = 8.59 x 10-4, genesets 2-3:
p-value = 2.36 x 10-51). 49% of genes from geneset 3 (from
pheochromoytoma of the rat adrenal medulla) were shared with geneset 2
(from human lung epithelial carcinoma'), and 2.84% with geneset 1 (genes
ontologically related with HPA axis). 57% of genes in geneset 1 were unique
to geneset 1, 92% of genes in geneset 2 were unique to geneset 2, and 50%
of genes in geneset 3 were unique to geneset 3.
Table 3.2 The functional analysis of genes from geneset 1  
Top 5 gene ontology terms. 
Category  GO ID  Name  Count   p‐value  FDR q‐value 
BP  GO:0051384  response to glucocorticoid  136  5.93x10‐240  8.07x10‐236 
BP  GO:0031960  response to corticosteroid  139  1.11x10‐239  7.59x10‐236 
BP  GO:0048545  response to steroid hormone  151  2.28x10‐176  1.04x10‐172 
BP  GO:0009725  response to hormone  176  2.73x10‐165  9.28x10‐162 
BP  GO:0033993  response to lipid  165  1.03x10‐144  2.79x10‐141 
MF  GO:0005102  receptor binding  114  6.44x10‐45  2.73x10‐41 
MF  GO:0001664  G‐protein coupled receptor binding  36  1.62x10‐22  3.42x10‐19 
MF  GO:0051427  hormone receptor binding  30  4.02x10‐21  5.68x10‐18 
MF  GO:0005126  cytokine receptor binding  31  1.52x10‐16  1.61x10‐13 
MF  GO:0035259  glucocorticoid receptor binding  9  2.29x10‐16  1.94x10‐13 
CC  GO:0005615  extracellular space  93  4.84x10‐34  7.82x10‐31 
CC  GO:0044421  extracellular region part  150  2.91x10‐24  2.35x10‐21 
CC  GO:0005576  extracellular region  79  7.33x10‐20  3.95x10‐17 
CC  GO:0044444  cytoplasmic part  213  8.91x10‐16  3.60x10‐13 






Category  GO ID  Name  Count  p‐value  FDR q‐value 
BP  GO:0044763  single‐organism cellular process  2791  5.30x10‐39  7.22x10‐35 
BP  GO:0048518  positive regulation of biological process  1670  1.61x10‐36  1.09x10‐32 
BP  GO:0044699  single‐organism process  3236  3.99x10‐35  1.81x10‐31 
BP  GO:0010646  regulation of cell communication  1007  9.30x10‐32  3.16x10‐28 
BP  GO:0023051  regulation of signalling  963  2.21x10‐31  6.01x10‐28 
MF  GO:0019899  enzyme binding  570  4.52x10‐20  1.92x10‐16 
MF  GO:0008092  cytoskeletal protein binding  312  3.72x10‐18  7.88x10‐15 
MF  GO:0005515  protein binding  2902  7.01x10‐18  9.92x10‐15 
MF  GO:0003779  actin binding  165  1.54x10‐13  1.64x10‐10 
MF  GO:0043168  anion binding  816  2.09x10‐13  1.78x10‐10 
CC  GO:0044444  cytoplasmic part  2221  2.17x10‐20  3.50x10‐17 
CC  GO:0005737  cytoplasm  1452  8.21x10‐18  6.63x10‐15 
CC  GO:0030054  cell junction  406  3.77x10‐17  2.03x10‐14 
CC  GO:0070161  anchoring junction  205  6.18x10‐17  2.50x10‐14 





Category  GO ID  Name  Count   p‐value  FDR q‐value 
BP  GO:0048522  positive regulation of cellular process  215  1.61x10‐10  2.19x10‐6 
BP  GO:0044699  single‐organism process  437  1.47x10‐9  9.98x10‐6 
BP  GO:0048518  positive regulation of biological process  236  2.14x10‐9  9.69x10‐6 
BP  GO:0044763  single‐organism cellular process  375  1.06x10‐8  3.62x10‐5 
BP  GO:0032502  developmental process  212  1.84x10‐8  5.01x10‐5 
MF  GO:0004672  protein kinase activity  39  2.07x10‐5  8.77x10‐2 








CC  GO:0030054  cell junction  70  8.81x10‐8  1.44x10‐4 
CC  GO:0044456  synapse part  42  1.52x10‐7  1.24x10‐4 
CC  GO:0097458  neuron part  67  4.42x10‐6  2.40x10‐3 
CC  GO:0044444  cytoplasmic part  302  8.63x10‐6  3.52x10‐3 
CC  GO:0097060  synaptic membrane  23  9.06x10‐6  2.95x10‐3 
BP biological process, MF molecular function, CC cellular component, Count is the number of genes from the 
geneset. 
Overlapping genes with geneset 1 are highlighted in Appendix B: 
Supplementary Table 1. Just 16 genes (ARNTL, ASS1, C1QTNF1, CDKN1A, 
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CRY2, DKK3, DUSP1, GAL, IL6R, KLF9, NEFL, PER1, PIK3R1, SFTPB, 
SLIT3, STAT5B) were shared within all three glucocorticoid-related genesets 
(Figure 3.1). Gene ontology terms enriched in this set of overlapping genes 
were sought. Enriched biological processes are shown in Table 3.5 and 
Appendix B: Supplementary Figure 10. There was no gene ontology term 
enriched in molecular functions or cellular component categories (p-threshold 
= 1 x 10-5). The top biological process was that of rhythmic process that 
contained seven genes including PER1 (Period Circadian Regulator 1), the 
primary circadian pacemaker in the mammalian brain. Genes in the PER 
family encode components of the circadian rhythms of locomotor activity, 
metabolism, and behaviour. PER1 is upregulated by CLOCK/ARNTL 
heterodimers but then represses this upregulation in a feedback loop using 
PER/CRY heterodimers to interact with CLOCK/ARNTL385. Notably, ARNTL 
and CRY2, also fall within this set of overlapping genes. 
Figure  3.1  Venn  diagram.  Representation  of  overlapping  genes  between 
glucocorticoid‐related genesets. 
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Table  3.5  The  functional  analysis  of  16  genes  overlapping  all  three  genesets  (biological 
processes) 
GO ID  Name  p‐value  FDR q‐value  Genes 
GO:0048511  rhythmic process  5.13x10‐10  8.00x10‐6 
ARNTL, SLIT3, CRY2, ASS1, STAT5B, 
PER1 and KLF9. 
GO:0009725  response to hormone  5.46x10‐10  4.25x10‐6 
GAL, DUSP1, SLIT3, NEFL, CDKN1A, 
ASS1, STAT5B, KLF9 and PIK3R1 
GO:0051384  response to glucocorticoid  1.10x10‐9  5.72x10‐6 
DUSP1, SLIT3, NEFL, CDKN1A, ASS1 and 
KLF9 
GO:0031960  response to corticosteroid  2.16x10‐9  8.41x10‐6 
DUSP1, SLIT3, NEFL, CDKN1A, ASS1 and 
KLF9 

































GO:0007623  circadian rhythm  6.29x10‐8  8.17x10‐5  ARNTL, CRY2, ASS1, PER1 and KLF9 





















GO:0033993  response to lipid  9.77x10‐7  8.96x10‐5 
DUSP1, SLIT3, NEFL, CDKN1A, ASS1, 
STAT5B and KLF9 
GO:0042493  response to drug  1.03x10‐6  8.93x10‐5 
GAL, DUSP1, SLIT3, NEFL, CDKN1A, ASS1 
and KLF9 














GO:1901698  response to nitrogen compound  2.63x10‐6  1.87x10‐5 
GAL, DUSP1, NEFL, CDKN1A, ASS1, PER1 
and PIK3R1 





















3.3.2 PRS prediction of MDD risk 
The amount of variance in MDD explained by each effect in comparison to 
genome-wide prediction in regard to sample size across genesets (i.e. 
subsamples of genome-wide dataset with different number of SNPs) is shown 
in Figure 3.2. The pattern shows a higher risk of MDD explained within 
genesets than that expected in regard to their sample size (i.e. the number of 
SNPs). Particularly, for stress-sensitivity in geneset 3, the set of genes 
overlapping a glucocorticoid receptor binding sequence derived from a 
neuronal cell line. Given the number of SNPs that each geneset represent 
from the entire genome-wide dataset (Table 3.1) and the variance explained 
by this genome-wide dataset (reported in chapter 2), we estimated the 
variance expected to be explained by each dataset if such risk of MDD was 
homogeneously distributed along the genome. The enrichment of risk of MDD 
within each glucocorticoid-related geneset was estimated as the ratio between 
the risk observed and the risk expected (see Table 3.6 and Table 3.7). 
Therefore, if the risk was not clustered in specific loci we would expect an 
enrichment of x1. No significant enrichment was found in any geneset using 
the stress-sensitivity PRS (PRSSS) alone. (GS G1: x9.52, Empirical-p = 0.797; 
GS G2: x1.42, Empirical-p = 0.265; GS G3: x6.00, Empirical-p = 0.575; UKB 
G1: x15.64, Empirical-p = 0.880; UKB G2: x1.20, Empirical-p = 0.796; UKB 
G3: x18.41, Empirical-p = 0.274; Table 3.6 and Table 3.7). The genetic 
contribution of PRSD weighted by additive main effects of MDD or PRSN
weighted by additive main effects of neuroticism on MDD risk was only 
significant in geneset 2 (the largest set; ~40% of the genome-wide data), 
predicting on UKB (GS as discovery sample; PRSD: x1.44, Empirical-p = 
0.004; PRSN: x2.02, Empirical-p = 0.002).  
Enrichment of the full MDD risk conferred by the combined contributions of 
risk conferred by PRSMDD, PRSN and PRSSS effects together was significant in 
both cohorts only on “down-stream” cortisol release sets (genesets 2 and 3), 
but not in the “up-stream” geneset (geneset 1), suggesting that MDD risk is 
found and enriched in glucocorticoid response genes but not in glucocorticoid 
signalling genes (see Table 3.7).  
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Enrichment of MDD risk explained by PRSSS, above that already explained by 
PRSD and PRSN combined together (model 5 vs. model 4) was significant on 
“down-stream” glucocorticoid response genes from genesets 2 and 3 in one 
cohort but not on the other. Enrichment was significant for geneset 2 in GS 
(x1.4, Empirical-p = 0.027) but this did not cross-validate in UKB (x1.26, 
Empirical-p = 0.147). Conversely, geneset 3 was significantly enriched in UKB 
(x19.6, Empirical-p = 0.034) but it did not cross-validate in GS (x6.18, 
Empirical-p = 0.056). As with the combined MDD risk conferred by all PRS 
effects together, these findings suggest that stress-sensitivity effect is 
enriched in glucocorticoid response genes, particularly in those found in 
neuronal cells (geneset 3). Such enrichment is detected from the remaining 
variance after taking into account the additive main contributions of MDD and 
neuroticism (see Table 3.7). The empirical cumulative distributions derived to 















Genetic effect  MDD  Neuroticism  Stress‐sensitivity 
Geneset  G 1  G 2  G 3  G 1  G 2  G 3  G 1  G 2  G 3 
Enrichment  x4.49  x1.00  x3.57  x4.20  x1.31  x3.35  x9.52  x1.42  x6.01 
Observed p‐value  0.206  0.013  0.075  0.251  7.91x10‐3  0.106  0.144  0.019  0.067 
Empirical p‐value  0.914  0.209  0.797  0.905  0.119  0.554  0.797  0.265  0.575 
Target sample  UK Biobank 
Genetic effect  MDD  Neuroticism  Stress‐sensitivity 
Geneset  G 1  G 2  G 3  G 1  G 2  G 3  G 1  G 2  G 3 
Enrichment  x6.64  x1.44  x1.90  x2.93  x2.02  x5.10  x15.64  x1.20  x18.41 
Observed p‐value  0.057  2.35x10‐4  0.109  0.245  6.02x10‐5  0.015  0.219  0.157  0.035 









Geneset  G 1  G 2  G 3  G 1  G 2  G 3 
Enrichment  x5.03  x1.11  x4.65  x8.33  x1.40  x6.18 
Observed p‐value  0.230  9.34x10‐4  0.019  0.171  0.020  0.062 
Empirical p‐value  0.247  0.001  0.016  0.189  0.027  0.056 
Target sample  UK Biobank 
Genetic effect  MDD, neuroticism and stress‐sensitivity together  Stress‐sensitivity (on top of MDD and neuroticism) 
Geneset  G 1  G 2  G 3  G 1  G 2  G 3 
Enrichment  x6.79  x1.66  x5.39  x16.32  x1.26  x19.60 
Observed p‐value  0.098  7.44x10‐6  5.99x10‐3  0.217  0.155  0.033 















Biobank.  Results  from  geneset  1  are  shown  in  first  column,  geneset  2  in  second 




to  compare model  5  (which  includes all  PRS  fitted  together)  against  a null model. 
And the 5th  row shows the empirical cumulative distribution of p‐values derived to 
compare model  5  (which  includes  all  PRS  fitted  together)  against model  4  (which 
includes the main effects of MDD and neuroticism) to assess the significance of PRSSS 
weighted by stress‐sensitivity effect. All models were permuted 1,000 times. X‐axis 
shows  the  p‐value  estimated  by  a  likelihood  ratio  test.  A  vertical  dark  blue  line 





In this chapter, I assessed whether genetic contributions to risk of MDD are 
enriched within set of genes related to the HPA axis and the glucocorticoid 
signalling and response pathway. Overall, results indicate that genetic 
contributions to risk of MDD, rather than being homogeneously distributed 
along the genome, are enriched within “down-stream” glucocorticoid 
response genes, but not within “up-stream” glucocorticoid signalling genes. 
Noteworthy, the genetic contribution to the stress-sensitivity trait derived in 
chapter 2 was enriched in sets of glucocorticoid response genes when the 
additive main contributions to MDD and neuroticism were taken into account. 
Three different glucocorticoid-related genesets were defined from HPA-
related gene ontology terms (geneset 1) and glucocorticoid response 
expression studies on: human non-neuronal cell line (geneset 2)367 and rat 
neuronal cell line (geneset 3)368. As expected, geneset 1 was enriched in 
genes responding to glucocorticoid pathways, mostly, with receptor binding 
functions in either extracellular or cytoplasmic parts, including neuron part. 
Genes overlapping glucocorticoid receptor binding sites in the neuronal cell 
line were enriched in biological process such as regulation of phosphate 
metabolism, single-organism process, developmental process, cellular 
process, cellular component movement and response to chemical; molecular 
functions such as protein kinase activity, voltage-gated cation channel 
activity, enzyme binding and anion binding; and in cell components such as 
synapse part, neuron part, cytoplasmic part and cell junction; showing the 
relation with the neuronal context where these genes come from. Notably, 
previous pathway analyses have also associated, among others, neuron and 
synapse parts, cell junctions or voltage-gated cation channels with 
depression150,151,160. Some ontologies such as positive regulation of biological 
process, anion binding function, cytoplasmic part and cell junction were 
similarly enriched in genes overlapping glucocorticoid receptor binding sites 
in both neuronal and non-neuronal cells, the latest with most enriched 
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biological process related to regulation of intracellular signal transduction. 
There was poor overlap between genes from each designed glucocorticoid-
related geneset. This supports glucocorticoid receptor occupancy and, 
therefore, glucocorticoid receptor regulation being highly cell type specific, as 
it was already suggested by Polman et al.368. Gene-expression profiles 
induced by glucocorticoid receptors are cell-type specific, so genomic binding 
sites binding glucocorticoid receptors may differ from a cell-line to another. 
However, some degree of overlap was expected given the negative feedback 
loop between glucocorticoids and the HPA axis. At certain levels of cortisol 
released in response to stressful stimulus, cortisol exerts a negative 
feedback through glucocorticoid receptor signalling inhibiting the release of 
CRF in the hypothalamus and ACTH in the pituitary362. This regulatory 
mechanism restores hormone levels to normality when stress has ceased 
and maintains secretion within physiological levels, thus, protecting against 
the prolonged effects of stress. Noteworthy, the top biological process 
detected in the functional analysis of genes overlapping all glucocorticoid-
related genesets was ”rhythmic process” with 7 of the 16 overlapping genes 
included. 5 of them (ARNTL, CRY2, ASS1, PER1 and KLF9) were related to 
“circadian rhythm”. Stress has great influence in the circadian system386, 
whose disruption shows robust effects on mood instability, adverse wellbeing 
outcomes and reduced cognitive function, including an increased risk of 
MDD387. Therefore, the circadian clock may mediate the association between 
stress and stress-related conditions. 
We saw that the MDD risk predicted by glucocorticoid-related genesets 
deviated from that expected given the number of SNPs they included (Figure 
3.2). The small difference between the stress-sensitivity effect alone and 
when combined with main additive effects of MDD and neuroticism suggests 
that genetic contributions to stress-sensitivity within glucocorticoid-related 
genes is independent of main contributions to MDD and neuroticism. The 
most substantial deviation and the greatest enrichment of stress-sensitivity 
effect (table 3.6 and table 3.7) were found within geneset 3, which includes 
human orthologous genes overlapping or within 50 kb from a genomic 
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binding site derived by ChipSeq from a neuronal cell line from rat (i.e. PC12 
cells). This geneset, that only included 5.7% of the genome-wide SNPs, 
showed a significant prediction of risk of MDD more than 19 times higher 
than expected in UKB. This enrichment also approached significance in GS 
(x6.18, Empirical-p = 0.056). Although this neuronal cell line come from rat 
and not human, finding highlights the need of targeting approaches like this 
in neuronal cell types. Given the effects of glucocorticoids on neuronal 
plasticity and brain functioning350,351, the use of data on genomic binding 
sites binding glucocorticoid receptor, and on its glucocorticoid response 
elements, characterized from neuronal tissues coming from human should be 
an essential key point to study genetic stress responses determining 
glucocorticoid signalling underlying the risk of depression. However, Chip-
seq data on glucocorticoid binding sites from human neuronal-lines was not 
available. 
The results suggest that genes within “down-stream” glucocorticoid response 
genesets explain more variation in MDD risk than expected. The gene-based 
test analysis from chapter 2 identified ZNF366, which may, directly or 
indirectly, effect glucocorticoid receptor-regulated gene expression, 
suggesting that the genetic component identified affecting sensitivity to 
environmental stress (so-called stress-sensitivity) may act, although likely not 
exclusively, through glucocorticoid receptor-related pathways and 
extensively, the HPA axis and cortisol signalling. However, the results 
presented in this chapter suggest that such stress-sensitivity effect is found in 
“down-stream” glucocorticoid-response genes but not in “up-stream” 
signalling genes involved in the HPA axis. Several polymorphisms from 
genes associated to the HPA axis such as CRH1, FKBP5, NR3C1 and 
NR3C2 have been investigated as potential modulators of the effect of stress 
on depression372-375,388,389. The interaction of early life stress and PRS 
constructed using the aggregated number of high-risk alleles from some of 
these polymorphisms have been report to predict cortisol levels, hippocampal 
volumes and amygdala function376,390, and to increase depressive symptoms 
in offspring of depressed mothers, with the greatest effect in those 
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experiencing the highest levels of stress375. Thus, suggesting that genetic 
variants from genes related to the HPA axis may moderate the association 
between stress reactivity and depression. CRH1 and NR3C2 were included 
in genes ontologically-related to the HPA axis in geneset 1, and FKBP5 
overlapped with glucocorticoid receptor binding sites in the human non-
neuronal cell line and thus, included in geneset 2. NR3C1, as well as BDNF, 
another candidate gene widely investigated in previous GxE studies391-393, 
were also included in geneset 1 and geneset 2.  However, none of these 
genes overlapped glucocorticoid receptor binding sites tested in a rat 
neuronal cell line (i.e. not included in geneset 3). Findings suggest to target 
glucocorticoid response genes rather than genes involved in the HPA axis as 
candidate genes for GxE studies. An enrichment of stress-sensitivity effect 
(i.e. genetic contributions to the MDD-depended change in neuroticism) 
contributing to risk of MDD was seen in the “down-stream” sets of 
glucocorticoid response genes from the residual variance after taking into 
account the additive main effects of both MDD and neuroticism (the genetic 
contributions to the stable component of neuroticism), supporting gene-
environment interaction effects in the glucocorticoid response pathway. Such 
enrichment of MDD risk and stress-sensitivity effect in glucocorticoid 
response genes may help to explain why more than 70% of patients with 
active Cushing’s syndrome, which is caused by excessive endogenous levels 
of circulating free cortisol, report co-morbid disorders ranging from anxiety to 
psychosis (stress-related conditions), with MDD being the most common394; 
or patients with Adison’s disease, which is characterized by low cortisol 
levels, report depression as a significant co-morbidity395. 
In a previous study, Arloth et al. suggested that the risk of developing MDD 
after adverse life events may be influenced by an individual’s sensitivity to 
the transcriptional effects of cortisol released during the stressful adverse 
events377. Using a stimulated eQTL approach, they highlighted that one 
putative biological mechanism underlying the interaction of both genetic and 
environmental risk factors conferring risk of depression may implicates 
variability in the glucocorticoid regulation induced by cortisol in response of 
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stress. My results support such findings from Arloth et al. and suggest that, at 
least in a subset of patients, such individual’s sensitivity to stress could 
depend on a specific genetic architecture distinct from the additive main 
contributions to an individual’s risk detected in GWAS of either MDD or 
neuroticism.  
There are few caveats to consider in the analysis presented in this chapter. 
First, many different approaches to define glucocorticoid-related genesets 
could be applied, providing sets of different sizes and thus being more or less 
representative of the entire genome. For example, more “up-stream” 
glucocorticoid signalling set of genes that may reflect better HPA axis activity 
than those genes ontologically related to the HPA axis could be defined using 
genes expected to explain cortisol secretion396 or genes previously linked to 
the regulation of the HPA axis activity identified in other studies397. In 
addition, although many glucocorticoid receptor likely bind glucocorticoid 
response elements within promoter or enhancer regions of a gene and thus 
stimulating its transcription, other genes modulated by glucocorticoid receptor 
may be far from such genomic binding sites. Therefore, taking the 
overlapping or closest gene to each genomic binding site may not provide the 
best candidate gene to be included in all regions. Furthermore, using 
genotype data on hundreds of thousands of SNPs, rather than imputed or 
whole-genome sequencing data on millions of SNPs, followed by a round of 
clumping to select independent SNPs in linkage equilibrium resulted in a very 
low number of SNPs representative of each gene. Some loci with a 
glucocorticoid receptor binding site may even lack of SNP representation, as 
seen in few genes without SNP data in GS, resulting in a loss of information. 
For example, there was a lack of SNPs covering MAOA (Appendix B: 
Supplementary Table 2), a gene overlapped with glucocorticoid receptor 
binding sites in the human cell line and a candidate to interact with stress in 
previous GxE studies398,399. A less stringent clumping step would reduce the 
loss of informative data in detrimental of linkage equilibrium across SNPs. 
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In summary, we detected more genetic variation in risk of MDD within sets of 
glucocorticoid response genes than expected, and particularly in MDD risk 
conferred by the MDD-dependent stress-sensitivity effect derived in chapter 
2, independently of main additive contributions of MDD. The results 
presented suggest that the association between environmental stress and 
MDD may be mediated by an individual’s sensitivity to the transcriptional 
effects of glucocorticoid receptors following cortisol release during stressful 
events, as suggested by Arloth et al.377. A deeper understanding on the 
relationship between psychological stress and MDD through adaptive 
changes in stress response would facilitate the discovery of novel pathways 
and thus identify new targets for drug discovery. 
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Chapter 4 A validation of the diathesis-stress 
model for depression in Generation 
Scotland 
The cornerstone of the preceding chapters was a proxy for sensitivity to 
stress derived without the requirement of direct measures of SLE. In contrast, 
in order to study GxE effects underlying liability to major depressive disorder, 
in the following chapters, I incorporate variables to measure the number of 
SLE occurring during a specific time period prior to assessment of depressive 
symptoms. In this chapter and the following ones, I use quantitative scores to 
assess depression, rather than MDD diagnosis. 
As detailed in the Background chapter 1 (section 1.6.4.3), Colodro-Conde et 
al. reported a significant PRSxSLE effect on liability to depression under a 
diathesis-stress model. In this chapter, I validate this result by testing the 
diathesis-stress model for depression in a subsample of Generation Scotland 
that took part in a longitudinal follow-up study including assessment of SLE. 
To properly replicate Colodro-Conde et al. study, the same instruments to 
assess GxE effects should be applied, but such instruments are not available 
in Generation Scotland. However, I apply the same methodology and 
diathesis-stress framework as the original study, adapting my study to the 
available instruments that attempt to capture the same underlying context.  
Measures of recent SLE were collected through a brief life events 
questionnaire based on the List of Threatening Experiences (the 
questionnaire can be seen in Appendix D.5). The data reported was used to 
construct variables of SLE from the 6 months preceding a self-reported 
questionnaire of depressive symptoms. This data was collected using the 
General Health Questionnaire (GHQ), a reliable and validated psychometric 
screening tool developed by Goldberg and Hillier in 1972, which takes less 
than 5 minutes to complete, and consists of four subscales (somatic 
symptoms, anxiety and insomnia, social dysfunction, and severe depression) 
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designed to detect common psychiatric disorders, or current mental distress, 
on adults and adolescents (but not children) by non-psychiatric clinical 
professionals (e.g. researchers). The General Health Questionnaire is 
copyrighted, therefore, I cannot show the questions involved. The use of the 
questionnaire is licensed by GL Assessment (https://www.gl-
assessment.co.uk/products/general-health-questionnaire-ghq/). A license 
agreement must be completed beforehand and a user fee is required to all 
users (commercial and academic users). 
This chapter has been published in Translational Psychiatry and is presented 
as submitted, which explains the use of “we” within the chapter. I confirm that 
the work of this chapter is my own work under guidance from my supervisor 
Dr. Pippa Thomson. I performed all the analyses myself. The published 
article and Supplementary Material can be found in Appendix C. 
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Depression has well-established influences from genetic and environmental 
risk factors.  This has led to the diathesis-stress theory, which assumes a 
multiplicative gene-by-environment interaction (GxE) effect on risk. Recently, 
Colodro-Conde et al. empirically tested this theory, using the polygenic risk 
score for major depressive disorder (PRS, genes) and stressful life events 
(SLE, environment) effects on depressive symptoms, identifying significant 
GxE effects with an additive contribution to liability. 
We have tested the diathesis-stress theory on an independent sample of 
4,919 individuals.  
We identified nominally significant positive GxE effects in the full cohort (R2 = 
0.08%, p = 0.049) and in women (R2 = 0.19%, p = 0.017), but not in men (R2 
= 0.15%, p = 0.07). GxE effects were nominally significant, but only in 
women, when SLE were split into those in which the respondent plays an 
active or passive role (R2 = 0.15%, p = 0.038; R2 = 0.16%, p = 0.033, 
respectively). High PRS increased the risk of depression in participants 
reporting high numbers of SLE (p = 2.86 x 10-4). However, in those 
participants who reported no recent SLE, a higher PRS appeared to increase 
the risk of depressive symptoms in men (β = 0.082, p = 0.016) but had a 
protective effect in women (β = -0.061, p = 0.037). This difference was 
nominally significant (p = 0.017). 
Our study reinforces the evidence of additional risk in the aetiology of 
depression due to GxE effects. However, larger sample sizes are required to 




Stressful life events (SLE) have been consistently recognized as a 
determinant of depressive symptoms, with many studies reporting significant 
associations between SLE and major depressive disorder (MDD)84,90,93-
95,400,401. Some studies suggest that severe adversity is present before the 
onset of illness in over 50% of individuals with depression402 and may 
characterize a subtype of cases403. However, some individuals facing severe 
stress never present symptoms of depression404. This has led to a 
suggestion that the interaction between stress and an individual’s 
vulnerability, or diathesis, is a key element in the development of depressive 
symptoms. Such vulnerability can be conceived as a set of biological factors 
that predispose to illness. Several diathesis-stress models have been 
successfully applied across many psychopathologies225,405-408.  
The diathesis-stress model proposes that a latent diathesis may be activated 
by stress before psychopathological symptoms manifest. Some levels of 
diathesis to illness are present in everybody, with a threshold over which 
symptoms will appear. Exceeding such a threshold depends on the 
interaction between diathesis and the degree of adversity faced in SLE, 
which increases the liability to depression beyond the combined additive 
effects of the diathesis and stress alone225. Genetic risk factors can, 
therefore, be conceived as a genetic diathesis. Thus, this genetically driven 
effect produced by the diathesis-stress interaction can be seen as a gene-by-
environment interaction (GxE).  
MDD is characterized by a highly polygenic architecture, composed of 
common variants with small effect and/or rare variants150. Therefore, 
interactions in depression are also expected to be highly polygenic. In recent 
years, with the increasing success of genome-wide association studies, GxE 
studies in depression have shifted towards hypothesis-free genome-wide and 
polygenic approaches that capture liability to depression using genetic 
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data83,86,113,169,267-269,275,276. Recent advances in genomics and the massive 
effort from national institutions to collect genetic, clinical and environmental 
data on large population-based samples now provide an opportunity to 
empirically test the diathesis-stress model for depression. The construction of 
polygenic risk scores (PRS) offers a novel paradigm to quantify genetic 
diathesis into a single genetic measure, allowing us to study GxE effects with 
more predictive power than any single variant409-412. PRS are genetic 
indicators of the aggregated number of risk alleles carried by an individual 
weighted by their allelic effect estimated from genome-wide association 
studies. This polygenic approach to assessing the diathesis-stress model for 
depression has been tested using either childhood trauma83,86,275 or adult 
SLE86,169,276 as measures of environmental adversity.  
Recently, Colodro-Conde et al.169 provided a direct test of the diathesis-
stress model for recent SLE and depressive symptoms. In this study, 
Colodro-Conde et al. used PRS weighted by the most recent genome-wide 
meta-analysis conducted by the Psychiatric Genetics Consortium (PGC; N = 
159,601), and measures of three environmental exposures: lack of social 
support, “personal” SLE, and “network” SLE.  Colodro-Conde et al. reported 
a significant additive risk on liability to depression due to a GxE effect in 
individuals who combine a high genetic predisposition to MDD and a high 
number of reported “personal” SLE, mainly driven by effects in women. A 
significant effect of interaction was not detected in males. They found no 
significant interaction between the genetic diathesis and “network” SLE or 
social support. They concluded that the effect of stress on risk of depression 
was dependent on an individual’s diathesis, thus supporting the diathesis-
stress theory. In addition, they suggested possible sex-specific differences in 
the aetiology of depression. However, Colodro-Conde et al. findings have 
not, to our knowledge, been independently validated. 
In the present study we aim to test the diathesis-stress model in an 
independent sample of 4,919 unrelated white British participants from a 
further longitudinal follow-up from Generation Scotland and assess the 
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differences between women and men, using self-reported depressive 
symptoms and recent SLE.
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4.3 Materials and methods 
 
4.3.1 Sample description 
Generation Scotland is a family-based population cohort recruited throughout 
Scotland by a cross-disciplinary collaboration of Scottish medical schools and 
the National Health Service (NHS) between 2006 and 2011305. At baseline, 
blood and salivary DNA samples from Generation Scotland participants were 
collected, stored and genotyped at the Wellcome Trust Clinical Research 
Facility, Edinburgh. Genome-wide genotype data were generated using the 
Illumina HumanOmniExpressExome-8 v1.0 DNA Analysis BeadChip (San 
Diego, CA, USA) and Infinium chemistry413. The procedures and further 
details for DNA extraction and genotyping have been extensively described 
elsewhere307,414. In 2014, 21,525 participants from Generation Scotland 
eligible for re-contact were sent self-reported questionnaires as part of a 
further longitudinal assessment funded by a Wellcome Trust Strategic Award 
“STratifying Resilience and Depression Longitudinally” (STRADL)415 to collect 
new and updated mental health questionnaires including psychiatric 
symptoms and SLE measures. 9,618 re-contacted participants from 
Generation Scotland agreed to provide new measures to the mental health 
follow-up415 (44.7% response rate). Duplicate samples, those showing sex 
discrepancies with phenotypic data, or that had more than 2% missing 
genotype data, were removed from the sample, as were samples identified 
as population outliers in principal component analysis (mainly non-
Caucasians and Italian ancestry subgroup). In addition, individuals with 
diagnoses of bipolar disorder, or with missing SLE data, were excluded from 
the analyses. SNPs with more than 2% of genotypes missing, Hardy-
Weinberg Equilibrium test p < 1 x 10−6, or a minor allele frequency lower than 
1%, were excluded. Individuals were then filtered by degree of relatedness 
(pi-hat < 0.05) using PLINK v1.9273, maximizing retention of those 
participants reporting higher numbers of SLE (see phenotype assessment 
below). After quality control, the final dataset comprised 4,919 unrelated 
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individuals of European ancestry and 560,351 SNPs (mean age at 
questionnaire: 57.2, s.d. = 12.2, range 22-95; women: n = 2,990 - 60.8%, 
mean age 56.1, s.d. = 12.4; men: n = 1,929 - 39.2%, mean age 58.7, s.d. = 
11.8). Further details on the recruitment procedure and Generation Scotland 
profile are described in detail elsewhere124,304-307. All participants provided 
written consent. All components of Generation Scotland and STRADL 
obtained ethical approval from the Tayside Committee on Medical Research 
Ethics on behalf of the National Health Service (reference 05/s1401/89). 
Generation Scotland data is available to researchers on application to the 
Generation Scotland Access Committee (access@generationscotland.org). 
4.3.2 Phenotype assessment 
Participant self-reported current depressive symptoms through the 28-item 
scaled version of The General Health Questionnaire416,417. The General 
Health Questionnaire is a reliable and validated psychometric screening tool 
to detect common psychiatric and non-psychotic conditions (General Health 
Questionnaire Cronbach alpha coefficient: 0.82 – 0.86)197. This consists of 28 
items designed to identify whether an individual’s current mental state has 
changed over the last 2 weeks from their typical state. The questionnaire 
captures core symptoms of depression through subscales for severe 
depression, emotional (e.g. anxiety and social dysfunction) and somatic 
symptoms linked to depression. These subscales are highly correlated418 and 
suggest an overall general factor of depression419. Participants rated the 28 
items on a four-point Likert scale from 0 to 3 to assess its degree or 
severity197 (e.g., Have you recently felt that life is entirely hopeless? “Not at 
all”, “No more than usual”, “Rather more than usual”, “Much more than 
usual”), resulting on an 84-point scale depression score. The Likert scale, 
which provides a wider and smoother distribution197, could be more sensitive 
to detect changes in mental status in those participants with chronic 
conditions or chronic stress who may feel their current symptoms as 
“usual”420, and to detect psychopathology changes as response to stress. 
The final depression score was log transformed to reduce the effect of 
positive skew and provide a better approximation to a normal distribution. In 
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addition, participants completed the Composite International Diagnostic 
Interview–Short Form, which diagnoses lifetime history of MDD according to 
DSM-IV criteria421. The depression score predicted lifetime history of MDD 
(odd ratio = 1.91, 95% confidence intervals 1.80-2.02, p = 1.55 x 10-102, N = 
8,994), with a 3.8-fold increased odd of having a lifetime history of MDD 
between participants in the top and bottom deciles, thus supporting the 
usefulness of the depression score in understanding MDD. For a better 
interpretation, we scaled the depression score to a mean of 0 when required 
(Figure 4.3). 
Data from a self-reported questionnaire based on the List of Threatening 
Experiences99 was used to construct a measure of common SLE over the 
previous 6 months. The List of Threatening Experiences is a reliable 
psychometric device to measure psychological “stress”422,423. It consists of a 
12-item questionnaire to assess SLE with considerable long-term contextual 
effects (e.g., Over last 6 months, did you have a serious problem with a close 
friend, neighbour or relatives?). A final score reflecting the total number of 
SLE (TSLE) ranging from 0 to 12 was constructed by summing the “yes” 
responses. Additionally, TSLE was split into two categories based on those 
items measuring SLE in which the individual may play and active role 
exposure to SLE, and therefore in which the SLE is influenced by genetic 
factors and thus subject to be “dependent” on an individual’s own behaviour 
or symptoms (DSLE; 6 items, e.g., a serious problem with a close friend, 
neighbour or relatives may be subject to a respondent’s own behaviour), or 
SLE that are not influenced by genetic factors, likely to be independent on a 
participant’s own behaviour (ISLE; 5 items, e.g., a serious illness, injury or 
assault happening to a close relative is potentially independent of a 
respondent’s own behaviour)99,100. The item “Did you/your wife or partner 
give birth?” was excluded from this categorization. In addition, SLE reported 
were categorized to investigate the diathesis effect at different levels of 
exposure, including a group to test the diathesis effect when SLE is not 
reported. 3 levels of SLE reported were defined (0 SLE = “none”, 1 or 2 SLE 
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= “low”, and 3 or more SLE = “high") to retain a large enough sample size for 
each group to allow meaningful statistical comparison. 
4.3.3 Polygenic profiling & statistical analysis 
Polygenic risk scores (PRS) were generated by PRSice313, whose 
functionality relies mostly on PLINK v1.9273, and were calculated using the 
genotype data of Generation Scotland participants (i.e. target sample) and 
summary statistics for MDD from the PGC-MDD2 GWAS release (July 2016, 
discovery sample) used by Colodro-Conde et al.169, with the added 
contribution from QIMR cohort and the exclusion of Generation Scotland 
participants, resulting in summary statistics for MDD derived from a sample 
of 50,455 cases and 105,411 controls.  
Briefly, PRSice removed strand-ambiguous SNPs and clump-based pruned 
(r2 = 0.1, within a 10Mb window) our target sample to obtain the most 
significant independent SNPs in approximate linkage equilibrium. 
Independent risk alleles were then weighted by the allelic effect sizes 
estimated in the independent discovery sample and aggregated into PRS. 
PRS were generated for eight p thresholds (p thresholds: < 5 x 10-8, < 1 x 10-
5, < 0.001, < 0.01, < 0.05, < 0.1, < 0.5, <=1) determined by the discovery 
sample and standardized (See Appendix C: Supplementary Table 1 for 
summary of PRS).  
A genetic relationship matrix (GRM) was calculated for each dataset (i.e. full 
cohort, women and men) using GCTA 1.26.0176. Mixed linear models using 
the GRM were used to estimate the variance in depression score explained 
by PRS, SLEs and their interaction; and stratified by sex. 20 principal 
components were calculated for the datasets. 
The mixed linear model used to assess the effects of PRS is as follows: 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝛽 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
Mixed linear models used to assess the effect of the stressors are as follows: 
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𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝛽 𝛽 𝑇𝑆𝐿𝐸 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝛽 𝛽 𝐷𝑆𝐿𝐸 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝛽 𝛽 𝐼𝑆𝐿𝐸 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
Following Colodro-Conde et al.169, covariates (i.e. age, age2, sex, age-by-sex 
and age2-by-sex interactions, and 20 principal components) were regressed 
from PRS (PRS’) and SLE scores (i.e. TSLE’, DSLE’ and ISLE’; SLEs’) 
before fitting models in GCTA to guard against confounding influences on the 
PRS-by-SLEs interactions424. PRS’ and SLEs’ were standardized to a mean 
of 0 and a standard deviation of 1. The Mixed linear models (i.e. the 
diathesis-stress model) used to assess GxE effects are as follows: 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 𝛽 𝑇𝑆𝐿𝐸′ 𝛽 𝑃𝑅𝑆 𝑥𝑇𝑆𝐿𝐸′ 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 𝛽 𝐷𝑆𝐿𝐸′ 𝛽 𝑃𝑅𝑆 𝑥𝐷𝑆𝐿𝐸′ 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 𝛽 𝐼𝑆𝐿𝐸′ 𝛽 𝑃𝑅𝑆 𝑥𝐼𝑆𝐿𝐸′ 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
Covariates fitted in the models above were age, age2, sex, age-by-sex, age2-
by-sex and 20 principal components.  Sex and its interactions (age-by-sex 
and age2-by-sex) were omitted from the covariates when stratifying by sex. 
All parameters from the models were estimated using GCTA and the 
significance of the effect (𝛽) from fixed effects assessed using a Wald test. 
The significance of main effects (PRS and SLEs) allowed for nominally 
testing the significance of interactions at p-threshold = 0.05. To account for 
multiple testing correction, a Bonferroni’s adjustment correcting for 8 PRS 
and 3 measures of SLE tested (24 tests) was used to establish a robust 
threshold for significance at p = 2.08 x 10-3.  
The PRS effect on depression score at different levels of exposure was 
further examined for the detected nominally significant interactions by 
categorizing participants on three groups based on the number of SLE 
reported (i.e. “none”, “low” or “high”). Using linear regression, we applied a 
least squares approach to assess PRS’ effects on the depression score in 
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each SLE category. Further conservative Bonferroni correction to adjust for 
the 3 SLE categories tested established a threshold for significance of p = 
6.94 x 10-4. 
Differences on the estimated size of GxE effect between women and men 
were assessed by comparing a z-score to the standard normal distribution (α 
= 0.05, one-tailed). Z-scores were derived from GxE estimates (𝛽 ) and 
standard errors (SE) detected in women and men as follows: 
Z score
β β





PRS for MDD significantly predicted the depression score across the whole 
sample (β = 0.080, s.e. = 0.014, p = 7.53 x 10-9) explaining 0.64% of the 
variance at its best p-threshold (p-threshold = 0.1; Figure 4.1a). Stratifying 
by sex, PRS significantly predicted the depression score in both sexes, 
explaining 0.59% in men and 0.67% in women (men: p-threshold = 0.1, β = 
0.077, s.e. = 0.022, p = 2.09 x 10-4; women: p-threshold = 0.1, β = 0.082, s.e. 
= 0.018, p = 4.93 x 10-6; Figure 4.1a). Self-reported SLE over the last 6 
months (TSLE, mean = 1.3 SLE, s.d. = 1.5) also significantly predicted 
depression score for the whole sample and stratified by sex (full cohort: 
variance explained = 4.91%, β = 0.222, s.e. = 0.014, p = 9.98 x 10-59; men: 
4.19%, β = 0.205, s.e. = 0.021, p = 2.23 x 10-22; women: 5.33%, β = 0.231, 
s.e. = 0.018, p = 7.48 x 10-38; Figure 4.1b).  Overall, significant additive 
contributions from genetics and SLE in depression score were detected in all 
participants and across sexes. There was no significant difference in the 
direct effect of TSLE between women and men (p = 0.17). However, the 
variance in depression score explained by the TSLE appeared to be lower 
than the variance explained by the measure of personal SLE (PSLE) used in 
Colodro-Conde et al.169 (12.9%). This may, in part, be explained by different 
contributions of dependent and independent SLE items screened in Colodro-
Conde et al. compared to our study. Although questions about dependent 
SLE (DSLE, mean = 0.4 SLE) represented over 28% of the TSLE-items 
reported in our study, the main effect of DSLE explained approximately 93% 
of the amount of variance explained by TSLE (full cohort: variance explained 
= 4.56%, β = 0.212, s.e. = 0.014, p = 1.73 x 10-54; men: 3.74%, β = 0.193, 
s.e. = 0.021, p = 9.66 x 10-21; women: 5.07%, β = 0.225, s.e. = 0.018, p = 
8.09 x 10-35; Figure 4.1b). Independent SLE (ISLE, mean = 0.85 SLE), which 
represented over 69% of TSLE-items, explained approximately 57% of the 
amount of variance explained by TSLE (full cohort: variance explained = 
2.80%, β = 0.167, s.e. = 0.014, p = 1.32 x 10-33; men: 2.44%, β = 0.156, s.e. 
= 0.022, p = 2.88 x 10-13; women: 3.02%, β = 0.174, s.e. = 0.018, p = 5.20 x 
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10-22; Figure 4.1b). To explore the contribution from each measure, we
combined DSLE and ISLE together in a single model. DSLE explained 3.34%
of the variance of depressive score compared to 1.45% of the variance being
explained by ISLE, suggesting that DSLE have a greater effect on liability to
depressive symptoms than ISLE.
A diathesis-stress model for depression was tested to assess GxE effects. 
We detected significant, albeit weak, GxE effects on depression score 
(Figure 4.2). The PRS interaction with TSLE was nominally significant in the 
full cohort (β = 0.028, s.e. = 0.014, R2 = 0.08%, p = 0.049) and slightly 
stronger in women (β = 0.044, s.e. = 0.018, R2 = 0.19%, p = 0.017; Figure 
4.2a), compared to men in which the effect was not significant (β = 0.039, 
s.e. = 0.022, R2 = 0.15%, p = 0.07). However, these results did not survive
correction for multiple testing (p > 2.08 x 10-3).
The best-fit threshold was much lower in women (p-threshold = 1 x 10-5) 
compared to the full sample (p-threshold = 0.01). The size of GxE across 
sexes at p-threshold = 1 x 10-5 were significantly different (GxE*sex p = 
0.017), but not at the best p-threshold in the full cohort (p-threshold = 0.01, 
GxE*sex p = 0.32; Figure 4.2a). In women, GxE effect with DSLE predicted 
depression score (p-threshold = 1 x 10-5; β = 0.039, s.e. = 0.019, R2 = 0.15%, 
p = 0.038; Figure 4.2b and Appendix C: Supplementary Figure 1a), as did 
the GxE effect with ISLE (p-threshold = 1 x 10-5; β = 0.040, s.e. = 0.019, R2 = 
0.16%, p = 0.033; Figure 4.2c and Appendix C: Supplementary Figure 1b). 
No significant interaction was detected in men (best-fit p-threshold = 0.1) with 
either TSLE (β = 0.039, s.e. = 0.022, R2 = 0.15%, p = 0.072; Figure 4.2a), 
DSLE (β = 0.024, s.e. = 0.022, R2 = 0.06%, p = 0.28; Figure 4.2b) or ISLE (β 
= 0.043, s.e. = 0.022, R2 = 0.18%, p = 0.055; Figure 4.2c). 
To examine these results further and investigate the diathesis effect at 
different levels of stress, nominally significant GxE were plotted between 
PRS and categories of SLE (i.e, “none”, “low” and “high” SLE reported; 
Figure 4.3). Examining the interaction found at the full cohort (PRS at PGC-
MDD GWAS p-threshold = 0.01), we detected a significant direct diathesis 
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effect on the risk of depressive symptoms in those participants reporting SLE, 
with a higher risk when greater numbers of SLE were reported (“low” number 
of SLE reported: PRS’ β = 0.043, s.e. = 0.021, p = 0.039; “high” number of 
SLE reported: PRS’ β = 0.142, s.e. = 0.039, p = 2.86 x 10-4; see Table 4.1 
and Figure 4.3a). Whereas, in participants who reported no SLE over the 
preceding 6 months, the risk of depressive symptoms was the same 
regardless of their diathesis risk (“none” SLE reported: PRS’ β = 0.021, s.e. = 
0.022, p = 0.339). Stratifying these results by sex, we found the same pattern 
as in the full cohort in women (“none”: p = 0.687; “low”: p = 0.023; “high”: p = 
2 x 10-3), but not in men (“none”: p = 0.307; “low”: p = 0.728; “high”: p = 
0.053; see Table 4.1 and Figure 4.3a). However, the lack of significant 
diathesis effect in men may be due to their lower sample size and its 
corresponding reduced power. 
Examining the interaction with PRS (at PGC-MDD GWAS p-threshold = 1 x 
10-5) with which a significant interaction was detected in women, we only
detected a significant diathesis effect on depression score when stratifying by
sex in those participants who did not reported SLE over the last 6 months
(see Table 4.1). The diathesis effect was positive in men (PRS’ β = 0.082,
s.e. = 0.034, p = 0.016, R2 = 0.7%; Figure 4.3b), consistent with the
contribution of risk alleles. Conversely, the diathesis effect was negative in
women (PRS’ β = -0.061, s.e. = 0.029, p = 0.037, R2 = 0.4%; Figure 4.3b),
suggesting a protective effect of increasing PRS in those women reporting no
SLE, and consistent with the contribution of alleles to individual sensitivity to
both positive and negative environmental effects (i.e. “plasticity alleles” rather
than “risk alleles”)229,230. This PRS accounted for the effect of just 34 SNPs,
and the size of its GxE across sexes were significantly different (GxE*sex p =
0.017; Figure 4.2a), supporting possible differences in the underlying stress-




Sample  *FULL COHORT WOMEN  MEN 
SLE 
category 
none  low  high  none  low  high  none  low  high 
N  1833  2311  775  1041  1459  490  792  852  285 
Effect  0.021  0.043  0.142  0.0118  0.0617  0.1538  0.0346  0.0113  0.1227 
s.e. 0.022  0.021  0.039  0.029  0.027  0.049  0.034  0.032  0.063 
t 0.957  2.07  3.644  0.403  2.274  3.112  1.021  0.348  1.947 
p value  0.339  0.039  2.86x10‐4  0.687  0.023  0.002  0.307  0.728  0.053 
CI (95%)  ‐0.022, 0.065  0.002, 0.084  0.065, 0.218  ‐0.046, 0.069  0.008, 0.115  0.057, 0.251  ‐0.032, 0.101  ‐0.052, 0.075  ‐0.001,0.247 
PRS at p value threshold = 1 x 10‐5 
Sample  FULL COHORT  *WOMEN MEN 
SLE 
category 
none  low  high  none  low  high  none  low  high 
N  1833  2311  775  1041  1459  490  792  852  285 
Effect  ‐0.0022  0.0032  0.0705  ‐0.061  0.014  0.078  0.082  ‐0.0176  0.0548 
s.e. 0.022  0.021  0.04  0.029  0.027  0.049  0.034  0.033  0.07 
t ‐0.098  0.153  1.76  ‐2.086  0.541  1.609  2.416  ‐0.537  0.778 
p value  0.922  0.878  0.079  0.037  0.589  0.108  0.016  0.592  0.437 








(main  effects,  one‐sided  tests).  PRS  were  generated  at  8  p‐threshold  levels  using 
summary  statistics  from  the Psychiatric Genetic  Consortium MDD GWAS  (released 
July  2016) with  the  exclusion  of  Generation  Scotland  participants.  The  depression 
score was derived from The General Health Questionnaire. The Y‐axis represents the 
%  of  variance  of  depression  score  explained  by  PRS main  effects.  The  full  cohort 
(yellow) was split into men (blue) and women (red). In Colodro‐Conde et al., PRS for 
MDD significantly explained up to 0.46% of depression score in their sample (~0.39% 
in women and  ~0.70%  in men). b)  Association  between  reported  number  of  SLE 
and  depression  score  (main  effect,  one‐sided  tests,  results  expressed  in  %  of 
depression  score  explained).  SLE  were  self‐reported  through  a  brief  life‐events 
questionnaire  based  on  the  List  of  Threatening  Experiences  and  categorized  into: 
total number of SLE reported (TSLE), dependent SLE (DSLE) or independent SLE (ISLE). 
The full cohort (yellow) was split into men (blue) and women (red). In Colodro‐Conde 
et  al.,  “personal”  SLE  significantly  explained  up  to  12.9%  of  depression  score 
variance in their sample (~11.5% in women and ~16% in men). 
Figure 4.2 Association between GxE effect and depression score. The results represent percentage of depression score explained by the 
interaction  term  (two‐sided  tests)  fitted  in  linear  mixed  models  to  empirically  test  the  diathesis‐stress  model.  Red  numbers  show 
significant interactions p‐values. *Shows significance of difference between sexes when comparing the size of the estimated GxE effects. 
The full cohort (yellow) was split into men (blue) and women (red). PRS were generated at 8 p‐threshold levels using summary statistics 
from  the  Psychiatric Genetic  Consortium MDD GWAS  (released  July  2016) with  the  exclusion  of Generation  Scotland  participants.  The 
interaction effect was tested with a) the number of SLE reported (TSLE), b) dependent SLE (DSLE) and c) independent SLE (ISLE). In Colodro‐









each  participant  (dot)  as  environmental  exposures  at  three  SLE  levels  represented  by  colours.  Blue:  0  SLE,  “no  stress”,  n  = 







The findings reported in this study support those from Colodro-Conde et 
al.169, in an independent sample of similar sample size and study design, and 
also support possible sex-specific differences in the effect of genetic risk of 
MDD in response to SLE. 
Both Colodro-Conde et al. and our study suggest that individuals with an 
inherent genetic predisposition to MDD, reporting high number of recent SLE, 
are at additional risk of depressive symptoms due to GxE effects, thus 
validating the diathesis-stress theory.  We identified nominally significant GxE 
effects in liability to depression at the population level (p = 0.049) and in 
women (p = 0.017), but not in men (p = 0.072). However, these interactions 
did not survive multiple testing correction (p > 2.08 x 10-3) and the power of 
both studies to draw robust conclusions remains limited170. With increased 
power these studies could determine more accurately both the presence and 
magnitude of a GxE effect in depression. To better understand the effect of 
PRS at different levels of exposure to stress, we examined the nominally 
significant interactions detected in the full sample by categorizing participants 
on three groups based on the number of SLE reported (i.e. “none”, “low” or 
“high”). We detected a significant diathesis effect on risk of depression only in 
those participants reporting SLE, but not in those participants that reported 
no SLE over the last 6 month. Furthermore, the diathesis effect was stronger 
on those participants reporting a “high” number of SLE (β = 0.142, p = 2.86 x 
10-4) compared to those participants reporting a “low” number of SLE (β =
0.043, p = 0.039). The former effect was robustly significant and survived a
conservative Bonferroni correction to adjust for multiple testing (p < 6.94 x
10-4). This finding corroborates the diathesis-stress model for depression and
supports Colodro-Conde et al. results using an independent sample.
To investigate the relative contribution of the GxE to the variance of 
depression, we examined in the full cohort the total variance of depression 
130
score explained by the PRS main effect and the significant GxE effect jointly. 
Together, they explained 0.34% of the variance, of which 0.07% of the 
variance of the depression score was attributed to the GxE effect (p-
threshold = 0.01; PRS p = 1.19 x 10-4, GxE p = 0.049; both derived from the 
full diathesis-model with TSLE). This is lower than the proportion of variance 
attributed to common SNPs (8.9%) in the full PGC-MDD analysis150. As 
Colodro-Conde et al. noted, this result aligns with estimates from 
experimental organisms suggesting that around 20% of the heritability may 
be typically attributed to the effects of GxE425, although it is inconsistent with 
the majority of human traits with the potential exception of depression82. 
Consistent with PRS predicting “personal” SLE in Colodro-Conde et al., PRS 
for MDD predicted SLE in our study (see Appendix C: Supplementary Figure 
2), although not at the p-threshold at which significant GxE effects were 
detected. Genetic factors predisposing to MDD may contribute to individuals 
exposing themselves to, or showing an increased reporting of, SLE via 
behavioural or personality traits79,98. Such genetic mediation of the 
association between depression and SLE would disclose a gene-
environment correlation (i.e. genetic effects on the probability of undergoing a 
SLE) that hinders to interpret our findings as pure GxE effects74,426. To 
address this limitation and assess this aspect, following Colodro-Conde et al., 
we split the 12-items TSLE measure into SLE that are either potentially 
“dependent” on a participant’s own behaviour (DSLE; therefore, potentially 
driven by genetic factors) or not (“independent” SLE; ISLE)99,100. DSLE are 
reported to be more heritable and have stronger associations with MDD than 
ISLE98,100,109. In our sample, reporting DSLE is significantly heritable (h2SNP = 
0.131, s.e. = 0.071, p = 0.029), supporting a genetic mediation of the 
association, whereas reporting ISLE is not significantly heritable (h2SNP = 
0.000, s.e. = 0.072, p = 0.5)427. Nominally significant GxE effects were seen 
in women for both DSLE and ISLE, suggesting that both GxE and gene-
environment correlation co-occur. Colodro-Conde et al. did not identify 
significant GxE using independent SLE as the exposure. 
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Between-sex differences on stress response could help to explain previous 
differences seen between sexes in depression such as those in associated 
risk (i.e. approximately 1.5 - 2-fold higher in women), symptoms reported 
and/or coping strategies (e.g., whereas women tend to cope through verbal 
and emotional strategies, men tend to cope by doing sport and consuming 
alcohol)49-53. This also aligns with an increased risk associated with a lack of 
social support seen in women compared to men169. Furthermore, although 
we do not know whether participants experienced recent events with positive 
effects, we saw a protective effect in those women who did not experienced 
recent SLE (p = 0.037), suggesting that some genetic variants associated 
with MDD may operate as “plasticity alleles” and not just as “risk 
alleles”229,230. This effect was neutralized in the full cohort due to an opposite 
effect in men (p = 0.016), but it is supported by previous protective effects 
reported when using a serotoninergic multilocus profile score and absence of 
SLE in young women428. These findings would be consistent with a 
differential-susceptibility model226,227 of depression, also suggested by the 
interaction effects seen between the serotonin transporter linked promoter 
region gene (5-HTTLPR) locus and family support and liability to adolescent 
depression in boys429. However, our results and the examples given are only 
nominally significant and will require replication in larger samples. Robustly 
identified sex-specific differences in genetic stress-response could improve 
personalized treatments and therapies such as better coping strategies. 
There are notable differences between our study and Colodro-Conde et al. to 
consider before accepting our findings as a replication of Colodro-Conde et 
al. results. First, differences in PRS profiling may have affected replication 
power. We used the same equivalent PGC-MDD2 GWAS as discovery 
sample. However, whereas Colodro-Conde et al. generated PRS in their 
target sample containing over 9.5M imputed SNP, in this study we generated 
PRS in a target sample of over 560K genotyped SNPs (see Appendix C: 
Supplementary Table 1 for comparison). This potentially results in a less 
informative PRS in our study, with less predictive power, although the 
variance explained by our PRS was slightly larger (0.64% vs. 0.46%). The 
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size of the discovery sample is key to constructing an accurate predictive 
PRS, but to exploit the most of the variants available may be an asset170. 
Secondly, different screening tools were used to measure both current 
depression and recent environmental stressors across the two studies. Both 
studies transformed their data, using item response theory or by log-
transformation, to improve the data distribution. However, neither study used 
depression scores that were normally distributed. The scale of the 
instruments used and their corresponding parameterization to test an 
interaction could have a direct effect on the size and significance of their 
interaction425,430; so findings from GxE must be taken with caution. 
Furthermore, although both screening methods have been validated and 
applied to detect depressive symptoms, different questions may cover and 
emphasise different features of the illness, which may result in different 
outputs. The same applies to the measurement of environmental stressors in 
the two studies. Both covering of a longer time-period and upweighting by 
dependent SLE items may explain the increased explanatory power of 
“personal” SLE (12.9%) in Colodro-Conde et al. to predict depression score 
compared to our “total” SLE measure (4.91%). Finally, the unmeasured 
aspects of the exposure to SLE or its impact may also contribute to lack of 
stronger replication and positive findings.  
In conclusion, despite differences in the measures used across studies, we 
saw concordance and similar patterns between our results and those of 
Colodro-Conde et al.169. Our findings are consistent with Colodro-Conde et 
al. and, therefore, add validity to the diathesis-stress theory for depression. 
Empirically demonstrating the diathesis-stress theory for depression would 
validate recent113,267-269 and future studies using a genome-wide approach to 
identify genetic mechanisms and interactive pathways involved in GxE 
underpinning the causative effect of “stress” in the development of 
depressive symptoms and mental illness in general. This study adds to our 
understanding of gene-by-environment interactions, although larger samples 
will be required to confirm differences in diathesis-stress effects between 
women and men. 
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Chapter 5 Genome-wide by environment 
interaction studies (GWEIS) of 
depressive symptoms and 
psychosocial stress in UK Biobank 
and Generation Scotland 
As seen in chapter 4, I detected a significant PRSxE effect on depression 
score supporting, under a diathesis-stress model, the presence of GxE 
effects underlying MDD. My findings are in accordance with Colodro-Conde 
et al. results and, together, validate the implementation of hypothesis-free 
GxE studies at the SNP level through genome-wide by environment 
interaction studies (GWEIS). Therefore, whereas in chapter 4 I sought 
interactions at the individual level using PRS as an individual’s vulnerability 
score, in this chapter I seek interactions at the SNP level by performing 
GWEIS in the subsample from Generation Scotland, and a second sample 
from UK Biobank, using measures for the construction of SLE reported and 
depression score. 
This chapter is published in Translational Psychiatry and is shown as it has 
been accepted, which explains the use of “we” within the chapter. I confirm 
that the work of this chapter is my own work under guidance from my 
supervisor Dr. Pippa Thomson. I carried out all the analyses myself. 
Appendix D includes the published article and all Supplementary Material.  
Publication: 
Arnau-Soler, A. et al. Genome-wide by environment interaction studies 
(GWEIS) of depressive symptoms and psychosocial stress in UK Biobank 




 Stress is associated with poorer physical and mental health. To improve our 
understanding of this link, we performed genome-wide association studies 
(GWAS) of depressive symptoms and genome-wide by environment 
interaction studies (GWEIS) of depressive symptoms and stressful life events 
(SLE) in two UK population cohorts (Generation Scotland and UK Biobank). 
No SNP was individually significant in either GWAS, but gene-based tests 
identified six genes associated with depressive symptoms in UK Biobank 
(DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; p < 2.77 x 10-6). Two 
SNPs with genome-wide significant GxE effects were identified by GWEIS in 
Generation Scotland: rs12789145 (53kb downstream PIWIL4; p = 4.95 x 10-
9; total SLE) and rs17070072 (intronic to ZCCHC2; p = 1.46 x 10-8; 
dependent SLE). A third locus upstream CYLC2 (rs12000047 and 
rs12005200, p < 2.00 x 10-8; dependent SLE) when the joint effect of the 
SNP main and GxE effects was considered. GWEIS gene-based tests 
identified: MTNR1B with GxE effect with dependent SLE in Generation 
Scotland; and PHF2 with the joint effect in UK Biobank (p < 2.77 x 10-6). 
Polygenic risk scores (PRS) analyses incorporating GxE effects improved the 
prediction of depressive symptom scores, when using weights derived from 
either the UK Biobank GWAS of depressive symptoms (p = 0.01) or the PGC 
GWAS of major depressive disorder (p = 5.91 x 10-3). Using an independent 
sample, PRS derived using GWEIS GxE effects provided evidence of shared 
aetiologies between depressive symptoms and schizotypal personality, heart 
disease and COPD.  Further such studies are required and may result in 
improved treatments for depression and other stress-related conditions. 
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5.2 Introduction 
Mental illness results from the interplay between genetic susceptibility and 
environmental risk factors12,74. Previous studies have shown that the effects 
of environmental factors on traits may be partially heritable97 and moderated 
by genetics114,169. Major depressive disorder (MDD) is the most common 
psychiatric disorder with a lifetime prevalence of approximately 14% globally9 
and with a heritability of approximately 37%119. There is strong evidence for 
the role of stressful life events (SLE) as risk factor and trigger for 
depression84,90,93,95,401. Genetic control of sensitivity to stress may vary 
between individuals, resulting in individual differences in the depressogenic 
effects of SLE, i.e., genotype-by-environment interaction 
(GxE)103,115,169,378,431. Significant evidence of GxE has been reported for 
common respiratory diseases and some forms of cancer432-437, and GxE 
studies have identified genetic risk variants not found by genome-wide 
association studies (GWAS)438-442. 
Interaction between polygenic risk of MDD and recent SLE are reported to 
increase liability to depressive symptoms169,431; validating the implementation 
of genome-wide approaches to study GxE in depression. Most GxE studies 
for MDD have been conducted on candidate genes, or using polygenic 
approaches to a wide range of environmental risk factors, with some 
contradictory findings252,253,275,290,443. Incorporating knowledge about recent 
SLE into GWAS may improve our ability to detect risk variants in depression 
otherwise missed in GWAS233. To date, four studies have performed 
genome-wide by environment interaction studies (GWEIS) of MDD and 
SLE113,267-269, but this is the first study to perform GWEIS of depressive 
symptoms using adult SLE in cohorts of relatively homogeneous European 
ancestry. 
Interpretation of GxE effects may be hindered by gene-environment 
correlation. Gene-environment correlation denotes a genetic mediation of 
137
associations through genetic influences on exposure to, or reporting of, 
environments74,426. Genetic factors predisposing to MDD may contribute to 
exposure and/or reporting of SLE98. To tackle this limitation, measures of 
SLE can be broken down into SLE likely to be independent of a respondent’s 
own behaviour and symptoms, or into dependent SLE, in which participants 
may played an active role exposure to SLE99,100. Different genetic influences 
with a higher heritability for reported dependent SLE than independent 
SLE98,109-112 suggest that whereas GxE driven by independent SLE is likely to 
reflect a genetic moderation of associations between SLE and depression, 
GxE driven by dependent SLE may result from a genetic mediation of the 
association through genetically driven personality or behavioural traits. To 
test this we analysed dependent and independent SLE scores separately in 
Generation Scotland. 
Stress contributes to many human conditions, with evidence of genetic 
vulnerability to the effect of SLE444. Therefore, genetic stress-response 
factors in MDD may also underlie the aetiology of other stress-linked 
disorders, with which MDD is often co-morbid3,4 (e.g. cardiovascular 
diseases66, diabetes,67 chronic pain68 and inflamation69). We tested the 
hypothesis that pleiotropy and shared aetiology between mental and physical 
health conditions may be due in part to genetic variants underlying SLE 
effects in depression. 
In this study we conduct GWEIS of depressive symptoms incorporating data 
on SLE in two independent UK-based cohorts. We aimed to: i) identify loci 
associated with depressive symptoms through genetic response to SLE; ii) 
study dependent and independent SLE to support a contribution of 
genetically mediated exposure to stress; iii) assess whether GxE effects 
improve the proportion of phenotypic variance in depressive symptoms 
explained by genetic additive main effects alone; and iv) test for a significant 
overlap in the genetic aetiology of the response to SLE and mental and 




genetically mediated  exposure  to  stress;  iii)  assess whether GxE  effects  improve  the  proportion  of  phenotypic  variance  in  depressive 
symptoms explained by genetic additive main effects alone and iv) test whether there is significant overlap in the genetic aetiology of the 
response to SLE and mental and physical stress‐related phenotypes. Two core cohorts are used, Generation Scotland (GS) and UK Biobank 
(UKB).  Summary  statistics  from  Genome‐Wide  Association  Studies  (GWAS)  and  Genome‐Wide  by  Environment  Interaction  Studies 
(GWEIS)  are  used  to  generate  Polygenic  Risk  Scores  (PRS).  Summary  statistics  from  Psychiatric  Genetic  Consortium  (PGC)  Major 
Depressive Disorder  (MDD) GWAS are  also  used  to  generate  PRS  (PRSMDD).  PRS weighted by:  additive  effects  (PRSD  and PRSMDD), GxE 
effects (PRSGxE) and joint effects (the combined additive and GxE effect; PRSJoint), are used for phenotypic prediction. TSLE stands for Total 
number of SLE reported. DSLE stands for SLE dependent on an individual’s own behaviour. Conversely, ISLE stands for independent SLE. N 




5.3 Materials and methods 
The core workflow of this study is summarized at Figure 5.1. 
5.3.1 Cohort descriptions 
5.3.1.1 Generation Scotland (GS) 
Generation Scotland is a family-based population cohort representative of the 
Scottish population305. At baseline, blood and salivary DNA samples were 
collected, stored and genotyped at the Wellcome Trust Clinical Research 
Facility, Edinburgh. Genome-wide genotype data was generated using the 
Illumina HumanOmniExpressExome-8 v1.0 DNA Analysis BeadChip (San 
Diego, CA, USA) and Infinium chemistry413. The procedures and details for 
DNA extraction and genotyping have been extensively described 
elsewhere307,414. 21,525 participants were re-contacted to participate in a 
follow-up mental health study (Stratifying Resilience and Depression 
Longitudinally, STRADL), of which 8,541 participants responded providing 
updated measures in psychiatric symptoms and SLE through self-reported 
mental health questionnaires415. Samples were excluded if: they were 
duplicate samples, had diagnoses of bipolar disorder, no SLE data (non-
respondents), were population outliers (mainly non-Caucasians and Italian 
ancestry subgroup), had sex mismatches, or were missing more than 2% of 
genotypes. SNPs were excluded if: missing more than 2% of genotypes, 
Hardy-Weinberg Equilibrium test p < 1 x 10−6, or minor allele frequency less 
than 1%. Further details of the GS and STRADL cohort are available 
elsewhere124,305,306,415. All components of GS and STRADL obtained ethical 
approval from the Tayside Committee on Medical Research Ethics on behalf 
of the NHS (reference 05/s1401/89). After quality control, individuals were 
filtered by degree of relatedness (pi-hat < 0.05), maximizing retention of 
those individuals reporting a higher number of SLE. The final dataset 
comprised data on 4,919 unrelated individuals (1,929 men; 2,990 women) 
and 560,351 SNPs.  
141
5.3.1.2 Independent GS datasets 
Additional datasets for a range of stress-linked medical conditions and 
personality traits were created from GS (N = 21,525) excluding respondents 
and their relatives (N = 5,724). Following the same quality control criteria 
detailed above, we maximized unrelated non-respondents for retention of 
cases, or proxy cases (see below), to maximize the information available for 
each phenotype. This resulted in independent datasets with unrelated 
individuals for each trait. Differences between respondents and non-
respondents are noted in the legend of Table 5.1. 
5.3.1.3 UK Biobank (UKB) 
This study used data from 99,057 unrelated individuals (47,558 men; 51,499 
women) from the initial release of UKB genotyped data (released 2015; 
under UK Biobank project 4844). Briefly, participants were removed based on 
UKB genomic analysis exclusion, non-white British ancestry, high 
missingness, genetic relatedness (kinship coefficient > 0.0442), QC failure in 
UK BiLEVE study, and gender mismatch. GS participants and their relatives 
were excluded and GS SNPs imputed to a reference set combining the 
UK10K haplotype and 1000 Genomes Phase 3 reference panels445. After 
quality control, 1,009,208 SNPs remained. UK Biobank received ethical 
approval from the NHS National Research Ethics Service North West 
(reference: 11/NW/0382). Further details on UKB cohort description, 
genotyping, imputation and quality control are available elsewhere301,302,446.  
All participants provided informed consent. 
5.3.2 Phenotype assessment 
5.3.2.1 Stressful life events (SLE) 
GS participants reported SLE experienced over the preceding 6 months 
through a self-reported brief life events questionnaire based on the 12–item 
List of Threatening Experiences99,422,423 (Appendix D: Supplementary Table 
1a). The total number of SLE reported (TSLE) consisted of the number of 
‘yes’ responses. TSLE were subdivided into SLE potentially dependent or 
secondary to an individual’s own behaviour (DSLE, questions 6-11 in 
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Appendix D: Supplementary Table 1a), and independent SLE (ISLE, 
questions 1-5 in Appendix D: Supplementary Table 1a; pregnancy item 
removed) following Brugha et al.99,100. Thus, 3 SLE measures (TSLE, DSLE 
and ISLE) were constructed for GS. UKB participants were screened for 
“illness, injury, bereavement and stress” (Appendix D: Supplementary Table 
1b) over the previous 2 years using 6 items included in the UKB Touchscreen 
questionnaire. A score reflecting SLE reported in UKB (TSLEUKB) was 
constructed by summing the number of ‘yes’ responses. 
5.3.2.2 Psychological assessment 
GS participants reported whether their current mental state over the 
preceding 2 weeks differed from their typical state using a self-administered 
28-item scaled version of The General Health Questionnaire (GHQ)197,416,417.
Participants rated the degree and severity of their current symptoms with a
four-point Likert scale (following Goldberg et al., 1997197). A final log-
transformed GHQ was used to detect altered psychopathology and thus,
assess depressive symptoms as results of SLE. In UKB participants, current
depressive symptoms over the preceding 2 weeks were evaluated using 4
psychometric screening items (Appendix D: Supplementary Table 2),
including two validated and reliable questions for screening depression447,
from the Patient Health Questionnaire (PHQ) validated to screen mental
illness310,311. Each question was rated in a four-point Likert scale to assess
impairment/severity of symptoms. Due to its skewed distribution, a four-point
PHQ score was formed from PHQ (0 = 0; 1 = 1-2; 2 = 3-5; 3 = 6 or more) to
create a more normal distribution.
5.3.2.3 Stress-related traits 
Targeted GS stress-related phenotypes and sample sizes are shown in 
Table 5.1 and detailed elsewhere305. These conditions were selected from 
literature review based on previous evidence of a link with stress444 (see also 
Appendix D.3). Furthermore, we created additional independent samples 
using mapping by proxy, where individuals with a self-reported first-degree 
relative with a selected phenotype were included as proxy cases. This 
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approach provides greater power to detect susceptibility variants in traits with 
low prevalence448.  
5.3.3 Statistical analyses 
5.3.3.1 SNP-heritability and genetic correlation 
 Restricted maximum likelihood approach was applied to estimate SNP-
heritability (h2SNP) of depressive symptoms and self-reported SLE measures, 
and within samples bivariate genetic correlation between depressive 
symptoms and SLE measures using GCTA176. 
5.3.3.2 GWAS analyses 
GWAS were conducted in PLINK273. In GS, age, sex and 20 principal 
components (PCs) were fitted as covariates. In UKB, age, sex, and 15 PCs 
recommended by UKB were fitted as covariates. The genome-wide 
significance threshold was p = 5 x 10-8. 
5.3.3.3 GWEIS analyses 
GWEIS were conducted on GHQ (the dependent variable) for TSLE, DSLE 
and ISLE in GS and on PHQ for TSLEUKB in UKB fitting the same covariates 
detailed above to reduce error variance.  GWEIS were conducted using an R 
plugin for PLINK273 developed by Almli et al.272 (https://epstein-
software.github.io/robust-joint-interaction). This method implements a robust 
test, that jointly considers SNP and SNP-environment interaction effects from 
a full model ( 𝑌~𝛽 𝛽𝑆𝑁𝑃 𝛽𝑆𝐿𝐸 𝛽𝑆𝑁𝑃𝑥𝑆𝐿𝐸 𝛽𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠  against a 
null model where both the SNP and SNPxSLE effects equal 0, to assess the 
joint effect (the combined additive main and GxE genetic effect at a SNP) 
using a nonlinear statistical approach that applies Huber-White estimates of 
variance to correct possible inflation due to heteroscedasticity (unequal 
variances across exposure levels). This robust test should reduce 
confounding due to differences in variance induced by covariate interaction 
effects424 if present.  Additional code was added (courtesy of Prof. Michael 
Epstein272; Appendix D.1) to generate beta-coefficients and the p-value of 
the GxE term alone. In UKB, correcting for 1,009,208 SNPs and 1 exposure 
we established a Bonferroni-adjusted threshold for significance at p = 2.47 x 
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10-8 for both joint and GxE effects. In GS, correcting for 560,351 SNPs and 3
measures of SLE we established a genome-wide significance threshold of p
= 2.97 x 10-8.
5.3.3.4 Post-GWAS/GWEIS analyses 
GWAS and GWEIS summary statistics were analysed using FUMA316 
including: gene-based tests, functional annotation, gene prioritization and 
pathway enrichment (Appendix D.2). 
5.3.3.5 Polygenic profiling & prediction 
Polygenic risk scores (PRS) weighting by GxE effects (PRSGxE) were 
generated using PRSice-2313 (Appendix D.2) in GS using GxE effects from 
UKB-GWEIS. In UKB, PRSGxE were constructed using GxE effects from all 
three GS-GWEIS (TSLE, DSLE and ISLE as exposures) independently. PRS 
were also weighted in both samples using either UKB-GWAS or GS-GWAS 
statistics (PRSD), and summary statistics from Psychiatric Genetic 
Consortium (PGC) MDD-GWAS (released 2016; PRSMDD) that excluded GS 
and UKB individuals when required (NnoGS = 155,866; NnoUKB = 138,884). 
Furthermore, we calculated PRS weighted by the joint effects (the combined 
additive main and GxE genetic effects; PRSJoint) from either the UKB-GWEIS 
or GS-GWEIS. PRS predictions of depressive symptoms were permuted 
10,000 times. Multiple regression models fitting PRSGxE and PRSMDD, and 
both PRSGxE and PRSD were tested. All models were adjusted by same 
covariates used in GWAS/GWEIS. Null models were estimated from the 
direct effects of covariates alone. The predictive improvement of combining 
PRSGxE and PRSMDD/PRSD effects over PRSMDD/PRSD effect alone was 
tested for significance using the likelihood-ratio test (LRT).  
Prediction of PRSD, PRSGxE and PRSJoint on stress-linked traits were adjusted 
by age, sex and 20 PCs; and permuted 10,000 times. Empirical-p-values 
after permutations were further adjusted by false discovery rate (conservative 
threshold at Empirical-p = 6.16 x 10-3). The predictive improvement of fitting 
PRSGxE combined with PRSD and covariates over prediction of a phenotype 
using the PRSD effect alone with covariates was assessed using LRT, and 
145




Trait  N  Males/Females  N SNPs  N Cases  N Controls 
Alzheimer (R)  3377  1475/1903  560622  655  2722 
Asthma  3390  1500/1890  560569  555  2835 
Asthma (R)  3375  1470/1905  560432  910  2465 
Bowel cancer (R)  3386  1495/1891  560630  672  2714 
Breast cancer  3388  1486/1902  560611  83  3305 
Breast cancer (R)  3386  1482/1904  560579  564  2822 
Chronic obstructive pulmonary disease  3387  1496/1891  560591  73  3314 
Chronic obstructive pulmonary disease (R)   3387  1474/1913  560620  553  2834 
Depression  3385  1495/1890  560584  483  2902 
Depression (R)   3382  1506/1876  560514  731  2651 
Diabetes  3388  1497/1891  560469  185  3203 
Diabetes (R)   3389  1481/1908  560584  1144  2245 
Heart disease  3392  1504/1888  560526  212  3180 
Heart disease (R)   3377  1483/1894  560479  2254  1123 
High blood preasure  3402  1501/1901  560508  729  2673 
High blood preasure (R)   3372  1464/1908  560569  1901  1471 
Hip fracture (R)   3388  1489/1899  560572  421  2967 
Lung cancer (R)   3379  1492/1887  560600  798  2581 
Osteoarthritis  3395  1486/1909  560640  411  2984 
Osteoarthritis (R)   3383  1466/1917  560516  961  2422 
Parkinson (R)   3388  1488/1900  560590  236  3152 
Prostate cancer (R)   3381  1495/1886  560570  329  3052 
Rheumatoid arthritis  3387  1490/1897  560618  93  3294 
Rheumatoid arthritis (R)   3380  1487/1893  560543  765  2615 
Stroke  3387  1492/1895  560613  81  3306 
Stroke (R)   3385  1463/1922  560478  1506  1879 
Neuroticism*  3421  1521/1900  560484  ‐  ‐ 
Extraversion*  3420  1520/1900  560476  ‐  ‐ 
Schizotypal personality*  2386  1065/1321  560369  ‐  ‐ 
Mood disorder*  2307  1040/1267  560318  ‐  ‐ 
Samples were maximized for retention of cases to maximize the information available for each trait. There 
was  no  preferential  selection  of  relatives  in  pairs  for  quantitative  phenotypes,  in  order  to  retain  the 
underlying distribution. All individuals involved in the datasets listed above were non‐respondents to the 
GS  follow‐up  study. Compared  to  individuals  included at GS GWEIS  (respondents  in GS  follow‐up),  non‐
respondents  were  significantly:  younger,  from  more  socioeconomically  deprived  areas,  generally  less 
healthier  and  wealthier.  Non‐respondents  were  more  likely  to  smoke,  and  less  likely  to  drink  alcohol, 
although  they  consumed  more  units  per  week,  compared  with  respondents.  At  GS  baseline,  non‐
respondents  experienced more psychological  distress  and  reported higher  scores  in  symptoms of GHQ‐
depression and GHQ‐anxiety than respondents415. The total target sample size (N), number of males and 







5.4.1 Phenotypic and genetic correlations 
Depressive symptoms scores and SLE measures were positively correlated 
in both UKB (r2 = 0.22, p < 2.2 x 10-16) and GS (TSLE-r2 = 0.21, p =1.69 x 10-
52; DSLE-r2 = 0.21, p = 8.59 x 10-51; ISLE-r2 = 0.17, p = 2.33 x 10-33). 
Significant bivariate genetic correlation between depression and SLE scores 
was identified in UKB (rG = 0.72; p < 1 x 10-5, N = 50,000), but not in GS (rG 
= 1, p ≥ 0.056, N = 4,919; Appendix D: Supplementary Table 3a). 
5.4.2 SNP-heritability (h2SNP) 
In UKB, a significant h2SNP of PHQ was identified (h2SNP = 0.090; p < 0.001; N 
= 99,057). This estimate remained significant after adjusting by TSLEUKB 
effect (h2SNP = 0.079; p < 0.001), suggesting a genetic contribution unique of 
depressive symptoms. The h2SNP of TSLEUKB was also significant (h2SNP = 
0.040, p < 0.001; Appendix D: Supplementary Table 3b). In GS, h2SNP was 
not significant for GHQ (h2SNP = 0.071, p = 0.165; N = 4,919). However, in an 
ad hoc estimation from the baseline sample of 6,751 unrelated GS 
participants (details in Appendix D: Supplementary Table 3b) we detected a 
significant h2SNP for GHQ (h2SNP = 0.135; p < 5.15 x 10-3), suggesting that the 
power to estimate h2SNP in GS may be limited by sample size. Estimates 
were not significant for neither TSLE (h2SNP = 0.061, p = 0.189; Appendix D: 
Supplementary Table 3b) nor ISLE (h2SNP = 0.000, p = 0.5), but h2SNP was 
significant for DSLE (h2SNP = 0.131, p = 0.029), supporting a potential genetic 
mediation and gene-environment correlation.  
5.4.3 GWAS of depressive symptoms 
No genome-wide significant SNPs were detected by GWAS in either cohort. 
Top findings (p < 1 x 10-5) are summarized in Appendix D: Supplementary 
Table 4. Manhattan and QQ plots are shown in Appendix D: Supplementary 
Figures 1-4. There was no evidence of genomic inflation (all λ1000 < 1.01).  
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5.4.4 Post-GWAS analyses 
Gene-based test identified six genes associated with PHQ using UKB-GWAS 
statistics at genome-wide significance (Bonferroni-corrected p = 2.77 x 10-6; 
DCC, p = 7.53 x 10-8; ACSS3, p = 6.51 x 10-7; DRD2, p = 6.55 x 10-7; 
STAG1, p = 1.63 x 10-6; FOXP2, p = 2.09 x 10-6; KYNU, p = 2.24 x 10-6; 
Appendix D: Supplementary Figure 8). Prioritized genes based on position, 
eQTL and chromatin interaction mapping are detailed in Appendix D: 
Supplementary Table 5. No genes were detected in GS-GWAS gene-based 
test (Appendix D: Supplementary Figures 9). No tissue enrichment was 
detected from GWAS in either cohort. Significant gene-sets and GWAS 
catalog associations for UKB-GWAS are reported in Appendix D: 
Supplementary Table 6. These included the biological process: positive 
regulation of long term synaptic potentiation, and GWAS catalog 
associations: brain structure, schizophrenia, response to amphetamines, 
age-related cataracts (age at onset), fibrinogen, acne (severe), fibrinogen 
levels, and educational attainment; all adjusted-p < 0.01. There was no 
significant gene-set enrichment from GS-GWAS. 
5.4.5 GWEIS of depressive symptoms 
Manhattan and QQ plots are shown in Appendix D: Supplementary Figures 
1-4. There was no evidence of GWEIS inflation for either UKB or GS (all λ1000 
< 1.01). No genome-wide significant GWEIS associations were detected for 
SLE in UKB. GS-GWEIS using TSLE identified a significant GxE effect (p < 
2.97 x 10-8) at an intragenic SNP on chromosome 11 (rs12789145, p = 4.95 x 
10-9, β = 0.06, closest gene: PIWIL4; Appendix D: Supplementary Figure 5), 
and using DSLE at an intronic SNP in ZCCHC2 on chromosome 18 
(rs17070072, p = 1.46 x 10-8, β = -0.08; Appendix D: Supplementary Figure 
6). In their corresponding joint effect tests both rs12789145 (p = 2.77 x 10-8) 
and rs17070072 p = 1.96 x 10-8) were significant. GWEIS for joint effect 
using DSLE identified two further significant SNPs on chromosome 9 
(rs12000047, p = 2.00 x 10-8, β = -0.23; rs12005200, p = 2.09 x 10-8, β = -
0.23, LD r2 > 0.8, closest gene: CYLC2; Appendix D: Supplementary Figure 
7). None of these associations replicated in UKB (p > 0.05), although the 
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effect direction was consistent between cohorts for the SNP close to PIWL1 
and SNPs at CYLC2. No SNP achieved genome-wide significant association 
in GS-GWEIS using ISLE as exposure. Top GWEIS results (p < 1 x 10-5) are 
summarized in Appendix D: Supplementary Tables 7-10. 
5.4.6 Post-GWEIS analyses: gene-based tests 
All results are shown in Appendix D: Supplementary Figures 10-17. Two 
genes were associated with PHQ using the joint effect from UKB-GWEIS 
(ACSS3 p = 1.61 x 10-6; PHF2, p = 2.28 x 10-6; Appendix D: Supplementary 
Figure 11). ACSS3 was previously identified using the additive main effects, 
whereas PHF2 was only significantly associated using the joint effects. 
Gene-based tests identified MTNR1B as significantly associated with GHQ 
on GS-GWEIS using DSLE in both GxE (p = 1.53 x 10-6) and joint effects (p = 
2.38 x 10-6; Appendix D: Supplementary Figures 14-15).  
5.4.7 Post-GWEIS analyses: tissue enrichment 
We prioritized genes based on position, eQTL and chromatin interaction 
mapping in brain tissues and regions. In UKB, prioritized genes with GxE 
effect were enriched for up-regulated differentially expressed genes from 
adrenal gland (adjusted-p = 3.58 x 10-2). Using joint effects, prioritized genes 
were enriched on up-regulated differentially expressed genes from artery 
tibial (adjusted-p = 4.34 x 10-2). In GS, prioritized genes were enriched: in up-
regulated differentially expressed genes from artery coronary (adjusted-p = 
4.55 x 10-2) using GxE effects with DSLE; in down-regulated differentially 
expressed genes from artery aorta tissue (adjusted-p = 4.71 x 10-2) using 
GxE effects with ISLE; in up-regulated differentially expressed genes from 
artery coronary (adjusted-p = 5.97 x 10-3, adjusted-p = 9.57 x 10-3) and artery 
tibial (adjusted-p = 1.05 x 10-2, adjusted-p = 1.55 x 10-2) tissues using joint 
effects with both TSLE and DSLE; and in down-regulated differentially 
expressed genes from lung tissue (adjusted-p = 3.98 x 10-2) and in up- and 
down-regulated differentially expressed genes from the spleen (adjusted-p = 
4.71 x 10-2) using joint effects with ISLE. There was no enrichment using 
GxE effect with TSLE. 
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5.4.8 Post-GWEIS analyses: gene-sets enrichment 
Significant gene-sets and GWAS catalog hits from GWEIS are detailed in 
Appendix D: Supplementary Tables 11-14, including for UKB Biocarta: 
GPCR pathway; Reactome: opioid signalling, neurotransmitter receptor 
binding and downstream transmission in the postsynaptic cell, transmission 
across chemical synapses, gastrin CREB signalling pathway via PKC and 
MAPK; GWAS catalog: post bronchodilator FEV1/FVC ratio, migraine and 
body mass index. In GS, enrichment was seen using TSLE and DLSE for 
GWAS catalog: age-related macular degeneration, myopia, urate levels and 
Heschl’s gyrus morphology; and using ISLE for biological process: regulation 
of transporter activity. All adjusted-p < 0.01. 
5.4.9 Cross-cohort prediction 
In GS, PRSD weighted by UKB-GWAS of PHQ significantly explained 0.56% 
of GHQ variance (Empirical-p < 1.10-4), similar to PRSMDD weighted by PGC 
MDD-GWAS (R2 = 0.78%, Empirical-p < 1.10-4). PRSGxE weighted by UKB-
GWEIS GxE effects explained 0.15% of GHQ variance (Empirical-p = 0.03,
Appendix D: Supplementary Table 15). PRSGxE fitted jointly with PRSMDD
significantly improved prediction of GHQ (R2 = 0.93%, model p = 6.12 x 10-11;
predictive improvement of 19%, LRT-p = 5.91 x 10-3) compared to PRSMDD
alone. Similar to PRSGxE with PRSD (R2 = 0.69%, model p = 2.72 x 10-8;
predictive improvement of 23%, LRT-p = 0.01). PRSJoint weighted by UKB-
GWEIS also predicted GHQ (R2 = 0.58%, Empirical-p < 1.10-4), although the
variance explained was significantly reduced compared to the model fitting
PRSGxE and PRSD together (LRT-p = 4.69 x 10-7), suggesting that additive
and GxE effects should be modelled independently for polygenic approaches
(Figure 5.2a).
In UKB (Figure 5.2b), both PRSD weighted by GS-GWAS of GHQ and 
PRSMDD significantly explained 0.04% and 0.45% of PHQ variance, 
respectively (both Empirical-p < 1.10-4; Appendix D: Supplementary Table 
15). PRSGxE derived from GS-GWEIS GxE effect did not significantly 
predicted PHQ (TSLE-PRSGxE Empirical-p = 0.382; DSLE-PRSGxE Empirical-
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p = 0.642; ISLE-PRSGxE Empirical-p = 0.748). Predictive improvements by 
PRSGxE effect fitted jointly with PRSMDD or PRSD were not significant (all LRT-
p > 0.08). PRSJoint significantly predicted PHQ (TSLE-PRSJoint: R2 = 0.032%, 
Empirical-p < 1.10-4; DSLE-PRSJoint: R2 = 0.012%, Empirical-p = 4.3 x 10-3; 
ISLE-PRSJoint: R2 = 0.032%, Empirical-p < 1.10-4), although the variances 
explained were significantly reduced compared to the models fitting PRSGxE 
and PRSD together (all LRT-p < 1.48 x 10-3). 
5.4.10 Prediction of stress-related traits 
Prediction of stress-related traits in independent samples using PRSD, 
PRSGxE and PRSJoint are summarized in Figure 5.3a and Appendix D: 
Supplementary Table 16. Significant trait prediction after FDR adjustment 
(Empirical-p < 6.16 x 10-3, FDR-adjusted Empirical-p < 0.05) using both UKB 
and GS PRSD was seen for: depression status, neuroticism and schizotypal 
personality. PRSGxE weighted by GS-GWEIS GxE effect using ISLE 
significantly predicted depression status mapping by proxy (Empirical-p = 
7.00 x 10-4, FDR-adjusted Empirical-p = 9.54 x 10-3). 
Nominally significant predictive improvements (LRT-p < 0.05) of fitting 
PRSGxE over the PRSD effect alone using summary statistics generated from 
both UKB and GS were detected for schizotypal personality, heart diseases 
and COPD by proxy (Figure 5.3b). PRSGxE weighted by GS-GWEIS GxE 
effect using ISLE significantly improved prediction over PRSD effect alone of 
depression status mapping by proxy after FDR adjustment (LRT-p = 1.96 x 
10-4, FDR-adjusted LRT-p = 2.35 x 10-2).
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was  seen  in  Generation  Scotland  when  PRSGxE  was  incorporated  into  a  multiple 
regression model along with PRSD; and of about 19% when PRSGxE was incorporated 
into a multiple regression model along with PRSMDD. Such gain was not seen  in UK 
Biobank, but  it must be noted  that both PRSD and PRSMDD also explains much  less 
variance  of  PHQ  in  UK  Biobank  than  of  GHQ  in  Generation  Scotland.  To  note  a 






to  traits  using  mapping  by  proxy  approach  (i.e.  where  first‐degree  relatives  of 
individuals with the disease are considered proxy cases and included into the group 
of  cases).  Y‐axis  shows  the  discovery  sample  and  the  effect  used  to  weight  PRS. 
Numbers  in  cells  indicate  the %  of  variance  explained,  also  represented  by  colour 
scale.  Significance  is  represented  by  “*”  according  to  the  following  significance 
codes: p‐values **** < 1 x 10‐4 < *** < 0.001 < ** < 0.01 * < 0.05; in grey Empirical‐
p‐values after permutation  (10,000  times) and  in yellow FDR‐adjusted Empirical‐p‐
values.  b)  Predictive  improvement  by  GxE  effect  in  independent  GS  datasets. 
Heatmanp illustrating the predictive improvement as a result of incorporating PRSGxE 
into  a multiple model  along  with  PRSD  and  covariates  (full  model),  over  a model 
fitting PRSD alone with covariates (null model); predicting a wide range of traits from 
GS listed in the x‐axis (Table 5.1). Covariates: age, sex and 20 PCs. (R) refers to traits 
using  mapping  by  proxy  approach  (i.e.  where  first‐degree  relatives  of  individuals 
with  the  disease  are  consider  proxy  cases  and  included  into  the  group  of  cases). 
PRSGxE are weighted by GWEIS using GxE effects. PRSD were weighted by the GWAS 
of  depressive  symptoms  additive  main  effects.  The  Y‐axis  shows  the  discovery 
sample used to weight PRS.  Numbers in cells indicate the % of variance explained by 
the  PRSGxE,  also  represented  by  colour  scale.  Notice  that  those  correspond  to  the 
PRSGxE  predictions  in  Figure  5.3a  when  PRSGxE  are  weighted  by  GxE  effects. 
Significance was  tested by  Likelihood  ratio  tests  (LRT):  full model  including PRSD + 
PRSGxE  vs.  null  model  with  PRSD  alone  (covariates  adjusted).  Significance  is 





This study performs GWAS and incorporates data on recent adult stressful 
life events (SLE) into GWEIS of depressive symptoms, identifies new loci and 
candidate genes for the modulation of genetic response to SLE; and provides 
insights to help disentangle the underlying aetiological mechanisms 
increasing genetic liability through SLE to both depressive symptoms and 
stress-related traits.  
SNP-heritability of depressive symptoms (h2SNP = 9-13%), were slightly 
higher than estimates from African American populations113, and over a third 
larger than estimates in MDD from European samples182. h2SNP for PHQ in 
UKB (9.0%) remained significant after adjusting for SLE (7.9%). Thus, 
although some genetic contributions may be partially shared between 
depressive symptoms and reporting of SLE, there is still a relatively large 
genetic contribution unique to depressive symptoms. Significant h2SNP of 
DSLE in GS (13%) and TSLEUKB in UKB (4%), which is mainly composed of 
dependent SLE items, were detected similar to previous studies (8% and 
29%)112,113. Conversely, there was no evidence for heritability of independent 
SLE. A significant bivariate genetic correlation between depressive 
symptoms and SLE (rG = 0.72) was detected in UKB after adjusting for 
covariates, suggesting that there are shared common variants underlying 
self-reported depressive symptoms and SLE. This bivariate genetic 
correlation was smaller than that estimated from African American 
populations (rG = 0.97; p= 0.04; N = 7,179)113. Genetic correlations between 
SLE measures and GHQ were not significant in GS (N = 4,919; rG = 1; all p 
> 0.056), perhaps due to a lack of power in this smaller sample.
Post-GWAS gene-based tests detected six genes significantly associated 
with PHQ (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU). Previous 
studies have implicated these genes in liability to depression (see Appendix 
D: Supplementary Table 17), and three of them are genome-wide significant 
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in gene-based tests from the latest meta-analysis of major depression that 
includes UKB (DCC, p = 2.57 x 10-14; DRD2, p = 5.35 x 10-14; and KYNU, p = 
2.38 x 10-6; N = 807,553)151. This supports the implementation of quantitative 
measures such as PHQ to detect genes underlying lifetime depression 
status449. For example, significant gene ontology analysis of the UKB-GWAS 
identified enrichment for positive regulation of long-term synaptic 
potentiation, and for previous GWAS findings of brain structure450, 
schizophrenia451 and response to amphetamines452. 
The key element of this study was to conduct GWEIS of depressive 
symptoms and recent SLE. We identified two loci with significant GxE effect 
in GS. However, none of these associations replicated in UKB (p > 0.05). 
The strongest association was using TSLE at 53kb down-stream of PIWIL4 
(rs12789145). PIWIL4 is brain-expressed and involved in chromatin-
modification453, suggesting it may moderate the effects of stress on 
depression. It encodes HIWI2, a protein thought to regulate OTX2, which is 
critical for the development of forebrain and for coordinating critical periods of 
plasticity disrupting the integration of cortical circuits454,455. Indeed, an intronic 
SNP in PIWIL4 was identified as the strongest GxE signal in ADHD using 
mother’s warmth as environmental exposure456. The other significant GxE 
identified in our study was in ZCCHC2 using DSLE. This zinc finger protein is 
expressed in blood CD4+ T-cells and is down regulated in individuals with 
MDD457 and in those resistant to treatment with citalopram458. No GxE effect 
was seen using ISLE as exposure.  
No significant locus or gene with GxE effect was detected in UKB-GWEIS. 
Nevertheless, joint effects (combined additive main and GxE genetic effects) 
identified two genes significantly associated with PHQ (ACSS3 and PHF2; 
see Appendix D: Supplementary Table 17). PHF2 was recently detected as 
genome-wide significant at the latest meta-analysis of depression151. Notably, 
PHF2 paralogs have already been link with MDD through stress-response in 
three other studies343,344,459. Joint effects in GS also detected an additional 
significant association upstream CYLC2, a gene nominally associated (p < 1 
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x 10-5) with obsessive-compulsive disorder and Tourette’s Syndrome460. 
Gene-based test from GS-GWEIS identified a significant association with 
MTNR1B, a melatonin receptor gene, using DSLE (both GxE and joint effect; 
Appendix D: Supplementary Table 17). Prioritized genes using GxE effects 
were enriched in differentially expressed genes from several tissues including 
the adrenal gland, which releases cortisol into the blood-stream in response 
to stress, thus playing a key role in the stress-response system, reinforcing a 
potential role of GxE in stress-related conditions.  
The different instruments and sample sizes available make it hard to 
compare results between cohorts. Whereas GS contains deeper phenotyping 
measurements of stress and depressive symptoms than UKB, the sample 
size is much smaller, which may be reflected in the statistical power required 
to detect reliable GxE effects. Furthermore, the presence and size of GxE are 
dependent on their parameterization (i.e. the measurement, scale and 
distribution of the instruments used to test such interaction)425. Thus, GxE 
may be incomparable across GWEIS due to differences in both phenotype 
assessment and stressors tested. Although our results suggest that both 
depressive symptom measures are correlated with lifetime depression status, 
different influences on depressive symptoms from the SLE covered across 
studies may contribute to lack of stronger replication. Instruments in GS 
cover a wider range of SLE and are more likely to capture changes in 
depressive symptoms as consequence of their short-term effects. 
Conversely, UKB could capture more marked long-term effects, as SLE were 
captured over 2 years compared to 6 months in GS. New mental health 
questionnaires covering a wide range of psychiatric symptoms and SLE in 
the last release of UKB data provides the opportunity to create more similar 
measures to GS in the near future. Further replication in independent studies 
with equivalent instruments is required to validate our GWEIS findings. 
Despite these limitations and a lack of overlap in the individual genes 
prioritised from the two GWEIS, replication was seen in the predictive 
improvement of using PRSGxE derived from the GWEIS GxE effects to predict 
stress-related phenotypes. 
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The third aim of this study was to test whether GxE effect could improve 
predictive genetic models, and thus help to explain deviation from additive 
models and missing heritability of MDD82. Multiple regression models 
suggested that inclusion of PRSGxE weighted by GxE effects could improve 
prediction of an individual’s depressive symptoms over use of PRSMDD or 
PRSD weighted by additive effects alone. In GS, we detected a predictive 
gain of 19% over PRSMDD weighted by PGC MDD-GWAS, and a gain of 23% 
over PRSD weighted by UKB-GWAS (Figure 5.2a). However, these findings 
did not surpass stringent Bonferroni-correction and could not be validated in 
UKB. This may reflect in the poor predictive power of the PRS generated 
from the much smaller GS discovery sample. The results show a noticeably 
reduced prediction using PRSJoint weighted by joint effects, which suggests 
that the genetic architecture of stress-response is at least partially 
independent and differs from genetic additive main effects. Therefore, our 
results from multiple regression models suggest that for polygenic 
approaches main and GxE effects should be modelled independently. 
SLE effects are not limited to mental illness444. Our final aim was to 
investigate shared aetiology between GxE for depressive symptoms and 
stress-related traits. Despite the differences between the respondents and 
non-respondents (Table 5.1 legend), a significant improvement was seen 
predicting depressive status mapping by proxy cases using GxE effect from 
GS-GWEIS with independent SLE (FDR-adjusted LRT-p = 0.013), but not 
with dependent SLE. GxE effects using statistics generated from both 
discovery samples, despite the differences in measures, nominally improved 
the phenotypic prediction of schizotypal personality, heart disease and the 
proxy of COPD (LRT-p < 0.05). Other studies have found evidence 
supporting a link between stress and depression in these phenotypes that 
support our results (see Appendix D.3 for extended review) and suggest, for 
instance, potential pleiotropy between schizotypal personality and stress-
response. Our findings point to a potential genetic component underlying a 
stress-response-depression-comorbidities link due, at least in part, to shared 
stress-response mechanisms. A relationship between SLE, depression and 
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coping strategies such as smoking suggests that perhaps, genetic stress-
response may modulate adaptive behaviours such as smoking, fatty diet 
intake, alcohol consumption and substance abuse. This is discussed further 
in the Appendix D.3. 
In this study, evidence for SNPs with significant GxE effects came primarily 
from the analyses of dependent SLE and not from independent SLE. This 
supports a genetic effect on probability of exposure to, or reporting of SLE, 
endorsing a gene-environment correlation. Chronic stress may influence 
cognition, decision-making and behaviour eventually leading to higher risk-
taking461. These conditions may also increase sensitivity to stress amongst 
vulnerable individuals, including those with depression, who also have a 
higher propensity to report SLE, particularly dependent SLE98. A potential 
reporting bias in dependent SLE may be mediated as well by heritable 
behavioural, anxiety or psychological traits such as risk-taking112,462. 
Furthermore, individuals vulnerable to MDD may expose themselves into 
environments of higher risk and stress103. This complex interplay, reflected in 
the form of a gene-environment correlation effect, would hinder the 
interpretation of GxE effects from GWEIS as pure interactions. A mediation of 
associations between SLE and depressive symptoms through genetically 
driven sensitivity to stress, personality or behavioural traits would support the 
possibility of subtle genotype-by-genotype (GxG) interactions, or genotype-
by-genotype-by-environment (GxGxE) interactions contributing to 
depression463,464. In contrast, PRS prediction of the stress-related traits: 
schizotypal personality, heart disease and COPD, was primarily from derived 
weights using independent SLE, suggesting that a common set of variants 
moderate the effects of SLE across stress-related traits and that larger 
sample sizes will be required to detect the individual SNPs contributing to 
this. Thus, our finding supports the inclusion of environmental information 
into GWAS to enhance the detection of relevant genes. Results of studying 
dependent and independent SLE support a contribution of genetically 
mediated exposure to and/or reporting of SLE, perhaps through sensitivity to 
stress as mediator. 
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This study emphasises the relevance of GxE in depression and human 




Chapter 6 A new test of the diathesis-stress 
framework for depression: 
contributions to liability from 
genetics underlying sensitivity and 
response to psychosocial stress 
 
I have generated summary data on two distinct SNP effects related to genetic 
response to environmental stress: the effect of a proxy for MDD-dependent 
sensitivity to stress derived in chapter 2, and the GxE effect to reported SLE 
on depression score derived in chapter 5. In chapter 4, I implemented a 
diathesis-stress framework in order to investigate GxE effects in depression. 
However, the SNP effects used to weight the PRS, included in the PRSxSLE 
term, were derived from PGC GWAS of MDD and, therefore, based in the 
main additive effects of MDD. In this chapter, I incorporate the data I 
generated in chapter 2 and chapter 5 in order to test the diathesis-stress 
model implemented in chapter 4 using alternative weightings for the PRS. I 
implement new tests of the diathesis-stress model for depression using 
weightings for stress-sensitivity and stress-response in order to test for the 
presence of GxE effect with reported SLE, and compare these results to 
those in chapter 4. 
The following chapter has been formatted for publication to PLOS Genetics, 
which explains the use of “we” along the chapter and the inclusion of an 
author summary. I confirm that the work presented is my own work under 
guidance from my supervisor Dr. Pippa Thomson. I performed all the 
analyses myself.  
Expected publication: 
Arnau-Soler, A. et al. A new test of the diathesis-stress framework for 
depression: contributions to liability from genetics underlying sensitivity and 




Gene-by-environment interactions (GxE) for risk of depression have been 
evaluated under diathesis-stress models assuming that most genetic variants 
with additive effects also contribute to GxE. An alternative hypothesis is that 
GxE effects may be displayed by variants with negligible additive effects. 
We implement polygenic risk scores (PRS) weighted by either a Genome-
Wide Interaction Study of a proxy for stress-sensitivity (𝑃𝑅𝑆 ) or a Genome-
Wide by Environment Interaction Study for depressive symptoms (𝑃𝑅𝑆 ) to 
predict depression, both independently and combined with PRS for major 
depressive disorder (𝑃𝑅𝑆 ) and reported stressful life events (SLE), in a 
sample of 4,919 unrelated individuals. 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , and 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interactions are used to test diathesis-stress theory for 
depression, and differences between women and men examined. 
Both 𝑃𝑅𝑆  and 𝑃𝑅𝑆  predict liability to depressive symptoms not 
accounted for by 𝑃𝑅𝑆 . A nominally significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction 
was detected in the full sample, but not with 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  or 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 . In 
comparison, a previous subset of the discovery sample for MDD did not 
detect a significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  effect, suggesting that with large enough 
discovery samples more robust GxE effects could be achieved. We detected 
a significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction in men explaining 0.42% of the variance 
in depression (p = 2.1 x 10-3) in addition to 0.50% explained by 𝑃𝑅𝑆 . The 
effect of 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  was significantly different across sexes (p = 1.00 x 10-3). 
Categorizing the number of SLE reported in none, low (1 or 2) and high (3 or 
more), 𝑃𝑅𝑆  increased the risk of depression in men who reported high 
numbers of SLE (p = 1.84 x 10-4), following similar patterns in the full sample 
(p = 7.37 x 10-3) and in women (p = 0.03).  
Our study investigates the potential of two genome-wide alternatives to 
standard GWAS, for the detection of common variants with effects related to 
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stress response significantly contributing to depression, and for using its 
estimated effects as new weights to test the diathesis-stress theory. 
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6.2 Author summary 
Stress has implications for many human conditions, including depression, a 
complex psychiatric disorder that requires from both genetic and 
environmental factors to manifest. Standard genome-wide association 
studies have identified common genetic variants displaying a direct 
association with depression. However, such variants may be distinct from 
those responding to the effects of stress and undetectable when the 
environment is not taken in to account. Here we show that common variants 
with stress-related effects add an additional risk of suffering depressive 
symptoms. Our findings show that people, particularly men, are at higher risk 
of depression due to genetic sensitivity to stress when they report high 
numbers of recent stressful life events. The results suggest an important 
contribution to psychiatric genetic research of alternative genome-wide 
approaches as discovery sample sizes increase. Identifying the presence of 
genetic pathways with modulatory effects to psychological stress could lead 
to better treatments and prevention strategies not only in depression, but also 




Major depressive disorder (MDD) develops from the complex interplay of 
many genetic factors forming an individual’s polygenic vulnerability and the 
environment119,226,465. Twin studies estimate that for MDD, genetic factors 
account for about 40% of the phenotypic variance119, the contribution of 
common genetic variants in liability to MDD is approximately 10%150, and 
genome-wide association studies (GWAS) have already identified genetic 
risk variants robustly associated with MDD149,150,152,153,184. However, results 
from twin studies estimate that environmental influences account for up to 
63% of the liability to MDD119, of which stressful life events (SLE) are among 
the environmental factors most consistently associated84,90,94,402.  
The diathesis-stress theory conceptualizes the development of 
psychopathologies as the combined effect of genetic and environmental risk 
factors228. It suggests that individuals have a latent inherent vulnerability or 
predisposition to depression, a so-called diathesis, that is variable across 
individuals225. However, it assumes that this diathesis is not enough and 
some environmental trigger, such as SLE, is required for the development of 
symptoms225. According to the theory, people with a higher diathesis for MDD 
will require lower amounts of stress to develop symptoms, and vice versa. 
However, these additive effects may not be enough and some additional 
effect may be required to exceed the threshold at which the clinical disorders 
manifest. Thus, the diathesis-stress theory proposes the presence of a 
genotype-by-environment interaction (GxE) effect between an individual’s 
vulnerability and psychological stress that plays a key role in the onset and 
development of MDD. However, the nature of the GxE effect underpinning 
the development of depressive symptoms remains elusive.  
Polygenic risk scores (PRS) are quantitative metrics of an individual's overall 
genetic vulnerability aggregating the additive effects of many common 
genetic risk variants466. Therefore, PRS can be conceptualized as indicators 
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of the diathesis (i.e. genetic vulnerability or predisposition to disease). This 
allows the diathesis-stress theory to be empirically tested in a model that 
takes into account the diathesis effect (operationalized as PRS), the stress 
effect of SLE (operationalized as a self-reported measure of SLE), and the 
diathesis-stress interaction effect (operationalized as a GxE interaction 
product of 𝑆𝐿𝐸𝑥𝑃𝑅𝑆). Thus providing an empirical method to seek evidence 
of GxE effects in liability to MDD. A PRSxE approach has successfully 
identified GxE effects in other traits such as obesity with physical activity467 or 
with sugar sweetened beverages468. Despite the reduction in statistical power 
caused by using a PRS that may include SNPs without a truly modulatory 
effect, the gain in explanatory power of PRS compared to single SNPs 
remains considerable274.  
Following the expansion and success of GWAS and polygenic approaches, 
GxE studies have empirically tested this diathesis-stress model for 
depression with adult SLE86,169,276,431, reporting the first evidence of a 
genome-wide GxE effect169,431.  However, a plausible explanation for the 
weakly significant GxE effects identified may be the rationale behind the 
construction of the diathesis-stress model in these studies. These studies 
generated PRS using the additive effect at each SNP for MDD from 
Psychiatric Genomics Consortium genome-wide association studies 
(𝑃𝑅𝑆 ) to weight both the additive and GxE terms. However, some genetic 
factors contributing to GxE effects in depression may not display additive 
main contributions to MDD in the absence of stress. Indeed, there is 
evidence that polymorphisms in genes such as BDNF and HTR1A, may only 
influence the development of MDD through a direct effect on vulnerability to 
the effects of stress and/or environmental adversity464,469-473. In accordance 
with this, the expression of BDNF in the hippocampus of rats is dependent on 
the amount of stress474 and important for long-term synapse potentiation475. 
Nevertheless, BDNF was not identified in the latest GWAS of MDD involving 
807,553 individuals151. Hence, the effect of genetic variants with stress-
related effects on risk of depression may remain hidden in current GWAS 
that do not take into account environmental influences. It also suggests that 
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the SNPs involved in the additive main effects and the GxE effects may 
correspond to different biological pathways. An alternative model could be 
built using distinct PRS to operationalize the main diathesis effect and the 
interaction effect with SLE for depression. In this study we examine two 
possible alternate weightings for the GxE term derived from studies of stress-
sensitivity and genome-wide by environment interaction studies (GWEIS)378. 
In a previous study, we generated a proxy for individual’s sensitivity to 
negative outcomes by modelling the interaction between SNP allele and 
MDD status on neuroticism score through a genome-wide interaction study 
(GWIS) 378. Individuals with MDD score higher in tests of neuroticism213,214, 
an heritable personality trait476 thought to mediate or moderate the effects of 
adverse experiences79,222. This GWIS identified common genetic variants 
that showed MDD-dependent effects on neuroticism and implicated 
glucocorticoid receptor function as a mediator of sensitivity to stress. PRS 
weighted by the genetic contributions to such proxy for stress-sensitivity 
(𝑃𝑅𝑆 ) significantly predicted the liability to MDD not attributable to additive 
main effects of either MDD or neuroticism378.  
External weights from GWEIS may also increase the power to detect GxE477. 
GWEIS evaluate the association between a trait of interest and the GxE 
effect of a SNP allele and an environmental risk factor at the genome-wide 
scale. To date, only a very few GWEIS of depression and SLE are 
available113,267-269,427. All of which use relatively small sample sizes (N = 320 - 
99,057), despite this, all report at least one significant locus. PRS weighted 
by GxE effects (𝑃𝑅𝑆 ) using the results of GWEIS significantly improve the 
prediction of depressive symptoms427.  
In this study, we aim to test whether the non-additive genetic contributions 
are relevant in predicting the risk of depression using weightings derived from 
GWIS and GWEIS in UK Biobank (N = 23,092 and 99,057, respectively); and 
to assess whether the implementation of these alternative weightings to the 
diathesis-stress model would improve the evidence for GxE effects. First, we 
test the liability to a depression score explained by PRS weighted by the 
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effects estimated in UK Biobank GWIS and GWEIS in a sample of 4,919 
unrelated white Caucasian participants from Generation Scotland. Then, we 
investigate the contribution of each diathesis in a full model accounting for 
the additive effects of SLE, 𝑃𝑅𝑆 , 𝑃𝑅𝑆 , and 𝑃𝑅𝑆  together. Finally, we 
compare the detected GxE effects with reported SLE in a diathesis-stress 
framework replacing the diathesis-stress interaction term by 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , or 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 . In all three scenarios the main diathesis term in 
the diathesis-stress model is fixed to the best 𝑃𝑅𝑆 431 weighted by the 
Psychiatric Genomics Consortium (PGC) MDD GWAS169. Significant 
interactions are further investigated by level of exposure. By stratifying by sex 
we seek to explore differences between women and men in stress response 
underlying the aetiology of depression. We show an increased risk of 
depression not account for additive main contributions to MDD from variants 
displaying stress sensitivity and stress response effects. At current discovery 
sample sizes, the best estimates of a GxE effect come from testing the 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction. However, it is possible that alternative 
implementations could achieve better prediction as sample sizes increase in 






6.4 Materials and methods 
6.4.1 Cohort description 
This study is conducted in data from Generation Scotland (GS), a family-
based population cohort representative of the population of Scotland305. GS 
is a Biobank of biological samples, health and lifestyle data established 
through a multi-institutional, cross-disciplinary collaboration. Blood and 
salivary DNA samples from donors across Scotland ware obtained at 
baseline, stored and genotyped at the Wellcome Trust Clinical Research 
Facility, Edinburgh. The Illumina HumanOmniExpressExome-8 v1.0 DNA 
Analysis BeadChip (San Diego, CA, USA) and Infinium chemistry413 was 
used to generate genome-wide genotype data. Details for DNA extraction 
and genotyping have been described elsewhere307,414. Invitation to take part 
in a follow-up mental health study (Stratifying Resilience and Depression 
Longitudinally, STRADL)415 designed to investigate the aetiology of 
depression were sent to 21,525 eligible participants who gave consent for re-
contact415. From those participants who agreed to provide new updated 
questionnaires to the follow-up, 8,541 respondents reported all the required 
measures for our study. These cover a wide range of psychiatric symptoms 
and stressful life events (SLE; see assessments below). We removed 
samples duplicated, population outliers not recorded as “white British” or 
outliers detected by principal component analysis (mainly non-Caucasians 
and Italian ancestry subgroup), participants who had a diagnosis of bipolar 
disorder, and samples with sex discrepancies or more than 2% missing 
genotype data. SNPs with a call rate < 98%, deviation from Hardy-Weinberg 
Equilibrium (p < 1 x 10-6), or a minor allele frequency < 0.01 were excluded 
from the analysis. Finally, participants were filtered by degree of relatedness 
(pi-hat < 0.05) maximising retention of those individuals reporting higher 
number of SLE. The final sample consisted of 4,919 unrelated individuals of 
white-European ancestry and 560,351 genotyped SNPs. The full cohort 
dataset (N = 4,919) was split by sex in two additional datasets: women (N = 
2,990; mean age at 56.1) and men (N = 1,929; mean age at 58.7). 
Description of this study cohort has been previously published169,431. Further 
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details on the cohort profile of GS and STRADL are detailed elsewhere124,304-
306,415. Ethical approvals were obtained from the Tayside Committee on 
Medical Research Ethics on behalf of the NHS (reference 05/s1401/89) and 
all data is available to researchers on application to the Generation Scotland 
Access Committee (access@generationscotland.org). All participants 
provided written consent. 
6.4.2 Assessment of depressive symptoms  
A self-administered 28-item scaled version of The General Health 
Questionnaire (GHQ)416,417 was used to assess symptoms of depression. 
GHQ is a validated psychometric screening tool to detect current depressive 
symptoms197, among other psychiatric conditions, and designed to identify 
whether the mental state of a participant at the time of reporting has changed 
over the preceding two weeks from their typical state. The questionnaire is 
composed of subscales of symptoms linked to depression (i.e. severe 
depression, anxiety, social dysfunction and somatic symptoms) highly 
correlated418. Thus, an overall general factor of depression is implied419. 
Participants used the Likert scoring to rate the severity of symptoms (e.g. 
Have you recently felt that life is not worth living? “Not at all”, “No more than 
usual”, “Rather more than usual”, “Much more than usual”). The Likert 
scoring has the potential advantage to be more sensitive to psychopathology 
changes as response to stress in participants with chronic conditions (i.e. 
whose current symptoms do not differ from their typical state)420, and to 
provide a wider and smoother distribution than the summation scoring of 
number of symptoms197. To approximate to a normal distribution and reduce 
the effect of positive skew, the score was log-transformed to generate the 
final depression score. To validate the usefulness of our score as a measure 
of depression, we used self-reported questionnaire data on the Composite 
International Diagnostic Interview–Short Form, which diagnoses lifetime 
history of MDD according to DSM-IV criteria42. Depression score was scaled 
to a mean of 0 for a better interpretation of illustrations in Figure 6.3b. 
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6.4.3 Stressful life events (SLE) 
A measure of recent SLE was constructed from a self-reported brief life 
events questionnaire based on the 12-item List of Threatening 
Experiences99. Participants reported SLE experienced over the preceding 6 
months. This is a reliable psychometric screening tool to measure 
psychological stress with considerable long-term contextual effects (e.g. Over 
last 6 months, did a parent, spouse/partner, child, brother or sister of yours 
die?)422,423. A measure reflecting the total number of SLE reported was 
constructed by combining the number of “yes” responses.  
6.4.4 Polygenic profiling 
Polygenic risk scores (PRS) aggregate the number of risk alleles carried by 
an individual weighted by their allelic effects estimated in a genome-wide 
study from an independent discovery sample. We created four sets of PRS 
using summary statistics from four different studies: two Psychiatric Genetic 
Consortium (PGC) GWAS for MDD (stage 1: 9,240 cases and 9,519 controls; 
and updated version: 50,455 cases and 105,411 controls)147,169; a Genome-
Wide Interaction Study (GWIS) conducted on 23,092 unrelated white British 
participants from UK Biobank378; and a Genome-Wide by Environment 
Interaction Study (GWEIS) of depressive symptoms and psychological stress 
involving 99,057 unrelated white British individuals from UK Biobank476. The 
last three studies had Generation Scotland participants excluded. PRS were 
generated by PRSice-2313 and calculated from individual-level genotype data 
on each participant (N = 4,919). PRSice-2 removed strand-ambiguous SNPs 
and obtained the most significant independent SNPs in approximate linkage 
equilibrium by accounting for linkage disequilibrium (LD) among SNPs (LD-
clump-based pruning: r2 = 0.1, within a 10Mb window). First, two sets of 
𝑃𝑅𝑆  were generated using summary statistics from the PGC-MDD GWAS 
and weighted by main additive effects for MDD147,169. A third set of 𝑃𝑅𝑆  was 
generated using summary statistics from the UK Biobank GWIS and 
weighted by stress-sensitivity effects378. Finally, a fourth set of 𝑃𝑅𝑆  was 
generated using summary statistics from the UK Biobank GWEIS and 
weighted by stress-response (GxE) effects427. PRS were generated for seven 
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p thresholds (p threshold < 1 x 10-5, < 0.001, < 0.01, < 0.05, < 0.1, < 0.5, 
<=1) determined by each discovery sample. 𝑃𝑅𝑆 , 𝑃𝑅𝑆  and 𝑃𝑅𝑆  
represent three distinct genetic components or metrics of diathesis.  
PGC GWAS results are available at https://www.med.unc.edu/pgc/results-
and-downloads. Statistics excluding GS participants may be obtained under 
request. GWIS results are fully available378. Requests for the GWEIS results 
should be made at the Institute of Genetics and Molecular Medicine, 
Edinburgh, by contacting Dr. Pippa Thomson (pippa.thomson@ed.ac.uk). 
6.4.5 PRS models 
For each dataset (full sample, women and men), we constructed a genetic 
relatedness matrix (GRM) to fit into mixed linear models implemented in 
GCTA 1.26.0176. First, we tested the effect of both 𝑃𝑅𝑆  and 𝑃𝑅𝑆  
predicting both the depression score and reported SLE using mixed linear 
models as follow: 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑑 𝑆𝐿𝐸  𝛽 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑑 𝑆𝐿𝐸  𝛽 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠
Covariates include: age, age2, sex, age-by-sex and age2-by-sex interactions 
and 20 principal components. The significance of 𝛽  (i.e. the effect of PRS) 
was assessed using a one-sided Wald-test. To account for multiple testing 
correction, we established a threshold for significance at p = 3.57 x 10-3 after 
correcting for seven thresholds and two different diathesis effects tested (14 
tests).  
We assessed the effect of 𝑃𝑅𝑆  to predict depression score weighting by 
the past stage 1 PGC-MDD GWAS (referred as 𝑃𝑅𝑆 )147 to 





largest sample size previously reported169,431. The effect of 𝑃𝑅𝑆  predicting 
the depression score and reported SLE using the largest PGC-MDD GWAS, 
as well as the effect of the total number of reported SLE predicting the 
depression score, are published elsewhere431.  
6.4.6 A multi-PRS model 
To investigate the contribution of each diathesis we combined both SLE, 
𝑃𝑅𝑆 , 𝑃𝑅𝑆  and 𝑃𝑅𝑆  into a model in the full sample and stratifying by 
sex as follows: 
𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒  𝛽 𝛽 𝑆𝐿𝐸 𝛽 𝑃𝑅𝑆 𝛽 𝑃𝑅𝑆 𝛽 𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 
Covariates adjusted were the same detailed above for the diathesis models. 
The variance in depression score explained by all parameters and the 
significance of each effect coefficient (𝛽 , 𝛽 , 𝛽  and 𝛽 ) was estimated using 
a one-sided Wald test. 
6.4.7 Diathesis-stress models 
In our set of GS individuals, 𝑃𝑅𝑆  generated at the PGC-MDD GWAS p 
threshold = 0.1 (𝑃𝑅𝑆 _ .  was previously reported as the best predictor of 
the depression score169,431. To test the different diathesis-stress models for 
depression, we used 𝑃𝑅𝑆 _ .  to keep the main diathesis effect 
unchangeable across studies. Following previous implementations of the 
diathesis-stress model169,431, we fitted 𝑃𝑅𝑆 _ .  into the main term of the 
model (i.e. the main diathesis effect) and replaced the interactive product 
term (i.e. the diathesis-stress interaction effect) with either 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆  or 𝑃𝑅𝑆 . 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  were tested using both 𝑃𝑅𝑆  and 
𝑃𝑅𝑆 _  to assess how increasing the discovery sample size influence 
the final output.  The tested models were as follows: 
𝑀𝑜𝑑𝑒𝑙 1: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣. 
𝑀𝑜𝑑𝑒𝑙 2: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 _ 𝐺𝑅𝑀 𝐶𝑜𝑣. 
𝑀𝑜𝑑𝑒𝑙 3: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎. 
178
𝑀𝑜𝑑𝑒𝑙 4: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛  𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣. 
Covariates (Cov.) include: age, age2, sex, age-by-sex and age2-by-sex 
interactions and 20 principal components. In order to adjust for covariate 
interactions424, the covariates were previously regressed out from all PRS 
and SLE and the residuals standardized to a mean of 0 and standard 
deviation of 1. This allows to account for potential confounding influences on 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆 interactions424.  Therefore, PRS and SLE represent the residuals of 
these metrics. Sex, age-by-sex and age2-by-sex were not fit when stratifying 
by sex. All models were stratified by sex. All parameters from the models and 
the variance in depression score explained by the interactive component 
were estimated. The significance of 𝛽  (i.e. the effect of the diathesis-stress 
interaction term) was nominally assessed using a two-sided Wald-test. To 
account for multiple testing correction, a Bonferroni’s adjustment correcting 
for seven thresholds and three different diathesis-stress effects tested (21 
tests) was used to establish a threshold for significance at p = 2.38 x 10-3.  
6.4.8 Differences across estimates 
Z-scores derived from the effect estimates (β) and standard errors (SE) were
calculated and compared to the standard normal distribution (α = 0.05, one-
tailed) to assess significant differences between pairs of estimated effects
(either within a model or across models). For example, z-score is calculated




𝑆𝐸 β 𝑆𝐸 β
6.4.9 Examination of 𝑷𝑹𝑺𝑺𝑺 effects by levels of exposure 
For the significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 detected (i.e. 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 ), the number of SLE 
reported were categorized to examine the PRS effect at different levels of 
SLE. To retain a large enough sample size for each category and thus allow 
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meaningful statistical comparison, three categories were defined: “none” for 0 
SLE reported, “low” for 1 or 2 SLE reported, and “high” for 3 or more SLE 
reported. We explored the diathesis effect of 𝑃𝑅𝑆  on the depression score 
at each category of SLE reported using the threshold where we detected a 
significant interaction in men surviving multiple testing (𝑃𝑅𝑆  p-threshold = 
0.01) and using the best interactive threshold at full sample ( 𝑃𝑅𝑆  p-
threshold = 1 x 10-5). For comparison, we examine the effect in the full 
sample, men and women. The method of least squares to test the 𝑃𝑅𝑆  
effect on the depression score was applied in each category of SLE reported. 
The prior significance threshold p = 2.38 x 10-3 to assess the diathesis-stress 
interaction was further adjusted for the 3 SLE categories tested resulting in a 
threshold for robust significance set at p = 7.94 x 10-4 in this analysis.  
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6.5 Results 
6.5.1 Do the 𝑷𝑹𝑺𝑺𝑺  and 𝑷𝑹𝑺𝑮𝒙𝑬  predict depression score or 
number of SLE?  
The depression score significantly predicted lifetime history of MDD screened 
with the Composite International Diagnostic Interview–Short Form in GS 
respondents (odd ratio = 1.91, 95% confidence intervals 1.80-2.02, p-value = 
1.55 x 10-102, N = 8,994), with those respondents in the top versus bottom 
depression score decile with odds ratio of 3.8 of having a lifetime history of 
MDD. 
Previously, 𝑃𝑅𝑆  was reported to explain 0.64% of the depression score 
variation in our sample (β = 0.080, s.e. = 0.014, p = 7.53 x 10-9)431, whereas 
𝑃𝑅𝑆  weighted by the effects derived at a lower sample size using past 
PGC-MDD1 GWAS (9,240 cases and 9,519 controls; referred as 
𝑃𝑅𝑆 ) explained 0.21% of variation (β = 0.046, s.e. = 0.014, p = 
5.99 x 10-4)147. Similarly we tested both 𝑃𝑅𝑆  and 𝑃𝑅𝑆 ; both PRS 
significantly predicted the depression score in the full target sample (N = 
4,919) explaining a maximum variance of 0.24% and 0.15%, respectively 
(𝑃𝑅𝑆 : β = 0.049, s.e. = 0.014, p = 2.63 x 10-4; 𝑃𝑅𝑆 : β = 0.038, s.e. = 
0.014, p = 3.28 x 10-3; Figure 6.1a). After stratifying the target cohort by sex, 
predictions were nominally significant in both women and men for both 𝑃𝑅𝑆  
and 𝑃𝑅𝑆  (Figure 6.1a). However, only prediction of 𝑃𝑅𝑆  in men 
remained significant after multiple testing corrections (β = 0.076, s.e. = 0.022, 
p = 2.09 x 10-4; see Figure 6.1a). Similar pattern was seen with 
𝑃𝑅𝑆  (men: β = 0.064, s.e. = 0.022, R2 = 0.42%, p = 1.52 x 10-3; 
women: β = 0.037, s.e. = 0.019, R2 = 0.13% s, p = 0.025). The variance 
explained by 𝑃𝑅𝑆  in men (maximum R2 = 0.59%) was nominally greater 
than in women (maximum R2 = 0.13%), but not significantly (p = 0.068 at the 
best p-threshold 0.1). 
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The effects and variance in SLE explained by both 𝑃𝑅𝑆  has been 
previously published elsewhere431. 𝑃𝑅𝑆  significantly explained 0.23% of 
variation in SLE reported (p = 3.64 x 10-4) in the full sample, and 0.41% (p = 
2.22 x 10-3) and 0.22% (p = 4.86 x 10-3) in men and women, respectively431. 
Unlike the 𝑃𝑅𝑆 , neither 𝑃𝑅𝑆  or 𝑃𝑅𝑆  predicted the variation in the 
number of SLE reported (𝑃𝑅𝑆 : full sample: R2 = 0.02%, p = 0.079; men: R2 
= 0.05%, p = 0.060; women: R2 = 0.01%, p = 0.204; and 𝑃𝑅𝑆 : full sample: 
R2 = 0.01%, p = 0.879; men: R2 = 0.08%, p = 0.973; women: R2 = 0.01%, p = 
0.243; Figure 6.1b).  
6.5.2 A multi-PRS model for depression score  
In each sample, we combined the measure of self-reported SLE with the best 
predictors from all three indicators of diathesis (i.e. 𝑃𝑅𝑆 , 𝑃𝑅𝑆  and 
𝑃𝑅𝑆 ) in a multi-PRS model of depression score (see Table 6.1 and Figure 
6.2). All three PRS had a significant contribution to depression score in the 
full sample (𝑃𝑅𝑆 : R2 = 0.58%, p = 7.38 x 10-8; 𝑃𝑅𝑆 : R2 = 0.19%, p = 7.38 
x 10-4; 𝑃𝑅𝑆 : R2 = 0.08%, p = 0.019), accounting for a total amount of 
variance in depression score of 0.86%; and in men (𝑃𝑅𝑆 : R2 = 0.47%, p = 
7.46 x 10-4; 𝑃𝑅𝑆 : R2 = 0.49%, p = 5.36 x 10-4; 𝑃𝑅𝑆 : R2 = 0.13%, p = 
0.049), accounting for 1.08% of depression score; but not in women, as the 
contribution of 𝑃𝑅𝑆  effect was not significant (𝑃𝑅𝑆 : R2 = 0.68%, p = 
2.91 x 10-6; 𝑃𝑅𝑆 : R2 = 0.11%, p = 0.032; 𝑃𝑅𝑆 : R2 = 0.06%, p = 0.081), 
with the PRS effects accounting for 0.86% of depression score (Table 6.1 
and Figure 6.2). In the full sample, the genetic contributions to depression 
score attributable to additive main effects of MDD were higher than those 
attributable to effects of a proxy for stress-sensitivity (p = 0.05) or attributable 
to GxE effects (p = 7.59 x 10-3). Similar pattern was seen in women, with the 
contribution of 𝑃𝑅𝑆  higher than the contribution of 𝑃𝑅𝑆  (p = 0.03) or 
𝑃𝑅𝑆  (p = 0.01). However, in men, the estimated contribution of 𝑃𝑅𝑆  to 
depression score was not significantly greater than the contribution of 𝑃𝑅𝑆  
(p = 0.46) or 𝑃𝑅𝑆  (p = 0.13; Table 6.1 and Figure 6.2). Findings suggest 





to additive main effects of MDD at the current discovery sample sizes may be 
as relevant as the effects detected in standard GWAS of MDD to explain 
variation in risk of depression. Women have a higher prevalence of MDD 
than men; therefore, standard GWAS may be bias towards female-specific 
additive effects. However, the estimated PRS effects were not different 
between women and men (𝑃𝑅𝑆 : p = 0.329; 𝑃𝑅𝑆 : p = 0.087; 𝑃𝑅𝑆 : p = 
0.476). There was no difference in the effects of reported SLE across sexes 
(p = 0.186). These results require of further replication in independent studies 
and larger sample sizes to draw robust conclusions. However, they suggest a 
significant genetic contribution from genetic stress response mechanisms not 
detected as additive main effects by GWAS and emphasize the potential of 
alternative genome-wide approaches. 
6.5.3 GxE effects, 𝑷𝑹𝑺𝑺𝑺  and 𝑷𝑹𝑺𝑮𝒙𝑬 , to test the diathesis-
stress model 
We investigated the presence of a GxE effect with reported SLE in a 
diathesis-stress framework replacing the diathesis-stress interaction term by 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 , or 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 . In all diathesis-stress models, the 
GxE effect was considerably smaller than the main additive effect 
(operationalized as 𝑃𝑅𝑆 _ .  at the best predictive p-threshold 0.1 across 
all models; see Table 6.2). We did not detect significant GxE effects of either 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (R2 =0.04%, p = 0.132) nor 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (R2 =0.02%, p = 0.330) in 
the full sample (Table 6.2 and Figure 6.3a). The only prediction surviving 
Bonferroni correction was for a 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction in men (Figure 6.3). 
This significantly contributed to the prediction of the depression score at 
GWIS p-threshold = 0.01 in men (R2 = 0.42%, β = 0.065, s.e. = 0.021, p = 2.1 
x 10-3; see Table 6.2) and had a significantly greater effect in men than in 
women (p = 1.08 x 10-3). Estimation of a 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝑥𝑠𝑒𝑥 in the full sample 
supported this sex-specific GxE effect (p = 1.00 x 10-3; 𝑃𝑅𝑆  p-threshold = 
0.01).  
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Overall, the full diathesis-stress models predicted depression score better in 
women than in men, due to an increased ability of the number of SLE 
reported to predict liability, regardless of the GxE weightings (Table 6.2).  
To assess whether the evidence of GxE effects would likely increase with 
larger discovery sample sizes we tested the 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction effect 
using 𝑃𝑅𝑆  weighted by either PGC MDD2 GWAS (50,455 cases and 
105,411 controls)169 or PGC MDD1 GWAS (9,240 cases and 9,519 controls; 
referred as 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 )147. In the full sample, we detected nominally 
significant effects of 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (R2 = 0.08%, p = 0.044), as reported 
previously431, but not of 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (R2 = 0.03%, p = 0.201; Table 
6.2 and Figure 6.3a), showing the relevance of large enough discovery 
sample size to detect GxE effects. Nominally significant effects were also 
detected for 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  in women (p = 0.016). Our results suggest that the 
best diathesis-stress indicator to test for the presence of GxE effects across 
the entire population with the current discovery sample sizes available is the 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆 . However, as seen in comparison to results using 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆 _ , using alternative weightings could provide better results 
with large enough GWIS and discovery samples. 
6.5.4 Examination of the 𝑺𝑳𝑬𝒙𝑷𝑹𝑺𝑺𝑺 effect by SLE categories 
Given the detection of a significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction in men (p-threshold 
= 0.01), we further examined the effect of 𝑃𝑅𝑆  on depression score at 
different levels of stress using three categories of SLE reported (i.e., “none”, 
“low” or “high” number of SLE reported; see Table 6.3 and Figure 6.3b). For 
comparison, we also assessed such 𝑃𝑅𝑆  effect (𝑃𝑅𝑆  p-threshold = 0.01) 
in all three subsamples (Table 6.3). The results suggest that the depression 
score is higher the larger the number of SLE reported. In men, the effect of 
SLE was modulated by 𝑃𝑅𝑆 . We found that high 𝑃𝑅𝑆  (i.e. a high genetic 
load for a stress-sensitivity proxy) significantly increased depression score in 
men who reported a high number of SLE (N = 285, β = 0.246, s.e. = 0.065, p 
= 1.84 x 10-4; Table 6.3). This effect was also nominally significant in the full 
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sample (N = 1833, β = 0.079, s.e. = 0.04, p = 0.047), but not in women (N = 
490, β = -0.019, s.e. = 0.05, p = 0.71). 
 In addition, we investigate the diathesis effect of 𝑃𝑅𝑆  by levels of SLE 
using the threshold displaying the strongest 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction in the full 
sample (p = 0.13, 𝑃𝑅𝑆  p threshold = 1 x 10-5). This includes only 5 top 
independent SNPs from the GWIS of a proxy for stress-sensitivity. The 
diathesis effect conferred by these 5 SNPs increased the risk of depression 
in participants who reported high number of SLE (N = 775, β = 0.108, s.e. = 
0.04, p = 7.37 x 10-3; see Table 6.3 and Figure 6.3b). However, this finding 
did not survive multiple testing correction. This effect was also nominally 
detected in women (N = 490, β = 0.111, s.e. = 0.051, p = 0.03), but not in 
men (N = 285, β = 0.105, s.e. = 0.066, p = 0.114) maybe due to their lower 
sample size and the corresponding reduced power of considering the effect 
from just 5 SNPs.  
Table 6.1 A full diathesis single‐model for depression score 
FULL COHORT  MEN  WOMEN 
Parameter  SLE  PRSMDD  PRSSS  PRSGxE  SLE  PRSMDD  PRSSS  PRSGxE  SLE  PRSMDD  PRSSS  PRSGxE 
best p‐threshold  ‐  0.1  0.1  0.1  ‐  0.1  0.1  0.1  ‐  0.1  0.05  0.1 
beta  0.210  0.076  0.044  0.029  0.195  0.069  0.072  0.035  0.220  0.082  0.033  0.026 
s.e. 0.014  0.014  0.014  0.014  0.021  0.022  0.022  0.021  0.018  0.018  0.018  0.018 
z‐score  15.12  5.50  3.18  2.07  9.13  3.18  3.27  1.66  12.07  4.53  1.84  1.40 
p value  5.96x10‐52  1.83x10‐8  7.38 x10‐4 0.019  3.43x10‐20  7.46x10‐4  5.36x10‐4  0.049  7.15x10‐34  2.91x10‐6  0.032  0.081 
r2 (%)  4.409  0.585  0.195  0.083  3.802  0.466  0.492  0.126  4.836  0.681  0.113  0.065 
Genetics r2 (%)  0.862  1.085  0.859 
Total r2 (%)  5.271  4.887  5.695 






MODEL 1: PRSMDD MODEL 2: PRSMDD  (PGC MDD1)  MODEL 3: PRSSS MODEL 4: PRSGxE 
FULL COHORT 
Parameter  PRSMDD_0.1  SLE  SLExPRSMDD  PRSMDD_0.1  SLE  SLExPRSMDD_stage1  PRSMDD_0.1  SLE  SLExPRSSS  PRSMDD_0.1  SLE  PRSGxE 
p‐threshold  0.1  ‐  0.01  0.1  ‐  1x10‐3 0.1 ‐  1x10‐5  0.1  ‐  0.5 
beta  0.075  0.218  0.028  0.071  0.219  ‐0.018  0.078  0.217  0.021  0.078  0.218  ‐0.013 
s.e. 0.014  0.014  0.014  0.014  0.014  0.014  0.014  0.014  0.014  0.014  0.014  0.014 
z‐score  5.38  15.90  2.01  5.15  15.95  ‐1.28  5.70  15.79  1.50  5.68  15.90  ‐0.97 
p value  3.76x10‐8  3.41x10‐8  0.044  1.29x10‐7  1.44x10‐57  0.201  6.09x10‐9  1.71x10‐56  0.132  6.76x10‐9  3.04x10‐57  0.330 
r2 (%)  0.557  4.763  0.078  0.502  4.796  0.031  0.613  4.715  0.043  0.609  4.764  0.018 
Total r2 (%)  5.398  5.329  5.37  5.391 
MEN 
Parameter  PRSMDD_0.1  SLE  SLExPRSMDD  PRSMDD_0.1  SLE  SLExPRSMDD_stage1  PRSMDD_0.1  SLE  SLExPRSSS  PRSMDD_0.1  SLE  SLExPRSGxE 
p‐threshold  0.1  ‐  0.1  0.1  ‐  0.1  0.1  ‐  0.01  0.1  ‐  0.05 
beta  0.081  0.202  0.039  0.072  0.203  ‐0.018  0.071  0.205  0.065  0.072  0.201  ‐0.018 
s.e. 0.022  0.021  0.022  0.022  0.021  0.021  0.021  0.021  0.021  0.021  0.021  0.021 
z‐score  3.70  9.55  1.80  3.30  9.59  ‐0.86  3.34  9.71  3.08  3.41  9.52  ‐0.84 
p value  1.07x10‐4  6.57x10‐22  0.072  4.75x10‐4  4.25x10‐22  0.388  4.19x10‐4  1.43x10‐22  2.10x10‐3  3.31x10‐4  9.01x10‐22  0.401 
r2 (%)  0.65  4.07  0.153  0.512  4.11  0.034  0.486  4.195  0.424  0.523  4.054  0.032 
Total r2 (%)  4.873  4.656  5.106  4.609 
WOMEN 
Parameter  PRSMDD_0.1  SLE  SLExPRSMDD  PRSMDD_0.1  SLE  SLExPRSMDD_stage1  PRSMDD_0.1  SLE  SLExPRSSS  PRSMDD_0.1  SLE  SLExPRSGxE 
p‐threshold  0.1  ‐  1x10‐5 0.1 ‐ 1x10‐3  0.1  ‐  0.05  0.1  ‐  0.5 
beta  0.071  0.227  0.044  0.069  0.228  ‐0.033  0.082  0.227  ‐0.028  0.081  0.227  ‐0.025 
s.e. 0.018  0.018  0.018  0.018  0.018  0.018  0.018  0.018  0.018  0.018  0.018  0.018 
z‐score  3.96  12.63  2.41  3.87  12.65  ‐1.82  4.55  12.60  ‐1.56  4.53  12.64  ‐1.39 
p value  3.79x10‐5  7.37x10‐37  0.016  5.40x10‐5  5.37x10‐37  0.069  2.66x10‐6  1.05x10‐36  0.118  3.01x10‐6  6.19x10‐37  0.165 
r2 (%)  0.508  5.163  0.189  0.479  5.189  0.108  0.683  5.137  0.08  0.664  5.171  0.063 
Total r2 (%)  5.861  5.776  5.899  5.898 
Model 1: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒 ~𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠. 
Model 2: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒 ~𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 _ 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠. 
Model 3: 𝐷𝑒𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒 ~𝛽 𝛽 𝑃𝑅𝑆 _ . 𝛽 𝑆𝐿𝐸 𝛽 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝐺𝑅𝑀 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠. 





Sample  FULL COHORT  MEN  WOMEN 
SLE category  none  low  high  none  low  high  none  low  high 
N  1833  2311  775  792  852  285  1041  1459  490 
Effect  0.0122  0.0218  0.0791  ‐0.0018  0.045  0.2465  0.0219  0.0086  ‐0.0186 
CI (95%)  ‐0.030, 0.055  ‐0.019, 0.063  0.001, 0.157  ‐0.068, 0.064  ‐0.019, 0.109  0.119, 0.375  ‐0.034, 0.078  ‐0.045, 0.062  ‐0.117, 0.079 
s.e. 0.022  0.021  0.04  0.034  0.033  0.065  0.029  0.027  0.05 
t 0.562  1.038  1.986  ‐0.055  1.378  3.79  0.764  0.313  ‐0.372 
p value  0.574  0.299  0.047  0.956  0.169  1.84x10‐4  0.445  0.754  0.71 
diathesis  Stress‐sensitivity effect derived from GWIS at p value threshold = 1x10‐5 
Sample  FULL COHORT  MEN  WOMEN 
SLE category  none  low  high  none  low  high  none  low  high 
N  1833  2311  775  792  852  285  1041  1459  490 
Effect  0.0036  0.0152  0.1083  ‐0.0227  0.0057  0.1044  0.0242  0.021  0.1108 
CI (95%)  ‐0.039, 0.046  ‐0.026, 0.057  0.029, 0.187  ‐0.086, 0.040  ‐0.057, 0.069  ‐0.025,  0.234  ‐0.033,  0.082  ‐0.033,  0.075  0.010, 0.211 
s.e. 0.022  0.021  0.04  0.032  0.032  0.066  0.029  0.028  0.051 
t 0.168  0.723  2.687  ‐0.707  0.176  1.585  0.827  0.761  2.17 





Figure  6.1  Association  between 𝑷𝑹𝑺𝑺𝑺 and 𝑷𝑹𝑺𝑮𝒙𝑬 with  depression  score.  PRS 
were generated using external weights from analyses using UK Biobank participants 
with the exclusion of Generation Scotland participants and their  relatives a) 𝑃𝑅𝑆  
were generated using weights  from a Genome‐Wide  Interaction Study  (GWIS) of a 
proxy  for  stress‐sensitivity  b) 𝑃𝑅𝑆  were  generated  using  GxE  effects  from  a 
Genome‐Wide  by  Environment  Interaction  Study  (GWEIS)  of  depressive  symptoms 
and common stressful life events. Y‐axis represents the % of variance of depression 
score  explained  by  each  PRS  (main  effects,  one‐sided  Wald‐tests).  Red  numbers 




number  of  SLE  reported. 𝑃𝑅𝑆  weighted  by  the  effects  from  the  Psychiatric 
Genetic  Consortium MDD  GWAS. 𝑃𝑅𝑆  weighted  by  the  effects  from  a  Genome‐
Wide Interaction Study (GWIS) of a proxy for stress‐sensitivity. 𝑃𝑅𝑆  weighted by 
the  GxE  effects  from  Genome‐Wide  by  Environment  Interaction  Study  (GWEIS)  of 
depressive  symptoms and common stressful  life events. Y‐axis  represents  the % of 
variance  of  depression  score  explained  by  each  parameter  from  the  multi‐PRS 
model.  Red  numbers  show  significant  p‐values  (one‐sided Wald‐tests).  Differences 




Figure  6.3  a)  Association  between  diathesis‐stress  interaction  (GxE)  effects  and 
depression  score.  The  interaction  effect  was  tested  as: 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (top  row) 
using 𝑃𝑅𝑆  weighted  by  either  the  PGC  GWAS  for  MDD  (50,455  cases  and 
105,411 controls;  top‐left) or a past stage 1 PGC GWAS for MDD (9,240 cases and 
9,519  controls;  top‐right); 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (bottom‐left); 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (bottom‐right). 
𝑃𝑅𝑆  weighted by the effects  from a Genome‐Wide Interaction Study (GWIS) of a 
proxy for stress‐sensitivity. 𝑃𝑅𝑆  weighted by the GxE effects from Genome‐Wide 
by  Environment  Interaction  Study  (GWEIS)  of  depressive  symptoms  and  common 
stressful  life  events.  Discovery  samples  had  Generation  Scotland  participants 
excluded.  SLE:  the  total  number  of  SLE  reported.    Results  represent  variation  of 
depression  score  explained  by  the  diathesis‐stress  interaction  term  fitted  in  linear 
mixed models to empirically test the diathesis‐stress model for depression. The same 
main  effect  of 𝑃𝑅𝑆  as  additive main  diathesis  term  (i.e.  genetic  additive main 
contributions  to  major  depressive  disorder)  was  taken  into  account  across  all 
models. Red numbers show nominally significant p‐values. Full cohort (yellow) was 
split  into men  (blue)  and women  (red).  PRS were  generated  at  7  GWIS/GWEIS  p‐
threshold  levels.    b)  Scatterplots  of  diathesis‐stress  interactions  between 𝑷𝑹𝑺𝑺𝑺 
and  levels  of  SLE  reported  on  the  risk  of  depression  score.  Top  row:  GWIS  p‐
threshold  with  which  a  significant  interaction  was  detected  in  men  (centre,  red 
square).  For  comparison,  we  show  results  at  the  same  p‐threshold  from  the  full 
sample  (left)  and  women  (right).  Bottom  row:  GWIS  p‐threshold  displaying  the 
strongest interaction in the full sample (p = 1 x 10‐5). The number of SLE reported by 
each participant  (dot) were categorized at 3  levels  represented by colours. Blue: 0 
SLE,  “no  stress”,  n  =  1,833/1,041/792;  green:  1  or  2  SLE,  “low  stress”,  n  = 
2,311/1,459/852;  red:  3  or  more  SLE,  “high  stress”,  n  =  775/490/285;  in  the  full 
cohort/women/men,  respectively.  Y‐axis  reflects  depression  score  standardized  to 
mean of 0 and standard deviation of 1. Lines represent the increment of depression 




The depressogenic effects of SLE may not act exclusively through interaction 
with known genetic risk factors of MDD, but also through the interplay with 
alternative genetic factors specific to sensitivity and response to stress469-471. 
The rational of previous studies assessing 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 interactions (i.e. 
conceptualized as the interaction term on a diathesis-stress model) relied on 
the untested assumption that those genetic variants that display an additive 
main effect for MDD in case/control GWAS, and that are used to construct 
the PRS as indicators of diathesis, are the same common genetic variants 
implicated in GxE. In contrast, this study combined the main additive 
contributions for MDD (𝑃𝑅𝑆  with alternative interaction terms weighted 
by either genetic stress-sensitivity ( 𝑃𝑅𝑆  or stress-response ( 𝑃𝑅𝑆  
effects, while controlling for the direct effect of reported SLE. While using 
these weightings did not improve the results using the main additive 
weightings, it is possible that such alternative implementations could improve 
the testing of GxE effects with big enough discovery sample sizes. Our 
results support a genetic contribution to risk of depression from genetic 
responses to stress non-attributable to additive main contributions of MDD 
detected in current GWAS. 
Both 𝑃𝑅𝑆 , weighted by the effects estimated in a Genome-Wide Interaction 
Study (GWIS) of a proxy for stress-sensitivity378, and 𝑃𝑅𝑆 , weighted by 
GxE effects with a measure of common SLE derived from a Genome-Wide 
by Environment Interaction Study (GWEIS)427, significantly predicted 
variation in the depression score (0.24% and 0.15%, respectively) in the full 
sample. This is in contrast to the 0.64% of the variance explained by 𝑃𝑅𝑆  
weighted by common additive main effects of MDD in this same sample, and 
reported elsewhere431, but aligns with the variance explained by 
𝑃𝑅𝑆 _  (0.21%) weighted by past PGC-MDD1 GWAS at lower 
discovery sample size (N = 9,240 cases and 9,519 controls)147. Stratifying by 
sex, the effect of 𝑃𝑅𝑆  in men remained significant after multiple testing 
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correction (R2 = 0.59%, p = 2.09 x 10-4), with an overall explanatory power 
equivalent to the explanatory power of 𝑃𝑅𝑆 431. Unlike 𝑃𝑅𝑆 431, neither 
𝑃𝑅𝑆  nor 𝑃𝑅𝑆  predicted variation in the number of SLE reported, 
suggesting that the implementation of such alternative weightings to test for 
GxE effects could reduce a potential confounding bias due to a gene-
environment correlation effect426,478. Individuals vulnerable to MDD may have 
behavioural traits that increase their likelihood of experiencing a SLE103,107 
and those with the disease have a propensity to report more SLE than 
healthy controls98. Genetic sensitivity to stress and stress response may 
moderate the causal relationship between stress and depression. Evidence 
from life-course GxE approaches suggests that such mediation is dependent 
and modulated by previous cumulative interactions experienced over 
lifespan479-481.  
Jointly fitting the three PRS and SLE in a single model of depression score 
suggests that the PRS effects tested are relevant to depression (Table 6.2 
and Figure 6.2). However, in this multi-PRS model we found that the 
contribution of 𝑃𝑅𝑆  to depression score was significantly higher than that 
from PRS related to response to stress in women, but not in men. In men, 
genetic contributions in depression score were not different across PRS. We 
did not detect significant differences in the estimated effects of PRS across 
sexes. However, the variance of depression score explained by 𝑃𝑅𝑆  
alone was 1.46 times higher in women than in men, whereas also 
considering the contributions from genetic responses to stress and SLE 
effects such difference in the variance of depression score was reduced to 
1.16 times higher in women than in men. This may help to explain reports 
that the effect of sex on the onset of major depression is greater when 
psychological stress is not present; whereas for neuroticism, the personality 
trait from which the proxy for stress-sensitivity was derived, the impact 
increases with increasing adversity79. Notably, a significant 𝑃𝑅𝑆  prediction 
in men arose from a much smaller discovery sample size (GWIS N = 7,834 
cases and 15,258) compared to the PGC-MDD GWAS discovery sample size 
used to weight 𝑃𝑅𝑆  (PGC-MDD2 GWAS N = 50,455 cases and 105,411 
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controls)150 or the GWEIS (N = 99,057 with a continuous measure of 
depressive symptoms).  
Using the full sample, we detected nominally significant SLExPRS effects in 
diathesis-stress models for depression score only with 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  (R2 = 
0.08%. p = 0.044; as previously reported431) when using weightings from the 
largest PGC-MDD GWAS (49,524 cases and 110,074 controls). Such GxE 
effect remained undetectable using past PGC-MDD1 GWAS with a lower 
discovery sample size (9,240 cases and 9,519 controls; R2 = 0.03%. p = 
0.201). These results concur with the output from a previous test of the 
diathesis-stress model for depression reporting that whereas PRS weighted 
by PGC-MDD1 GWAS barely nominally predicted depression (p = 0.018), 
and therefore, being underpowered to test for a PRSxE effect, PRS weighted 
by an updated and largest PGC-MDD GWAS strongly predicted depression 
(p = 4.3 x 10-8) and displayed a nominally significant diathesis-stress 
interaction in their full sample (p = 7.6 x 10-3) and in women (p = 2.2 x 10-3). 
Our results suggest that the interaction effect of 𝑃𝑅𝑆  is smaller than 
𝑃𝑅𝑆 , of whose effect in turn is smaller than 𝑃𝑅𝑆 . Conversely, the 
sample size of the GWIS (N = 7,834 cases and 15,258) is lower than the 
sample size of the GWEIS (N = 99,057) and much lower than the sample 
size of the PGC GWAS (N = 50,455 cases and 105,411 controls). Our 
findings suggest that such studies are still underpowered to detect significant 
𝑆𝐿𝐸𝑥𝑃𝑅𝑆  and 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interactions in a diathesis-stress framework. 
Therefore, much larger sample sizes are required to detect robust effects, 
particularly with 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 . At current available discovery sample sizes, 
𝑃𝑅𝑆  is the best instrument to test the presence of a diathesis-stress 
interaction effect. However, robust 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction effects may 
improve prediction of depression symptoms further as sample sizes increase.  
Studies like this remain limited by statistical power. The statistical power 
required to detect GxE effects is higher than for marginal main effects due to 
their weaker effect sizes. Hence, such studies require larger sample sizes to 
detect similar significance levels482-484. However, in addition to increasing 
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sample size, improving the accuracy and robustness of measures of both 
SLE and trait may provide a more powerful strategy to detect robust GxE 
effects485 by reducing measurement errors. The availability of high-quality 
environmental data and larger sample sizes to achieve statistical power are 
the main challenges GxE studies must face259.  Approaches such as the 
GWIS that do not require direct measures of the environment (e.g. SLE 
experienced) and take advantage of a much more abundant measure in 
current population-based cohorts (e.g. neuroticism score) to model a proxy 
trait (e.g. stress-sensitivity) could help to address such limits. Considering the 
GWIS sample size (N = 7,834 cases and 15,258) and the significant 
prediction of 𝑃𝑅𝑆  detected, our findings enhance the potential of the GWIS 
approach to complement other tools in psychiatric genetic research466 and 
maximize the power to detect relevant genetic factors underlying the 
aetiology of depression, particularly in men. Conducting genome-wide 
approaches split by sex may help to improve the accuracy of sex-specific 
effects; although a greater gain would likely arise from maximizing sample 
sizes154.  
By stratifying the diathesis-stress model by sex, our aim was to investigate 
GxE effects as a potential difference between women and men in genetic 
stress responses. Female sex increases liability to and shows higher 
prevalence of depression48. Differences in GxE effects displayed between 
girls and boys have been reported for adolescent depression486,487. We 
detected a significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction surviving multiple testing 
correction in men (p = 2.1 x 10-3; 𝑃𝑅𝑆  weighted by GWIS of a proxy for 
stress-sensitivity at p-threshold = 0.01), which explained an extra 0.42% of 
variation in depression score in addition to the 0.50% explained by additive 
main effects on MDD. Compared to women, the estimated GxE effect size of 
such 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction in men was significantly higher (p = 1.06 x 10-2), 
supported by a significant 𝑆𝐿𝐸𝑥𝑃𝑅𝑆 𝑥𝑠𝑒𝑥 interaction in the full sample (p = 
1.00 x 10-3). This suggests an additional risk of depression in men with high 
inherent stress sensitivity, not captured by main additive contributions to 
MDD. Consistently, the analysis by categories of SLE reported for this
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𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction showed that, in men who reported high number of SLE 
(3 or more), the depression score increased with increasing 𝑃𝑅𝑆  score (p = 
1.84 x 10-4; Table 6.3). This effect was also nominally detected in the high 
SLE subset in the full sample (p = 0.047) but not in women (p = 0.71). To 
extend this, we assessed the diathesis effect of 𝑃𝑅𝑆  at the p-threshold 
displaying the strongest interaction in the full cohort (p-threshold = 1 x 10-5). 
Although such 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  interaction effect was not significant (p = 0.13) at 
this alternative GWIS threshold in the continuous model, we detected a 
nominally significant effect of this 𝑃𝑅𝑆  in those participants reporting a high 
number of SLE (N = 775, p = 7.37 x 10-3), and in women (N = 490, p = 0.03), 
but not in men (N = 285, p = 0.11), perhaps due to the low sample size 
combined to the fact that the latter 𝑃𝑅𝑆  tested captures the aggregated 
effect of just 5 independent top SNPs from the GWIS of a proxy for stress-
sensitivity (p < 1 x 10-5). Consistent with the diathesis-stress theory225, the 
increase in depression score seen in those individuals, particularly in men, 
with high 𝑃𝑅𝑆  and reporting high number of SLE suggests an additional risk 
of depression due to the influences from a genetically driven stress-sensitive 
trait. Although more statistical power is required to draw robust conclusions, 
our results support patient’s sex as a relevant factor of stress-regulation in 
stress-related disorder. Differences in the aetiology of depression between 
sexes have been already suggested by previous tests of the diathesis-stress 
model169,431, including in this sample, reporting differences in 𝑆𝐿𝐸𝑥𝑃𝑅𝑆  
interaction effects nominally significant between women and men169,431.  
In summary, alternative genome-wide approaches show the potential to 
identify relevant genetic variants in liability to depression that differs from 
those contributing to the additive main effects of MDD detected in standard 
GWAS.  Overall, the evidence suggests a lack of power to robustly detect 
and replicate genetic variants with an effect in MDD as a response to 
environmental stress, rather than the absence of such variants. Consistent 
with results in twin-studies of recurrent depressive disorder reporting a 
departure from a model of additive genetic contributions82, we showed that 
contributions from both 𝑃𝑅𝑆  and 𝑃𝑅𝑆  are relevant in depression score 
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and not accounted for by 𝑃𝑅𝑆  or SLE contributions. The detection of GxE 
effects using variants displaying modulatory effects of psychological stress 
with potential negligible main effects (i.e. not detected on GWAS for 
depression) has implication for future research strategies. Although 
replication and larger samples are required to find robust evidence, we show 
the potential benefits of identifying genetically mediated and modulator 
effects derived from these approaches. Understanding how men and women 
differentially respond to stress and identifying different stress-response 
mechanism underlying depression could help individuals to benefit from 
different types of prevention for stress-related disease. 
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Chapter 7 Summary and general discussion 
7.1 Summary of main findings 
The main aim of this thesis has been to advance our understanding of the 
genetic response to psychological stress underlying MDD. Throughout the 
last decades, robust evidence has arisen for an effect of both genetic and 
environmental risk factors such as SLE on risk of MDD. There is currently 
growing interest in understanding if, when, and how genetics and 
environmental risk factors interact, and the effects of such interactions on the 
development of MDD and other psychiatric disorders. Although many aspects 
surrounding the complexity of GxE remain unclear, I hope that the studies 
presented here contribute and help to push forward the research on this field. 
In chapter 1, I presented the background of this thesis, providing the 
knowledge, evidence and concepts required to understand where we are in 
understanding how genetic effects responds to environmental exposures on 
liability to MDD and to show from where, how and why this thesis comes 
from. 
In chapter 2 and chapter 3, the main focus was a new trait conceptualized 
as a proxy for sensitivity to stressful and adverse life events dependent on 
MDD. In chapter 2, I conceptualized such a proxy as the higher levels in
neuroticism shown in individuals with MDD. I detected putative loci involved
in such trait through a genome-wide interaction study identifying a potential
link with alcohol-related traits, and a significant gene-based association with
ZNF366. I showed that the MDD-dependent stress-sensitivity component
significantly improves the prediction of MDD, independently of main additive
contributions from loci associated with both neuroticism and MDD.
In chapter 3 I detected that genetic contributions to the MDD-dependent 
stress-sensitivity proxy were enriched within sets of genes responding to 
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glucocorticoid signalling, showing that variation in MDD risk within 
glucocorticoid signalling pathways was higher than expected, particularly due 
to genetic contributions to the proxy for stress-sensitivity. The findings 
pointed to the disruption of circadian rhythms as a potential mechanism for 
stress to lead to MDD and stress-related disorders. 
In chapter 4, chapter 5 and chapter 6, the focus was shifted to test 
quantitative measures of depressive symptoms, rather than dichotomized 
MDD diagnostic status, and to incorporate reported measures of recent SLE 
in order to investigate GxE effects underlying depression. 
In chapter 4, following recent evidence supporting the diathesis-stress model 
for depression, I detected a significant GxE effect in liability to depression. 
Individuals with an inherent genetic predisposition to MDD that reported high 
number of recent SLE were at higher risk of depression. Therefore, my 
results, albeit weak, were consistent with previous evidence to support the 
diathesis-stress theory. These findings, supporting the presence of a GxE 
effect underlying MDD at an individual’s genetic vulnerability level, validate 
the implementation of genome-wide GxE studies at the SNP level such as 
the one presented in chapter 5. 
In chapter 5, I assessed GxE between SNPs and reported SLE, aiming to 
identify genetic variants associated with depression through genetic 
response to recent environmental stress. Applying gene-based tests into 
GWAS summary results, I first identified genes directly associated with 
depressive symptoms. Afterward, I reported two SNPs with genome-wide 
significant GxE effects in PIWIL4 and ZCCHC2, and a SNP with genome-
wide significant association with the combined main additive and GxE effect 
upstream CYLC2. In gene-based tests analyses, MTNR1B and PHF2 were 
also significantly associated with GxE and the joint effect, respectively. 
Dependent SLE were shown to be heritable, but not independent SLE, 
supporting the hypothesis that dependent SLE are likely reliant on an 
individual’s own behaviour, and are also likely to be strongly driven by 
genetic variability. PRS aggregating the GxE effects improved prediction of 
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depressive symptoms beyond PRS weighted by main additive effects of 
MDD. Furthermore, I showed that the aggregated GxE effect overlap with a
wide range of stress-related conditions providing evidence that an underlying
genetic architecture of stress response is shared between depression and
common stress-related comorbidities. Whereas significant GxE effects came
primarily from the analyses of GxE using dependent SLE, significant PRS
prediction of stress-related traits came primarily from derived weights of GxE
using independent SLE.
In chapter 6, I brought together data from chapter 2, chapter 4 and chapter 
5 to investigate the relative contribution to liability to depression of stress-
sensitivity and stress-response effects estimated in chapter 2 and chapter 5, 
respectively. I applied these weightings within the diathesis-stress framework 
to test whether my new approach using weightings for genetic responses to 
stress in order to test for a GxE effect underlying MDD, rather than main 
additive effects of MDD, could improve the results from the standard 
diathesis-stress model implemented in chapter 4. I showed that both 
reported SLE, genetic sensitivity to stress, genetic response to reported SLE 
and genetic additive effects of MDD significantly contribute to increase risk of 
depression, both independently and together. At current sample sizes, stress 
sensitivity and stress response effects could not improve the diathesis-stress 
model implemented in chapter 4, but my results suggest that alternative 
tests such as the ones implemented in chapter 6 could provide better 
predictions of GxE effects underlying MDD given larger sample sizes. 
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7.2 Discussion of thesis findings 




a  set  of  genes  with  an  effect  on  liability  to  MDD  through  genetically  mediated 
phenotypic  traits  with  a  direct  effect  on  MDD;  alternative  analysis  such  as  the 
genome‐wide  interaction  studies  (GWIS)  could  identify  such  genes.  Gene  set3 
represent  a  set  of  genes  with modulatory  effect  on  the  direct  effect  of  stress  on 
MDD. Such  genes  could  be  identified  through  genome‐wide  by  environment
interaction  studies  (GWEIS).  Arrows  show  some  of  the  interrelations  between  risk
factors  and  depression  addressed  in  this  thesis  that  reflect  the  complex  system
biology underlying MDD. Figure adapted from Gonda et al.488
The aetiology of MDD is highly complex and heterogeneous. It depends on 
many genetic and environmental factors. Therefore, and as Kendler and 
Eaves already stated more than 30 years ago, to fully understand the 
complexity of the disorder, we need to understand the complex interplay 
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between risk factors. As seen above, there are many interrelations between 
genetic and non-genetic factors that may shape the aetiology of MDD. In 
Figure 7.1, I outline the interrelations underlying MDD examined in this 
thesis. Loci and genes (gene set1), such as the ones identified in chapter 5 
using a gene-based test of summary statistics from the UK Biobank GWAS 
for a depression score, are likely to have a direct effect on liability. When I 
started my PhD in early 2015, no GWAS had detected loci associated with 
MDD. The largest PGC study, at that time, had been conducted in a sample
including 9,240 cases of MDD and a similar number of healthy controls and
had failed to detect any associated locus147. However, soon the first
successful studies were reported and four years later the latest and largest
meta-GWAS of MDD reported 269 genes associated with depression,
involving 807,553 individuals including 246,363 cases151. Notably, the first
study to detect significant loci achieved that by shifting from the mainstream
approach, which was (and still is) based on increasing sample sizes while
assuming that the inclusion of enough individuals will balance any phenotypic
heterogeneity, to a specific study design focused on a sample of only female
cases with a severe clinical depression phenotype with the same
methodology and genotype platform applied to the entire cohort149. Together,
recent successful studies underscored the fact that alleles conferring a higher
risk of depression leading to, eventually, the manifestation of the clinical
disorder can be found; we require enough power and the proper study
designs to detect them.
Personality, cognition and behaviour may shape both the aetiology of illness 
and the environment. Several genetic factors contribute to such heritable 
traits (gene set2). Thus, several genetic factors underpinning these inherent 
traits likely also contribute to mediate the effects of environmental stress in 
the pathoetiology of MDD. Potentially, through a wide range of mechanisms 
(e.g. exposure to stress, sensitivity to stress, perception of stress, regulation 
of pathways involved in stress-response systems, such as glucocorticoid-
regulated systems and circadian rhythms, etc.) and thus, indirectly contribute 
to liability to MDD, and other stress-related conditions. In chapter 2, I 
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introduced a potential approach to partially target this genetic component by 
modelling of a proxy trait for an inherent MDD-dependent sensitivity to stress. 
Genetic contributions to this inherent trait (gene set2) were shown to increase 
the risk of MDD beyond contributions attributed to genes with a direct effect 
on MDD (gene set1). As shown in chapter 3, such contributions were 
enriched within sets of genes selected as candidate respondents of 
glucocorticoid receptor signalling. In addition to the foregoing, there are other 
genetic factors (gene set3) that modulate the effects of environmental 
exposures. The added risk of depression due to GxE effects was validated in 
chapter 4 and chapter 6 supporting the diathesis-stress theory. 
Furthermore, several genes displaying GxE effects were detected in chapter 
5 through GWEIS. In chapter 6, I showed that contributions from all set of 
genes represented in Figure 7.1 were significantly relevant on risk of 
depression. This high heterogeneity of potential mechanism reflects the high 
phenotypic heterogeneity seen in MDD, in which different causal pathways 
and distinct genetic and physiological mechanisms may underpin different 
subtypes of MDD patients. Hence, a diverse range of approaches to integrate 
different aspects of the pathophysiological system underlying MDD, including 
among others the ones presented in this thesis, should help to detect new 
genetic risk factors. These genetic factors may contribute to stratify MDD 
based on genetic and pathophysiological mechanisms underpinning, at least, 
subtypes with strong genetic components related to an individual’s response 
to psychological stress. These, perhaps, also contribute to the shift from the 
traditional dichotomized nosology of MDD to new ways of classifying MDD 
patients using alternative transnosology approaches such as the Research 
Domain Criteria (RDoC)489,490. Consistent with this, I have introduced two 
alternative hypothesis-free genome-wide approaches to the standard GWAS: 
GWIS and GWEIS. Genes with direct effect on MDD detected on GWAS may 
be unfeasible as therapeutic targets, as they are likely involved in basic 
functions488. However, alternative approaches may reveal new risk variants, 
which may not contribute directly to the disorder, but have relevant 
contributions to liability representing thus a subset of potential therapeutic 
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targets488. Incorporating environmental data in genomic analyses such as the 
ones presented in this thesis may boost the detection of such therapeutic 
targets, not only in MDD, but in other fields as well. 
Currently, available large population-based cohorts containing data on 
genetic factors, medical conditions and measures of SLE, allow us to study 
the interaction between genetics and SLE underlying the aetiology of MDD 
using different strategies. These strategies should allow a better 
understanding of the effects of SLE on liability to MDD, provide insights on 
the biological mechanism underpinning genetic sensitivity to stress and 
provide insights on the biological mechanism underlying the link between 
stress and MDD. This knowledge may provide potential applications and 
implications for policy and treatment, among others, to the health system and 
medical research. 
7.2.2 The proxy for stress-sensitivity as a candidate 
endophenotype for depression 
In chapter 1, I introduced the endophenotype concept, sometimes called 
“internal phenotype”, as an entity employed to detect causal mechanisms 
between the genetic aetiology underlying a psychiatric disorder and the final 
manifestation of its clinical symptoms. Personality traits are thought to 
perform such role, neuroticism being the best candidate for MDD reported to 
date198. However, the benefits of neuroticism as endophenotype may be 
overestimated, as it is also a highly complex trait that does not seem to be 
more genetically simple than MDD and is placed between the causal 
pathways and the clinical diagnosis of MDD, but at a similar clinical 
phenotypic level. Nevertheless, the MDD-dependent stress-sensitivity trait 
conceptualized in chapter 2 could be a better candidate. As this trait is 
dependent on MDD and neuroticism levels, it may involve fewer genetic 
factors than either MDD or neuroticism itself, involving fewer pathways and 
representing a closer trait to a genetic level in the causal chain to clinical 
disorders. Although it has not been tested, such proxy for stress-sensitivity as 
a trait is likely to meet the criteria to have the credentials of an 
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endophenotype of MDD. It is likely that it also meets the criteria to be an 
endophenotype of neuroticism, as I reported that: the proxy for stress-
sensitivity is an inheritable trait; it predicts and associates with MDD status; 
although the detection of its genetic component is dependent on MDD, as 
this inherent trait reflects changes in neuroticism levels (and neuroticism is 
state-independent of MDD), it must be present regardless of the 
manifestation of MDD; as it is dependent on MDD and inheritable, it is likely 
to co-segregate within families; and to be enriched in unaffected family 
members. Furthermore, as I showed in chapter 3, its genetic component is 
enriched in sets of genes linked to glucocorticoid receptor binding sites likely 
triggered by cortisol signalling through glucocorticoid response elements. 
Morning cortisol and cortisol awakening response have been reported as 
potential endophenotypes for depression192. Therefore, the proxy for stress-
sensitivity, as endophenotype, may improve the power to identify genetic risk 
factors contributing to liability, help to better understand some 
pathophysiological pathway involved, and enhance stratification of MDD. 
7.2.3 The proxy for stress-sensitivity as mediator of stress 
response 
The genetic effect of such an “endophenotype” may mediate the association 
between stress and MDD, but also the association between stress and other 
conditions linked to both sensitivity to stress and MDD. This could be the 
case of alcohol-related phenotypes (discussed in the next section) and other 
personality, cognitive and behavioural traits. Perhaps via 
regulation/disruption of circadian rhythms, thus implicating the circadian clock 
in such mediation between association of stress and disease as suggested in 
chapter 3. In chapter 3, I reported higher genetic variability in MDD risk 
conferred by genetic contributions to the stress-sensitivity proxy within 
glucocorticoid-related pathways, consistent with the function of ZNF366, the 
single genome-wide significant gene detected from the GWIS in chapter 2. 
ZNF366 encodes for DC-SCRIPT, a zinc finger family protein preferentially 
expressed in dendritic cells involved in repressive activity on transcription 
through interaction with CtBP1491, a C-terminal tail-binding protein that acts 
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as repressor of multiple transcriptional factors and is integrated in 
glucocorticoid receptor complexes492. Thus, ZNF366 regulates gene 
expression mediated by glucocorticoid receptor331. ZNF366 is the epitome for 
the genetic architecture modelled in chapter 2, supporting such genetic 
architecture as a truly underlying genetic component to a stress-sensitivity 
proxy. Furthermore, ZNF366 specificity to be expressed in dendritic cells 
supports the need highlighted in chapter 3 of targeting investigations on 
genetic response to glucocorticoid signalling as response to environmental 
stress in neuronal regions. Overall, the stress-sensitivity proxy may reflect 
the genetic architecture of sensitivity to the transcriptional effects triggered by 
cortisol signalling after experiencing stressful and adverse events, which 
Arloth et al. suggested may mediate the risk of MDD377. Notably, it has been 
suggested that genetic variation in cortisol-related neuroendocrine pathways 
may mediate the controversial interaction between polymorphisms in the 5-
HTT gene and stress (including childhood maltreatment and broad life stress) 
in current or lifetime depression, which may explain the lack of replicability 
and robust evidence supporting such an interaction493. Consistent with a 
system model with a high number of complex interrelations as represented in 
Figure 7.1. Perhaps, the stress-sensitivity proxy could contribute to 
disentangling such a puzzle. 
7.2.4 The relevance of stress-sensitivity on treatment of 
comorbid alcohol dependency 
As introduced in chapter 3, dysfunction of the HPA axis and glucocorticoid-
response pathways is associated with alcohol dependence and problematic 
related behaviours, but also craving and damage in the brain’s reward 
system362. Interactions between such alterations in stress-response systems 
and stressful exposures also increase the liability to alcohol-related 
disorders362,363. Thus, the vulnerability to alcohol abuse likely arises from the 
interplay between genetics and the environment, including GxE effects494. In 
regards to the proxy for stress-sensitivity, the strongest association detected 
in chapter 2 through GWIS was in the PTP4A1-PHF3-EYS locus. This locus 
has been associated with several alcohol-related phenotypes326-330, and in 
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alcoholic individuals the abuse of alcohol may up-regulate PHF3 expression 
in the frontal cortex495. In chapter 6, I showed that the MDD risk (diathesis) 
conferred by the aggregated effect of only 5 independent SNPs from 
suggestive loci for the proxy for stress-sensitivity (p < 1 x 10-5) increased the 
risk of depression in those individuals who reported high number of recent 
SLE. 3 of these SNPs were genotyped from intronic regions of OPCML, 
PHF3 and EYS. In addition to PHF3 and EYS (that form part of the PTP4A1-
PHF3-EYS locus), OPCML is also associated with alcohol dependence, as 
well as with depression, schizophrenia and behavioural disinhibition496-498. 
This gene encodes a protein required for coupling between G proteins and 
opioid receptors thus being essential in opioid signalling. Endogenous opioid 
systems are linked to the development of alcoholism499. Moreover, findings in 
chapter 6 suggest a potential role of PRS weighted by the stress-sensitivity 
effect as moderator of the association between SLE and depression, 
particularly in men. Curiously, the variant in EYS (from the PTP4A1-PHF3-
EYS locus), a gene also detected as genome-wide significant in the latest 
meta-analysis of MDD151, is a potential eQTL for LGSN, the most significant 
gene in males in a study of sex differences for MDD334.  
The link between sensitivity to stress and depression is consistent with a 
potential relationship between depression, SLE and coping strategies 
reported in chapter 5. This suggests that genetic responses to environmental 
stress may modulate adaptive behaviours such as smoking or alcohol 
consumption, among others. Differences between women and men on 
genetic stress responses (further discussed in chapter 4 and chapter 6) 
could help explain differences between sexes reported in the literature, not 
only in depression, but also in other stress-related conditions. In accordance 
with this theory, sex-specific differences in developmental pathways for 
depression have been suggested proposing a specific gene-environment 
interplay leading to alcoholism in men53. Significant three-way interaction 
between sex, depressive symptoms and drinking strategies to alleviate stress 
have been published, showing that the motives to drink alcohol as a coping 
strategy were more strongly associated with problems among men reporting 
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‘higher’ in depressive symptoms than among women500. Unlike women, men 
are at greater risk for increased drinking and also tend to cope with stress by 
consuming more alcohol52.  
These findings are consistent with previous evidence for a link between 
environmental stress (including genetic responses to), MDD and alcohol-
related conditions335-340. These could help to detect genetic factors with a 
mediator role on the effects of stress, behavioural traits and depression (i.e. a 
mediation between the interrelations of all three “square boxes” in Figure 
7.1), maximize the power required to identify relevant genetic factors in 
stress-response systems underlying not only the aetiology of MDD but also 
the aetiology of other stress-related conditions such as alcohol-related traits, 
and thus lead to treatable pathophysiological mechanisms that may inform 
better personalized treatment for comorbidities such as alcohol dependence 
and for at least a subtype of MDD patients. 
7.2.5 Sex-specific differences in genetic responses to 
environmental stress 
The results detailed above add to the evidence introduced in chapter 1 to 
suggest that sex-specific differences may be present in genetic response to 
environmental stress and adversity. Among patients with panic disorder, sex 
differences have been reported in the types of SLE experienced, coping 
styles, agoraphobia and physical functioning, suggesting that sex-specific 
intervention could be required to provide better assessment and treatment to 
patients with panic disorders501. As was concluded in chapter 6, sex may be 
an essential factor to consider in genetic responses and the regulation of 
stress response systems in stress-related disorders. However, to draw robust 
conclusion we require stronger evidence from more independent studies. 
Understanding such differences in genetic responses to stress between 
women and men underlying depression may help to elucidate differences 
seen between both sexes in several aspects of the illness such as disease 
prevalence, symptoms reported or copying strategies49-53. This may be 
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extended to other stress-related conditions that present sex-specific 
differences. 
7.2.6 Genetic-response to stress as a single trait within 
pathogenesis of stress-related disorders 
Many human disorders, both mental and physical, could be categorized as 
stress-related disorders. Most of them are heritable and many of them co-
occur and overlap in time, being comorbidities of each other. As suggested in 
chapter 5, genetic and physiological mechanisms underlying stress 
response systems are likely to be shared and partially explain pleiotropic 
effects detected between some of these disorders502. Although the genetics 
of stress response likely plays a central role in the pathogenesis of many 
stress-related disorders, it may have its own polygenic architecture that 
constitutes a unique entity (i.e. the genetic architecture of stress response 
systems). However, to investigate genetic factors integrated in stress 
response pathways that increase liability to illness, we generally require of a 
target phenotype to assess its detrimental effects. Correlation of SLE is 
stronger with psychiatric disorders than with medical or physical illness444. 
Furthermore, MDD is one of the disorders more closely linked to such 
pathophysiological mechanisms, together with anxiety and posttraumatic 
stress disorder, although contributions of genetics of stress extends to other 
psychiatric disorders as well92. Therefore, to model genetic responses and 
GxE effects, through GWEIS or other alternative strategies, on depressive 
symptoms and MDD may be a promising initial approach to investigate 
shared aetiologies with other illnesses through stress-response systems. In 
chapter 5, I provided evidence of a partial shared genetic overlap between 
genetic response in depression and other mental and physical health 
conditions linked to the negative effects of stress such as schizotypal 
personality disorder or cardiovascular diseases, reflecting a potential 
pleiotropic effect and shared aetiology due to the genetics of stress 
response. Genetic responses to stress may shape personality and adaptive 
behaviours that will in turn mediate the association between genetic factors 
underlying stress response pathways and stress-related traits. As the size of 
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discovery samples to estimate genome-wide GxE effects increase, it is likely 
that new associations driven by genetic responses to stress across stress-
related traits arise.  
7.2.7 PHF, a family of stress response genes 
Perhaps one of the most relevant findings from this thesis, with regards to 
identifying genetic factors involved in genetic responses to environmental 
stress, is the significant detection of PHF2 using a joint effect in GWEIS 
reported in chapter 5. As Kraft et al. reported, joint test of marginal genetic 
effect and GxE has, in general, greater power than a simple marginal test (as 
implemented in GWAS) when the genetic effect is only expressed in 
individuals exposed to the environmental risk factor233. In line with this, Wong 
et al. used whole-genome screening of functional variants to perform a 
GWAS including 203 mild to moderate MDD cases and 193 controls while 
considering the levels of stress experienced by the control population. They 
used a sample of Mexican American population from Los Angeles comprised 
of individuals born in Mexico most of which were recent immigrants that had 
experienced significant hyperactivation of the HPA axis as consequence of 
suffering recent SLE related with challenge, distress and acculturation 
issues343. They detected common and rare functional variants associated in 
44 genes, but only associations within PHF2F1B, also known as PHF4, gene 
replicated in a European cohort. Furthermore, they found that Phf21b 
hippocampal gene expression is significantly decreased in rats resilient to 
chronic restraint stress when compared with non-chronically stressed rats 
and thus modulates the chronic stress response. Therefore, they reported 
PHF21B as a gene associated with MDD and stress response343. In mouse, 
the loss of phf8 effects resilience to anxiety and depression-like behaviours, 
both with high contributions from stressful factors344. PHF8 (also known as 
KDM7B) is a paralog of PHF2 (also known as KDM7C) with antagonistic 
effects that compete for binding ribosomal DNA. While PHF8 promotes 
ribosomal RNA gene transcription, PHF2 plays a repressive role459. Both 
genes belong to a subfamily of Jumonji domain-containing histone-lysine 
demethylases (Jmj-KDMs or KDM7s). As Wong et al. highlighted, PHF21A, a 
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prominent gene from the same family, is highly expressed in the brain, 
encodes a component of a histone deacetylase complex and inhibits 
transcriptional activity during neurodevelopment periods503-505. PHF2, like 
PHF3 discussed previously in regard to the stress-sensitivity proxy, PHF21B 
(also called PHF4), PHF21A and PHF8, encodes for a PHD finger motif 
protein (PHF). PHF proteins specifically bind a wide range of histone marks 
associated with the regulation of transcriptional activity and enriched at gene 
promoters459,506,507. This is a family of sophisticated histone code readers that 
interact with different histone modifications in order to regulate gene 
expression through the recruitment of transcription factors and protein 
regulators. Thus, interpreting and interplaying with the epigenome508. 
Furthermore, they have been related to oncogenesis and epigenetic 
inflammatory signalling506. Noteworthy, PHD finger motifs, and in particular 
PHF proteins, have been suggested as candidate targets with a strong 
therapeutic potential507,509. PHF may play a key role modulating stress-
response through epigenetic regulation and chromatin remodelling510, thus 
providing directions for future research on genetics of stress response.  
7.2.8 Relevance in a clinical setting 
The findings presented in this thesis do not have direct and immediate 
implications for clinical practice; the importance of such findings is yet of 
limited clinical relevance. Nowadays, MDD diagnosis relies predominantly in 
the patient’s behaviour and symptoms rather than on clinical tests for 
biomarkers. In this sense, the findings presented in this thesis contribute to 
identifying new loci with potential as biomarkers for MDD risk and to help to 
advance in our understanding of key pathways involved in pathogenesis and 
stress-response. However, the extremely high heterogeneity and complexity 
of MDD limit the immediate utility of findings from genome-wide studies. 
Thus, their potential use is still far from clinical application. Nevertheless, a 
better understanding of the genetic mechanism and risk factors leading to 
MDD could support more efficient risk profiling, diagnosis, tailoring therapy 
and prognosis. Overall, the findings presented represents part of the vast 
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literature and accumulated knowledge required to, in the future, drive more 
effective prevention and treatment strategies.  
We just recently started to identify genetic risk variants for MDD over the last 
few years. The identification of new risk loci opens broad avenues for future 
mechanistic studies that may contribute to future clinical relevance. In this 
sense, results obtained from present and future genome-wide studies (e.g. 
GWAS, GWIS, GWEIS) may contribute to ground future clinical trials. There 
are a few examples of translation of genetic findings from GWAS of complex 
traits towards clinical applications511. The challenge now is turning this 
knowledge of the genetic and biological mechanisms of MDD into clinical 
applications. However, before translating findings from genome-wide studies 
of MDD into clinical research some other challenge must be faced512, such as 
confirming target gene predictions, understanding target gene functions and 
their role in MDD risk, and identifying prioritized targets for drug 
development, among others. 
Any such individual common genetic variants detected in genome-wide 
studies is incapable of predicting or stratifying MDD alone. However, PRS 
have a greater precision of risk identification and could be relevant in clinical 
settings. The estimation of an individual’s genetic risk would be one of the 
earliest measurable contributors to risk of MDD, with potential clinical utility 
on early disease detection, prevention and intervention. However, the utility 
of PRS is currently limited by its simplicity. Nowadays, clinical risk prediction 
usually relies on demographic characteristics, family history, health 
parameters, life factors and experienced events. Currently, PRS lack 
predictive power, but ever-increasing sample sizes contribute to increase 
their power with greater accuracy. Therefore, recent advances in PRS have 
major implications for its clinical potential. PRS have been already 
extensively applied over the last decade, not in a clinical setting for the 
prediction of individual’s risk but in applications that facilitate new 
experimental designs and discoveries511. There is already evidence 
supporting the clinical utility of PRS in other complex diseases513 and, in 
psychiatry, the possibility of adapting PRS for clinical use has been already 
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considered514,515. In other diseases, PRS have already showed promise in 
their capability to identify subgroups of patients that may benefit from more 
personalized strategies513. However, PRS are not expected to be a 
diagnostic tool able to classify between healthy and depressed individuals 
but likely to be used in prognosis and prediction of the likelihood that the 
onset of MDD will occur in each individual or subgroup of individuals. PRS 
could be used as a tool to determine a patient’s position in a distribution of 
genetic risk so that patients falling on the tail above a threshold would be 
consider of high risk514, allowing us to identify groups of individuals who may 
benefit from the knowledge derived from genome-wide studies on their 
probabilistic susceptibility to MDD or to respond adversely to environmental 
stress. In combination with other clinical risk factors, distinct PRS could 
support stratification of patients with distinct degrees of absolute risk and 
thus, could help drive clinical decision-making. Hence, a plausible 
implementation of PRS into a clinical setting in the near future is the 
identification of subsets of individuals with higher risk of MDD on the basis of 
genetic factors in combination with other clinical risk factors. As our 
knowledge of the genetic basis of MDD increases, PRS could support a more 
targeted therapeutic approach516. However, large-scale prospective studies 
assessing the clinical utility of PRS are still required. At the end of the day, 
we must acknowledge that for disorders and potential subtypes of MDD with 
low heritability, genetic scores may never become clinically useful. Moreover, 
there are still some scientific, clinical and social hurdles to bring PRS into 
practice, such as, among others, the uncertainty about causal variants 
determining the genetic risk estimated in an individual, the lack of knowledge 
about how to interpret PRS or their unwanted psychosocial impact517. 
Besides, the use of PRS in clinical contexts, most prominently in psychiatry, 
could have ethical implications, support reductive interpretations and feed 





7.3 Methodological remarks and limitations on GxE 
research 
 
There are still many methodological challenges to tackle in GxE research, 
including some limitations shared with other genome-wide studies. Unlike 
GWAS, when I started my PhD the first genome-wide GxE study in regard to 
MDD had yet to be conducted. Hence, we are still in the early stages of 
success and, in comparison to GWAS, the growing explosion of genome-
wide GxE approaches is likely to be slower. Further progress in GxE 
research will require, at least, addressing the following methodological issues 
and limitations.  
 
7.3.1 Sample size, statistical power and false positive 
findings 
Like other genome-wide approaches, sample size is a key limiting factor in 
achieving statistical power. Having sufficient statistical power to detect true 
signals and avoid false positive or negative results is a major concern for 
genetic studies in general. In chapter 1, I introduced how after Caspi et al. 
studies on 2003 there was a huge proliferation of GxE studies in candidate 
genes. Most of these studies were conducted on samples ranging between 
100 and 3,000 participants. Nevertheless, larger sample sizes are required in 
order to conduct the well-powered direct replication studies that are essential 
for GxE findings to gain credibility443. Studies with small sample sizes would 
only be well powered under the assumption that common variants with GxE 
effects explain a fairly large proportion of the trait variance274. Thus, some 
suggest that most (if not all) of the positive findings reported on such studies 
were likely false positives251,443, as it is not clear how robust and replicable 
these findings are518. Furthermore, most genetic effects found so far in 
psychiatric disorders explain far less than 1% of phenotypic variability so we 
know that, on average, like main additive effects modelled by GWAS, most 
GxE effects must be very small. However, it is hard to know what GxE effect 
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sizes are reasonable to predict MDD. For example, one of the largest GxE 
effects ever reported was detected for an interaction between smoking and a 
polymorphism in CHRNA5 on smoking-related diseases which was 
equivalent to only 0.5% of the variance519. Assuming that a GxE effect may 
explain 0.1% of the variability in depression-related traits, then sample sizes 
~10,000 individuals would be required, if we reject a null hypothesis at the 
5% level (α = 0.05). If GxE effects explained 0.01% of the variability, 
~100,000 individuals would be required to conduct well-powered studies. 
Nowadays, samples over a 1 million individuals are available to conduct 
GWAS for MDD, and although sample sizes big enough to also perform 
reasonable well-powered GxE studies at genome-wide scale are being 
recruited (which should solve most of the limitations of previous candidate 
gene studies), sample sizes available to conduct GWEIS are yet a few 
magnitudes behind GWAS due to lack of data on measures of environmental 
exposures. Moreover, as discussed in chapter 6, to detect GxE effects 
requires, in general, more statistical power than detection of additive effects 
and, therefore, GWEIS may require even larger sample sizes than GWAS in 
order to detect effects at similar significant levels482-484,520,521.  
If GxE studies are underpowered, we would expect a high false discovery 
rate with a consequent low replication rate. Indeed, another main concern is 
the possible inflation of false positive findings when heteroscedasticity is not 
taken into account. However, as it was reflected by genomic inflation 
estimates (λ1000) in QQ plots from GWEIS reported in chapter 4 (Appendix 
C), this concern seems to be well solved with the implementation of a 
nonlinear statistical approach that uses robust estimates of standard 
errors272. Other tools, different to the one I implemented, also apply robust 
standard errors and have been also used in order to correct for such biases 
in GWEIS113. Which tool performs better in such analyses is still unclear and 
the choice of one above the other should probably depend on study design. 
Nevertheless, some of the most popular tools to conduct genomic analysis, 
like PLINK, allow testing for interactions but do not take into account such 
potential bias, resulting in an inflation of false positives in some scenarios, 
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unless you incorporate an external plugin specifically design to adjust for 
heteroscedasticity effects. Heteroscedasticity is a statistical phenomena 
unknown by most researchers, not only in psychiatric genetics but in other 
biomedical fields as well, that has been largely ignored by previous studies 
testing GxE effects. This could bias and lead to false positive findings like the 
non-inclusion of PCs to adjust by population structure which, in contrast, is a 
mainstream approach to properly adjust studies. Therefore, caution must be 
taken when selecting software to conduct GxE analyses. 
As I showed in chapter 4 and chapter 6, a promising alternative in order to 
detect GxE effects is to test interactions using PRS, rather than single SNPs, 
as they have much power to detect phenotypic variability and reduce multiple 
hypotheses testing. This approach is getting more popular. However, 
following the rationale behind using PRS to predict a trait weighting by the 
genetic effects on such trait, if we want to use PRS to predict GxE effects, 
logic should lead to think about using weightings for GxE or environmental-
response effects. In chapter 6, I address this point and, although at current 
sample sizes this approach is not yet the best alternative to implement, the 
results suggest that, in the future, with good enough GxE estimates from 
large enough sample sizes, this could be the best practice. It must be said 
that potential limitations could arise in PRS approach when discovery and 
target samples come from different population ancestry. Therefore, it is 
important to target GWEIS not only to European-descent samples. 
7.3.2 Improper implementation of control variables 
Another consideration to consider is to properly control for the effect that 
covariates may have on GxE effects. This is something that most studies 
have also omitted in the past, as it was thought that confounding effects were 
already adjusted by fitting the proper covariates into linear models. However, 
Keller MC demonstrated that confounding effects on GxE effects could 
remain if covariate by gene and covariate by environment interactions were 
not also adjusted424. Let’s take as example Caspi et al. findings reporting 
GxE effects between SLE and 5-HTT gene on depression. Imagine that 
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females “hypothetically” were much more likely to report SLE (i.e. SLE is 
highly correlated with being female). Under such assumption, high SLE 
would be a proxy for being female and thus, Caspi’s results may reflect an 
interaction effect between 5-HTT gene and sex. Therefore, the GxE effect 
reported would be attributable to an interaction between 5-HTT gene and 
female sex, rather than SLE. The method proposed by Keller is as simple as 
adjusting the model by the interaction between 5-HTT gene and sex. If then 
we still estimate a significant GxE effect with SLE, we could draw the robust 
conclusion that it is not confounded by sex. However, it must be considered 
that incorporating all covariate interactions into a model may overfit it and, 
although it should be acknowledged now that covariate interactions must be 
adjusted to properly adjust GxE models, it could be argued whether all 
covariate interactions must be fitted, rather than only those ones we consider 
that could have a confounding effect on the GxE. Perhaps, for example, 
interactions with PCs (if fitted into the model) could be discarded for the sake 
of avoiding overfitting.  
7.3.3 Phenotypic and environmental measures: the quality of 
data 
The instruments used to diagnose and measure both the phenotype and the 
environment are key factors, and its parameterization, including scale and 
units used, could have direct effects on the GxE modelling425,430. This is an 
important point to consider for those traits that do not have natural units. In 
fact, any non-linear transformation could create spurious GxE effects. This 
highlights the importance of being able to defend a particular choice of units 
(e.g. number of SLE, years of education, height in cm, standard deviations, 
etc.). Probably, the best approach on phenotypes without natural scale would 
be to standardize the units used to capture such a phenotype (e.g. score 
from self-reported depressive symptoms) in order to represent a trait that is 
distributable in your sample (preferentially under a normal distribution), so it 
can be measured by standard deviations from the mean and it is not 
arbitrary. In regards to traits like self-reported depression, a psychometrically 
defined phenotype to reflect the dimensions of complex self-reported traits, 
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rather than summation scores like the ones used in this thesis to assess 
depressive symptoms, may further improve GxE studies and the investigation 
of genetic associations with MDD522. 
7.3.4 The issue of self-reported data 
As seen above, accurate phenotyping is a crucial factor for investigating 
GxE. Therefore, GxE research requires accurate and robust high-quality 
measures of the environmental exposure261. Studies with relative small 
sample sizes often use higher-precision prospective measures that reduce 
the odds of false positives, as they assess environmental variables with less 
measurement error than larger studies. Data on environmental factors such 
as SLE in studies with large sample sizes (if available) tend to use low-
precision retrospective reports such as self-reported questionnaires. 
However, the primary method applied to measure SLE or other life events 
(e.g. childhood trauma, diet or physical activity) is through self-reported 
questionnaires. Self-reported questionnaires are an economical and quick 
method in research for assessing a wide range of constructs based on a 
battery of questions. The application of this kind of measures often carries a 
number of limitations. Furthermore, although some instruments are design to 
cover the same underlying effects or contextual environment, different 
questions may cover and emphasise different features of stress, the 
environment, or indeed of the illness. 
 In regard to this thesis, the most important issue lies with the temporal order 
of SLE reported and diagnosis recorded. To investigate GxE effects, we 
require SLE measures to cover a time period preceding MDD diagnostics or 
reported phenotypic data. It may not be feasible to collect new measures of 
SLE covering the time period preceding the phenotypic records available in 
population-cohorts. But if we now collect data on recent SLE, we also need to 
collect new phenotypic data on MDD status or depressive symptoms. This is 
a main limiting factor to have larger sample sizes available to conduct GxE 
studies. Another important issue concerning the use of self-reported 
questionnaires to measure the amount of stress that an individual has 
220
suffered during a specific period of time lies with its validity and whether it 
can fully capture the construct of psychological stress. The amount of stress 
registered can vary across different events and different causes investigated 
to determine the state of such psychological stress (i.e. depending on the 
questions assessed) and the units used (e.g. number of stressful events 
suffered vs. severity of such events). These limitations including retrospective 
and response bias (i.e. information remembered and willing to provide, and 
preference towards giving particular answers) are extensive to the use of any 
self-reported questionnaire and can altogether affect the final data collected 
through the questionnaires523. Difference in instruments used may explain 
lack of replication. For example, the measures used in chapter 5 for UKB 
participants, both for SLE and depression score, were less informative (i.e. 
covering a substantially reduced spectrum of symptoms over a larger time 
period) than for GS participants. Therefore, although UKB GWEIS was 
conducted in a substantially larger sample size, it may explain the lack of 
replication and significant GxE reported in UKB. Different findings reported in 
chapter 5 between self-reported measures of SLE in GS (i.e. total, 
dependent and independent SLE) reflect how using different items that cover 
different environmental effects produce different results, highlighting the 
importance of using the same instruments to replicate results. It must be 
noted that despite its validity and robustness, such tools, like the List of 
Threatening Experiences used in this thesis, may not cover a wide range of 
minor events with potential long-term or mild to moderate contextual stress, 
that likely impacts on the final adversity faced by an individual and thus on 
liability. 
7.3.5 The aetiological model for GxE underlying MDD 
In addition to the foregoing, most instruments to measure environmental 
events are designed to cover only those events with potential negative 
effects, but omit the full range of events with potential positive contributions. 
Most etiological models investigated in psychiatric disorders to date have 
been conceptualized under the diathesis-stress theory. As shown in chapter 
4 and chapter 6, there is multiple evidence to support such theory in order to 
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understand the aetiology of MDD. However, such theory only covers one side 
of the full environmental spectrum to which we are exposed to. As introduced 
in chapter 1, there are a few alternatives to the diathesis-stress theory such 
as the vantage sensitivity theory, which only considers the positive 
contributions from the environment, or the differential susceptibility theory. 
Both the diathesis-stress and the vantage sensitivity theories have its own 
conceptual space inside the differential susceptibility theory (see Figure 1.2). 
Moreover, it is plausible to think that individual differences in sensitivity to 
environmental factors contributing to depression are not exclusive of negative 
exposures with adverse effects, but also of positive events with resilient 
effects. Perhaps, the same underlying mechanisms support both hypotheses. 
We would need uniform environmental information along the entire spectrum 
from positive to negative events to disentangle such question. In addition, if 
we consider a broader spectrum of contributions from the exposome, the 
odds of crossover interactions, rather than fan-shaped interactions, increase, 
supporting the differential susceptibility theory. Altogether, this would support 
the existence of alleles with “plastic” effects, rather than “risk” or “resilient” 
effects. In fact, in chapter 4, I suggested the possibility that some alleles 
could be operating as plastic alleles, rather than risk alleles. However, as 
noted, we do not know whether the same alleles are involved in both 
mechanisms (vulnerability and resilience). But, if the concept of genetic 
plasticity conferring sensitivity to both positive and negative environmental 
effects was true, it could explain the lack of replicability and the inconsistent 
findings reported by GxE studies in candidate genes. These studies may 
have tested polymorphisms that act as “plasticity alleles” while only 
considering one side of the environmental spectrum. Therefore, not only 
potential disadvantages, but also potential advantages, of genetic variability 
in sensitivity to environmental exposures underlying MDD should be 
considered. A better understanding of how genetic variants interact with the 
environment may lead to policies that provide the right environment to help 
patients reach their full potential524. Furthermore, understanding both 
desirable and undesirable effects due to the response to specific 
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environments as a function of an individual’s genotype may lead to 
personalized and targeted policy interventions. Unfortunately, measures of 
positive life events are much more limited than measures of adverse life 
events in most cohorts with genomic data. 
7.3.6 How should we interpret GxE? 
In chapter 1 I introduced a basic equation to study GxE as follows: 
𝑦   𝛽 𝛽 𝐺 𝛽 𝐸 𝛽 𝐺 𝑥𝐸  𝜖  
However, GxE effects have at least two possible biological interpretations 
that are indistinguishable through standard GxE approaches based on this 
model. These interpretations could be stated with the following equations 
(note that both are equivalent to the equation above): 
 𝑦   𝛽 𝛽   𝛽 𝐸  ∙ 𝐺 𝛽 𝐸  𝜖  
𝑦   𝛽 𝛽 𝐺 𝛽 𝛽 𝐺  ∙ 𝐸  𝜖  
On one side (1st equation), it would be the environment that moderates the 
association between the genotype and the phenotypic outcome, in which 
case the effect of the genotype depends on the environment. So, if both 𝛽  
and 𝛽  are positive, the larger the effect of the environment, the larger the 
effect of the genotype on the final outcome. On the other side (2nd equation), 
another plausible interpretation could be that it is the genotype that 
moderates the association between the environment and the outcome. In this 
case, it is the coefficient on the environmental effect that depends on the 
genotype. Although the first scenario seems more plausible, from a biological 
perspective it is unlikely that either of these is the right interpretation alone, 
but rather both working together. Perhaps, in the future, more sophisticated 
approaches to study GxE effects identifying the underlying mechanism 
implicated allow disentangling such puzzle in order to decipher how GxE 
effects should be better interpreted. Mendelian randomisation approaches 
may help to identify causal paths and directions linked to the effects of 
SLE525,526. 
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7.3.7 GxE vs. GxG effects 
 A limiting factor to interpret results from GxE studies is whether the reported 
estimates truly reflect GxE effects or, instead, they are due to gene-
environment correlation74,426. As Kendler and Eaves introduced in their 3rd 
model, genetic contributions to exposure to SLE (or reporting of self-reported 
measures in retrospective studies) are likely to occur. Therefore, if we take 
again as example the interaction between 5-HTT gene and SLE on MDD, 
even under the assumption that such interaction was robustly estimated and 
well-replicated in large enough sample sizes, we could not prove that it is the 
result of a pure GxE. The only way to tackle this is to ensure that the 
environmental measure does not capture any genetic influences or, if SLE 
does capture genetic influences, that GxE is not driven by gene-environment 
correlation. I addressed this in chapter 4 and chapter 5 by using SLE 
defined as dependent and independent. However, evidence supports either 
that both measures partially cover the same underlying effects (e.g. self-
reporting bias), or the biological mechanisms involved in both the direct and 
GxE effects of each SLE measure differ, or both. It is important to prove that 
a detected significant GxE truly reflects an interaction between a genetic and 
environmental component if we want to properly understand the mechanism 
of how such association with MDD arise. Evidence suggests that to ensure 
that SLE does not capture genetic influences through depressive status, 
personality or behavioural traits, among others, is unfeasible using self-
reported measures. 
However, we should distinguish between what it is a real GxE and what 
derives from the 3rd model proposed by Kendler and Eaves about a genetic 
control of exposure to environment, or what others call “nature via nurture”. If 
an estimated GxE was driven by the genetic component and not by the 
environmental component of SLE, such estimate would arise from gene-
environment correlation and would reflect a subtle GxG interaction rather 
than a GxE interaction. Although such findings could be relevant to liability for 
MDD. Such contribution of genetically mediated reporting of SLE may be
driven by inherent traits such as sensitivity to environmental stress. As
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previously discussed, identifying genetic contributions mediating the 
association between SLE and MDD could contribute to understand the 
aetiology of MDD, and epistasis could be another mechanism modulating the 
effect of environmental stress (i.e. GxGxE interaction). This has been 
supported, for example, by GxE studies on the risk of asthma as a result of 
smoking and polymorphisms in genes for xenobiotic metabolizing enzymes. It 
has been reported that epistatic GxG effects among such enzymes in 
smoking individuals increased the risk of asthma above the expected risk 
without an epistatic effect435. In fact, behaviour, coping style and personality 
traits influence susceptibility to stress, and their genetic contributions likely 
interact within genetics of responses to stress.  
7.3.8 Early by late stressful life events and a life-course 
approach  
There is ample evidence that interactions between SLE occur over lifespan 
(i.e. environment-environment interactions, ExE) and also contribute to the 
risk of MDD527-531. Furthermore, sex-specific effects may contribute to 
modulate ExE532-534. Three main theories have been developed in order to 
conceptualize a dose-response interaction between the number of SLE, or its 
severity, over the lifespan (see Figure 7.2) that could modulate liability to 
MDD: the stress-amplification, the stress-inoculation and the stress-
sensitization theories534,535. 
Under the stress-amplification theory, the effect of earlier SLE (e.g. childhood 
trauma) enhances the effect of later life SLE on MDD liability534. Conversely, 
under the stress-inoculation theory, the effect of earlier SLE makes you more 
resilient to the adverse effects of later SLE, suggesting that mild to moderate 
levels of stress would boost the development of adaptive mechanisms 
contributing to better coping later in life and thus, reducing the adverse effect 
of later stress536,537. In fact, it has been suggested that not all SLE have 
negative effects444. Finally, under the stress-sensitization theory, individuals 
who experience SLE became more sensitive to the negative effects of later 
SLE and thus, their threshold to trigger symptoms of illness is reduced over 
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time527,538. This is consistent with the diathesis-stress theory, in which 
individuals are vulnerable to develop symptoms with low levels of adult 
psychological stress. Nevertheless, under the stress-sensitization theory, 
such individuals are vulnerable because they had experienced high levels of 
earlier stress, rather than because they carry a high load of risk alleles. This 
could contribute to the lack of positive findings to empirically support the 
diathesis-stress theory. It may also link to the kindling hypothesis for 
depression, in which sensitivity to SLE is increased by an episode of MDD, 
increasing the autonomy for the onset of new episodes of MDD539. Perhaps, 
all three forms of ExE co-exist. Hence, evidence for ExE and gene-
environment-environment interactions (GxExE) along lifespan influencing 
psychiatric disorders suggests that genetic sensitivity towards the effects of 
stress (stress-sensitization) is dependent and modulated by previous 
cumulative interactions experienced over lifespan479-481 and highlights the 
need to integrate SLE at different time-points in life540. GxE effects 
(particularly facing early childhood adversities) may result in neurological, 
physiological and/or cognitive-emotional consequences that contribute to 
modulate the effect of future GxE. This was supported by reported significant 
evidence in children with high PRS for genetic environmental sensitivity480. 
Those sensitive children exposed to negative environments exhibited 
increased sensitivity to SLE in adulthood. Conversely, those sensitive 
children exposed to positive environments early in life were significantly more 
resilient to adversity in adulthood through GxExE effects479,481. If MDD, as 
other psychiatric and stress-related disorders, was the result of a 
GxE1xE2xE3xE4…xEn interaction along lifespan, assessing a time-point 
interaction (e.g. GxEn>4) in adulthood without taking into account modulating 
effects of previous environments, specially at early developmental stages, 
may result on negative or contradictory findings. Furthermore, as we have 
already discussed, GxE may be mediated by genetic contributions, such as 
an inherent genetic sensitivity to stress. Evidence points to a complex 
interactive system between the genome and the environment underlying the 
aetiology of MDD. Therefore, life-course GxE approaches including the full 
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range of environments from early childhood to adulthood may be required to 
elucidate stress-response mechanisms underpinning the development of 
depressive symptoms and to fully understand GxE effects. Furthermore, the 
presence of modern and exponentially increasing environmental inputs with 
potential stressful effects characteristic of a western lifestyle, which may not 
be captured and evaluated by current screening tools, may induce new GxE 
effects through environmentally-induced changes in effect sizes of causal 




inoculation  (centre):  high  levels  of  stress  in  early  SLE  buffers  against  the  adverse 
effects  of  later  SLE.  Stress‐sensitization  (right):  high  levels  of  early  stress  increase 
sensitivity  to  deleterious  effects  of  later  SLE,  increasing  the  risk  of MDD  in  those 
individuals  experiencing  low  adversity  in  later  SLE  but with  no  differential  risk  in 
those  experiencing  high  levels  of  later  psychological  stress.  Figure  adapted  from 
Rudolph et al.534  
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7.4 Future perspectives 
After a decade of scepticism about research on GxE in psychiatric genetics 
due to the inconsistency of findings, the dramatic increase in data and 
resources available foretell a promising future for research on GxE 
underlying MDD, as well as other psychiatric and mental illnesses. The 
identification of robust genetic risk variants from recent and future GWAS, 
GWIS and GWEIS, among other strategies, will provide the knowledge 
required to select new sets of candidate polymorphisms, genes and 
pathways with potential therapeutic effects. Although research on GxE may 
identify new variants with a very small overall effect on MDD, it could reveal 
new therapeutic pathways to target in therapeutic approaches. However, 
much remains to be investigated to fully understand the background of such 
disorder. Our actual knowledge of the complex interplay between genetic 
factors, environmental stress and stress response mechanisms underlying 
MDD is still limited. Furthermore, although MDD is a well-recognized public-
health priority due to its huge economic and health burden growing over time, 
depressive disorders (and psychiatric disorders in general) are among the 
most underfunded illness in biomedical research542. This trend will need to 
reverse in the future. Hopefully, the work presented in this thesis contributes 
to demonstrating the relevance of GxE research, pushing forward this field, 
and attracting more funding from engaged institutions.  
For the near future, I think progress can be expected from analysing the 
recent release of UK Biobank data from over 500K individuals with available 
data on a wide range of medical conditions and updated new mental health 
questionnaires covering a wide range of psychiatric symptoms (including 
neuroticism levels) and SLE. This data of great value provides a unique 
opportunity to complement the results I have presented by performing GWIS 
and GWEIS studies on substantially larger sample sizes, and thus to expand 
the line of investigation covered in this thesis. Meanwhile, though, better 
implementations of GxE genome-wide approaches in a time-efficient manner, 
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as discovery sample sizes increase, are a priority. The performance of 
GWEIS can be highly time consuming in sample sizes exceeding 100K 
individuals when robust estimates of standard errors are applied (i.e. when 
we implement a nonlinear statistical approach that uses Huber-White 
standard errors to correct for a potential inflation of the GxE effect estimated 
due to heteroscedasticity), the exposure has a wide range of levels, and we 
test for large numbers of genetic variants (~1M SNPs or more). Therefore, 
new computational strategies may be needed to conduct genome-wide GxE 
studies in the order of 500K–1M individuals. Furthermore, the implementation 
of life-course approaches, or promising and more complex alternative 
methods to investigate interactions such as Bayesian networks, is even more 
computationally demanding.  
Present and future efforts should also be put into collecting more accurate 
and reliable phenotypic measures, not only retrospective but longitudinally. 
Personally, I think that, in a future, data with contextual stress should be 
extracted and integrated with other sources of data directly from linkable 
electronic resources. Some information requested in questionnaires about 
SLE could be extracted directly from national resources without requiring 
direct reports from participants. New strategies to extract data on life events 
directly from national population-based electronic records, smart devices and 
social networks, covering the full spectrum of positive and negative 
environmental influences, should allow us to construct more replicable 
measures across studies, with the advantage of reducing sources of bias 
(e.g. due to self-reporting measures), and longitudinal scores over lifespan. 
This may establish future resources for GxE studies, with potential to be 
implemented under a life-course approach and a diathesis susceptibility 
perspective. A life-course approach using linkable resources could improve 
the detection of GxE effects, while reducing potential confounding effects; 
improving our understanding of the effects of stress and the etiological 
mechanisms underpinning MDD, mental health and stress-related disease in 
general. However, to define and validate the best measures derived from 
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linkable data in order to cover all contextual stress with effects on MDD is 
going to be tricky.  
In addition, current advances in sequencing technologies allow for affordable 
whole-genome and whole-exome sequencing that allows the design of well-
powered association study of rare (including de novo mutations) and 
structural variants. Wong et al. is a nice example of how to take advantage of 
this new technology with still relative low samples sizes343. The potential of 
new sequencing technologies, added to the increasing sample sizes 
accompanied with better environmental measures provide the basis for future 
well-powered GxE research. These strategies should allow us to better 
understand how an individual’s exposure to SLE modulates the effect of 
genetic risk factors on liability to MDD, and how GxE contribute to its 
aetiology and “missing heritability”543. However, to understand the genetic 
responses to psychological stress underlying the aetiology of MDD is only 
one of many strategies to provide insights on the biological mechanism 
underlying MDD. Eventually, the implementation of such data and knowledge 
into systems biology approaches would likely enhance our understanding of 
the disorder by integrating multilevel genomic (e.g. epigenomic, 
transctiptomic, metabolomics, etc.), environmental and phenotypic data, 
sophisticated statistical and theoretical methods, and high-performance 
computing; this is going to allow us to fully determine individual risk, allowing 
stratifying MDD and providing high-quality level of personalized medicine. 
Nevertheless, new collaborative efforts and the development of new 
computational approaches to conduct these high computationally demanding 
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Appendix A contains supplementary material for chapter 2: Genome-wide 
interaction study of a proxy for stress-sensitivity and its prediction of major 
depressive disorder. The published article in PLOS ONE is also included. 
A.1 DEPICT analyses
Gene sets were analysed using DEPICT (https://github.com/perslab/depict)1 
to (i) prioritise genes in independent loci, (ii) identify reconstituted gene sets 
enriched by genes selected, which may represent biologically relevant 
pathways and systems, and (iii) determine enriched tissue/cell types. 
SNPs from meta-analyzed GWIS with stress-sensitivity (SS) effect with p < 
2x10-5 (see Appendix A.5 Supplementary Figure 2) were clumped using 
PLINK v1.92 to identify 12 independently associated “lead SNPs” (LD r2 > 0.1; 
physical kb threshold = 500kb; 1000 Genomes Project Phase 1 CEU, GBR, 
TSI genotype data3). Associated regions were defined by linkage 
disequilibrium (LD) around the 12 “lead SNPs” (LD r2 > 0.5; 1000 Genomes 
Project Phase 1 CEU, GBR, TSI genotype data) and genes were selected if 
they mapped within or overlapping the regions identified (genome build 
GRCh37). Genes within the high LD HLA locus (chr6:25000000-35000000) 
were removed and overlapping regions merged. If no gene was present in a 
region, the nearest gene was selected. 13 unique genes were finally selected. 
By comparing these associated regions with genome-wide randomly-selected 
loci and matched for gene density, DEPICT determined whether these genes 
share biological function, based on the hypothesis that genes truly associated 
with stress-sensitivity will be part of the same mechanisms underlying this 
trait. No significant pathway or mechanism was found at FDR < 0.05. DEPICT 
is based on predicted function of genes derived using the results of 77,840 
microarrays from two human, one rat and one mouse Affymetrix gene 
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expression platforms from the Omnibus (GeO) database4, each covering 
expression of 19,997 genes. 
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A.2 Polygenic risk profiling and MDD models
PRS weighted by SS effect ( 𝛽 ) for each individual on GS:SFHS were 
estimated using GWIS statistics from UKB as follows, 
𝑖      𝑃𝑅𝑆 𝛽 𝑆𝑁𝑃  
Using MDD-GWAS statistics from UKB (discovery sample), we estimated for 
each SNP (ii) the main additive effect on MDD and (iii) the main additive effect 
on EPQN, from the following additive genetic models, 
𝑖𝑖      𝑀𝐷𝐷  𝛽 𝑆𝑁𝑃 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆  ε 
𝑖𝑖𝑖      𝐸𝑃𝑄𝑁  𝛽 𝑆𝑁𝑃 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆  ε 
Where 𝑖 𝜖 1 … 𝑛 ; n = total number of SNPs on UKB sample (n = 557,813). 
Using these effects, we created MDD and EPQN PRS for each individual 
weighting by 𝛽  (PRSD) and 𝛽  PRSN on GS:SFHS (target sample) as follows, 
𝑖𝑖      𝑃𝑅𝑆 𝛽 𝑆𝑁𝑃  
𝑖𝑖𝑖      𝑃𝑅𝑆 𝛽 𝑆𝑁𝑃  
Where 𝑘 𝜖 1 … 𝑙 ; l ≤ n; l = number of SNPs at best MDD prediction fit in 
GS:SFHS and 𝑝 𝜖 1 … 𝑡 ; t ≤ n;  t = number of SNPs at best EPQN prediction 
fit  in GS:SFHS. 
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All PRS at best fit (i.e. PRSSS, PRSD and PRSN) were combined on several 
general linear models to assess MDD status (case-control) prediction on 
GS:SFHS as follows, 
null model: 𝑀𝐷𝐷 ~ 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 1:  𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 2: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 3: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 4: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 5: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
model 6: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
full model: 𝑀𝐷𝐷 ~ 𝑃𝑅𝑆 𝑃𝑅𝑆  𝑃𝑅𝑆 𝐶𝑂𝑉𝐴𝑅𝐼𝐴𝑇𝐸𝑆 
Before determining the scores, strand-ambiguous SNPs were removed from 
the genotype data. SNPs present in both the discovery and target samples 
were clumped to obtain a set of independent SNPs in approximate linkage 
equilibrium (r2 < 0.1, within a 250kb window). PRS were generated for up to 
13 p thresholds (< 0.001, < 0.005, < 0.01, < 0.02, < 0.03, < 0.04,  < 0.05, < 
0.1, < 0.2, < 0.3, < 0.4, < 0.5, <=1). Scores were standardized to a mean of 0 
and a standard deviation of 1 for use in further analyses. Each score was 
regressed on MDD status using logistic regression models adjusted for sex, 
age and 20 PCs and permuted 10,000 times to assess association with MDD 
status. Nagelkerke’s R2 coefficients, a likelihood-based measure extensively 
used in prediction of psychiatric disorders5,6 reflecting the proportion of MDD 
risk explained by each model at the observed scale, were calculated and 
converted into R2 coefficients at the liability scale using Hong Lee’s 
transformation7 available from GEAR: GEnetic Analysis Repository8. To 
assess MDD risk explained at the population level, we used prevalence of 
12.2% in GS:SFHS9 and 25.8% in UKB10. Significance of each PRS was 
assesses by likelihood ratio test. Cross-validation was performed following the 
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same procedure above using GS:SFHS as discovery sample and UKB as 
target sample to predict MDD phenotype (dependent variable) under a quasi-
binomial distribution after being pre-adjusted by centre, array and genotyping 
batch as random effects, in a general linear regression model adjusting by 
sex, age and 15 PCs. Finally, the analysis was replicated and cross-validated 
as detailed above using summary statistics from the most recent Psychiatric 
Genetic Consortium MDD meta-analysis and the Genetics of Personality 
Consortium neuroticism meta-analysis to weight PRSD and PRSN by the main 
MDD and neuroticism additive effects, respectively. 
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Controls  MDD cases  p value  Controls  MDD cases  p value 
n  5 145  2 010  ‐  2 010  2 010  ‐ 
Sex = females (%)  2095 (40.7)  1340 (66.7)  < 0.001  1 329 (66.1)  1 340 (66.7)  0.738 
Age mean (s.d.)  51.80 (11.78)  46.99 (12.06)  < 0.001  47.52 (11.90)  46.99 (12.06)  0.155 
PRSD mean (s.d.)  ‐0.04 (0.68)  0.09 (0.69)  < 0.001  0.09 (0.66)  0.09 (0.69)  0.99 
EPQN mean (s.d.)  3.16 (2.89)  6.42 (3.32)  < 0.001  3.56 (3.00)  6.42 (3.32)  < 0.001 
UKB (N = 23 092) 
Unmatched samples  Matched samples 
Controls  MDD cases  p value  Controls  MDD cases  p value 
n  15 258  7 834  ‐  7 834  7 834  ‐ 
Sex = females (%)  6 654 (43.6)  4 856 (62.0)  < 0.001  4 857 (62.0)  4 856 (62.0)  1 
Age mean (s.d.)  58.30 (8.06)  56.64 (7.92)  < 0.001  56.71 (8.23)  56.64 (7.92)  0.631 
PRSD mean (s.d.)  ‐0.06 (0.99)  0.11 (1.00)  < 0.001  0.11 (0.98)  0.11 (1.00)  0.542 
EPQN mean (s.d.)  2.79 (2.62)  5.64 (3.30)  < 0.001  2.97 (2.66)  5.64 (3.30)  < 0.001 
Matched samples: cases and controls were matched for PRS weighted by MDD‐PGC GWAS (PRSD), sex and age. 
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11  rs2221540  132716369  G  ‐0.1362  0.06346  0.5033  0.1096  0.6395  4.41x10‐7  intronic  OPCML  ‐ 
6  rs319924  64487247  G  0.08516  0.03036  ‐0.2229  0.05302  ‐0.30806  4.62x10‐7  intronic  EYS  ‐ 
10  rs2256220  24856314  C  ‐0.07145  0.03121  0.2416  0.05459  0.31305  6.43x10‐7  intergenic  ARHGAP21  16224 
16  rs4783107  84996447  T  ‐0.1134  0.04602  0.3404  0.08248  0.4538  1.55x10‐6  intergenic  ZDHHC7  13502 
10  rs2265265  24854876  T  ‐0.06464  0.03012  0.2206  0.05277  0.28524  2.68x10‐6  intergenic  ARHGAP21  17662 
19  rs1078734  39308874  C  0.08035  0.03003  ‐0.2066  0.05328  ‐0.28695  2.71x10‐6  intronic  ECH1/HNRNPL  ‐ 
11  rs4575282  132719646  C  ‐0.1084  0.06247  0.4692  0.107  0.5776  3.16x10‐6  intronic  OPCML  ‐ 
6  rs1057530  64427095  T  0.0948  0.03001  ‐0.1876  0.05283  ‐0.2824  3.34x10‐6  intergenic  PHF3  ‐3491 
6  rs10485358  64386060  T  0.09146  0.03004  ‐0.1902  0.05277  ‐0.28166  3.51x10‐6  intronic  PHF3  ‐ 
5  rs3913723  41560079  G  0.1371  0.06798  ‐0.4449  0.1153  ‐0.582  1.37x10‐5  intergenic  PLCXD3  ‐49451 
A1 minor allele, BETA1 SNP effect in neuroticism score (EPQN) within MDD controls, BETA2 SNP effect in EPQN within MDD cases, BETA stress‐sensitivity 
effect  (i.e.  differential  allelic  effect  in  EPQN between MDD  cases  and  controls;  BETA2  effect minus  BETA1  effect),  p  value  reflects  significance  of  BETA 
coefficient, P.TYPE SNP's position type, GENE closest gene within 100kb, G.POSITION position of the closest gene (bp). In bold hits from intragenic SNPs. 
Supplementary Table 2 Top 10 SNPs from GWIS on UK Biobank 
CHR  SNP  BP  A1  BETA1  SE1  BETA2  SE2  BETA  p value  P.TYPE GENE  G.POSITION
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Supplementary Table 3 Top 10 SNPs from GWIS on Generation Scotland: Scottish Family Health Study 
CHR  SNP  BP  A1  BETA1  SE1  BETA2  SE2  BETA  p value  P.TYPE GENE  G.POSITION
3  rs10510908  63762994  A  ‐0.07792  0.02704  0.1588  0.04224  0.23672  2.36x10‐6  intergenic  THOC7  56302 
11  rs7934698  134412739  A  ‐0.0633  0.03157  0.2141  0.04959  0.2774  2.37x10‐6  intergenic  ‐  ‐ 
2  rs7606549  115490198  A  0.02374  0.02006  ‐0.154  0.03187  ‐0.17774  2.37x10‐6  intronic  DPP10  ‐ 
4  rs6851779  45487679  A  0.09384  0.03685  ‐0.2235  0.05645  ‐0.31734  2.51x10‐6  intergenic  ‐  ‐ 
2  rs319858  115530841  G  0.05248  0.01983  ‐0.1204  0.03181  ‐0.17288  4.00x10‐6  intronic  DPP10  ‐ 
3  rs13098181  63749405  A  ‐0.07987  0.02695  0.1452  0.04225  0.22507  7.11x10‐6  intergenic  THOC7  13358 
3  rs12108177  63673795  G  ‐0.07852  0.0261  0.1383  0.04087  0.21682  7.76x10‐6  intergenic  SNTN  ‐9349 
20  rs6063840  51208949  G  0.06519  0.02116  ‐0.1145  0.03416  ‐0.17969  7.77x10‐6  intergenic  LINC01524  28178 
12  rs4765723  3352543  C  ‐0.04887  0.02382  0.1471  0.03699  0.19597  8.39x10‐6  intronic  TSPAN9  ‐ 








Trait  SNP  Chr  Location  Context  Gene  p value  Source  PubMed 
Cholesterol, LDL  rs10515153  5  71989150  intergenic  ZNF366  2.18 x10‐25 dbGaP  17903299 
Alcohol Drinking  rs10515153  5  71989150  intergenic  ZNF366  3.50 x10‐15 dbGaP  0 
Cholesterol, LDL  rs10515153  5  71989150  intergenic  ZNF366  9.38 x10‐12 dbGaP  17903299 
Echocardiography  rs10515153  5  71989150  intergenic  ZNF366  4.78 x10‐08 dbGaP  17903301 
Mental Competency  rs3858216  10  24689550  intron  KIAA1217  7.72 x10‐16 dbGaP  17903295 
Respiratory Function Tests  rs1941212  11  133288335  intron  OPCML  4.91 x10‐10 dbGaP  17903307 
Respiratory Function Tests  rs1941212  11  133288335  intron  OPCML  8.44 x10‐10 dbGaP  17903307 
Respiratory Function Tests  rs1941212  11  133288335  intron  OPCML  4.58 x10‐08 dbGaP  17903307 
Respiratory Function Tests  rs1941211  11  133288419  intron  OPCML  5.78 x10‐12 dbGaP  17903307 
Respiratory Function Tests  rs1941211  11  133288419  intron  OPCML  1.18 x10‐11 dbGaP  17903307 
Exercise Test  rs1941211  11  133288419  intron  OPCML  4.56 x10‐11 dbGaP  17903301 
Body Mass Index  rs1941211  11  133288419  intron  OPCML  3.22 x10‐10 dbGaP  17903300 
Cardiovascular Diseases  rs1941211  11  133288419  intron  OPCML  6.05 x10‐10 dbGaP  17903304 
Cardiovascular Diseases  rs1941211  11  133288419  intron  OPCML  9.36 x10‐10 dbGaP  17903304 
Body Mass Index  rs1941211  11  133288419  intron  OPCML  1.27 x10‐09 dbGaP  17903300 
Angiography  rs1941211  11  133288419  intron  OPCML  2.65 x10‐09 dbGaP  17903301 
Cardiovascular Diseases  rs1941211  11  133288419  intron  OPCML  2.81 x10‐09 dbGaP  17903304 
Angiography  rs1941211  11  133288419  intron  OPCML  1.54 x10‐08 dbGaP  17903301 
Body Mass Index  rs1941211  11  133288419  intron  OPCML  2.03 x10‐08 dbGaP  17903300 
Respiratory Function Tests  rs1941211  11  133288419  intron  OPCML  2.08 x10‐08 dbGaP  17903307 
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Respiratory Function Tests  rs1941211  11  133288419  intron  OPCML  3.05 x10‐08 dbGaP  17903307 
Cholesterol, HDL  rs10507129  12  101478127  intron  ANO4  1.44 x10‐10 dbGaP  17903299 
Cardiovascular Diseases  rs2278075  16  78291173  intron  WWOX  5.32 x10‐09 dbGaP  17903304 
Body Mass Index  rs9319533  16  79088978  intron  WWOX  3.56 x10‐11 dbGaP  17903300 
C‐Reactive Protein  rs9319533  16  79088978  intron  WWOX  6.00 x10‐11 dbGaP  17903293 
Insulin  rs9319533  16  79088978  intron  WWOX  6.89 x10‐10 dbGaP  17903298 
Body Weight  rs9319533  16  79088978  intron  WWOX  9.54 x10‐10 dbGaP  17903300 
Body Mass Index  rs9319533  16  79088978  intron  WWOX  2.82 x10‐09 dbGaP  17903300 
Trait  SNP  CHR  BP  Context  Gene  p value  Source  PubMed 
Mental Competency  rs3858216  10  24689550  intron  KIAA1217  7.72 x10‐16 dbGaP  17903295 
Cardiovascular Diseases  rs1941211  11  133288419  intron  OPCML  6.05 x10‐10 dbGaP  17903304 
Sleep  rs1939966  11  132297204  intron  OPCML  7.82 x10‐06 dbGaP  17903308 
Diabetes Mellitus  rs7927989  11  133356488  intron  OPCML  7.89 x10‐06 dbGaP  0 
Schizophrenia  rs7125438  11  132402910  intron  OPCML  2.08 x10‐05 dbGaP  0 
Attention Deficit Disorder with Hyperactivity  rs10786284  10  98135505  intron  TLL2  2.00 x10‐06 NHGRI  18839057 
Cardiovascular Diseases  rs2278075  16  78291173  intron  WWOX  5.32 x10‐09 dbGaP  17903304 
Intuition  rs17706989  16  78569957  intron  WWOX  1.00 x10‐06 NHGRI  21107309 
Diabetes Mellitus  rs414723  16  79228250  intron  WWOX  2.34 x10‐05 dbGaP  0 
Bipolar Disorder  rs8047442  16  78764097  intron  WWOX  2.97 x10‐05 dbGaP  0 
Schizophrenia  rs7200634  16  79176337  intron  WWOX  7.11 x10‐05 dbGaP  0 
Alcohol Drinking  rs10515153  5  71989150  intergenic  ZNF366  3.50 x10‐15 dbGaP  0 





Supplementary Table 5 Top 25 hits from gene-based analysis of GWIS meta-
analysis
SYMBOL  CHR  START  STOP  NSNPS  p value 
ZNF366  5  71728479  71813554  22  1.48x10‐7 
PHF3  6  64335725  64499229  13  1.02x10‐5 
ANO4  12  101101304  101532419  142  1.81x10‐5 
ABCC10  6  43385104  43428168  15  1.02x10‐4 
LATS2  13  21537171  21645686  24  1.04x10‐4 
ABCA2  9  139891686  139933367  4  1.06x10‐4 
PRKG1  10  52740945  54068110  378  1.27x10‐4 
PPARA  22  46536424  46649653  40  1.50x10‐4 
C9orf139  9  139911916  139941234  8  1.73x10‐4 
AMBRA1  11  46407964  46625675  10  1.83x10‐4 
ZFYVE28  4  2261309  2430390  36  2.76x10‐4 
C4orf22  4  81246874  81894910  54  2.86x10‐4 
ATG13  11  46628826  46706368  9  2.9x10‐4 
CBR4  4  169774921  169941426  20  3.42x10‐4 
MDK  11  46392306  46415375  1  3.6x10‐4 
ABCG1  21  43609799  43727354  77  5.49x10‐4 
F2  11  46730730  46771056  5  5.57x10‐4 
PRKCD  3  53180025  53236733  10  6.54x10‐4 
SMARCA4  19  11061598  11186071  17  6.76x10‐4 
PTPN3  9  112127746  112270590  34  6.98x10‐4 
FUT7  9  139914626  139937462  6  7.36x10‐4 
DGKZ  11  46344455  46412104  3  7.48x10‐4 
MYOM3  1  24372525  24448665  37  7.8x10‐4 
LCE3D  1  152541857  152562980  4  7.9x10‐4 
LIMK2  22  31598225  31686066  9  8.09x10‐4 
START/STOP  the  annotation  boundaries  of  the  gene  including  10kb  window  on  each  side. 
NSNPS  the  number  of  SNPs  annotated  to  that  gene  that  were  found  in  the  meta‐analysis 
summary statistics. 
Supplementary Table 6 Summary results from polygenic risk score (PRS) analysis using PRSice-2
MDD risk prediction in UK Biobank 
Summary Statistics  Threshold  R2  p  β coefficient   S.E. # SNP  Empirical‐p 
GS GWIS  0.001  1.49 x10‐5  0.549664  0.00175134  0.00292733  345  ‐ 
GS GWIS  0.005  5.99 x10‐5  0.230563  0.00348988  0.0029108  1526  0.684132 
GS GWIS  0.01  4.22 x10‐6  0.750409  0.000927105  0.00291447  2894  ‐ 
GS GWIS  0.02  3.24 x10‐6  0.780509  ‐0.00081019  0.00290746  5363  ‐ 
GS GWIS  0.03  7.06 x10‐6  0.680748  ‐0.00119544  0.00290545  7616  ‐ 
GS GWIS  0.04  1.23 x10‐6  0.863456  0.000498521  0.00289875  9795  ‐ 
GS GWIS  0.05  1.12 x10‐6  0.869843  0.00047545  0.00290157  11829  ‐ 
GS GWIS  0.1  3.75 x10‐6  0.764254  ‐0.000873876  0.00291387  21270  ‐ 
GS GWIS  0.2  8.86 x10‐6  0.644935  ‐0.00133834  0.00290428  37187  ‐ 
GS GWIS  0.3  7.40 x10‐6  0.673605  ‐0.00122346  0.00290462  50757  ‐ 
GS GWIS  0.4  1.36 x10‐5  0.567393  ‐0.00166105  0.00290442  62367  ‐ 
GS GWIS  0.5  3.15 x10‐5  0.384791  ‐0.00252527  0.00290555  72518  ‐ 
GS GWIS  1  2.99 x10‐5  0.397284  ‐0.00246053  0.00290671  105965  ‐ 
GS GWAS MDD  0.001  8.88 x10‐5  0.144516  0.00423867  0.00290473  321  ‐ 
GS GWAS MDD  0.005  0.000678024  5.51 x10‐‐5  0.0116971  0.00289997  1551  ‐ 
GS GWAS MDD  0.01  0.000509482  0.000472948  0.0100827  0.00288396  2950  ‐ 
GS GWAS MDD  0.02  0.000877145  4.49 x10‐6  0.0133017  0.00289912  5421  ‐ 
GS GWAS MDD  0.03  0.000959139  1.61 x10‐6  0.0140196  0.00292193  7725  0.0001 
GS GWAS MDD  0.04  0.000931599  2.27 x10‐6  0.0138323  0.00292524  9972  ‐ 
GS GWAS MDD  0.05  0.000752813  2.14 x10‐5  0.0124522  0.00292971  12107  ‐ 
GS GWAS MDD  0.1  0.000718807  3.29 x10‐5  0.0121979  0.00293704  21666  ‐ 
279 
GS GWAS MDD  0.2  0.000558608  0.000251893  0.0107481  0.00293592  37657  ‐ 
GS GWAS MDD  0.3  0.000533753  0.000346304  0.0105007  0.00293441  50970  ‐ 
GS GWAS MDD  0.4  0.00055274  0.000271534  0.0106857  0.00293433  62381  ‐ 
GS GWAS MDD  0.5  0.000509722  0.00047149  0.0102732  0.00293775  72553  ‐ 
GS GWAS MDD  1  0.000451602  0.000998201  0.0096645  0.00293624  105850  ‐ 
GS GWAS EPQN  0.001  0.000379194  0.00256452  0.00877471  0.00290943  397  ‐ 
GS GWAS EPQN  0.005  0.00067407  5.80 x10‐5  0.0117385  0.00291877  1689  ‐ 
GS GWAS EPQN  0.01  0.000481373  0.000679289  0.00991287  0.00291704  3049  ‐ 
GS GWAS EPQN  0.02  0.000669562  6.14 x10‐5  0.0116189  0.00289876  5651  ‐ 
GS GWAS EPQN  0.03  0.000623175  0.000110568  0.0112464  0.00290845  7957  ‐ 
GS GWAS EPQN  0.04  0.000739668  2.53 x10‐5  0.0122976  0.00291895  10159  ‐ 
GS GWAS EPQN  0.05  0.000774376  1.63 x10‐5  0.0125928  0.00292121  12296  0.0005 
GS GWAS EPQN  0.1  0.00062769  0.000104398  0.0112937  0.00291014  21790  ‐ 
GS GWAS EPQN  0.2  0.000755408  2.07 x10‐5  0.0124031  0.00291313  37772  ‐ 
GS GWAS EPQN  0.3  0.000483159  0.000663811  0.00991244  0.00291151  51115  ‐ 
GS GWAS EPQN  0.4  0.000604933  0.000139459  0.0110822  0.00290889  62611  ‐ 
GS GWAS EPQN  0.5  0.000600135  0.00014825  0.0110556  0.0029135  72724  ‐ 
GS GWAS EPQN  1  0.00056519  0.00023156  0.0107335  0.00291479  106022  ‐ 
PGC2 GWAS MDD  0.001  0.00240871  2.86 x10‐14  0.0221036  0.00290481  692  ‐ 
PGC2 GWAS MDD  0.005  0.00367058  5.98 x10‐21  0.0273938  0.00291439  2259  ‐ 
PGC2 GWAS MDD  0.01  0.00414411  1.88 x10‐23  0.0290898  0.00291192  3818  ‐ 
PGC2 GWAS MDD  0.02  0.00480299  6.26 x10‐27  0.0312117  0.00290113  6501  ‐ 
PGC2 GWAS MDD  0.03  0.00548407  1.60 x10‐30  0.0333745  0.00290212  8830  ‐ 
PGC2 GWAS MDD  0.04  0.00618157  3.34 x10‐34  0.0353636  0.00289534  10975  ‐ 
PGC2 GWAS MDD  0.05  0.00598545  3.61 x10‐33  0.0347968  0.00289553  12975  ‐ 
PGC2 GWAS MDD  0.1  0.0063685  3.45 x10‐35  0.0360319  0.00290615  21544  ‐ 
280 
PGC2 GWAS MDD  0.2  0.00634524  4.57 x10‐35  0.0360177  0.00291037  35023  ‐ 
PGC2 GWAS MDD  0.3  0.00655498  3.58 x10‐36  0.0366449  0.00291297  46240  ‐ 
PGC2 GWAS MDD  0.4  0.00659633  2.17 x10‐36  0.0367308  0.00291056  55832  ‐ 
PGC2 GWAS MDD  0.5  0.00674968  3.36 x10‐37  0.0371502  0.00290994  64113  0.0001 
PGC2 GWAS MDD  1  0.00659775  2.13 x10‐36  0.0367369  0.00291073  90514  ‐ 
GPC GWAS EPQN  0.001  5.93x10‐5  0.232975  0.0034842  0.00292112  450  ‐ 
GPC GWAS EPQN  0.005  0.00047754  0.000713734  0.00984361  0.00290826  1923  ‐ 
GPC GWAS EPQN  0.01  0.000349011  0.0038147  0.00846158  0.00292446  3508  ‐ 
GPC GWAS EPQN  0.02  0.000389339  0.00224533  0.00896142  0.00293236  6310  ‐ 
GPC GWAS EPQN  0.03  0.000484233  0.000654681  0.00996823  0.00292465  8761  0.005999 
GPC GWAS EPQN  0.04  0.000389933  0.00222793  0.00895165  0.00292693  11106  ‐ 
GPC GWAS EPQN  0.05  0.000431876  0.00128937  0.00942108  0.00292695  13319  ‐ 
GPC GWAS EPQN  0.1  0.000412993  0.00164856  0.00918914  0.00291946  23043  ‐ 
GPC GWAS EPQN  0.2  0.000404552  0.00184043  0.00905106  0.00290545  38773  ‐ 
GPC GWAS EPQN  0.3  0.000337535  0.00443948  0.00827244  0.0029073  51732  ‐ 
GPC GWAS EPQN  0.4  0.000309518  0.00644059  0.00793176  0.00291105  62532  ‐ 
GPC GWAS EPQN  0.5  0.000288657  0.00851247  0.00764975  0.00290725  71717  ‐ 
GPC GWAS EPQN  1  0.000335342  0.0045702  0.00824335  0.00290654  100702  ‐ 
MDD risk prediction in Generation Scotland 
Summary Statistics  Threshold  R2  p  β coefficient   S.E. # SNP  Empirical‐p 
UKB GWIS  0.001  0.000615863  0.0641373  0.0514063  0.0277688  359  ‐ 
UKB GWIS  0.005  0.00140702  0.00515954  0.0777816  0.0278099  1626  0.039896 
UKB GWIS  0.01  0.00134793  0.00617577  0.0762639  0.0278508  3093  ‐ 
UKB GWIS  0.02  0.00082812  0.0318182  0.0597164  0.0278179  5620  ‐ 
UKB GWIS  0.03  0.000783734  0.0367345  0.0582806  0.0279028  7910  ‐ 
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UKB GWIS  0.04  0.000783197  0.0367997  0.0583116  0.0279273  10172  ‐ 
UKB GWIS  0.05  0.000634099  0.0603104  0.05248  0.0279369  12296  ‐ 
UKB GWIS  0.1  0.000298689  0.197258  0.0361067  0.0280027  21828  ‐ 
UKB GWIS  0.2  5.56 x10‐5  0.5779  0.0156126  0.0280572  38016  ‐ 
UKB GWIS  0.3  1.47 x10‐5  0.774716  0.00803806  0.0280843  51652  ‐ 
UKB GWIS  0.4  8.31 x10‐6  0.829698  0.00603532  0.0280596  63278  ‐ 
UKB GWIS  0.5  1.24 x10‐6  0.933827  0.00233242  0.028091  73445  ‐ 
UKB GWIS  1  1.30 x10‐8  0.993204  ‐0.000239447  0.0281123  107168  ‐ 
UKB GWAS MDD  0.001  0.000178845  0.318403  0.0331873  0.0332622  459  ‐ 
UKB GWAS MDD  0.005  0.000806406  0.0341973  0.0659184  0.0311268  1819  ‐ 
UKB GWAS MDD  0.01  0.000404563  0.133579  0.0461141  0.0307399  3293  ‐ 
UKB GWAS MDD  0.02  0.000888844  0.0262094  0.0662525  0.0298019  6055  ‐ 
UKB GWAS MDD  0.03  0.00157766  0.00306888  0.088043  0.0297367  8577  ‐ 
UKB GWAS MDD  0.04  0.00181354  0.00150359  0.0936559  0.0295073  10795  ‐ 
UKB GWAS MDD  0.05  0.00168391  0.00222044  0.0898185  0.0293616  12997  ‐ 
UKB GWAS MDD  0.1  0.00265037  0.000125175  0.111487  0.029065  22771  0.0015 
UKB GWAS MDD  0.2  0.00243232  0.000238189  0.105894  0.0288175  38933  ‐ 
UKB GWAS MDD  0.3  0.00205055  0.000740482  0.0968134  0.0286928  52382  ‐ 
UKB GWAS MDD  0.4  0.00188791  0.00120425  0.0928607  0.0286796  63788  ‐ 
UKB GWAS MDD  0.5  0.00188513  0.00121414  0.092669  0.028641  73870  ‐ 
UKB GWAS MDD  1  0.0018228  0.00146334  0.0909943  0.0285978  107102  ‐ 
UKB GWAS EPQN  0.001  0.00257189  0.000157057  0.153412  0.0405891  937  ‐ 
UKB GWAS EPQN  0.005  0.00165949  0.00238208  0.111332  0.0366475  2886  ‐ 
UKB GWAS EPQN  0.01  0.00162997  0.00261083  0.104237  0.034628  4650  ‐ 
UKB GWAS EPQN  0.02  0.00192175  0.00108078  0.108054  0.0330582  7726  ‐ 
UKB GWAS EPQN  0.03  0.00222809  0.000434305  0.114407  0.0325177  10453  ‐ 
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UKB GWAS EPQN  0.04  0.00260106  0.000144048  0.121308  0.0319139  12922  ‐ 
UKB GWAS EPQN  0.05  0.00300612  4.39 x10‐5  0.129371  0.0316639  15217  ‐ 
UKB GWAS EPQN  0.1  0.00298832  4.62 x10‐5  0.125519  0.0308111  25209  ‐ 
UKB GWAS EPQN  0.2  0.00291587  5.70 x10‐5  0.121565  0.0302027  41077  ‐ 
UKB GWAS EPQN  0.3  0.00322564  2.31 x10‐5  0.126745  0.0299438  54140  ‐ 
UKB GWAS EPQN  0.4  0.00330371  1.84 x10‐5  0.128011  0.029884  65276  0.0002 
UKB GWAS EPQN  0.5  0.00322111  2.34 x10‐5  0.126075  0.029805  74888  ‐ 
UKB GWAS EPQN  1  0.0031251  3.09 x10‐5  0.124076  0.0297791  106865  ‐ 
PGC2 GWAS MDD  0.001  0.00414855  1.62 x10‐6  0.216448  0.0451304  770  ‐ 
PGC2 GWAS MDD  0.005  0.00521061  7.66 x10‐8  0.203259  0.0378157  2458  ‐ 
PGC2 GWAS MDD  0.01  0.00560683  2.47 x10‐8  0.196584  0.0352614  4098  ‐ 
PGC2 GWAS MDD  0.02  0.00596288  9.04 x10‐9  0.195246  0.0339684  6870  ‐ 
PGC2 GWAS MDD  0.03  0.00557897  2.67 x10‐8  0.18491  0.0332474  9285  ‐ 
PGC2 GWAS MDD  0.04  0.00548094  3.56 x10‐8  0.179858  0.0326349  11584  ‐ 
PGC2 GWAS MDD  0.05  0.00656878  1.63 x10‐9  0.193818  0.0321375  13556  ‐ 
PGC2 GWAS MDD  0.1  0.00774814  6.02 x10‐11  0.205598  0.0314216  22338  ‐ 
PGC2 GWAS MDD  0.2  0.00887224  2.59 x10‐12  0.216279  0.0309054  36238  ‐ 
PGC2 GWAS MDD  0.3  0.00939702  6.08 x10‐13  0.221812  0.030813  47465  ‐ 
PGC2 GWAS MDD  0.4  0.00968321  2.74 x10‐13  0.224167  0.0306811  57007  ‐ 
PGC2 GWAS MDD  0.5  0.00914253  1.23 x10‐12  0.217315  0.0305994  65574  ‐ 
PGC2 GWAS MDD  1  0.00992732  1.39 x10‐13  0.22645  0.0306121  92248  0.0001 
GPC GWAS EPQN  0.001  0.000771689  0.0382666  0.0579815  0.0279835  453  ‐ 
GPC GWAS EPQN  0.005  0.000879223  0.0269669  0.0617304  0.0279071  1933  ‐ 
GPC GWAS EPQN  0.01  0.00107656  0.0143831  0.0685033  0.0279885  3521  0.10379 
GPC GWAS EPQN  0.02  0.000736456  0.0429258  0.0568248  0.0280695  6348  ‐ 
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GPC GWAS EPQN  0.03  0.000494566  0.0971083  0.0463769  0.0279541  8807  ‐ 
GPC GWAS EPQN  0.04  0.000815662  0.0331399  0.0594976  0.0279281  11165  ‐ 
GPC GWAS EPQN  0.05  0.000549567  0.0803194  0.0488544  0.0279354  13399  ‐ 
GPC GWAS EPQN  0.1  0.000292343  0.202061  0.0356931  0.0279792  23180  ‐ 
GPC GWAS EPQN  0.2  0.000389567  0.140913  0.04123  0.0280019  39079  ‐ 
GPC GWAS EPQN  0.3  0.00031477  0.185646  0.0370725  0.0280095  52223  ‐ 
GPC GWAS EPQN  0.4  0.000457649  0.110546  0.0446962  0.0280096  63160  ‐ 
GPC GWAS EPQN  0.5  0.000539128  0.0833026  0.0485336  0.0280243  72494  ‐ 





Stratifier  Sample size  effect  SE  p value  effect  SE  p value  effect  SE  p value 
SPQ  1 093  0.181  0.223  0.416  0.189  0.218  0.387  ‐0.054  0.067  0.419 
MDQ  1 022  ‐0.079  0.179  0.659  0.002  0.177  0.99  0.037  0.054  0.496 
EPQN  2 010  0.265  0.121  0.028  0.09  0.12  0.453  ‐0.051  0.036  0.162 
MDD course  2 016  0.044  0.275  0.875  0.013  0.275  0.964  ‐0.029  0.083  0.726 
Age of onset  1 964  ‐0.419  0.375  0.264  ‐0.572  0.377  0.129  0.127  0.114  0.264 
Episode count  2 016  ‐0.332  0.381  0.384  ‐0.258  0.379  0.496  0.121  0.115  0.295 
Sex  2 016  0.008  0.017  0.626  0.01  0.017  0.545  ‐0.005  0.005  0.33 
SPQ Schizotypal Personality Questionnaire score, MDQ Mood Disorder Questionnaire score, EPQN Eysenck Personality Questionnaire‐Revised Short Form’s 
Neuroticism Scale. Model: Stratifier ~ MDD quintile + Stress‐sensitivity quintile + MDD*SS quintiles interaction + Age + Sex. 
Stratifier  mean  median  standard deviation  variance 
SPQ  5.90  5  4.47  19.97 
MDQ  3.85  3  3.56  12.68 
EPQN  6.42  7  3.32  10.99 
MDD course  1.49  1  0.50  0.25 
Age of onset  32.59  32  12.40  153.65 
Episode count  6.19  1  10.45  109.26 





Supplementary  Figure  1  Genetic  stress‐sensitivity  effect  representation.  Genetic 
stress‐sensitivity  effect  on  MDD  (βSS)  is  defined  as  the  difference  between  the 
regression  coefficient  in MDD  cases  (βA)  and  the  regression  coefficient  in  controls 
(βB) from linear models regressed on EPQN, adjusted by covariates. X‐axis represents 













Supplementary  Figure  4  Miami  plots  on  UK  Biobank  and  Generation  Scotland: 
Scottish Family Health Study. Miami plots showing comparison between association 




with  (up;  red  dots)  SS  effect  and  (down;  blue  dots) MDD.  Dot  line:  genome‐wide 
suggestive threshold (p = 1 x 10‐5) at the filtered effect; dashes lines: p value = 0.01 
and 0.05 at compared effect. 
Supplementary  Figure  5 Manhattan  plot  of  the  gene‐based  test  for  stress‐sensitivity. Manhattan plot  showing  gene‐based association of 




scale  by  each  PRS  in  UKB;  weighted  by  GWAS  main  additive  and  GWIS  stress‐sensitivity  effects  independently  and  combined.  (A)  Using 
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Abstract
Individual response to stress is correlated with neuroticism and is an important predictor of
both neuroticism and the onset of major depressive disorder (MDD). Identification of the
genetics underpinning individual differences in response to negative events (stress-sensitiv-
ity) may improve our understanding of the molecular pathways involved, and its association
with stress-related illnesses. We sought to generate a proxy for stress-sensitivity through
modelling the interaction between SNP allele and MDD status on neuroticism score in order
to identify genetic variants that contribute to the higher neuroticism seen in individuals with a
lifetime diagnosis of depression compared to unaffected individuals. Meta-analysis of
genome-wide interaction studies (GWIS) in UK Biobank (N = 23,092) and Generation Scot-
land: Scottish Family Health Study (N = 7,155) identified no genome-wide significance SNP
interactions. However, gene-based tests identified a genome-wide significant gene,
ZNF366, a negative regulator of glucocorticoid receptor function implicated in alcohol
dependence (p = 1.48x10-7; Bonferroni-corrected significance threshold p < 2.79x10-6).
Using summary statistics from the stress-sensitivity term of the GWIS, SNP heritability for
stress-sensitivity was estimated at 5.0%. In models fitting polygenic risk scores of both MDD
and neuroticism derived from independent GWAS, we show that polygenic risk scores
derived from the UK Biobank stress-sensitivity GWIS significantly improved the prediction of
MDD in Generation Scotland. This study may improve interpretation of larger genome-wide
association studies of MDD and other stress-related illnesses, and the understanding of the
etiological mechanisms underpinning stress-sensitivity.
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Introduction
Stressful life events are known to increase liability to mental illness and disease-related traits
[1] including neuroticism [2–4], major depressive disorder (MDD) [5–7], autoimmune dis-
eases [8] and some cancers [9, 10]. A greater understanding of the causal mechanism by which
negative events affect disease risk or outcome may be beneficial in identifying individuals for
targeted support. However, it has been proposed that sensitivity to stress may be an important
predictor of response to stress [11, 12]. In particular, the effect on an individual may result
more from the perceived stress than the event itself, and may be dependent on individual dif-
ferences in stress-sensitivity [13–18]. Studies of 5-HTT and twin studies suggest that stress-
sensitivity may, at least in part, be heritable [19–22]. Despite a complex interaction between
MDD, neuroticism and stress, multivariate structural equation models have confirmed a
genetic effect on perceived stress, overlapping that on MDD or neuroticism, but with a specific
genetic component [21]. The inter-relatedness of these traits may offer an approach to identify
the genetic variation that affects an individual’s stress-sensitivity, and improve genetic predic-
tion of an individual’s liability to negative outcomes. By modelling the interaction between
SNP allele and MDD status on neuroticism score through genome-wide interaction studies
(GWIS), we sought to investigate the genetics of stress-sensitivity.
The personality trait neuroticism is moderately heritable (30–50% estimates from twin
studies) [23–26], is higher in individuals with depression compared to controls [27, 28] and is
known to have shared genetic aetiology with depression [29–32]. Neuroticism is strongly cor-
related with measures of sensitivity to punishment but not reward [33], positively correlated
with perceived personal relevance of a stressor [34, 35] and has been used previously as a
proxy measure of stress-sensitivity [36]. Neuroticism is thought to mediate or interact with the
effects of adverse life events on risk of depression [5, 37]. It has a substantial stable component
[38], however, there is evidence for change, as well as stability, across the life span [2–4, 39].
Individual differences in neuroticism are enduringly influenced by both genetic and environ-
mental factors [40]. Whereas the stable component of neuroticism is strongly determined by
genetics, change in neuroticism score is attributed to the effects of unshared environment [39].
Persistent change in neuroticism score has been shown in response to life events [2–4]. Nega-
tive life events lead to small persistent increases in neuroticism over time [3]. However, recent
stressful life events (β = 0.14 95%CI 0.13–0.15, p< 0.001) have a stronger effect than distant
stressful life events suggesting a reduction of effect over time [3]. Long-lasting increases in
neuroticism associated with distant negative life events are mediated by depression [4].
Major depressive disorder (MDD) is a complex disorder influenced by both genetic contri-
butions and environmental risk factors, with heritability estimates from twin and family stud-
ies of between 31–42% [41, 42]. Confirmed environmental risk factors for MDD include
maternal infections, childhood maltreatment and negative life events [5–7, 43, 44]. However,
few genetic studies have such information and even fewer prospective studies exist. Incorpo-
ration of stressful life events has been shown to improve the ability to predict MDD [45, 46]
and, although stress is an environmental risk factor, it may have an independent genetic con-
tribution to risk of depression [46–50].
These studies suggest that a genetic variable derived from the difference in neuroticism lev-
els seen in individuals with MDD compared to controls may allow us to identify genetic loci
important for stress-sensitivity. We sought to identify the genetic underpinnings of individu-
al’s sensitivity to stress response (stress-sensitivity) by identifying variants that contribute to
the higher neuroticism levels seen in individuals with a lifetime diagnosis of MDD. Further,
polygenic risk scores (PRS) derived from this stress-sensitivity variable may improve predic-
tion of MDD over that based on MDD or neuroticism PRS alone.
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Using unrelated individuals from two large population-based samples, UK Biobank (UKB;
N = 23,092) and Generation Scotland: Scottish Family Health Study (GS:SFHS; N = 7,155), we
sought to identify genes involved in stress-sensitivity by performing GWIS for the interaction
between MDD status and SNP allele on neuroticism score. We identified a gene significantly
associated with stress-sensitivity and show that a PRS derived from the interaction term of the
GWIS, significantly predicts liability to depression independently of the PRS for MDD and/or
neuroticism.
Materials and methods
UK Biobank (UKB) participants
UKB is a major national health resource that aims to improve the prevention, diagnosis and
treatment of a wide range of illnesses. It recruited more than 500,000 participants aged from
middle to older age who visited 22 assessment centres across the UK between 2006 and 2010.
Data were collected on background and lifestyle, cognitive and physical assessments, sociode-
mographic factors and medical history. The scientific rationale, study design, ethical approval,
survey methods, and limitations are reported elsewhere [51, 52]. UKB received ethical
approval from the NHS National Research Ethics Service North West (Research Ethics Com-
mittee Reference Number: 11/NW/0382). All participants provided informed consent. The
present study was conducted on genome-wide genotyping data available from the initial
release of UKB data (released 2015). Details of sample processing specific to UKB project are
available at http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155583 and the Axiom array at
http://media.affymetrix.com/support/downloads/manuals/axiom_2_assay_auto_workflow_
user_guide.pdf. UKB genotyping and the stringent QC protocol applied to UKB data before it
was released can be found at http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580. SNPs
genotyped on GS:SFHS were extracted from the imputed UKB genotype data [53] (imputed by
UKB using a merged panel of the UK10K haplotype reference panel and the 1000 Genomes
Phase 3 reference panel) with quality > 0.9 was hard-called using PLINK v1.9 [54]. Individuals
were removed based on UKB genomic analysis exclusion (UKB Data Dictionary item #22010),
non-white British ancestry (#22006: genetic ethnic grouping; from those individuals who self-
identified as British, principal component analysis was used to remove outliers), high genotype
missingness (#22005), genetic relatedness (#22012; no pair of individuals have a KING-esti-
mated kinship coefficient > 0.0442), QC failure in UK BiLEVE study (#22050 and #22051: UK
BiLEVE Affymetrix and UK BiLEVE genotype quality controls for samples) and gender mis-
match (#22001: genetic sex). Further, from the initial release of UKB data and using PLINK pi-
hat< 0.05, individuals who were also participants of GS:SFHS and their relatives were
excluded to remove any overlap of individuals between discovery and target samples. A dataset
of 109,283 individuals with 557,813 SNPs remained for further analysis, aged 40–79 (57,328
female, 51,954 male; mean age = 57.1 years, s.d. = 7.99), of which 109,282 had data available
for neuroticism score and 23,092 had data available on MDD status (ncases = 7,834, ncontrols =
15,258, nfemale = 11,510, nmale = 11,582; mean age = 57.7 years, s.d. = 8.04). Thus, the final data-
set comprised 23,092 unrelated individuals.
Generation Scotland Scottish Family Health Study (GS:SFHS) participants
GS:SFHS is a family-based genetic epidemiology study which includes 23,960 participants
from ~ 7,000 Scottish family groups collected by a cross-disciplinary collaboration of Scottish
medical schools and the National Health Service (NHS) from Feb 2006 to Mar 2011. Partici-
pants were interviewed and clinically assessed for a wide range of health-related traits (includ-
ing high-fidelity phenotyping for Major Depressive Disorder and related endophenotypes),
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environmental covariates and linked to routine health records [55, 56]. All components of GS:
SFHS obtained ethical approval from the Tayside Committee on Medical Research Ethics on
behalf of the NHS (Research Ethics Committee Reference Number: 05/S1401/89) and partici-
pants provided written consent. The protocol for recruitment is described in detail in previous
publications [57, 58]. GS:SFHS genotyping and quality control is detailed elsewhere [59].
Briefly, individuals with more than 2% missing genotypes and sex discrepancies were removed,
as well as population outliers. SNPs with genotype missingness > 2%, minor allele
frequency< 1% and a Hardy-Weinberg Equilibrium test p< 1x10−6 were exclude. Finally,
individuals were removed based on relatedness (pi-hat < 0.05), maximizing retention of case
individuals, using PLINK v1.9 [54]. Genome-wide SNP data for further analysis comprised
7,233 unrelated individuals genotyped for 560,698 SNPs (nfemale = 3,476, nmale = 3,757; PLINK
v1.9 [54]), aged 18–92 (mean age = 50.4 years, s.d. = 12.06) of which: 7,190 had clinical data on
MDD; 7,196 individuals had data on neuroticism; and 7,155 had data on both neuroticism and
MDD.
Phenotype assessment
Neuroticism score (EPQN). Participants in both UKB and GS:SFHS cohorts were
assessed for neuroticism using 12 questions from the Eysenck Personality Questionnaire-
Revised Short Form’s Neuroticism Scale (EPQN) [60–63]. Neuroticism can be scored by add-
ing up the number of “Yes” responses on EPQN. This short scale has a reliability of more than
0.8 [64]. EPQN distributions were found to be sufficiently “normal” after assessment for skew-
ness and kurtosis to be analysed using linear regression (both coefficients were between -1
and 1).
MDD diagnoses. In UKB, the MDD phenotype was derived following the definitions
from Smith et al. [63] Current and previous depressive symptoms were assessed by items relat-
ing to the lifetime experience of minor and major depression [60], items from the Patient
Health Questionnaire [65] and items on help-seeking for mental health [63]. Using a touchsc-
reen questionnaire, participants were defined as probable cases if they i) answered “Yes” to the
question “Ever depressed for a whole week” (UKB field: 4598), plus at least 2 weeks duration
(UKB field: 4609), or ii) did report having seen a GP or psychiatrist for nerves, anxiety, tension
or depression (UKB fields: 2090 and 2010) and reported symptoms (UKB field: 4631) with at
least 2 weeks duration (UKB field: 5375). In our unrelated sample, 7,834 participants were
diagnosed with MDD (with single, moderate or recurrent episodes) and 15,258 were controls
(N = 23,092).
In GS:SFHS, participants took in-person clinical visits where they were screened for a his-
tory of psychiatric and emotional disorders (i.e., psychiatric, mood state/psychological distress,
personality and cognitive assessment) by trained researchers using the Structured Clinical
Interview for DSM-IV Non-Patient Version (SCID) [66], which is internationally validated to
identify episodes of depression. Those participants that were positive in the initial screening
continue through clinical interview and were administered the mood sections of the SCID.
The SCID elicited the presence or absence of a lifetime history of MDD, age of onset and num-
ber of episodes. Participants fulfilling the criteria for at least one major depressive episode
within the last month were defined as current MDD cases. Participants who were screened
positive for Bipolar I Disorder were excluded. Those participants who were negative during
the initial screening or did not fulfilled criteria for MDD were assigned as controls. Further
details regarding the diagnostic assessment are reported elsewhere [56, 57]. All interviewers
were trained for the administration of the SCID. Inter-rater reliability for the presence or
absence of a lifetime diagnosis of major depressive disorder was good (Kappa = 0.86,
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p< 0.001, 95%CI 0.7 to 1.0). In our unrelated GWIS sample (N = 7,155), 2,010 had a lifetime
diagnosis of MDD and 5,145 were controls.
Statistical methods
GWIS and derivation of a genetic stress-sensitivity effect. The effect size of an stress-
sensitivity effect (βSS) was derived by performing a GWIS for the effect of the MDD status and
SNP allele on EPQN (dependent variable) in both UKB and GS:SFHS cohorts using PLINK
1.90 (PLINK-command—gxe; fitting MDD diagnosis as a binary “group” effect) [54]. PLINK-
command—gxe estimates the difference in allelic association with a quantitative trait (EPQN)
between two groups (MDD cases vs. controls) producing effect estimates on each group and a
test of significance for the interaction between SNP allele and MDD status. The interaction p
value reflects the difference between the regression coefficient of the allelic effect in a linear
model for EPQN in MDD cases (βA) and the same regression coefficient in a linear model for
EPQN in controls (βB). The stress-sensitivity interaction effect was defined as the difference in
allele effect between MDD cases and control groups.
Considering one SNP, the effect it confers to EPQN can be modelled by MDD status (con-
trol = 0, MDD case = 1) as follows:
MDD ¼ 0; EPQN ¼ b0 þ bBSNPþ b0cCOV þ ε
MDD ¼ 1; EPQN ¼ b1 þ bASNPþ b1cCOV þ ε
(
This is equivalent to modelling the effect on MDD cases as follows:
MDD ¼ 0; EPQN ¼ b0 þ bBSNPþ b0cCOV þ ε
MDD ¼ 1; EPQN ¼ b1 þ bBSNPþ ðbA   bBÞSNPþ b1cCOV þ ε
(
Or, it can be modelled as a whole as:
EPQN ¼ b0 þ b2MDDþ bBSNPþ ðbA   bBÞSNP �MDDþ b0cCOV þ b2CCOV �MDDþ ε
Where COV stands for covariates, β2 stands for β1−β0, and β2c stands for β1c−β0c.
Thus, the interaction effect (βSS) can be estimated as the difference in allelic effect on EPQN
between MDD cases (βA) and controls (βB) as follows,
b̂SS ¼ b̂A   b̂B
b̂SS is therefore defined as the effect size reflecting the genetic stress-sensitivity effect on
MDD cases compared to controls (S1 Fig).
Stress-sensitivity GWIS, main additive effect GWASs, meta-analysis and gene-set analy-
sis. For GWIS and subsequent analyses, sample specific covariates were applied as follows:
UKB. All phenotypes were adjusted for centre, array and batch as random effects prior to anal-
yses. Analyses were adjusted for age, sex and 15 informative principal components (PCs; UKB
Data Dictionary items #22009.01 to #22009.15) as fixed effects to take account of possible pop-
ulation stratification. GS:SFHS. All the analyses were adjusted for age, sex and 20 PCs.
GWAS for MDD and neuroticism, using logistic and linear models of additive allelic effects
respectively, were conducted on the same sample sets for comparison and generation of
matched PRS using PRSice-2 [67].
Results from the GWIS of UKB and GS:SFHS were combined in a sample size weighted
meta-analysis performed using METAL [68]. While the use of standard error weighting is
more common, the different diagnostic scheme and MDD prevalence between the two cohorts
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(GS:SFHS; 12.2%, UKB: 25.8%) [57, 63] may indicate systematic differences in the measure-
ment of MDD. Generalized gene-based analysis of the meta-analysis was performed using
MAGMA [69] implemented through FUMA [70] (http://fuma.ctglab.nl). Briefly, SNP sum-
mary statistics were mapped to 17,931 protein-coding genes. Individual SNP p values from a
gene were combined into a gene test-statistic using a SNP-wise model and a known approxi-
mation of the sampling distribution used to obtain a gene-based p value. Genome-wide signifi-
cance was defined at p = 0.05/17,931 = 2.79x10-6.
LD Score regression. The summary statistics from the meta-analysis were used to exam-
ine the genetic overlap between the polygenic architecture of stress-sensitivity, MDD and neu-
roticism. LD score regression was used to derive the genetic correlations (rG) between these
traits [71, 72] using meta-analysed GWAS and GWIS summary statistics. SNP-based heritabil-
ity was also estimated using LD score regression, using the summary statistics from single-
SNP analyses.
Pathway, functional and gene expression analyses. Lead SNPs, independently associated
with the phenotype, were identified using PLINK 1.90 by clumping (p threshold < 2x10-5; LD
r2> 0.1; physical kb threshold = 500kb; 1000 Genomes Project Phase 1 CEU, GBR, TSI geno-
type data), and analysed using DEPICT [73]. Further detail is given in ‘DEPICT analyses’ in S1
Supporting Information.
Genes associated with lead SNPs were investigated for evidence of: phenotypic association
in the NCBI dbGaP database of genotypes and phenotypes [74] (https://www.ncbi.nlm.nih.
gov/gap/phegeni), regulatory DNA elements in normal cell lines and association with expres-
sion quantitative trait loci (eQTLs) using the RegulomeDB database [75] (http://www.
regulomedb.org) and the Genotype-Tissue Expression (GTEx) Portal [76] (http://www.
gtexportal.org).
Polygenic profiling. PRS were produced using PRSice-2 [67], permuted 10,000 times and
standardized to a mean of 0 and a standard deviation of 1. Using GWIS summary statistics, we
created PRS for stress-sensitivity (PRSSS) by weighting the sum of the reference alleles in an
individual by the stress-sensitivity effect (βSS). Additional PRS were generated weighting by
MDD main additive effects (PRSD) and neuroticism main additive effects (PRSN) using
GWAS summary statistics from GS:SFHS or UKB. In addition, PRSD and PRSN were also gen-
erated using summary statistics from the most recent Psychiatric Genetic Consortium (PGC)
MDD meta-analysis [42] (excluding GS:SFHS, and UKB individuals when required;
N = 155,866 & 138,884) and the Genetics of Personality Consortium (GPC) neuroticism meta-
analysis [24, 77] (N = 63,661). Generalized linear models were implemented in R 3.1.3 [78].
The direct effect of PRSSS (model 1), PRSD (model 2) and PRSN (model 3) on MDD risk were
assessed in independent logistic regression models on GS:SFHS (target cohort) using GWAS
and GWIS statistics from UKB (the largest cohort) as the discovery sample to weight PRS.
Multiple regression models fitting both PRSD and PRSN (model 4) and fitting each of them
separately with PRSSS (models 5 and 6) were also calculated. Finally, full additive multiple
regression models fitting PRS weighted by all three effects (full model) was assessed using both
PRSSS, PRSD and PRSN at their best-fit in independent models. Further, results were also
assessed using PRSD and PRSN weighted by PGC2 MDD [42] and GPC neuroticism [77] sum-
mary statistics. Further detail is given in ‘Polygenic Profiling’ in S1 Supporting Information.
All models were adjusted by sex, age and 20 PCs. A null model was estimated from the direct
effects of all covariates on MDD. 10,000 permutations were used to assess significance of each
PRS. The predictive improvement of combining the effects of multiple PRS over a single PRS
alone was tested for significance using the likelihood-ratio test.
Cross-validation was performed using UKB as target sample and GS:SFHS as discovery
sample. Additional analyses using PRSD and PRSN weighted by PGC2 MDD [42] and GPC
Stress-sensitivity proxy and depression
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neuroticism [77] summary statistics were also tested. MDD status on UKB was adjusted by
centre, array and genotyping batch as random effects and scaled (between 0 and 1) prior to
analysis, giving a quasi-binomial distribution of MDD status on UKB. Models implemented
on UKB (quasi-binomial regression) were adjusted by sex, age and 15 PCs. Nagelkerke’s R2
coefficients were estimated to quantify the proportion of MDD liability explained at the
observed scale by each model and converted into R2 coefficients at the liability scale (preva-
lence: 12.2% in GS:SFHS [57] and 25.8% in UKB [63]) using Hong Lee’s transformation [79]
available from GEAR: GEnetic Analysis Repository [80].
Using stress-sensitivity to stratify depression. GS:SFHS MDD cases (ncases = 2,016;
nfemale = 1,345, nmale = 671) have data available on MDD course (single or recurrent),
age of onset (n = 1,964) and episode count (n = 2,016), as well as on neuroticism (n =
2,010). In addition, a subset were evaluated by Mood Disorder Questionnaire [81]
(MDQ; n = 1,022) and Schizotypal Personality Questionnaire [82] (SPQ; n = 1,093). The
reduced sample number of MDQ and SPQ reflects the later addition of these question-
naires to the study and does not reflect a particular subgroup of GS:SFHS.
Difference in PRSSS and PRSD between MDD cases and controls on GS:SFHS were tested
using a Student’s two sample t-test (two tailed). Cases of MDD on GS:SFHS with data available
on each trait analyzed were stratified by quintiles based on PRSSS and PRSD (5x5 groups). Post
hoc, the effects on each trait of quintiles based on PRSSS and its interaction effect with quintiles
based on PRSD were assessed using linear regression models adjusting by sex and age in an
attempt to identify a characteristic subtype of MDD patients with differential stress-sensitivity
levels. The same analysis was reproduced using PRSs as continuous variables.
Results
We confirmed the elevated neuroticism score in MDD cases in our samples. Individuals
with a diagnosis of MDD had significantly higher EPQN scores compared to healthy con-
trols (all p < 1.9.x10-279) in both GS:SFHS (meancontrols = 3.16; meancases = 6.42) and UKB
(meancontrols = 2.79; meancases = 5.64). Neuroticism levels differ significantly between
males and females. To control for this and any age/polygenic effects, which may account
for differences in the prevalence of MDD, we created a matched set of cases and controls.
The difference in neuroticism levels between cases and controls remained significant after
matching the controls for PGC PRSD, sex and age. (GS:SFHS: meancontrols = 3.51; UKB:
meancontrols = 2.97; all p < 2.7x10-158; S1 Table).
Meta-analysis of stress-sensitivity in UKB and GS:SFHS
No SNPs were associated with stress-sensitivity at the genome-wide significant threshold
(p< 5x10-8, Fig 1). However, 14 SNPs from 8 loci achieved suggestive p value (p< 1x10-5)
ranging between p = 8.9x10-6–5.1x10-7 (summary statistics available in S1–S3 Files; Meta-anal-
ysis: Table 1; UKB and GS:SFHS: S2 and S3 Tables; Meta-analysis QQ-plot with λ: S2 Fig; UKB
and GS:SFHS QQ-plots: S3 Fig). Traits with prior evidence of association with the nearest
genes to the 8 lead SNPs were identified using dbGap and are shown in S4 Table. Comparison
between the SNP association profile along the genome between stress-sensitivity GWIS and
MDD GWAS meta-analyses is shown in Miami plots filtering for the most significant stress-
sensitivity or MDD SNPs (p< 0.001; Meta-analysis: Fig 2; UKB and GS:SFHS: S4 Fig). No
SNP with a p-value< 0.01 had a corresponding p-value in the alternate trait, suggesting that
different variants contribute to depression and stress-sensitivity. Gene-based test identified
ZNF366 as the only gene achieving genome-wide significance (p = 1.48x10-7; Bonferroni-cor-
rected significance threshold p< 2.79x10-6; S5 Table and S5 Fig). Using summary statistics
Stress-sensitivity proxy and depression
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from meta-analysis GWIS results, stress-sensitivity SNP-based heritability was estimated from
LD score regression at 5.0% (h2 = 0.0499, s.e. = 0.017, p = 1.67x10-3). Conversely, the SNP-
based heritability for MDD and neuroticism were estimated at 9.6% (h2 = 0.0962, s.e. = 0.0179,
p = 3.87x10-8) and 10.1% (h2 = 0.1006, s.e. = 0.0076, p = 3.47x10-40) respectively, using sum-
mary statistics from the meta-analysed GWAS of UKB and GS:SFHS.
Pathway enrichment, functional annotation and gene expression analyses
Lead SNPs from the GWIS meta-analysis were investigated using DEPICT. No gene showed
statistically significant links to stress-sensitivity at a DEPICT false discovery rate (FDR) <
0.05. No significant result was found for either gene set analysis or tissue enrichment analysis
Fig 1. Manhattan plots showing stress-sensitivity associations. Manhattan plots of the GWIS from (A) UKB, (B) GS:SFHS and (C) sample size weighted meta-
analysis of UKB and GS:SFHS. The x-axis is chromosomal position and y-axis is the p value (-log10 p value) of association with stress-sensitivity effect. Suggestive
genome-wide significance threshold (p = 1x10-5) is shown by solid line at y = 5. Genes or closest gene up- and down-stream from SNP position (/) are annotated. “-“:
No gene within 100kb of the SNP.
https://doi.org/10.1371/journal.pone.0209160.g001
Stress-sensitivity proxy and depression
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at FDR< 0.05. Evidence of regulatory elements on normal cell lines/tissues was identified for
5 of the 12 lead SNPs (i.e. rs3762096, rs10987199, rs2221540, rs246565, rs319924). Two lead
SNPs were associated with eQTLs: rs319924 (an intronic SNP in EYS) and rs9509508 (an
intronic SNP in LATS2) and potentially regulate LGSN/RP3-407E4.3 (p = 6.31x10-12/
p = 1.15x10-5) and LATS2 (p = 3.74x10-8), respectively.
Polygenic risk scores for stress-sensitivity predict MDD liability
PRS were used to investigate whether common variants affecting stress-sensitivity predict
MDD risk. We generated PRS (PRSSS) for stress-sensitivity based on the summary statistics
from the GWIS. After 10,000 permutations, PRSSS significantly predicted MDD risk in GS:
SFHS using weights from the larger UKB summary data (Empirical-p = 0.04; p = 5.2x10-3; β =
Table 1. Top 25 SNPs from meta-analysis of GWISs.
Rank CHR SNP BP A1 Z-score Effecta pb p (EPQN) c p (MDD) d GENE POSITIONe
1 6 rs319924 64487247 A 5.024 ++ 5.05x10-7 0.376 0.637 EYS Intronic
2 5 rs246565 71809247 A -4.684 — 2.82x10-6 0.248 0.589 ZNF366 5998bp 5’
3 10 rs2265265 24854876 A 4.604 ++ 4.15x10-6 0.035 0.084 KIAA1217 / ARHGAP21 18104bp 3’ / 17662bp 3’
4 6 rs1057530 64427095 A -4.556 — 5.21x10-6 0.636 0.840 PHF3/EYS 1677bp 3’ / 2781bp 3’
5 16 rs7199110 78790765 A -4.553 — 5.29x10-6 0.661 0.741 WWOX Intronic
6 6 rs10485358 64386060 A -4.546 — 5.46x10-6 0.390 0.902 PHF3 Intronic
7 12 rs10778077 101193988 A 4.54 ++ 5.62x10-6 0.614 0.430 ANO4 Intronic
8 5 rs13358894 71803446 A 4.527 ++ 5.99x10-6 0.257 0.651 ZNF366 197bp 5’
9 10 rs2256220 24856314 A -4.524 — 6.06x10-6 0.134 0.129 KIAA1217 / ARHGAP21 19542bp 3’ / 16224bp 3’
10 10 rs3762096 98136250 A -4.521 — 6.15x10-6 0.437 0.149 TLL2 Intronic
11 11 rs2221540 132716369 A -4.492 — 7.05x10-6 0.468 0.364 OPCML Intronic
12 5 rs10043659 71781839 A 4.483 ++ 7.37x10-6 0.339 0.808 ZNF366 Intronic
13 12 rs10778078 101195088 A -4.45 — 8.58x10-6 0.599 0.456 ANO4 Intronic
14 9 rs10987199 128968987 A -4.442 — 8.91x10-6 0.199 0.026 LOC101929116 63416bp 3’
15 5 rs10042132 71789021 A -4.416 — 1.01x10-5 0.418 0.538 ZNF366 Intronic
16 11 rs10894606 132671611 A -4.404 — 1.06x10-5 0.438 0.587 OPCML Intronic
17 12 rs7295089 2440464 A 4.372 ++ 1.23x10-5 0.266 0.212 CACNA1C Intronic
18 5 rs9293292 71696942 A -4.351 — 1.36x10-5 0.126 0.731 PTCD2/ZNF366 41762bp 3’ / 42292bp 3’
19 15 rs3097437 27872136 A 4.346 ++ 1.38x10-5 0.970 0.226 GABRG3 93762bp 3’
20 9 rs1999377 11919732 A 4.344 ++ 1.40x10-5 0.436 0.064 - Intragenic
21 5 rs6862221 71754962 A 4.342 ++ 1.41x10-5 0.543 0.823 ZNF366 Intronic
22 5 rs9293289 71683885 A -4.323 — 1.54x10-5 0.395 0.510 PTCD2/ZNF366 28705bp 3’ / 55349bp 3’
23 11 rs4575282 132719646 A -4.313 — 1.61x10-5 0.598 0.514 OPCML Intronic
24 9 rs2417008 128970219 A -4.3 — 1.71x10-5 0.208 0.026 LOC101929116 62184bp 3’
25 9 rs7021461 128972210 A 4.299 ++ 1.72x10-5 0.202 0.025 LOC101929116 60193bp 3’
aEffect direction in GS:SFHS and UK Biobank.
b,c,dSignificances of
bGWIS stress-sensitivity effect
cSNP main effect on neuroticism derived from GWAS meta-analysis of EPQN between UK Biobank and Generation Scotland
dSNP main effect on MDD derived from GWAS meta-analysis of MDD between UK Biobank and Generation Scotland.
ePosition of the SNP respect to closest gene transcripts within 100kb (including UTRs) from 5 prime (5’) or 3prime (3’).
LD score regression was performed to obtain genetic correlations between stress-sensitivity, MDD and neuroticism. As previously shown, there was a significant genetic
correlation between MDD and neuroticism (rG = 0.637, s.e. = 0.0704, p = 1.39x10-19). However, we found no evidence for a genetic correlation between stress-sensitivity
and MDD (rG = -0.099, s.e. = 0.182, p = 0.585) or between stress-sensitivity and neuroticism (rG = 0.114, s.e. = 0.107, p = 0.285).
https://doi.org/10.1371/journal.pone.0209160.t001
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0.078, s.e. = 0.028; best-fit p threshold = 0.005; S6 Table). On the liability scale, the MDD vari-
ance explained in GS:SFHS by PRSSS was modest (R
2 = 0.195%). This was less than predicted
by PRS weighted by the genetic main effects of MDD or neuroticism (PRSD: R
2 = 0.368%;
PRSN: R
2 = 0.459%; Table 2 and S6 Table). However, this association was not cross-validated
in UKB using summary data from the smaller GS:SFHS GWIS (Empirical-p = 0.68; p = 0.23;
β = 0.004, s.e. = 0.003; best-fit p threshold = 0.005; PRSSS R2 = 0.013%; S6 Table), likely due
to lack of power as a result of the small discovery sample size. PRSD (R
2 = 0.204%) and PRSN
(R2 = 0.166%) derived from GS:SFHS significantly predicted MDD in UKB (Table 2 and S6
Table).
Due to the known genetic correlations between MDD, neuroticism and stressful life events
[21], models jointly fitting the effects of multiple PRS were analysed. Multiple regression analy-
ses in GS:SFHS showed that, compared to PRSD effects alone, the stress-sensitivity effect
derived from the UKB GWIS effects significantly explains an additional 0.195% (a predictive
improvement of 53.1%, p = 5.1x10-3; PRSD: β = 0.112, s.e. = 0.029; PRSSS: β = 0.078, s.e. =
0.028). The inclusion of PRSSS in the full model, where PRSSS was fitted along with both PRSD
and PRSN weighted by GWAS summary statistics derived from UKB remained significant;
explaining an additional 0.172% (a predictive improvement of 24.6%, p = 8.5x10-3; PRSD:
Fig 2. Miami plots showing comparison between association profile between stress-sensitivity GWIS and MDD GWAS. Miami plots from meta-
analysis filter at p = 1x10-3: (A) filtering for stress-sensitivity p values (•), (B) filtering for MDD p values (×). The x-axis is chromosomal position and
y-axis is the p value (-log10 p value) of association with stress-sensitivity (up; red dots) and MDD p value (down; blue crosses). Dot line: genome-
wide suggestive threshold (p = 1x10-5) at the filtered effect; dashed lines: p = 0.01 and 0.05 at unfiltered effect.
https://doi.org/10.1371/journal.pone.0209160.g002
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β = 0.093, s.e. = 0.029; PRSN: β = 0.107, s.e. = 0.030; PRSSS: β = 0.073, s.e. = 0.028). In models
fitting PRSD and PRSN, the variances explained were non-additive, demonstrating the partial
overlap between MDD risk prediction from PRSD and PRSN main additive effects. This is con-
sistent with the known genetic correlation between these two traits. An overlap was not seen
between the variance explained by PRSSS effect and the variance explained by PRSD and/or
PRSN. Multiple regression analyses fitting PRSD and PRSN derived from worldwide con-
sortiums (Fig 3) showed that the increased sample size from GWAS used to derive PRSD
resulted in an increment of MDD variance explained in GS:SFHS by PRSD (from 0.368% to
1.378%). However, there was no change in the proportion of the variance explained by the
PRSSS in the full model (PRSSS p = 3.5x10-3). These results suggest that PRSSS explains a pro-
portion of MDD risk not accounted for by PRSD or PRSN at current sample sizes. However,
these findings were not cross-validated in UKB using PRSSS derived from GS:SFHS GWIS,
likely due to lack of power as a result of the small discovery sample size (S6 Fig).
Using stress-sensitivity to stratify MDD in GS:SFHS
MDD cases show significantly higher PRSSS (p = 2x10-3) and PRSD (p = 1.8x10-4) than con-
trols. Association between MDD-related traits and stress-sensitivity risk quintiles was assessed
Table 2. MDD risk prediction at best fits.
UKB predicting on GS:SFHS
Weighted effect Best fit threshold # SNPs R2 (%)d R2 (%)e p Empirical-p
Stress-sensitivity 0.005 1,626 0.141 0.195 5.2x10-3 0.0399
MDDa 0.1 22,771 0.265 0.368 1.3x10-4 0.0015
EPQNb 0.4 65,276 0.330 0.459 1.8x10-5 0.0002
MDDa + EPQNb - - 0.503 0.699 8.0x10-7 -
joint modelsc - - 0.627 0.871 1.2x10-7 -
PGC2 & GPC predicting on GS:SFHS
PGC2 MDDa 1 92,248 0.993 1.378 1.4x10-13 �0.0001
GPC EPQNb 0.01 3,521 0.108 0.149 0.014 0.1038
PGC2 MDD + GPC EPQNb - - 1.052 1.461 1.7x10-13 -
joint modelsc - - 1.203 1.671 1.6x10-14 -
GS:SFHS predicting on UKB
Weighted effect Best fit threshold # SNPs R2 (%)a R2 (%)b p Empirical-p
Stress-sensitivity 0.005 1,526 0.008 0.013 0.231 0.6841
MDDa 0.03 7,725 0.130 0.204 1.6x10-6 �0.0001
EPQNb 0.05 12,296 0.106 0.166 1.6x10-5 0.0005
MDDa + EPQNb - - 0.197 0.309 2.8x10-8 -
joint modelsc - - 0.206 0.322 6.6x10-8 -
PGC2 & GPC predicting on UKB
PGC2 MDDa 0.5 64,113 0.919 1.440 3.4x10-37 <0.0001
GPC EPQNb 0.03 8,761 0.066 0.104 6.5x10-4 0.006
PGC2 MDDa + GPC EPQNb - - 0.950 1.488 2.9x10-37 -
joint modelsc - - 0.958 1.501 1.5x10-36 -
amajor depressive disorder
bneuroticism score
ccombined effect fitting all 3 PRS weighted by all the effects (i.e. stress-sensitivity, MDD and EPQN)
dNagelkerke’s R2 at observed scale
eR2 on the liability scale.
https://doi.org/10.1371/journal.pone.0209160.t002
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Fig 3. MDD is best predicted using multiple PRS. MDD risk explained (R2 coefficient (%); top bar values) on the
liability scale by each PRS in GS:SFHS; weighted by GWAS main additive and GWIS stress-sensitivity effects
independently and combined. (A) Using summary statistics from UKB as discovery sample. There is an increment on
MDD risk prediction from adding PRSSS to PRSD model of 53.1% and 24.6% when combining PRSSS with both MDD
and neuroticism PRS. (B) Replication of fitting PRSD and PRSN using summary statistics from worldwide consortiums
(i.e. PGC &GPC). Significance codes: p values ��� < 0.001< �� < 0.01< � < 0.05< •< 0.1; derived from likelihood
ratio tests. SS stands for stress-sensitivity.
https://doi.org/10.1371/journal.pone.0209160.g003
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on MDD cases in order to identify a subgroup of MDD patients, perhaps defining a character-
istic aetiological subtype of MDD. However, stratification analysis failed, and no quintile based
on PRSSS nor its interaction with quintiles based on PRSD showed statistically significant
effects on any trait analyzed. Individuals with high PRSSS were not significantly different from
other cases for sex, MDD course, age of onset or episode count, nor neuroticism, mood disor-
der or schizotypal personality scores (p> 0.05; S7 Table). Results remained non significant
when PRSs were fitted as continuous variables (p> 0.05).
Discussion
The existence of genetic variants affecting an individual’s risk of depression in response to
stress has been predicted previously [46, 49, 50] and is consistent with the departure from a
simple additive genetic model seen in twin-studies of recurrent depressive disorder [83].
Through international research efforts such as the PGC and UK Biobank, there are ever-
increasing sample sizes available for understanding the genetics of MDD. These resources are
beginning, and will continue to, identify genome-wide significant loci [42, 84, 85]. However,
the lack of environmental data and/or their reliability, makes the study of genetic individual’s
response to their negative effects, and their contribution to the onset of MDD and other stress-
related disorders, difficult. As a way to address this limitation, we generated a proxy for stress-
sensitivity through modelling the interaction between SNP allele and MDD status on neuroti-
cism score in a GWIS approach. Thus, we sought to identify the genetic underpinnings of indi-
vidual’s sensitivity to stress response (stress-sensitivity) through those variants that contribute
to higher neuroticism levels only in individuals with a lifetime diagnosis of MDD but not in
healthy controls.
We performed a GWIS to identify loci showing differential effects on neuroticism scores in
individuals with and without MDD (so called stress-sensitivity proxy). No SNPs reached
genome-wide significance, but 14 SNPs from 8 loci reached suggestive significance levels (see
S4 Table for prior evidence of associated phenotypes). Enrichment analysis showed no evi-
dence for enrichment of specific pathways or tissues. The top two loci, PTP4A1-PHF3-EYS
and ZNF366 have been previously associated with alcohol dependence [86–90], alcohol intake
(dbGaP: phs000342) and glucocorticoid receptor function [91–93]. The most significant SNP
in this study, rs319924, is an intronic variant in EYS that is a potential eQTL for LGSN [76], a
gene previously associated with male-specific depression [94]. This is of particular interest
given previous studies linking alcohol consumption, stress and the risk of depression [95–
100]. However, findings should be interpreted with caution, as these loci did not reach
genome-wide significance at current sample size. Evidence of an eQTL effect was predicted for
a lead SNP in LATS2, a positive regulator of histone methyltransferase activity [101] a process
important in anxiety-related behaviours [102]. The prior association of the top two loci in this
study with alcohol related-phenotypes suggests that genes involved in the sensitivity to stress
may mediate the effects of stress on alcohol consumption. Some PHF3 paralogs have been
shown to be linked with depression and modulate stress response [103, 104].
Gene-based analysis identified a genome-wide significant association between ZNF366 and
stress-sensitivity. ZNF366 (also known as DC-SCRIPT) is a corepressor of transcription found
in nuclear receptor complexes including the glucocorticoid receptor. ZNF366 represses gluco-
corticoid receptor-mediated transcription in monocyte-derived dendritic cells [91]; and may
act through histone deacetylases to modulate immune response [92]. There is evidence from a
large-scale mRNA display study that PHF3, in the region underlying the most significant peak
in the single SNP analysis, may also interact, directly or indirectly, with the glucocorticoid
receptor (IntAct database [93]) but this has not been confirmed. These results reinforce the
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hypothesis that our proxy for stress-sensitivity truly reflects the genetic architecture of sensitiv-
ity to respond to stress.
We estimated a significant lower bound on common SNP-based heritability for stress-sen-
sitivity of 5%. Whilst the known genetic overlap between MDD and neuroticism was detect-
able, the lack of genetic correlation with stress-sensitivity, reinforced by results from multiple
regression analyses, indicated a lack of significant overlap in the genetics factors underpinning
stress-sensitivity and MDD or neuroticism. This analysis may be limited by our sample size,
although using the largest available meta-analyses of MDD and neuroticism [42, 77] did not
decrease the proportion of liability explained by the PRSSS. We note, that as such meta-analy-
ses increase in size it is likely, as with the effects of smoking in schizophrenia [105, 106], that
the indirect genetic effects of the environment on the risk of depression will be detected by
GWAS. However, through studies such as ours, or similar, the mechanism for the effect of the
risk alleles may be clarified.
Further, we show that such genetic information in stress-sensitivity could significantly
improve the proportion of liability to MDD predicted by PRS based only on additive genetic
effects on MDD identified by large GWAS. The summary results from the GWIS were used to
derive a PRS reflecting the genetic difference in stress-sensitivity. This variable significantly
predicted liability to MDD in GS:SFHS (p = 5.2x10-3, Empirical-p = 0.04 after 10,000 permuta-
tions), although this finding could not be replicated in UKB (Empirical-p = 0.68), likely due to
lack of power. This is consistent with the expectation that the larger the discovery sample (i.e.
UKB), the greater the accuracy of the weighting and the more predictive the PRS [107]. Multi-
ple regression models in GS:SFHS suggest that inclusion of PRS weighted by stress-sensitivity
significantly improves MDD prediction over use of either MDD and/or neuroticism weighted
PRS alone (improvement in full model p = 8.5x10-3). However, we were unable to identify a
subgroup of MDD cases with higher PRSss. The polygenic interaction approach used in our
study may, therefore, improve the interpretation of both positive and negative findings from
GWAS studies (i.e. pathways and mechanisms involved, lack of replication, or negative find-
ings in variants mediating environmental effects). Added to paralleling recent developments
in GWAS analyses, it may maximize our power to detect gene-by-environment effects in this
heterogeneous disorder.
Future studies will be required to further investigate the effects of adverse life events in indi-
viduals with high or low polygenic risk scores for stress-sensitivity. However, the methodology
presented allows addressing the genetic response to negative outcomes via proxy in the
absence of prospective environmental data.
Here we identify an independent set of risk variants for an individual’s response to negative
outcomes and show that incorporating information across many loci provides clear and repli-
cable evidence for a genetic effect of stress-sensitivity on MDD risk; identifying a potential
genetic link with alcohol intake. These results require further study, but may inform treatment
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S3 File. GWIS summary statistics from meta-analysis.
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S1 Fig. Genetic stress-sensitivity effect representation. Genetic stress-sensitivity effect on
MDD (βSS) is defined as the difference between the regression coefficient in MDD cases (βA)
and the regression coefficient in controls (βB) from linear models regressed on EPQN, adjusted
by covariates. A1: allele 1. A2 allele 2.
(TIFF)
S2 Fig. QQ plot from stress-sensitivity meta-analysis. QQ plot of GWIS from sample size
weighted meta-analysis (λ = 0.997; s.e. = 1.05x10-5). All SNPs wit p< 2x10-5, p threshold (dot
line) where some SNPs start to deviate from null distribution going outside 95% confidence
intervals (grey shadow), were selected to perform DEPICT analyses to assess pathway and
functional genomic analyses. 27 top variants from 12 independent loci were selected.
(TIFF)
S3 Fig. QQ plots of GWIS p values. QQ plots of GWIS from (A) UKB (λ = 1.014; s.e. =
1.027x10-5), (B) GS:SFHS (λ = 0.997; s.e. = 7.989x10-6). The 95% confidence interval is shaded
in grey.
(TIFF)
S4 Fig. Miami plots on UK Biobank and Generation Scotland: Scottish Family Health
Study. Miami plots showing comparison between association profile between SS and MDD
main additive effects. Miami plots from (A) UKB filtering for SS p values (top) and MDD p val-
ues (bottom), (B) GS:SFHS filtering for SS p values (top) and MDD p values (bottom). Filter at
p = 1x10-3. The x-axis is base-paired chromosomal position and y-axis is the significance
(-log10 p) of association with (up; red dots) SS effect and (down; blue dots) MDD. Dot line:
genome-wide suggestive threshold (p = 1x10-5) at the filtered effect; dashes lines: p value = 0.01
and 0.05 at compared effect.
(TIFF)
S5 Fig. Manhattan plot of the gene-based test for stress-sensitivity. Manhattan plot showing
gene-based association of stress-sensitivity. The x-axis is base-paired chromosomal position
and y-axis is the significance (-log10 p value) of association with SS effect. Genome-wide signif-
icance threshold showed by red dashed line was defined at p = 0.05/17,931 = 2.79x10-6.
(TIFF)
S6 Fig. PRS profiling predicting MDD in UK Biobank. MDD risk explained (R2 coefficient
(%); top bar values) on the liability scale by each PRS in UKB; weighted by GWAS main addi-
tive and GWIS stress-sensitivity effects independently and combined. (A) Using summary sta-
tistics from GS:SFHS as discovery sample. (B) Replication fitting PRSD and PRSN using
summary statistics from worldwide consortiums (i.e. PGC & GPC). Significance codes: p val-
ues ��� < 0.001 < �� < 0.01 < � < 0.05; derived from likelihood ratio tests. SS stands for
stress-sensitivity.
(TIFF)
S1 Table. EPQN comparison between MDD cases and healthy controls.
(XLSX)
S2 Table. Top 10 SNPs from GWIS on UK Biobank.
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S3 Table. Top 10 SNPs from GWIS on Generation Scotland: Scottish Family Health Study.
(XLSX)
S4 Table. Traits with significant evidence of association with closest gene to suggestive
stress-sensitive hits. The closest genes to SNPs associated with stress-sensitivity at suggestive
significance levels have prior evidence of association in dbGAP with a wide range of neuropsy-
chiatric traits such as schizophrenia, bipolar disorder, attention deficit disorder with hyperac-
tivity, mental competency, intuition, sleep or alcohol drinking.
(XLSX)
S5 Table. Top 25 hits from gene-based analysis of GWIS meta-analysis.
(XLSX)
S6 Table. Summary results from polygenic risk score (PRS) analysis using PRSice-2.
(XLSX)
S7 Table. MDD stratification.
(XLSX)
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Appendix B 
Appendix B contains supplementary material for chapter 3: Enrichment of 
genetic variation conferring MDD risk in glucocorticoid-related genesets: 
partitioning risk based on main additive contributions to MDD, neuroticism and 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix C contains a supplementary table and supplementary figures for chapter 4: A 
validation of the diathesis-stress model for depression in Generation Scotland. The 
published article in Translational Psychiatry is also included. 
C.1 Supplementary Table
Supplementary Table 1 Summary of SNPs used in PRS profiling. Number of SNPs 














the  risk  of  depressive  symptoms  in  women.  X‐axis  represents  the  direct  effect  of  PRS  (standard  deviations  from  the  mean)  based  on  p‐
threshold  =  1x10
‐5  using  a)  “dependent”  SLE  (DSLE)  or  b)  “independent”  SLE  (ISLE).  Levels  of  SLE  reported  by  each  participant  (dot)  are 
categorized  in  three  groups.  Blue:  0  SLE,  “none”;  green:  1  or  2  SLE,  “low”;  red:  3  or more  SLE,  “high”;  a)  “none”  n  =  3  574,”low”  n  =  1  
210,”high”  n = 135,  b) “none”  n  =  2  369,”low”  n  =  2  150,”high”  n  =  394.  Y‐axis  reflects  depression  score  standardized  to mean  of  0  and 




STRADL  participants.  PRS were weighted  by  summary  statistics  from  the  Psychiatric Genetic  Consortium MDD GWAS  (July  2016), with  the 
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A validation of the diathesis-stress model
for depression in Generation Scotland
Aleix Arnau-Soler 1, Mark J. Adams 2, Toni-Kim Clarke2, Donald J. MacIntyre 2, Keith Milburn3, Lauren Navrady 2,
Generation Scotland,Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium,
Caroline Hayward 4, Andrew McIntosh 2,5 and Pippa A. Thomson 1,5
Abstract
Depression has well-established influences from genetic and environmental risk factors. This has led to the diathesis-
stress theory, which assumes a multiplicative gene-by-environment interaction (GxE) effect on risk. Recently, Colodro-
Conde et al. empirically tested this theory, using the polygenic risk score for major depressive disorder (PRS, genes) and
stressful life events (SLE, environment) effects on depressive symptoms, identifying significant GxE effects with an
additive contribution to liability. We have tested the diathesis-stress theory on an independent sample of 4919
individuals. We identified nominally significant positive GxE effects in the full cohort (R2= 0.08%, p= 0.049) and in
women (R2= 0.19%, p= 0.017), but not in men (R2= 0.15%, p= 0.07). GxE effects were nominally significant, but only
in women, when SLE were split into those in which the respondent plays an active or passive role (R2= 0.15%, p=
0.038; R2= 0.16%, p= 0.033, respectively). High PRS increased the risk of depression in participants reporting high
numbers of SLE (p= 2.86 × 10−4). However, in those participants who reported no recent SLE, a higher PRS appeared
to increase the risk of depressive symptoms in men (β= 0.082, p= 0.016) but had a protective effect in women (β=
−0.061, p= 0.037). This difference was nominally significant (p= 0.017). Our study reinforces the evidence of
additional risk in the aetiology of depression due to GxE effects. However, larger sample sizes are required to robustly
validate these findings.
Introduction
Stressful life events (SLE) have been consistently
recognized as a determinant of depressive symptoms, with
many studies reporting significant associations between
SLE and major depressive disorder (MDD)1–7. Some
studies suggest that severe adversity is present before the
onset of illness in over 50% of individuals with depression8
and may characterize a subtype of cases9. However, some
individuals facing severe stress never present symptoms of
depression10. This has led to a suggestion that the
interaction between stress and an individual’s vulner-
ability, or diathesis, is a key element in the development of
depressive symptoms. Such vulnerability can be conceived
as a set of biological factors that predispose to illness.
Several diathesis-stress models have been successfully
applied across many psychopathologies11–15.
The diathesis-stress model proposes that a latent dia-
thesis may be activated by stress before psychopatholo-
gical symptoms manifest. Some levels of diathesis to
illness are present in everybody, with a threshold over
which symptoms will appear. Exceeding such a threshold
depends on the interaction between diathesis and the
degree of adversity faced in SLE, which increases the lia-
bility to depression beyond the combined additive effects
of the diathesis and stress alone11. Genetic risk factors
can, therefore, be conceived as a genetic diathesis. Thus,
this genetically driven effect produced by the diathesis-
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stress interaction can be seen as a gene-by-environment
interaction (GxE).
MDD is characterized by a highly polygenic archi-
tecture, composed of common variants with small effect
and/or rare variants16. Therefore, interactions in depres-
sion are also expected to be highly polygenic. In recent
years, with the increasing success of genome-wide asso-
ciation studies, GxE studies in depression have shifted
towards hypothesis-free genome-wide and polygenic
approaches that capture liability to depression using
genetic data17–23,24. Recent advances in genomics and the
massive effort from national institutions to collect genetic,
clinical and environmental data on large population-based
samples now provide an opportunity to empirically test
the diathesis-stress model for depression. The construc-
tion of polygenic risk scores (PRS) offers a novel paradigm
to quantify genetic diathesis into a single genetic measure,
allowing us to study GxE effects with more predictive
power than any single variant25–28. PRS are genetic indi-
cators of the aggregated number of risk alleles carried by
an individual weighted by their allelic effect estimated
from genome-wide association studies. This polygenic
approach to assessing the diathesis-stress model for
depression has been tested using either childhood
trauma17,19,24 or adult SLE18,23,24 as measures of envir-
onmental adversity.
Recently, Colodro-Conde et al.23 provided a direct test
of the diathesis-stressmodel for recent SLE and depressive
symptoms. In this study, Colodro-Conde et al. used PRS
weighted by the most recent genome-wide meta-analysis
conducted by the Psychiatric Genetics Consortium (PGC;
N= 159,601), and measures of three environmental
exposures: lack of social support, “personal” SLE, and
“network” SLE. Colodro-Conde et al. reported a sig-
nificant additive risk on liability to depression due to a
GxE effect in individuals who combine a high genetic
predisposition to MDD and a high number of reported
“personal” SLE, mainly driven by effects in women. A
significant effect of interaction was not detected in males.
They found no significant interaction between the genetic
diathesis and “network” SLE or social support. They
concluded that the effect of stress on risk of depression
was dependent on an individual’s diathesis, thus sup-
porting the diathesis-stress theory. In addition, they sug-
gested possible sex-specific differences in the aetiology of
depression. However, Colodro-Conde et al. findings have
not, to our knowledge, been independently validated.
In the present study, we aim to test the diathesis-stress
model in an independent sample of 4919 unrelated white
British participants from a further longitudinal follow-up
from Generation Scotland, and assess the differences
between women and men, using self-reported depressive
symptoms and recent SLE.
Materials and methods
Sample description
Generation Scotland is a family-based population
cohort recruited throughout Scotland by a cross-
disciplinary collaboration of Scottish medical schools
and the National Health Service (NHS) between 2006 and
201129. At baseline, blood and salivary DNA samples from
Generation Scotland participants were collected, stored
and genotyped at the Wellcome Trust Clinical Research
Facility, Edinburgh. Genome-wide genotype data were
generated using the Illumina
HumanOmniExpressExome-8 v1.0 DNA Analysis Bead-
Chip (San Diego, CA, USA) and Infinium chemistry30.
The procedures and further details for DNA extraction
and genotyping have been extensively described else-
where31,32. In 2014, 21,525 participants from Generation
Scotland eligible for re-contact were sent self-reported
questionnaires as part of a further longitudinal assessment
funded by a Wellcome Trust Strategic Award “STratifying
Resilience and Depression Longitudinally” (STRADL)33 to
collect new and updated mental health questionnaires
including psychiatric symptoms and SLE measures. 9618
re-contacted participants from Generation Scotland
agreed to provide new measures to the mental health
follow-up33 (44.7% response rate). Duplicate samples,
those showing sex discrepancies with phenotypic data, or
that had more than 2% missing genotype data, were
removed from the sample, as were samples identified as
population outliers in principal component analysis
(mainly non-Caucasians and Italian ancestry subgroups).
In addition, individuals with diagnoses of bipolar disorder,
or with missing SLE data, were excluded from the ana-
lyses. SNPs with more than 2% of genotypes missing,
Hardy-Weinberg Equilibrium test p < 1 × 10−6, or a minor
allele frequency lower than 1%, were excluded. Individuals
were then filtered by degree of relatedness (pi-hat < 0.05)
using PLINK v1.934, maximizing retention of those par-
ticipants reporting higher numbers of SLE (see phenotype
assessment below). After quality control, the final dataset
comprised 4919 unrelated individuals of European
ancestry and 560 351 SNPs (mean age at questionnaire:
57.2, s.d.= 12.2, range 22–95; women: n= 2990–60.8%,
mean age 56.1, s.d.= 12.4; men: n= 1 929–39.2%, mean
age 58.7, s.d.= 11.8). Further details on the recruitment
procedure and Generation Scotland profile are described
in detail elsewhere29,31,35–37. All participants provided
written consent. All components of Generation Scotland
and STRADL obtained ethical approval from the Tayside
Committee on Medical Research Ethics on behalf of the
National Health Service (reference 05/s1401/89). Gen-
eration Scotland data is available to researchers on
application to the Generation Scotland Access Committee
(access@generationscotland.org).
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Phenotype assessment
Participant self-reported current depressive symptoms
through the 28-item scaled version of The General Health
Questionnaire38,39. The General Health Questionnaire is a
reliable and validated psychometric screening tool to
detect common psychiatric and non-psychotic conditions
(General Health Questionnaire Cronbach alpha coeffi-
cient: 0.82–0.86)40. This consists of 28 items designed to
identify whether an individual’s current mental state has
changed over the last 2 weeks from their typical state. The
questionnaire captures core symptoms of depression
through subscales for severe depression, emotional (e.g.,
anxiety and social dysfunction) and somatic symptoms
linked to depression. These subscales are highly corre-
lated41 and suggest an overall general factor of depres-
sion42. Participants rated the 28 items on a four-point
Likert scale from 0 to 3 to assess its degree or severity40
(e.g., Have you recently felt that life is entirely hopeless?
“Not at all”, “No more than usual”, “Rather more than
usual”, “Much more than usual”), resulting on an 84-point
scale depression score. The Likert scale, which provides a
wider and smoother distribution40, may be more sensitive
to detect changes in mental status in those participants
with chronic conditions or chronic stress who may feel
their current symptoms as “usual”43, and to detect psy-
chopathology changes as response to stress. The final
depression score was log transformed to reduce the effect
of positive skew and provide a better approximation to a
normal distribution. In addition, participants completed
the Composite International Diagnostic Interview–Short
Form, which diagnoses lifetime history of MDD according
to DSM-IV criteria44. The depression score predicted
lifetime history of MDD (odd ratio= 1.91, 95% confidence
intervals 1.80–2.02, p= 1.55 × 10−102, N= 8994), with a
3.8-fold increased odds of having a lifetime history of
MDD between participants in the top and bottom deciles,
thus supporting the usefulness of the depression score in
understanding MDD. To improve interpretation, we
scaled the depression score to a mean of 0 when required
(Fig. 3).
Data from a self-reported questionnaire based on the
List of Threating Experiences45 was used to construct a
measure of common SLE over the previous 6 months. The
List of Threatening Experiences is a reliable psychometric
device to measure psychological “stress”46,47. It consists of
a 12-item questionnaire to assess SLE with considerable
long-term contextual effects (e.g., Over last 6 months, did
you have a serious problem with a close friend, neighbor or
relatives?). A final score reflecting the total number of SLE
(TSLE) ranging from 0 to 12 was constructed by summing
the “yes” responses. Additionally, TSLE was split into two
categories based on those items measuring SLE in which
the individual may play and active role exposure to SLE,
and therefore in which the SLE is influenced by genetic
factors and thus subject to be “dependent” on an indivi-
dual’s own behavior or symptoms (DSLE; 6 items, e.g., a
serious problem with a close friend, neighbor or relatives
may be subject to a respondent’s own behavior), or SLE
that are not influenced by genetic factors, likely to be
“independent” on a participant’s own behavior (ISLE; 5
items, e.g., a serious illness, injury or assault happening to
a close relative is potentially independent of a respon-
dent’s own behavior)45,48. The item “Did you/your wife or
partner give birth?” was excluded from this categorization.
In addition, SLE reported were categorized to investigate
the diathesis effect at different levels of exposure,
including a group to test the diathesis effect when SLE is
not reported. Three levels of SLE reported were defined (0
SLE= “none”, 1 or 2 SLE= “low”, and 3 or more SLE
= “high”) to retain a large enough sample size for each
group to allow meaningful statistical comparison.
Polygenic profiling and statistical analysis
Polygenic risk scores (PRS) were generated by PRSice49,
whose functionality relies mostly on PLINK v1.934, and
were calculated using the genotype data of Generation
Scotland participants (i.e., target sample) and summary
statistics for MDD from the PGC-MDD2 GWAS release
(July 2016, discovery sample) used by Colodro-Conde
et al.23, with the added contribution from QIMR cohort
and the exclusion of Generation Scotland participants,
resulting in summary statistics for MDD derived from a
sample of 50,455 cases and 105,411 controls.
Briefly, PRSice removed strand-ambiguous SNPs and
clump-based pruned (r2= 0.1, within a 10Mb window)
our target sample to obtain the most significant inde-
pendent SNPs in approximate linkage equilibrium. Inde-
pendent risk alleles were then weighted by the allelic
effect sizes estimated in the independent discovery sample
and aggregated into PRS. PRS were generated for eight p
thresholds (p thresholds: < 5 × 10−8, < 1 × 10−5, < 0.001, <
0.01, < 0.05, < 0.1, < 0.5, <= 1) determined by the dis-
covery sample and standardized (See Supplementary
Table 1 for summary of PRS).
A genetic relationship matrix (GRM) was calculated for
each dataset (i.e., full cohort, women, and men) using
GCTA 1.26.050. Mixed linear models using the GRM were
used to estimate the variance in depression score
explained by PRS, SLEs and their interaction; and strati-
fied by sex. Twenty principal components were calculated
for the datasets.
The mixed linear model used to assess the effects of PRS
is as follows:
Depression ¼ β0 þ β1PRS þ GRM þ Covariates
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Mixed linear models used to assess the effect of the
stressors are as follows:
Depression ¼ β0 þ β1TSLE þ GRM þ Covariates
Depression ¼ β0 þ β1DSLE þ GRM þ Covariates
Depression ¼ β0 þ β1ISLE þ GRM þ Covariates
Following Colodro-Conde et al.23, covariates (i.e., age,
age2, sex, age-by-sex and age2-by-sex interactions, and 20
principal components) were regressed from PRS (PRS’)
and SLE scores (i.e., TSLE’, DSLE’ and ISLE’; SLEs’) before
fitting models in GCTA to guard against confounding
influences on the PRS-by-SLEs interactions51. PRS’ and
SLEs’ were standardized to a mean of 0 and a standard
deviation of 1. The Mixed linear models (i.e., the
diathesis-stress model) used to assess GxE effects are as
follows:
Depression ¼ β0 þ β1PRS′ þ β2TSLE′
þ β3PRS′xTSLE′ þ GRM þ Covariates
Depression ¼ β0 þ β1PRS′ þ β2DSLE′
þ β3PRS′xDSLE′ þ GRM þ Covariates
Depression ¼ β0 þ β1PRS′ þ β2ISLE′ þ β3PRS′xISLE′
þGRM þ Covariates
Covariates fitted in the models above were age, age2,
sex, age-by-sex, age2-by-sex, and 20 principal compo-
nents. Sex and its interactions (age-by-sex and age2-by-
sex) were omitted from the covariates when stratifying by
sex. All parameters from the models were estimated using
GCTA and the significance of the effect (β) from fixed
effects assessed using a Wald test. The significance of
main effects (PRS and SLEs) allowed for nominally testing
the significance of interactions at p-threshold= 0.05. To
account for multiple testing correction, a Bonferroni’s
adjustment correcting for 8 PRS and 3 measures of SLE
tested (24 tests) was used to establish a robust threshold
for significance at p= 2.08 × 10−3.
The PRS effect on depression score at different levels of
exposure was further examined for the detected nominally
significant interactions by categorizing participants on
three groups based on the number of SLE reported (i.e.,
“none”, “low” or “high”). Using linear regression, we
applied a least squares approach to assess PRS’ effects on
the depression score in each SLE category. Further con-
servative Bonferroni correction to adjust for the 3 SLE
categories tested established a threshold for significance
of p= 6.94 × 10−4.
Differences on the estimated size of GxE effect between
women and men were assessed by comparing a z-score to
the standard normal distribution (α= 0.05, one-tailed). Z-
scores were derived from GxE estimates (β) and standard
errors (SE) detected in women and men as follows:





PRS for MDD significantly predicted the depression
score across the whole sample (β= 0.080, s.e.= 0.014,
p= 7.53 × 10−9) explaining 0.64% of the variance at its
best p-threshold (p-threshold= 0.1; Fig. 1a). Stratifying
by sex, PRS significantly predicted the depression score
in both sexes, explaining 0.59% in men and 0.67% in
women (men: p-threshold= 0.1, β= 0.077, s.e.= 0.022,
p= 2.09 × 10−4; women: p-threshold= 0.1, β= 0.082, s.
e.= 0.018, p= 4.93 × 10−6; Fig. 1a). Self-reported SLE
over the last 6 months (TSLE, mean= 1.3 SLE, s.d.=
1.5) also significantly predicted depression score for the
whole sample and stratified by sex (full cohort: variance
explained= 4.91%, β= 0.222, s.e.= 0.014, p= 9.98 ×
10−59; men: 4.19%, β= 0.205, s.e.= 0.021, p= 2.23 ×
10−22; women: 5.33%, β= 0.231, s.e.= 0.018, p= 7.48 ×
10−38; Fig. 1b). Overall, significant additive contribu-
tions from genetics and SLE to depression score were
detected in all participants and across sexes. There was
no significant difference in the direct effect of TSLE
between women and men (p= 0.17). However, the
variance in depression score explained by the TSLE
appeared to be lower than the variance explained by the
measure of personal SLE (PSLE) used in Colodro-
Conde et al.23 (12.9%). This may, in part, be explained
by different contributions of dependent and indepen-
dent SLE items screened in Colodro-Conde et al.
compared to our study. Although questions about
dependent SLE (DSLE, mean= 0.4 SLE) represented
over 28% of the TSLE-items reported in our study, the
main effect of DSLE explained approximately 93% of the
amount of variance explained by TSLE (full cohort:
variance explained= 4.56%, β= 0.212, s.e.= 0.014, p=
1.73 × 10−54; men: 3.74%, β= 0.193, s.e.= 0.021, p=
9.66 × 10−21; women: 5.07%, β= 0.225, s.e.= 0.018, p=
8.09 × 10−35; Fig. 1b). Independent SLE (ISLE, mean=
0.85 SLE), which represented over 69% of TSLE-items,
explained approximately 57% of the amount of variance
explained by TSLE (full cohort: variance explained=
2.80%, β= 0.167, s.e.= 0.014, p= 1.32 × 10−33; men:
2.44%, β= 0.156, s.e.= 0.022, p= 2.88 × 10−13; women:
3.02%, β= 0.174, s.e.= 0.018, p= 5.20 × 10−22; Fig. 1b).
To explore the contribution from each measure, we
combined DSLE and ISLE together in a single model.
DSLE explained 3.34% of the variance in depression
score compared to 1.45% of the variance being
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explained by ISLE, suggesting that DSLE have a greater
effect on liability to depressive symptoms than ISLE.
A diathesis-stress model for depression was tested to
assess GxE effects. We detected significant, albeit weak,
GxE effects on depression score (Fig. 2). The PRS inter-
action with TSLE was nominally significant in the full
cohort (β= 0.028, s.e.= 0.014, R2= 0.08%, p= 0.049) and
slightly stronger in women (β= 0.044, s.e.= 0.018, R2=
0.19%, p= 0.017; Fig. 2a), compared to men in which the
effect was not significant (β= 0.039, s.e.= 0.022, R2=
0.15%, p= 0.07). However, these results did not survive
correction for multiple testing (p > 2.08 × 10-3).
The best-fit threshold was much lower in women (p-
threshold= 1 × 10−5) compared to the full sample (p-
threshold= 0.01). The size of the GxE effects across sexes
at p-threshold= 1 × 10−5 were significantly different
(GxE*sex p= 0.017), but not at the best p-threshold in the
full cohort (p-threshold= 0.01, GxE*sex p= 0.32; Fig. 2a).
In women, GxE effect with DSLE predicted depression
score (p-threshold= 1 × 10−5; β= 0.039, s.e.= 0.019, R2
= 0.15%, p= 0.038; Fig. 2b and Supplementary Fig. 2a), as
did the GxE effect with ISLE (p-threshold= 1 × 10−5; β=
0.040, s.e.= 0.019, R2= 0.16%, p= 0.033; Fig. 2c and
Supplementary Fig. 2b). No significant interaction was
detected in men (best-fit p-threshold= 0.1) with either
TSLE (β= 0.039, s.e.= 0.022, R2= 0.15%, p= 0.072; Fig.
2a), DSLE (β= 0.024, s.e.= 0.022, R2= 0.06%, p= 0.28;
Fig. 2b) or ISLE (β= 0.043, s.e.= 0.022, R2= 0.18%, p=
0.055; Fig. 2c).
To examine these results further and investigate the
diathesis effect at different levels of stress, nominally
significant GxE were plotted between PRS and categories
of SLE (i.e, “none”, “low”, and “high” SLE reported; Fig. 3).
Examining the interaction found in the full cohort (PRS at
PGC-MDD GWAS p-threshold= 0.01), we detected a
significant direct diathesis effect on the risk of depressive
symptoms in those participants reporting SLE, with a
higher risk when greater numbers of SLE were reported
(“low” number of SLE reported: PRS’ β= 0.043, s.e.=
0.021, p= 0.039; “high” number of SLE reported: PRS’ β
= 0.142, s.e.= 0.039, p= 2.86 × 10−4; see Table 1 and Fig.
3a). Whereas, in participants who reported no SLE over
the preceding 6 months, the risk of depressive symptoms
was the same regardless of their diathesis risk (“none” SLE
reported: PRS’ β= 0.021, s.e.= 0.022, p= 0.339). Strati-
fying these results by sex, we found the same pattern as in
the full cohort in women (“none”: p= 0.687; “low”: p=
0.023; “high”: p= 2 × 10-3), but not in men (“none”: p=
0.307; “low”: p= 728; “high”: p= 0.053; see Table 1 and
Fig. 3a). However, the lack of a significant diathesis effect
in men may be due to their lower sample size and its
corresponding reduced power.
Examining the interaction with PRS at PGC-MDD
GWAS p-threshold= 1 × 10−5, with which a significant
Fig. 1 Prediction of depression symptoms and SLE using the PRS
for MDD. a Association between polygenic risk scores (PRS) and
depression score (main effects, one-sided tests). PRS were generated
at 8 p-threshold levels using summary statistics from the Psychiatric
Genetic Consortium MDD GWAS (released July 2016) with the
exclusion of Generation Scotland participants. The depression score
was derived from The General Health Questionnaire. The Y-axis
represents the % of variance of depression score explained by PRS
main effects. The full cohort (yellow) was split into men (blue) and
women (red). In Colodro-Conde et al. PRS for MDD significantly
explained up to 0.46% of depression score in their sample (~0.39% in
women and ~0.70% in men). b Association between reported number
of SLE and depression score (main effect, one-sided tests, results
expressed in % of variance in depression score explained). SLE were
self-reported through a brief life-events questionnaire based on the
List of Threatening Experiences and categorized into: total number of
SLE reported (TSLE), “dependent” SLE (DSLE) or “independent” SLE
(ISLE). The full cohort (yellow) was split into men (blue) and women
(red). In Colodro-Conde et al. “personal” SLE significantly explained up
to 12.9% of depression score variance in their sample (~11.5% in
women and ~16% in men)23
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interaction was detected in women, we detected a sig-
nificant diathesis effect on depression score only when
stratifying by sex in those participants who did not
reported SLE over the last 6 months (see Table 1). The
diathesis effect was positive in men (PRS’ β= 0.082, s.e.=
0.034, p= 0.016, R2= 0.7%; Fig. 3b), consistent with the
contribution of risk alleles. Conversely, the diathesis effect
was negative in women (PRS’ β= -0.061, s.e.= 0.029, p=
0.037, R2= 0.4%; Fig. 3b), suggesting a protective effect of
increasing PRS in those women reporting no SLE, and
consistent with the contribution of alleles to individual
sensitivity to both positive and negative environmental
effects (i.e., “plasticity alleles” rather than “risk
alleles”)52,53. This PRS accounted for the effect of just 34
SNPs, and the size of its GxE across sexes were sig-
nificantly different (GxE*sex p= 0.017; Fig. 2a), support-
ing possible differences in the underlying stress-response
mechanisms between women and men.
Discussion
The findings reported in this study support those from
Colodro-Conde et al.23, in an independent sample of
similar sample size and study design, and also supports
possible sex-specific differences in the effect of genetic
risk of MDD in response to SLE.
Both Colodro-Conde et al. and our study suggest that
individuals with an inherent genetic predisposition to
MDD, reporting high number of recent SLE, are at
additional risk of depressive symptoms due to GxE effects,
thus validating the diathesis-stress theory. We identified
nominally significant GxE effects in liability to depression
at the population level (p= 0.049) and in women (p=
0.017), but not in men (p= 0.072). However, these
interactions did not survive multiple testing correction (p
> 2.08 × 10−3) and the power of both studies to draw
robust conclusions remains limited54. With increased
power these studies could determine more accurately
both the presence and magnitude of a GxE effect in
depression. To better understand the effect of PRS at
different levels of exposure to stress, we examined the
nominally significant interactions detected in the full
sample by categorizing participants on three groups based
on the number of SLE reported (i.e., “none”, “low” or
“high”). We detected a significant diathesis effect on risk
of depression only in those participants reporting SLE, but
not in those participants that reported no SLE over the
preceding 6 months. Furthermore, the diathesis effect was
stronger on those participants reporting a “high” number
of SLE (β= 0.142, p= 2.86 × 10−4) compared to those
participants reporting a “low” number of SLE (β= 0.043,
p= 0.039). The former effect was significant and survived
a conservative Bonferroni correction to adjust for multiple
testing (p < 6.94 × 10−4). This finding corroborates the
diathesis-stress model for depression and supports the
results of Colodro-Conde et al. in an independent sample.
To investigate the relative contribution of the GxE to the
variance of depression, we examined in the full cohort the
total variance of depression score explained by the PRS
main effect and the significant GxE effect jointly. Together,
they explained 0.34% of the variance, of which 0.07% of the
variance of the depression score was attributed to the GxE
effect (p-threshold= 0.01; PRS p= 1.19 × 10−4, GxE p=
Fig. 2 Association between GxE effect and depression score. The plots show the percentage of depression score explained by the interaction
term (two-sided tests) fitted in linear mixed models to empirically test the diathesis-stress model. Red numbers show significant interactions p-values.
*Shows the significance of the difference in variance explained between sexes. The full cohort (yellow) was split into men (blue) and women (red).
PRS were generated at 8 p-threshold levels using summary statistics from the Psychiatric Genetic Consortium MDD GWAS (released July 2016) with
the exclusion of Generation Scotland participants. The interaction effect was tested with the number of: (a) SLE (TSLE), (b) “dependent” SLE (DSLE)
and c) “independent” SLE (ISLE). In Colodro-Conde et al., the variance of depression score explained in their sample by GxE was 0.12% (p= 7 × 10−3).
GxE were also significant in women (p= 2 × 10-3) explaining up to 0.25% of depression score variation, but not in men (p= 0.059; R2= 0.17%;
negative/protective effect on depression score)
Arnau-Soler et al. Translational Psychiatry            (2019) 9:25 Page 6 of 10
0.049; both derived from the full diathesis-model with
TSLE). This is lower than the proportion of variance
attributed to common SNPs (8.9%) in the full PGC-MDD
analysis16. As Colodro-Conde et al. noted, this result aligns
with estimates from experimental organisms suggesting
that around 20% of the heritability may be typically attrib-
uted to the effects of GxE55, although it is inconsistent with
twin studies of the majority of human traits with the
potential exception of depression56.
Consistent with PRS predicting “personal” SLE in
Colodro-Conde et al., PRS for MDD predicted SLE in our
study (see Supplementary Fig. 1), although not at the p-
threshold at which significant GxE effects were detected.
Genetic factors predisposing to MDD may contribute to
individuals exposing themselves to, or showing an
increased reporting of, SLE via behavioral or personality
traits57,58. Such genetic mediation of the association
between depression and SLE would disclose a gene-
environment correlation (i.e., genetic effects on the
probability of undergoing a SLE) that hinders interpretion
of our findings as pure GxE effects59,60. To address this
limitation and assess this aspect, following Colodro-
Conde et al., we split the 12-items TSLE measure into
SLE that are either potentially “dependent” of a partici-
pant’s own behavior (DSLE; therefore, potentially driven
by genetic factors) or not (“independent” SLE; ISLE)45,48.
DSLE are reported to be more heritable and have stronger
associations with MDD than ISLE48,61,57. In our sample,
DSLE is significantly heritable (h2SNP=0.131, s.e.= 0.071,
p= 0.029), supporting a genetic mediation of the asso-
ciation, whereas ISLE is not significantly heritable (h2SNP
= 0.000, s.e.= 0.072, p= 0.5)
62. Nominally significant GxE
effects were seen in women for both DSLE and ISLE,
suggesting that both GxE and gene-environment corre-
lation co-occur. Colodro-Conde et al. did not identify
significant GxE using independent SLE as the exposure.
Fig. 3 Scatterplot of diathesis-stress interactions on depression score. Interactions with PRS at which nominally significant GxE effects were
detected in (a) full cohort (p-threshold= 0.01) and (b) in women (p-threshold= 1 × 10–5) are shown. At bottom, the remaining samples (i.e., full
cohort, women or men) at same p-threshold are shown for comparison. The X-axis represents the direct effect of PRS (standard deviation from the
mean) based on (a) p-threshold= 0.01 and (b) p-threshold= 1 × 10–5, using the total number of SLE reported by each participant (dot) as
environmental exposures at three SLE levels represented by colors. Blue: 0 SLE, “no stress”, n= 1 833/1 041/792; green: 1 or 2 SLE, “low stress”, n= 2
311/1 459/852; red: 3 or more SLE, “high stress”, n= 775/490/285; in the full cohort, women and men, respectively. Y-axis reflects the depression score
standardized to mean of 0 and standard deviation of 1. Lines represent the increment in risk of depression at a certain degree of “stress” dependent
on a genetic predisposition (= diathesis)
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Between-sex differences in stress response could help to
explain previous differences seen between sexes in
depression such as those in associated risk (i.e., approxi-
mately 1.5–2-fold higher in women), symptoms reported
and/or coping strategies (e.g., whereas women tend to
cope through verbal and emotional strategies, men tend
to cope by doing sport and consuming alcohol)63–67. This
also aligns with an increased risk associated with a lack of
social support seen in women compared to men23. Fur-
thermore, although we do not know whether participants
experienced recent events with positive effects, we saw a
protective effect in those women who did not experienced
recent SLE (p= 0.037), suggesting that some genetic
variants associated with MDD may operate as “plasticity
alleles” and not just as “risk alleles”52,53. This effect was
neutralized in the full cohort due to an opposite effect in
men (p= 0.016), but it is supported by previous protective
effects reported when using a serotoninergic multilocus
profile score and absence of SLE in young women68.
These findings would be consistent with a differential-
susceptibility model of depression69,70, also suggested by
the interaction effects seen between the serotonin trans-
porter linked promoter region gene (5-HTTLPR) locus
and family support and liability to adolescent depression
in boys71. However, our results and the examples given
are only nominally significant and will require replication
in larger samples. Robust identification of sex-specific
differences in genetic stress-response could improve
personalized treatments and therapies such as better
coping strategies.
There are notable differences between our study and
Colodro-Conde et al. to consider before accepting our
findings as a replication of their results. First, differences in
PRS profiling may have affected replication power. We used
the same equivalent PGC-MDD2 GWAS as discovery
sample. However, whereas Colodro-Conde et al. generated
PRS in their target sample containing over 9.5M imputed
SNP, in this study we generated PRS in a target sample of
over 560 K genotyped SNPs (see Supplementary table 1 for
comparison). This potentially results in a less informative
PRS in our study, with less predictive power, although the
variance explained by our PRS was slightly larger (0.64% vs.
0.46%). The size of the discovery sample is key to con-
structing an accurate predictive PRS, but to exploit the
greatest number of the available variants may be an asset54.
Secondly, different screening tools were used to measure
both current depressive symptoms and recent environ-
mental stressors across the two studies. Both studies
transformed their data, using item response theory or by
log-transformation, to improve the data distribution.
Table 1 Diathesis effect on depression score in three SLE categories
Sample Full cohorta Women Men
SLE category None Low High None Low High None Low High
PRS at p value threshold= 0.01
N 1833 2311 775 1041 1459 490 792 852 285
Effect 0.021 0.043 0.142 0.0118 0.0617 0.1538 0.0346 0.0113 0.1227
s.e. 0.022 0.021 0.039 0.029 0.027 0.049 0.034 0.032 0.063
t 0.957 2.07 3.644 0.403 2.274 3.112 1.021 0.348 1.947
p value 0.339 0.039 2.86 × 10-4 0.687 0.023 0.002 0.307 0.728 0.053
CI (95%) −0.022, 0.065 0.002, 0.084 0.065, 0.218 −0.046, 0.069 0.008, 0.115 0.057, 0.251 −0.032, 0.101 −0.052, 0.075 −0.001,0.247
Sample Full cohort Womena Men
SLE category None Low High None Low High None Low High
PRS at p value threshold= 1 × 10−5
N 1833 2311 775 1041 1459 490 792 852 285
Effect −0.0022 0.0032 0.0705 −0.061 0.014 0.078 0.082 −0.0176 0.0548
s.e. 0.022 0.021 0.04 0.029 0.027 0.049 0.034 0.033 0.07
t –0.098 0.153 1.76 −2.086 0.541 1.609 2.416 −0.537 0.778
p value 0.922 0.878 0.079 0.037 0.589 0.108 0.016 0.592 0.437
CI (95%) −0.046, 0.041 −0.037, 0.044 −0.008, 0.149 −0.119,
−0.004
−0.038, 0.066 −0.017, 0.174 0.015,
0.149
−0.082,0.047 −0.084, 0.193
Note: Reported values at p-thresholds where nominally significant GxE effects were detected
aSample where nominally significant GxE was detected. SLE categories (number of SLE reported): 0 SLE= “none”, 1 or 2 SLE= “low”, and 3 or more SLE= “high”. In
italic, nominally significant effects. In bold, robustly significant effect after conservative Bonferroni correction (p < 6.94 × 10−4)
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However, neither study used depression scores that were
normally distributed. The scale of the instruments used and
their corresponding parameterization when testing for an
interaction could have a direct effect on the size and sig-
nificance of their interaction;55,72 so findings from GxE
must be taken with caution. Furthermore, although both
screening methods have been validated and applied to
detect depressive symptoms, different questions may cover
and emphasize different features of the illness, which may
result in different results. The same applies to the mea-
surement of environmental stressors in the two studies.
Both covering of a longer time-period and upweighting by
“dependent” SLE items may explain the increased expla-
natory power of “personal” SLE (12.9%) in Colodro-Conde
et al. to predict depression score compared to our “total”
SLE measure (4.91%). Finally, the unmeasured aspects of
the exposure to SLE or its impact may also contribute to the
lack of a stronger replication and positive findings.
In conclusion, despite differences in the measures used
across studies, we saw concordance and similar patterns
between our results and those of Colodro-Conde et al.23
Our findings, therefore, add validity to the diathesis-stress
theory for depression. Empirically demonstrating the
diathesis-stress theory for depression would validate
recent20–22 and future studies using a genome-wide
approach to identify genetic mechanisms and interactive
pathways involved in GxE underpinning the causative
effect of “stress” in the development of depressive symp-
toms and in mental illness in general. This study adds to
our understanding of gene-by-environment interactions,
although larger samples will be required to confirm dif-
ferences in diathesis-stress effects between women and
men.
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Appendix D 
Appendix D contains supplementary information and supplementary figures 
for chapter 5: Genome-wide by environment interaction studies (GWEIS) of 
depressive symptoms and psychosocial stress in UK Biobank and Generation 
Scotland. The published article in Translational Psychiatry is also included. 
D.1 R code to perform GWEIS.
The R script I used to perform GWEIS is a modified version from the original 
R script developed by Almli et al.1 (https://epstein-software.github.io/robust-
joint-interaction). The modifications added into the code output beta 
coefficients from both SNP and SNPxE terms and the p-value for just the 
interaction (GxE) term into the final GWEIS summary statistics. 
Using the original R script (version 20 Apr 2017), a version of the script as the 
one we used can be achieved by replacing from the source code: 
r <- c(p_model,p_robust) 
 with: 
wald_int_only<-((gee.fit$beta[3])^2)/gee.fit$vbeta[3,3]   # this is the robust wald 
test for just the interaction parameter only 
p_int_only<-pchisq(wald_int_only,1,lower.tail=F)    # this is the p-value for the 
wald test 
r <- c(p_model,p_robust,beta_est[c(2,3)],p_int_only) # The ‘beta_est’ vector 
contains all the regression coefficients for all parameters in the GEE model. 
These additional lines of code were courtesy of Prof. Michael Epstein1. 
Reference 
1. Almli, L.M. et al. Correcting systematic inflation in genetic association
tests that consider interaction effects: application to a genome-wide




Post-GWAS/GWEIS analyses. GWAS and GWEIS (for both GxE and joint 
effects) summary statistics were analysed using FUMA1 (http://fuma.ctglab.nl). 
Gene-based tests were conducted using MAGMA2 through FUMA platform 
using the default MAGMA settings. Genome-wide significance at gene-based 
test was set at the Bonferroni-corrected significance threshold p = 0.05/18,068 
= 2.77 x 10-6. FUMA was also used to assess functional annotation, gene 
prioritization and pathway enrichment using lead SNPs from associated 
genomic loci. SNPs were clumped according to linkage disequilibrium (r2 = 
0.6) using default settings to identify independent lead SNPs with a p < 1 x 10-
5. Gene mapping was performed in protein-coding genes under default
settings using: positional mapping, eQTL mapping in 10 brain tissues from 
GTEx, and chromatin interaction mapping using Hi-C data from two brain 
regions: dorsolateral/prefrontal cortex and hippocampus. The MHC region 
(25-34 Mb) was excluded from these analyses. We assessed gene-set 
enrichment of: differentially expressed genes in 53 tissue types, Canonical 
Pathways, and Gene Ontology terms. Previously reported associations from 
the GWAS catalog3 were reported for independent lead SNPs and/or their 
proxy SNPs. 
Polygenic profiling & prediction. Polygenic risk scores (PRS) were 
constructed using PRSice-24 (clump-based pruning r2 = 0.1, 10MB per 
window) for thirteen p thresholds (<0.001, <0.005, <0.01, <0.02, <0.03, <0.04, 
<0.05, <0.1, <0.2, <0.3, <0.4, <0.5, <=1) and standardized to a mean of 0. We 
calculated the proportion of variance explained using R2 and Nagelkerke’s R2 
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coefficients for binary traits. Polygenic risk scores weighting by GxE effects 
(PRSGxE) were generated as standard PRS5 using summary statistics from 
GWEIS as input (discovery sample), instead of summary statistics from 
GWAS. Thus, weighting PRS by GxE effects (or joint effects) instead of main 
additive effects. 
References 
1. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D.
Functional mapping and annotation of genetic associations with FUMA.
Nat Commun 8, 1826 (2017).
2. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA:
generalized gene-set analysis of GWAS data. PLoS Comput Biol 11,
e1004219 (2015).
3. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of
SNP-trait associations. Nucleic Acids Res 42, D1001-6 (2014).
4. Euesden, J., Lewis, C.M. & O'Reilly, P.F. PRSice: Polygenic Risk
Score software. Bioinformatics 31, 1466-8 (2015).
5. Dudbridge, F. Power and predictive accuracy of polygenic risk scores.
PLoS Genet 9, e1003348 (2013).
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D.3 Evidence supporting a link between stress and
depression in stress-related phenotypes
We  hypothesized  that  pleiotropy  between  stress‐related  conditions,  both  mental 
and physical, may be due  in part to shared genetic stress‐response mechanisms.  In 
this  study  we  report  evidence,  albeit  weak,  for  an  effect  of  GxE  involved  in 
depressive  symptoms  into  other  stress‐related  traits,  in  particular  for  schizotypal 
personality,  heart  disease  and  chronic  obstructive  pulmonary  disease  (COPD). We 
believe  that  at  least  partially,  genetics  underlying  GxE  detected  in  GWEIS  of 
depressive  symptoms belongs  to unique stress‐response mechanisms also  involved 
in the aetiology of these other phenotypes. There are many studies on the literature 




overlaps  with  autistic  personality  traits,  anxiety  and  depression9‐11.  Schizotypal 
personality  correlates  with  SLE  and  negative  coping  strategies  in  healthy 
individuals12.  The  effect  of  stress  on  schizotypal  personality  traits  is moderated by 
genetics13  and  mediated  by  dysfunctional  coping12,13.  Individuals  with  high 
schizotypal personality have been shown to report increased subjective stress and to 
display  blunted  and  delayed  cortisol  response  after  acute  psychosocial  stress, 
compared to  individuals with  low schizotypal personality, and have higher baseline 
cortisol  levels,  suggesting a  limited physiologically adaptation  to SLE and a  feasible 
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link  with  cardiovascular  comorbidities  through  chronic  overactivation  of  the 
sympathetic nervous system14.  
Heart disease. A direct relationship between the effects of psychological stress and 
cardiovascular  disease  has  been  extensively  reported15‐21.  Depression,  as  well  as 
anger and anxiety, may be a manifestation form underlying negative emotions, and 
it  has  been  proposed  that  such  underlying  negativity may  origin  the  link  between 
these  conditions  and  cardiovascular  disease22.  Psychosocial  stress  associated  with 
anxiety disorders increase autonomic arousal via the hypothalamic‐pituitary axis and 
circulating  cathecolamines,  which  is  associated  to  an  elevated  risk  of  pro‐
inflammatory state and hypertension leading to the development of coronary heart 
disease23. Previous studies also link anxiety disorder to cardiovascular disease16, and 
evidence  suggests  a  potential  role  for  inflammation  as  an  underlying  mechanism 
linking  chronic  stress  and  an  associated  increased  risk  of  coronary  heart 
disease16,17,24.  Psychological  stress  is  a  risk  factor  of  hypertension18,25,  acute 
myocardial  infarction21,  pathogenesis  of  coronary  artery  disease16,  cardiovascular 
morbidity  and  mortality19,  within  other  cardiovascular  disease,  with  a  potential 
elevated risk in women20. A consistent relationship between the occurrence of major 
depression  episodes  and  cardiovascular  disease  has  been  demonstrated,  and 
evidence  suggest  that  there  is  a  continuum  spectrum  of  risk  for  coronary  artery 
disease  associated  with  depression  according  to  the  magnitude  of  depressive 
symptoms16.  Smoking  is  a  coping  strategy26  and  behavioural  risk  factor  associated 




effect  in  depressive  symptoms  is  related  with  risk  of  COPD.  The  prevalence  of 
depressive  symptoms,  depression  and  risk  of  anxiety  is  higher  among  COPD 
patients29,30,31.  SLE  have  been  associated  with  increased  depressive  symptoms, 
anxiety  and  worse  quality  of  life  in  individuals  with  COPD  compared  to  healthy 
controls32,33,  with  significant  SLE‐by‐COPD  interaction  suggesting  a  substantially 
greater  detrimental  effect  of  stress  in  those  individuals  suffering  COPD32. 
Participants with COPD have reported to experience the same number and severity 
of non‐illness‐related occurrence of  SLE and perceived  stress as non‐COPD healthy 
participants,  suggesting  that  individuals  with  COPD  may  be  more  vulnerable  to 
detrimental  effects  of  SLE  than  healthy  controls32.  The  experience  of  anxiety  and 
distress  produced  by  breathing  difficulties  is  an  intrinsic  source  of  stress  directly 
related to COPD34,35. However, poor coping skills may be the principal psychological 
problem  that  contributes  to  psychological  distress  and  poor  quality  of  life  among 
COPD  patients36.  Depression  and  heart  failure  are  associated with  disease‐specific 




in  individuals  who  experienced  trauma,  and  exacerbated  by  post‐traumatic  stress 
disorder40.  Cigarette  smoke disrupts  homeostasis  of  the  alveolar  capillary  unit  and 
generates endogenous mediators of  inflammation  that could  result  in COPD41. The 
exposure to inhaled toxics from smoke activates a cellular integrated stress response 
implicated  in  pulmonary  pathology  and  lung  disease42.  However,  well‐known 
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behavioural risk factors such as smoking become extremely difficult to quit in those 
individuals  with  high  life  stress  and  depression  levels27,43.  In  addition,  although 
smokers often report smoking as a strategy to relieve stress, nicotine dependency is 
reported to exacerbate psychological stress, showing stress levels of smokers being 




also predicts number of cigarettes smoked  in an average week  in 75 smokers  from 
an independent GS sample (p = 4.43x10‐6). This was not replicated using the UKB GxE 
effect.  However,  it  suggests  that  genetic  stress‐response  and  stress‐related  traits 
may be partially related through GxE driven coping styles. Increased risk for smoking 
is  also  linked  to other psychiatric disorders where  smoking may play an  important 
role either as a causal factor, as an agent promoting brain changes, or as modulator 
of  medication’s  effect45.  Asthma,  a  separate  respiratory  disease,  has  also  shown 
robust  relationships with psychological stress, depression, neuro‐psychiatric  factors 
and neuroendocrine, immunologic and inflammatory systems24,46‐50. 
Other  stress‐related  traits.  Chronic  psychological  stress  has  been  recognised  to 
influence the immune system and to have an impact on many inflammatory process 
and  disease,  and  dysregulated  inflammatory  processes  have  been  linked  to major 
depressive  disorder  and  its  comorbidities  (e.g.  asthma,  diabetes,  cardiovascular 
disorders,  stroke)24,51.  Therefore,  the  list  of  stress‐related  conditions  link  to 
depression  through  genetic  stress‐response  mechanisms  may  be  larger,  including 
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other  personality  traits  such  as  extraversion  or  some  cancers,  among  others. 
Findings  suggest  that  extraversion was  improved  by  incorporating  SLE  GxE  effects 
into main additive effect as a combined joint effect; prediction otherwise missed by 
any  GxE  effect  or  UKB  main  (depressive  symptoms)  additive  effects  alone. 
Extraversion  mediates  (both  positive  and  negative)  life  events  and  resilience,  low 
extraversion  being  associated  with  higher  numbers  of  SLE24.  High  levels  of 
extraversion, which involves energy, positive emotionality and dominance,  is  linked 
with  stress  and  adversity  coping  strategies  through  positive  affective  style,  and 
related to resilience and higher level of social interaction allowing an environment of 
positive  networks  of  social  support52.  Indeed,  individuals  who  are  genetically 
predisposed  to  high  level  of  extraversion  my  perceive  (and  report)  life  events  as 
more  controllable  and  positive;  which  in  turn  may  lead  to  higher  level  of 
extraversion53.  Low  extraversion  is  associated  with  depression  and  depressive 
symptoms54,55. Another interesting case is the link between stress and cancer. Stress 
has  been  associated  with  cancer56‐59.  A  recent  study  with  lifetime  exposure  has 
reported that perceived stress, principally from workplace psychological stress over 
cumulative  duration  of more  than  15  years,  was  significantly  positively  associated 





and  potential  therapeutic  targets  for  breast  cancer61,62  and  gastric  cancer63.  The 
effects  of  stress  may  have  a  pronounced  impact  on  epigenetic  changes  like 
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evidence  for  other  stress‐related  comorbidities  of  depression  not  detailed  above 
such  as  diabetes66‐71  and  stroke72‐74,  among  others75.  Furthermore,  stress  may 
influence  the  extent  to  which  individuals  engage  with  behavioural  risk  factors  as 
coping  strategies;  including  smoking,  fatty  diet  intake,  excessive  alcohol  intake  or 
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Supplementary  Table  3a.  Genetic  correlation  with  depressive  symptoms  estimated  by 
bivariate REML using genome‐wide complex trait analyisis (GCTA). 
Trait  rG  SE  P  N 
UK Biobank 
PHQ‐SLE  0.723601  0.117723  < 0.00001  50000* 
Generation Scotland 
GHQ‐TSLE  1  0.83132  0.1145353  4919 
GHQ‐DSLE  1  0.630666  0.05644431  4919 




Supplementary  Table  3b.  SNP  heritability  estimates  from  genome‐wide  complex  trait 
analysis (GCTA) 
Trait  SNP‐heritability estimate  SE  P  N 
UK Biobank 
PHQ  0.089858  0.005001  < 0.00001  99057 
*PHQ (SLE adjusted) 0.078858  0.004928  < 0.00001  99057 
SLE  0.040449  0.004667  < 0.00001  99057 
Generation Scotland 
GHQ  0.071227  0.073081  0.1654  4919 
^GHQ  0.13536  0.053511  0.005146  6751 
TSLE  0.061389  0.071296  0.1895  4919 
DSLE  0.130571  0.071161  0.02879  4919 
ISLE  0.000001  0.072365  0.5  4919 
In  UK  Biobank,  models  were  adjusted  by  age,  sex  and  15PCs. 
In GS, models were adjusted by age, sex and 20 PCs. 
*SLE was added as a covariate.
^Heritability  for  GHQ  was  estimated  in  a  sample  of  6,751  unrelated  individuals  from  the  full  GS
cohort at baseline1. QC filters were applyied as described in the "Cohort description" at Materials &
Methods  section  for  the main  sample of  4,919 but  applying QC  steps  in  the  21,525 GS  individuals
sample  (instead of  the 8,541  individials  that  reported updated measures as part of STRADL  follow‐
up),  and  randomly  selecting  individuals  when  filtering  by  degree  of  relatedness  (instead  of






SNP  CHR  BP  G/I  MAF  A1  A2  BETA  STAT  P  Location  Closest gene (±25kb) 
GWAS of GHQ in Generation Scotland 
rs2381499  4  40211997  G  0.3454  A  G  0.05315  4.729  2.32x10‐6  Intronic  RHOH 
rs16870827  5  70976503  G  0.1787  G  A  0.06384  4.492  7.20 x10‐6 ‐  MCCC2(+21.97kb) 
rs4552473  4  40205742  G  0.2803  A  C  0.05236  4.445  8.98 x10‐6 Intronic  RHOH 
GWAS of PHQ in UK Biobank 
rs7954341  12  81419397  I  0.3191  G  A  0.022  5.229  1.71x10‐7  ‐  ‐ 
rs10862219  12  81430043  I  0.3198  T  C  0.02163  5.144  2.70x10‐7  ‐  ‐ 
rs11114720  12  81443764  G  0.3175  A  G  0.02157  5.114  3.15x10‐7  ‐  ‐ 
rs960379  2  208088537  I  0.3961  C  T  0.02052  5.108  3.27x10‐7  Intronic  LOC101927865 
rs7776980  7  117496319  I  0.3148  T  C  0.02186  5.054  4.35x10‐7  Intronic  CTTNBP2 
rs11114723  12  81449343  I  0.317  A  C  0.02114  5.025  5.03x10‐7  ‐  ACSS3(‐22.46kb) 
rs17007930  12  81445762  I  0.317  T  C  0.0211  5.017  5.26x10‐7  ‐  ‐ 
rs72707252  5  1128891  G  0.02572  T  C  0.06152  4.981  6.33x10‐7  ‐  SLC12A7(+16.72kb) 
rs2176912  12  81394117  I  0.3594  G  A  0.02039  4.958  7.13x10‐7  ‐  ‐ 
rs7782815  7  117585779  I  0.3122  G  A  0.02097  4.956  7.21x10‐7  ‐  ‐ 
rs17488728  7  117544180  I  0.4558  T  C  0.01946  4.939  7.85x10‐7  ‐  ‐ 
rs4275684  12  81465645  G  0.318  G  T  0.02075  4.921  8.64x10‐7  ‐  ACSS3(‐6.163kb) 
rs10272923  7  117572304  I  0.456  C  T  0.01929  4.898  9.69x10‐7  ‐  ‐ 
rs62471815  7  117582736  G  0.4561  A  G  0.01921  4.878  1.07x10‐6  ‐  ‐ 
rs11663824  18  50745236  I  0.3992  A  C  0.01944  4.833  1.35x10‐6  Intronic  DCC 
rs1024434  7  117580053  I  0.4567  A  C  0.01905  4.827  1.39x10‐6  ‐  ‐ 
rs11695409  2  208088987  G  0.365  G  A  0.01946  4.797  1.61x10‐6  Intronic   LOC101927865 
rs76549394  1  75935191  G  0.05128  G  A  ‐0.04215  ‐4.738  2.16x10‐6  Intronic  SLC44A5 
rs4717577  7  70493364  G  0.4296  A  G  ‐0.01855  ‐4.7  2.60x10‐6  ‐  ‐ 
rs912337  13  99141272  I  0.4263  C  T  0.01862  4.683  2.84x10‐6  Intronic  STK24 
rs10950237  7  70491251  G  0.3755  G  A  ‐0.01877  ‐4.648  3.36x10‐6  ‐  ‐ 
rs219174  2  33228292  I  0.4087  G  A  0.01843  4.615  3.93x10‐6  Intronic  LTBP1 
rs60939828  18  50729267  G  0.4323  C  T  0.01826  4.602  4.19x10‐6  Intronic  DCC 
rs6789329  3  136476862  I  0.359  C  T  0.01877  4.599  4.25x10‐6  ‐  STAG1(+5.617kb) 
381
rs219158  2  33218037  I  0.3867  G  A  0.01849  4.568  4.94x10‐6  Intronic  LTBP1 
rs847357  14  72780817  I  0.4749  G  A  0.01798  4.567  4.95x10‐6  Intronic  RGS6 
rs2360675  2  208059640  I  0.4439  C  A  0.01818  4.562  5.08x10‐6  Intronic  LOC101927865 
rs11114668  12  81366066  I  0.2337  G  A  0.02117  4.55  5.37x10‐6  ‐  ‐ 
rs8084351  18  50726559  I  0.4901  G  A  ‐0.0178  ‐4.536  5.74x10‐6  Intronic  DCC 
rs74546496  11  109813282  G  0.01132  G  A  0.08419  4.523  6.11x10‐6  ‐  ‐ 
rs6928738  6  30931059  G  0.07183  T  C  0.03418  4.511  6.47x10‐6  ‐  DPCR1(+9.061kb)|MUC21(‐20.42kb) 
rs17488727  18  50760933  I  0.4212  C  A  0.01799  4.507  6.59x10‐6  Intronic  DCC 
rs62100766  18  50737358  G  0.4009  T  G  0.01808  4.506  6.61x10‐6  Intronic  DCC 
rs4917447  10  107438736  I  0.3211  C  T  0.01893  4.495  6.98x10‐6  ‐  ‐ 
rs917284  14  72737111  I  0.4229  G  T  ‐0.01785  ‐4.494  7.01x10‐6  Intronic  RGS6 
rs9873767  3  135930406  G  0.2451  T  C  ‐0.02043  ‐4.489  7.16x10‐6  ‐  MSL2(+15.72kb) 
rs6589381  11  113378952  I  0.4345  A  C  ‐0.01773  ‐4.484  7.35x10‐6  ‐  ‐ 
rs1352309  11  21911419  G  0.238  T  C  0.02062  4.48  7.47x10‐6  ‐  ‐ 
rs7232543  18  50718757  I  0.4362  G  A  0.01774  4.479  7.52x10‐6  Intronic  DCC 
rs663895  11  78915746  G  0.4917  C  T  0.01749  4.477  7.57x10‐6  Intronic  TENM4 
rs4372758  18  50683306  G  0.4429  C  T  0.01766  4.475  7.66x10‐6  Intronic  DCC 
rs17487256  18  50718314  I  0.4015  T  C  0.0179  4.473  7.74x10‐6  Intronic  DCC 
rs1568404  14  72736969  I  0.4682  T  C  0.01762  4.471  7.80x10‐6  Intronic  RGS6 
rs9467626  6  25873746  G  0.1114  A  C  ‐0.02785  ‐4.471  7.81x10‐6  Intronic  SLC17A3 
rs6785876  3  44621285  G  0.3227  A  G  0.0187  4.467  7.94x10‐6  Intronic  ZKSCAN7|ZNF660(‐5.17kb) 
rs4863713  4  140907254  I  0.3577  T  C  0.01828  4.463  8.07x10‐6  Intronic  MAML3 
rs4842376  12  81437253  G  0.2312  C  T  0.02069  4.461  8.17x10‐6  ‐  ‐ 
rs10891540  11  113239082  I  0.4651  G  A  0.01758  4.458  8.28x10‐6  ‐  ANKK1(‐19.43kb)|TTC12(+1.968kb) 
rs16888206  5  57774538  I  0.09685  A  G  ‐0.02972  ‐4.445  8.78x10‐6  ‐  GAPT(‐12.79kb)|PLK2(+18.57kb) 
rs12727575  1  34052305  G  0.3741  T  C  0.0179  4.438  9.11x10‐6  Intronic  CSMD2 
rs586818  11  78929880  G  0.4984  G  A  0.01732  4.432  9.35x10‐6  Intronic  TENM4 
rs1538686  1  196397819  I  0.4133  G  A  ‐0.01773  ‐4.431  9.37x10‐6  Intronic  KCNT2 
rs4479021  11  113383394  I  0.4351  A  G  ‐0.01757  ‐4.425  9.65x10‐6  ‐  ‐ 
































NPs  ciMap  ciMapts  minGwasP  IndSigSNPs 
UK Biobank GWAS PHQ 
ENSG00000121904  CSMD2  1  33979609  34631443  ‐1  KNOWN  protein_coding  114784  CSMD2  NA  ‐0.899610176  6  2.526  0  No  NA  9.11x10‐6  rs12727575 
ENSG00000162624  LHX8  1  75594119  75627218  1  KNOWN  protein_coding  431707  LHX8  0.663323206  ‐0.679265544  1  5.74  0  No  NA  NA  rs76549394 
ENSG00000137968  SLC44A5  1  75667816  76076801  ‐1  KNOWN 
protein_coding 
204962  SLC44A5  0.03422869  0.661940842  9  6.207  0  No  NA  2.16x10‐6  rs76549394 
ENSG00000162687  KCNT2  1  196194909  196578355  ‐1  KNOWN  protein_coding  343450  KCNT2  0.666802214  0.148619072  76  19.32  0  No  NA  9.37x10‐6  rs1538686 
ENSG00000049323  LTBP1  2  33172039  33624576  1  KNOWN  protein_coding  4052  LTBP1  0.526234698  1.161890182  22  10.01  0  No  NA  3.93x10‐6  rs219174 
ENSG00000118263  KLF7  2  207938861  208031991  ‐1  KNOWN  protein_coding  8609  KLF7  0.929930709  ‐2.115394599  10  17.65  0  No  NA  2.31x10‐5  rs960379 
ENSG00000118260  CREB1  2  208394461  208468155  1  KNOWN  protein_coding  1385  CREB1  0.969960677  ‐0.523505755  0  0  0  Yes  Hippocampus  2.31x10‐5  rs960379 
ENSG00000179152  TCAIM  3  44379611  44450943  1  KNOWN  protein_coding  285343  TCAIM  4.46x10‐5  0.31315397  3  6.739  0  No  NA  NA  rs6785876 
ENSG00000185219  ZNF445  3  44481262  44519162  ‐1  KNOWN  protein_coding  353274  ZNF445  0.996478491  ‐1.777377016  17  8.948  0  No  NA  0.0002468  rs6785876 
383 
ENSG00000178917  ZNF852  3  44540462  44552128  ‐1  KNOWN  protein_coding  285346  ZNF852  6.54x10‐9  NA  5  3.349  0  No  NA  0.0001415  rs6785876 
ENSG00000196345  ZKSCAN7  3  44596685  44624975  1  KNOWN  protein_coding  55888  ZKSCAN7  1.18x10‐5  ‐0.800781432  52  12.42  0  No  NA  7.94x10‐6  rs6785876 
ENSG00000144792  ZNF660  3  44619715  44641186  1  KNOWN  protein_coding  285349  ZNF660  0.054805105  ‐1.658430892  36  14.13  0  No  NA  7.94x10‐6  rs6785876 
ENSG00000186448  ZNF197  3  44626380  44689963  1  KNOWN  protein_coding  10168  ZNF197  5.95x10‐14  0.135916243  46  16.95  0  No  NA  7.94x10‐6  rs6785876 
ENSG00000169981  ZNF35  3  44690219  44702283  1  KNOWN  protein_coding  7584  ZNF35  0.079290627  ‐0.732337005  6  16.95  0  No  NA  1.39x10‐5  rs6785876 
ENSG00000196653  ZNF502  3  44754135  44765323  1  KNOWN  protein_coding  91392  ZNF502  1.41x10‐5  0.25289851  4  7.863  0  No  NA  NA  rs6785876 
ENSG00000163808  KIF15  3  44803209  44914868  1  KNOWN  protein_coding  56992  KIF15  7.47x10‐13  ‐0.317071365  3  3.24  0  No  NA  4.02x10‐5  rs6785876 
ENSG00000169964  TMEM42  3  44903361  44907162  1  KNOWN  protein_coding  131616  TMEM42  0.306977503  ‐0.038932273  3  3.24  0  No  NA  4.02x10‐5  rs6785876 
ENSG00000163810  TGM4  3  44916100  44956482  1  KNOWN  protein_coding  7047  TGM4  1.14x10‐11  0.329751591  3  3.24  0  No  NA  4.02x10‐5  rs6785876 
ENSG00000073711  PPP2R3A  3  135684515  135866733  1  KNOWN  protein_coding  5523  PPP2R3A  0.920487875  ‐0.863679102  10  5.037  0  No  NA  3.13x10‐5  rs6789329 
ENSG00000174579  MSL2  3  135867764  135916083  ‐1  KNOWN  protein_coding  55167  MSL2  0.889663742  ‐1.742045868  2  3.974  0  Yes  Hippocampus  4.25x10‐6  rs6789329 
ENSG00000114054  PCCB  3  135969148  136056738  1  KNOWN  protein_coding  5096  PCCB  0.000735839  ‐0.385160254  20  15.38  0  No  NA  2.02x10‐5 
rs9873767;r
s6789329 
ENSG00000118007  STAG1  3  136055077  136471220  ‐1  KNOWN  protein_coding  10274  STAG1  0.99999991  ‐0.647637604  94  10.6  0  Yes  Hippocampus  4.25x10‐6  rs6789329 
ENSG00000196782  MAML3  4  140637907  141075338  ‐1  KNOWN  protein_coding  55534  MAML3  0.329895048  ‐0.192465137  61  16.03  0  No  NA  8.07x10‐6  rs4863713 
ENSG00000077063  CTTNBP2  7  117350705  117514193  ‐1  KNOWN  protein_coding  83992  CTTNBP2  2.60x10‐6  ‐0.293652714  22  21  0  No  NA  4.35x10‐7 
rs7776980;r
s17488728 
ENSG00000149256  TENM4  11  78363876  79151992  ‐1  KNOWN  protein_coding  26011  TENM4  0.999718776  ‐0.693242157  3  5.233  0  No  NA  7.57x10‐6  rs663895 
ENSG00000149292  TTC12  11  113185251  113254266  1  KNOWN  protein_coding  54970  TTC12  1.45x10‐7  ‐0.271528473  37  19.44  45  No  NA  8.28x10‐6  rs10891540 
ENSG00000170209  ANKK1  11  113258513  113271140  1  KNOWN  protein_coding  255239  ANKK1  2.51x10‐8  ‐0.017548171  18  8.304  0  No  NA  4.29x10‐5  rs10891540 
ENSG00000149295  DRD2  11  113280318  113346413  ‐1  KNOWN  protein_coding  1813  DRD2  0.733263889  NA  41  17.76  0  No  NA  1.51x10‐5 
rs10891540;
rs6589381 
ENSG00000111052  LIN7A  12  81186299  81331704  ‐1  KNOWN  protein_coding  8825  LIN7A  0.041148496  ‐1.3739659  2  3.063  0  No  NA  NA  rs11114668 




ENSG00000152767  FARP1  13  98794816  99102027  1  KNOWN  protein_coding  10160  FARP1  0.045263074  ‐0.444415571  1  4.372  0  No  NA  NA  rs912337 
ENSG00000102572  STK24  13  99102455  99230194  ‐1  KNOWN  protein_coding  8428  STK24  0.797998297  0.417068263  55  9.214  0  No  NA  2.84x10‐6  rs912337 
ENSG00000182732  RGS6  14  72399156  73030654  1  KNOWN  protein_coding  9628  RGS6  0.801361183  NA  106  16.13  0  No  NA  4.95x10‐6 
rs917284;rs
847357 
ENSG00000187323  DCC  18  49866542  51057784  1  KNOWN  protein_coding  1630  DCC  0.999998957  ‐0.239950445  160  18.83  0  No  NA  1.35x10‐6  rs11663824 
UK Biobank GWEIS ‐ GxE effect 
ENSG00000073282  TP63  3  189349205  189615068  1  KNOWN  protein_coding  8626  TP63  0.983222202  ‐0.204818685  25  9.698  0  No  NA  3.76x10‐6  rs7650285 
ENSG00000119471  HSDL2  9  115142217  115234690  1  KNOWN  protein_coding  84263  HSDL2  3.95x10‐5  ‐0.039855639  48  15.32  0  No  NA  5.86x10‐5  rs2593684 
ENSG00000230185  C9orf147  9  115196096  115249484  ‐1  KNOWN  protein_coding  100133204  C9orf147  NA  NA  25  15.32  0  No  NA  5.86x10‐5  rs2593684 
ENSG00000165185  KIAA1958  9  115249127  115431677  1  KNOWN  protein_coding  158405  KIAA1958  0.04900214  0.577176307  36  17.91  0  No  NA  3.60x10‐6  rs2593684 
ENSG00000139915  MDGA2  14  47308826  48144157  ‐1  KNOWN  protein_coding  161357  MDGA2  0.993216871  0.397758699  53  14.14  0  No  NA  8.44x10‐6  rs11844549 
384 
ENSG00000154864  PIEZO2  18  10666480  11148587  ‐1  KNOWN  protein_coding  63895  PIEZO2  0.603955313  NA  1  1.29  0  No  NA  9.68x10‐6  rs77317628 
UK Biobank GWEIS ‐ joint effect 
ENSG00000118263  KLF7  2  207938861  208031991  ‐1  KNOWN  protein_coding  8609  KLF7  0.929930709  ‐2.115394599  10  17.65  0  No  NA  0.000112279  rs960379 
ENSG00000118260  CREB1  2  208394461  208468155  1  KNOWN  protein_coding  1385  CREB1  0.969960677  ‐0.523505755  0  0  0  Yes  Hippocampus  0.000112279  rs960379 
ENSG00000185129  PURA  5  139487362  139496321  1  KNOWN  protein_coding  5813  PURA  0.845099484  ‐0.96108256  8  13.86  0  No  NA  5.99x10‐6  rs2974421 
ENSG00000182700  IGIP  5  139505521  139508391  1  KNOWN  protein_coding  492311  IGIP  0.419918844  ‐1.738238174  4  13.86  0  No  NA  5.99x10‐6  rs2974421 
ENSG00000112232  KHDRBS2  6  62389865  62996132  ‐1  KNOWN  protein_coding  202559  KHDRBS2  0.142878302  ‐0.85475727  1  3.892  0  No  NA  NA  rs77225982 
ENSG00000127928  GNGT1  7  93220885  93540577  1  KNOWN  protein_coding  2792  GNGT1  0.276892737  0.237481529  16  8.068  0  No  NA  4.46x10‐6  rs2724063 
ENSG00000184903  IMMP2L  7  110303110  111202573  ‐1  KNOWN  protein_coding  83943  IMMP2L  0.040760918  ‐0.338556389  22  16.6  0  No  NA  3.52x10‐6  rs2091309 
ENSG00000188938 
FAM120A
OS  9  96208776  96215874  ‐1  KNOWN  protein_coding  158293 
FAM120A
OS  0.514390707  0.007431442  7  4.179  0  No  NA  7.03x10‐5  rs10116422 
ENSG00000048828  FAM120A  9  96214004  96328397  1  KNOWN  protein_coding  23196  FAM120A  0.99990705  ‐0.298117336  86  14.9  0  No  NA  3.25x10‐5  rs10116422 
ENSG00000197724  PHF2  9  96338689  96441869  1  KNOWN  protein_coding  5253  PHF2  0.994132137  0.745197979  43  7.829  0  No  NA  8.08x10‐6  rs10116422 
ENSG00000197467  COL13A1  10  71561644  71724031  1  KNOWN  protein_coding  1305  COL13A1  0.003928968  0.409844169  3  4.856  0  No  NA  7.70x10‐6  rs7070915 
ENSG00000111058  ACSS3  12  81331594  81650533  1  KNOWN  protein_coding  79611  ACSS3  3.00x10‐11  ‐0.814138549  137  13.83  0  No  NA  4.37x10‐7  rs7954341 
ENSG00000166748  AGBL1  15  86685227  87572283  1  KNOWN  protein_coding  123624  AGBL1  3.60x10‐23  ‐0.103443516  269  22.1  0  No  NA  2.35x10‐6  rs8038215 
ENSG00000090863  GLG1  16  74485856  74641012  ‐1  KNOWN  protein_coding  2734  GLG1  0.997711424  ‐0.205896764  10  21.1  0  No  NA  5.15x10‐6  rs77995020 
Generation Scotland GWEIS using TSLE as exposure ‐ GxE effect 
ENSG00000154305  MIA3  1  222791428  222841354  1  KNOWN  protein_coding  375056  MIA3  0.471388106  ‐0.616197151  22  14.33  0  No  NA  NA  rs17163441 
ENSG00000186063  AIDA  1  222841355  222886552  ‐1  KNOWN  protein_coding  64853  AIDA  0.082372382  ‐1.192388865  27  14.95  0  No  NA  4.98x10‐6  rs17163441 
ENSG00000162819  BROX  1  222885895  222908538  1  KNOWN  protein_coding  148362  BROX  2.48x10‐5  1.32122969  17  9.915  0  No  NA  4.98x10‐6  rs17163441 
ENSG00000197520  FAM177B  1  222910549  222924147  1  KNOWN  protein_coding  400823  FAM177B  9.21x10‐6  ‐0.425513654  5  10.91  0  No  NA  5.89x10‐6  rs17163441 
ENSG00000137275  RIPK1  6  3064225  3115421  1  KNOWN  protein_coding  8737  RIPK1  0.4181774  ‐0.203587189  3  3.669  0  No  NA  5.06x10‐6  rs17548315 
ENSG00000137274  BPHL  6  3118608  3153812  1  KNOWN  protein_coding  670  BPHL  0.000194971  1.195504957  2  4.684  0  No  NA  5.06x10‐6  rs17548315 
ENSG00000137267  TUBB2A  6  3153903  3157760  ‐1  KNOWN  protein_coding  7280  TUBB2A  NA  NA  1  4.684  0  No  NA  NA  rs17548315 
ENSG00000111816  FRK  6  116252312  116381921  ‐1  KNOWN  protein_coding  2444  FRK  6.59x10‐10  2.58876413  2  4.816  0  No  NA  NA  rs11754507 
ENSG00000178425  NT5DC1  6  116422012  116570660  1  KNOWN  protein_coding  221294  NT5DC1  0.326411116  ‐0.101658908  1  7.132  0  Yes  Hippocampus  NA  rs11754507 
ENSG00000123500  COL10A1  6  116440086  116479910  ‐1  KNOWN  protein_coding  1300  COL10A1  6.36x10‐5  ‐0.141903212  1  7.132  0  No  NA  NA  rs11754507 
ENSG00000111817  DSE  6  116575336  116762424  1  KNOWN  protein_coding  29940  DSE  0.385415297  1.399470369  1  2.355  0  No  NA  1.04x10‐7  rs11754507 
ENSG00000173626  TRAPPC3L  6  116816152  116866773  ‐1  KNOWN  protein_coding  100128327  TRAPPC3L  NA  ‐0.063711938  3  2.09  0  No  NA  NA  rs11754507 
ENSG00000178033  FAM26E  6  116832809  116845955  1  KNOWN  protein_coding  254228  FAM26E  0.001108388  2.210740591  1  1.557  0  No  NA  NA  rs11754507 
ENSG00000164451  FAM26D  6  116850174  116880031  1  KNOWN  protein_coding  221301  FAM26D  0.033838822  0.383426399  4  2.09  0  No  NA  NA  rs11754507 
ENSG00000184672  RALYL  8  85095022  85834079  1  KNOWN  protein_coding  138046  RALYL  0.029690036  0.669570867  6  18.19  0  No  NA  1.07x10‐6  rs12677170 
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Generation Scotland GWEIS using TSLE as exposure ‐ joint effect 
ENSG00000160145  KALRN  3  123798870  124445172  1  KNOWN  protein_coding  8997  KALRN  0.999996915  ‐0.64291779  1  5.012  0  No  NA  5.69x10‐6  rs2289841 
ENSG00000137275  RIPK1  6  3064225  3115421  1  KNOWN  protein_coding  8737  RIPK1  0.4181774  ‐0.203587189  3  3.669  0  No  NA  8.18x10‐6  rs17548315 
ENSG00000137274  BPHL  6  3118608  3153812  1  KNOWN  protein_coding  670  BPHL  0.000194971  1.195504957  2  4.684  0  No  NA  8.18x10‐6  rs17548315 
ENSG00000137267  TUBB2A  6  3153903  3157760  ‐1  KNOWN  protein_coding  7280  TUBB2A  NA  NA  1  4.684  0  No  NA  NA  rs17548315 
ENSG00000111816  FRK  6  116252312  116381921  ‐1  KNOWN  protein_coding  2444  FRK  6.59x10‐10  2.58876413  2  4.816  0  No  NA  NA  rs11754507 
ENSG00000178425  NT5DC1  6  116422012  116570660  1  KNOWN  protein_coding  221294  NT5DC1  0.326411116  ‐0.101658908  1  7.132  0  Yes  Hippocampus  NA  rs11754507 
ENSG00000123500  COL10A1  6  116440086  116479910  ‐1  KNOWN  protein_coding  1300  COL10A1  6.36x10‐5  ‐0.141903212  1  7.132  0  No  NA  NA  rs11754507 
ENSG00000111817  DSE  6  116575336  116762424  1  KNOWN  protein_coding  29940  DSE  0.385415297  1.399470369  1  2.355  0  No  NA  3.50x10‐7  rs11754507 
ENSG00000173626  TRAPPC3L  6  116816152  116866773  ‐1  KNOWN  protein_coding  100128327  TRAPPC3L  NA  ‐0.063711938  3  2.09  0  No  NA  NA  rs11754507 
ENSG00000178033  FAM26E  6  116832809  116845955  1  KNOWN  protein_coding  254228  FAM26E  0.001108388  2.210740591  1  1.557  0  No  NA  NA  rs11754507 
ENSG00000164451  FAM26D  6  116850174  116880031  1  KNOWN  protein_coding  221301  FAM26D  0.033838822  0.383426399  4  2.09  0  No  NA  NA  rs11754507 
ENSG00000170786  SDR16C5  8  57212569  57233335  ‐1  KNOWN  protein_coding  195814  SDR16C5  0.00291744  0.076651261  1  1.231  0  No  NA  5.31x10‐6  rs4409393 
ENSG00000184672  RALYL  8  85095022  85834079  1  KNOWN  protein_coding  138046  RALYL  0.029690036  0.669570867  6  18.19  0  No  NA  3.66x10‐6  rs12677170 
ENSG00000151474  FRMD4A  10  13685706  14504141  ‐1  KNOWN  protein_coding  55691  FRMD4A  0.999986541  2.100618864  13  5.918  0  No  NA  6.01x10‐6  rs11259022 
Generation Scotland GWEIS using DSLE as exposure ‐ GxE effect 
ENSG00000111816  FRK  6  116252312  116381921  ‐1  KNOWN  protein_coding  2444  FRK  6.59x10‐10  2.58876413  2  4.816  0  No  NA  NA  rs11754507 
ENSG00000178425  NT5DC1  6  116422012  116570660  1  KNOWN  protein_coding  221294  NT5DC1  0.326411116  ‐0.101658908  1  7.132  0  Yes  Hippocampus  NA  rs11754507 
ENSG00000123500  COL10A1  6  116440086  116479910  ‐1  KNOWN  protein_coding  1300  COL10A1  6.36x10‐5  ‐0.141903212  1  7.132  0  No  NA  NA  rs11754507 
ENSG00000111817  DSE  6  116575336  116762424  1  KNOWN  protein_coding  29940  DSE  0.385415297  1.399470369  1  2.355  0  No  NA  2.11x10‐6  rs11754507 
ENSG00000173626  TRAPPC3L  6  116816152  116866773  ‐1  KNOWN  protein_coding  100128327  TRAPPC3L  NA  ‐0.063711938  3  2.09  0  No  NA  NA  rs11754507 
ENSG00000178033  FAM26E  6  116832809  116845955  1  KNOWN  protein_coding  254228  FAM26E  0.001108388  2.210740591  1  1.557  0  No  NA  NA  rs11754507 
ENSG00000164451  FAM26D  6  116850174  116880031  1  KNOWN  protein_coding  221301  FAM26D  0.033838822  0.383426399  4  2.09  0  No  NA  NA  rs11754507 
ENSG00000148468 
FAM171A
1  10  15253642  15413061  ‐1  KNOWN  protein_coding  221061  FAM171A1  0.987016298  ‐1.169213337  24  8.699  0  No  NA  5.35x10‐6  rs11259593 
ENSG00000134640  MTNR1B  11  92702886  92718232  1  KNOWN  protein_coding  4544  MTNR1B  0.00870273  ‐0.165792302  31  11.66  0  No  NA  1.76x10‐6  rs6483212 
Generation Scotland GWEIS using DSLE as exposure ‐ joint effect 
ENSG00000111816  FRK  6  116252312  116381921  ‐1  KNOWN  protein_coding  2444  FRK  6.59x10‐10  2.58876413  2  4.816  0  No  NA  NA  rs11754507 
ENSG00000178425  NT5DC1  6  116422012  116570660  1  KNOWN  protein_coding  221294  NT5DC1  0.326411116  ‐0.101658908  1  7.132  0  Yes  Hippocampus  NA  rs11754507 
ENSG00000123500  COL10A1  6  116440086  116479910  ‐1  KNOWN  protein_coding  1300  COL10A1  6.36x10‐5  ‐0.141903212  1  7.132  0  No  NA  NA  rs11754507 
ENSG00000111817  DSE  6  116575336  116762424  1  KNOWN  protein_coding  29940  DSE  0.385415297  1.399470369  1  2.355  0  No  NA  3.34x10‐6  rs11754507 
ENSG00000173626  TRAPPC3L  6  116816152  116866773  ‐1  KNOWN  protein_coding  100128327  TRAPPC3L  NA  ‐0.063711938  3  2.09  0  No  NA  NA  rs11754507 
ENSG00000178033  FAM26E  6  116832809  116845955  1  KNOWN  protein_coding  254228  FAM26E  0.001108388  2.210740591  1  1.557  0  No  NA  NA  rs11754507 
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ENSG00000164451  FAM26D  6  116850174  116880031  1  KNOWN  protein_coding  221301  FAM26D  0.033838822  0.383426399  4  2.09  0  No  NA  NA  rs11754507 
ENSG00000170786  SDR16C5  8  57212569  57233335  ‐1  KNOWN  protein_coding  195814  SDR16C5  0.00291744  0.076651261  1  1.231  0  No  NA  1.62x10‐6  rs4409393 
ENSG00000099810  MTAP  9  21802542  21931646  1  KNOWN  protein_coding  4507  MTAP  0.000179316  1.589224827  30  17.08  0  No  NA  8.56x10‐6  rs10811635 
ENSG00000151474  FRMD4A  10  13685706  14504141  ‐1  KNOWN  protein_coding  55691  FRMD4A  0.999986541  2.100618864  13  5.918  0  No  NA  4.64x10‐6  rs11259022 
ENSG00000134640  MTNR1B  11  92702886  92718232  1  KNOWN  protein_coding  4544  MTNR1B  0.00870273  ‐0.165792302  31  11.66  0  No  NA  5.52x10‐6  rs6483212 
Generation Scotland GWEIS using ISLE as exposure ‐ GxE effect 
ENSG00000137275  RIPK1  6  3064225  3115421  1  KNOWN  protein_coding  8737  RIPK1  0.4181774  ‐0.203587189  3  3.669  0  No  NA  2.57x10‐6  rs17548315 
ENSG00000137274  BPHL  6  3118608  3153812  1  KNOWN  protein_coding  670  BPHL  0.000194971  1.195504957  2  4.684  0  No  NA  2.57x10‐6  rs17548315 
ENSG00000137267  TUBB2A  6  3153903  3157760  ‐1  KNOWN  protein_coding  7280  TUBB2A  NA  NA  1  4.684  0  No  NA  NA  rs17548315 
ENSG00000186472  PCLO  7  82383329  82792246  ‐1  KNOWN  protein_coding  27445  PCLO  1  ‐0.00757724  1  5.158  0  No  NA  NA  rs10250565 
ENSG00000184672  RALYL  8  85095022  85834079  1  KNOWN  protein_coding  138046  RALYL  0.029690036  0.669570867  6  18.19  0  No  NA  2.09x10‐6  rs12677170 
ENSG00000053918  KCNQ1  11  2465914  2870339  1  KNOWN  protein_coding  3784  KCNQ1  2.45x10‐5  1.153237047  3  5.075  0  No  NA  4.40x10‐6  rs800336 
Generation Scotland GWEIS using ISLE as exposure ‐ joint effect 
ENSG00000064692  SNCAIP  5  121647049  121799914  1  KNOWN  protein_coding  9627  SNCAIP  0.000362968  NA  40  15.46  0  Yes  Hippocampus  5.08x10‐6  rs2242223 
ENSG00000137275  RIPK1  6  3064225  3115421  1  KNOWN  protein_coding  8737  RIPK1  0.4181774  ‐0.203587189  3  3.669  0  No  NA  3.89x10‐6  rs17548315 
ENSG00000137274  BPHL  6  3118608  3153812  1  KNOWN  protein_coding  670  BPHL  0.000194971  1.195504957  2  4.684  0  No  NA  3.89x10‐6  rs17548315 
ENSG00000137267  TUBB2A  6  3153903  3157760  ‐1  KNOWN  protein_coding  7280  TUBB2A  NA  NA  1  4.684  0  No  NA  NA  rs17548315 






GeneSet  N  n  p‐value  adjusted p  genes 
All Canonical Pathways 
kegg propanoate metabolism  32  2  2.40x10‐5  2.59x10‐2  ACSS3, PCCB 
reactome generic transcription pathway  340  4  3.02x10‐4  2.59x10‐2  ZNF445, ZKSCAN7, ZNF197, MAML3 
GO biological processes  
positive regulation of long term synaptic potentiation  14  2  1.80x10‐6  8.37x10‐3  DRD2, CREB1 
regulation of long term synaptic potentiation  19  2  4.76x10‐6  1.05x10‐2  DRD2, CREB1 
central nervous system neuron development  70  3  6.80x10‐6  1.05x10‐2  LHX8, DRD2, DCC 
neuron differentiation  870  8  1.41x10‐5  1.64x10‐2 
LHX8, TENM4, DRD2, FARP1, DCC, 
KLF7, CREB1, PPP2R3A 
neuron development  683  7  1.91x10‐5  1.77x10‐2 
LHX8, TENM4, DRD2, FARP1, DCC, 
KLF7, CREB1 
positive regulation of multicellular organism growth  32  2  2.40x10‐5  1.86x10‐2  DRD2, CREB1 
forebrain neuron development  34  2  2.89x10‐5  1.92x10‐2  LHX8, DRD2 
cell morphogenesis involved in neuron differentiation  367  5  3.91x10‐5  2.25x10‐2  DRD2, FARP1, DCC, KLF7, CREB1 
dendrite morphogenesis  42  2  5.49x10‐5  2.25x10‐2  FARP1, KLF7 
pituitary gland development  42  2  5.49x10‐5  2.25x10‐2  DRD2, CREB1 
neuron projection morphogenesis  400  5  6.31x10‐5  2.25x10‐2  DRD2, FARP1, DCC, KLF7, CREB1 
regulation of phosphatase activity  125  3  6.71x10‐5  2.25x10‐2  DRD2, FARP1, PPP2R3A 
visual behavior  50  2  9.28x10‐5  2.25x10‐2  DRD2, CREB1 
response to nicotine  51  2  9.84x10‐5  2.25x10‐2  DRD2, CREB1 
neurogenesis  1396  9  1.00x10‐4  2.25x10‐2 
LHX8, TENM4, DRD2, FARP1, STK24, 
DCC, KLF7, CREB1, PPP2R3A 
regulation of developmental growth  286  4  1.36x10‐4  2.25x10‐2  DRD2, DCC, CREB1, PPP2R3A 
regulation of phosphoprotein phosphatase activity  57  2  1.37x10‐4  2.25x10‐2  DRD2, PPP2R3A 
regulation of dephosphorylation  155  3  1.54x10‐4  2.25x10‐2  DRD2, FARP1, PPP2R3A 
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central nervous system neuron differentiation  166  3  2.01x10‐4  2.25x10‐2  LHX8, DRD2, DCC 
forebrain generation of neurons  66  2  2.12x10‐4  2.25x10‐2  LHX8, DRD2 
regulation of multicellular organism growth  66  2  2.12x10‐4  2.25x10‐2  DRD2, CREB1 
synapse assembly  67  2  2.22x10‐4  2.25x10‐2  DRD2, FARP1 
cell morphogenesis involved in differentiation  512  5  2.43x10‐4  2.25x10‐2  DRD2, FARP1, DCC, KLF7, CREB1 
associative learning  73  2  2.86x10‐4  2.34x10‐2  DRD2, CREB1 
diencephalon development  76  2  3.22x10‐4  2.40x10‐2  DRD2, CREB1 
neuron projection development  542  5  3.30x10‐4  2.40x10‐2  DRD2, FARP1, DCC, KLF7, CREB1 
dendrite development  79  2  3.61x10‐4  2.40x10‐2  FARP1, KLF7 
neuron projection guidance  204  3  4.40x10‐4  2.61x10‐2  DCC, KLF7, CREB1 
regulation of gliogenesis  90  2  5.30x10‐4  2.93x10‐2  TENM4, CREB1 
central nervous system development  865  6  6.63x10‐4  3.24x10‐2 
LHX8, TENM4, DRD2, DCC, CREB1, 
CTTNBP2 
memory  98  2  6.79x10‐4  3.24x10‐2  DRD2, CREB1 
cell part morphogenesis  631  5  7.38x10‐4  3.40x10‐2  DRD2, FARP1, DCC, KLF7, CREB1 
regulation of circadian rhythm  102  2  7.63x10‐4  3.44x10‐2  DRD2, CREB1 
cellular component morphogenesis  898  6  8.28x10‐4  3.47x10‐2 
TENM4, DRD2, FARP1, DCC, KLF7, 
CREB1 
cognition  250  3  9.42x10‐4  3.64x10‐2  LHX8, DRD2, CREB1 
neuron migration  110  2  9.50x10‐4  3.64x10‐2  DRD2, DCC 
regulation of embryonic development  114  2  1.05x10‐3  3.80x10‐2  TENM4, PPP2R3A 
positive regulation of hormone secretion  117  2  1.14x10‐3  4.00x10‐2  DRD2, CREB1 
endocrine system development  123  2  1.31x10‐3  4.30x10‐2  DRD2, CREB1 
regulation of g protein coupled receptor protein 
signaling pathway  126  2  1.41x10‐3  4.42x10‐2  DRD2, RGS6 
learning  130  2  1.54x10‐3  4.62x10‐2  DRD2, CREB1 
GO cellular components 
neuron spine  121  3  5.91x10‐5  3.45x10‐2  DRD2, FARP1, CTTNBP2 
GO molecular functions 





Age‐related cataracts (age at onset)  3  2  5.01x10‐9  5.39x10‐6  LIN7A, ACSS3 
Brain structure  16  2  2.76x10‐6  1.49x10‐3  CSMD2, FARP1 
Schizophrenia  450  6  1.12x10‐5  3.89x10‐3 
DRD2, RGS6, PPP2R3A, MSL2, PCCB, 
STAG1 
Response to amphetamines  33  2  2.64x10‐5  4.73x10‐3  CSMD2, FARP1 
Fibrinogen  41  2  5.10x10‐5  6.10x10‐3  MSL2, PCCB 
Acne (severe)  160  3  1.74x10‐4  7.82x10‐3  KIF15, TMEM42, TGM4 
Fibrinogen levels  67  2  2.22x10‐4  8.64x10‐3  PPP2R3A, PCCB 
Educational attainment  72  2  2.75x10‐4  9.25x10‐3  FARP1, STK24 
Waist circumference adjusted for body mass index  87  2  4.80x10‐4  1.36x10‐2  LTBP1, PPP2R3A 
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Supplementary Table 7. Top GWEIS results in UKB (p<1x10‐5) 
SNP  CHR  BP  G/I  MAF  A1  A2  BETA  p‐value  Location  Closest gene (<25kb) 
GxE effect 
rs582813  18  25079009  G  0.4665  C  T  0.0283718  1.13x10‐7  ‐  ‐ 
rs60757853  8  109854124  G  0.2061  T  C  0.0329474  3.79x10‐7  ‐  ‐ 
rs2671750  3  5059576  G  0.1597  T  C  0.0359233  5.66x10‐7  ‐  ‐ 
rs13253194  8  109857400  I  0.2058  A  G  0.0324246  6.06x10‐7  ‐  ‐ 
rs2593684  9  115347088  I  0.251  A  G  ‐0.02881  3.60x10‐6  Intronic  KIAA1958 
rs7650285  3  189500067  I  0.1107  A  G  0.0388284  3.76x10‐6  Intronic  TP63 
rs2480061  1  14808756  I  0.4092  G  T  0.0244273  6.64x10‐6  ‐  ‐ 
rs12630584  3  189498809  I  0.1106  A  G  0.0375951  7.60x10‐6  Intronic  TP63 
rs16864784  3  189499173  G  0.1108  G  A  0.0375224  8.29x10‐6  Intronic  TP63 
rs9831427  3  142955098  I  0.3298  C  A  0.0253031  8.31x10‐6  ‐  ‐ 
rs11844549  14  47310983  I  0.4905  T  C  0.0239575  8.44x10‐6  Exonic  MDGA2 
rs77317628  18  10900786  G  0.06402  T  C  ‐0.0481837  9.68x10‐6  Intronic  PIEZO2 
rs4979128  9  115289605  I  0.2497  C  T  ‐0.0274627  9.97x10‐6  Intronic  KIAA1958 
Joint effect 
rs7954341  12  81419397  I  0.3191  G  A  0.02107527  4.37x10‐7  ‐  ‐ 
rs582813  18  25079009  G  0.4665  C  T  0.0117316  5.84x10‐7  ‐  ‐ 
rs10862219  12  81430043  I  0.3198  T  C  0.02079495  5.95x10‐7  ‐  ‐ 
rs11114720  12  81443764  G  0.3175  A  G  0.02048935  7.19x10‐7  ‐  ‐ 
rs11114723  12  81449343  I  0.317  A  C  0.01993236  1.00x10‐6  ‐  ACSS3(‐22.46kb) 
rs17007930  12  81445762  I  0.317  T  C  0.01989167  1.04x10‐6  ‐  ‐ 
rs2176912  12  81394117  I  0.3594  G  A  0.01857864  1.35x10‐6  ‐  ‐ 
rs960379  2  208088537  I  0.3961  C  T  0.02318179  1.39x10‐6  Intronic  LOC101927865 
rs4275684  12  81465645  G  0.318  G  T  0.01933315  1.80x10‐6  ‐  ACSS3(‐6.163kb) 
rs60757853  8  109854124  G  0.2061  T  C  0.0135463  1.94x10‐6  ‐  ‐ 
rs2671750  3  5059576  G  0.1597  T  C  0.0133213  2.15x10‐6  ‐  ‐ 
rs8038215  15  87538753  G  0.05269  C  T  0.0027143  2.35x10‐6  Intronic  AGBL1 
rs13253194  8  109857400  I  0.2058  A  G  0.0136343  3.20x10‐6  ‐  ‐ 
rs2091309  7  110376327  I  0.3564  G  A  ‐0.02377593  3.52x10‐6  Intronic  IMMP2L 
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rs7239568  18  51964773  G  0.3341  C  A  ‐0.01611355  4.03x10‐6  ‐  ‐ 
rs2974421  5  139470240  I  0.1777  G  A  0.0090438  4.11x10‐6  ‐  LINC01024(‐12.27kb)|PURA(‐23.47kb) 
rs2724063  7  93401210  I  0.4467  A  G  ‐0.022144542  4.46x10‐6  ‐  ‐ 
rs77995020  16  74510544  G  0.0924  A  C  ‐0.0392394  5.15x10‐6  Intronic  GLG1 
rs10060173  5  139501147  I  0.1807  T  C  0.0085887  5.99x10‐6  ‐  IGIP(‐4.373kb)|LINC01024(+13.55kb)|PURA(+2.146kb) 
rs77225982  6  62328533  G  0.04729  G  A  ‐0.0252879  6.00x10‐6  ‐  ‐ 
rs2429310  5  139508705  G  0.1817  A  G  0.0080097  6.15x10‐6  ‐  IGIP(+0.314kb)|LINC01024(+21.11kb)|PURA(+9.704kb)
rs7070915  10  71652128  I  0.4949  C  T  0.02339642  7.70x10‐6  Intronic  COL13A1 
rs114608878  6  62266630  G  0.04717  T  C  ‐0.0247592  8.00x10‐6  ‐  MTRNR2L9(‐17.38kb) 
rs11852282  15  87555349  G  0.04482  A  G  ‐0.0057676  8.02x10‐6  Intronic  AGBL1 
rs10116422  9  96357739  I  0.3869  C  A  ‐0.02136075  8.08x10‐6  Intronic  PHF2 
rs4917447  10  107438736  I  0.3211  C  T  0.0240048  8.28x10‐6  ‐  ‐ 
rs10950237  7  70491251  G  0.3755  G  A  ‐0.01656725  8.44x10‐6  ‐  ‐ 
rs7908373  10  107479864  I  0.3008  T  C  0.0246885  8.68x10‐6  ‐  ‐ 
rs2881642  15  87560258  I  0.04366  A  G  ‐0.003438  9.62x10‐6  Intronic  AGBL1 
rs4376443  7  110391589  I  0.3384  T  C  ‐0.02346326  9.80x10‐6  Intronic  IMMP2L 392
Supplementary Table 8. Top TSLE GWEIS results in Generation Scotland (p<1x10‐5) ‐ Total SLE as exposure 
SNP  CHR  BP  MAF  A1  A2  BETA  p‐value  Location  Closest gene (<25kb) 
GxE effect 
rs12789145  11  94407736  0.08002  C  A  0.059937  4.95x10‐9  ‐  ‐ 
rs11754507  6  116697130  0.01701  G  A  0.126854  1.04x10‐7  Intronic  DSE 
rs17070072  18  60205542  0.3437  A  C  ‐0.0361116  9.02x10‐7  Intronic  ZCCHC2 
rs12677170  8  85446567  0.1169  C  A  ‐0.0539766  1.07x10‐6  Intronic  RALYL 
rs10003191  4  17336925  0.2646  G  A  ‐0.0347034  2.24x10‐6  ‐  ‐ 
rs2059710  2  60838156  0.1609  A  G  0.0393715  2.53x10‐6  ‐  ‐ 
rs614123  13  34946870  0.291  A  G  0.0367452  3.74x10‐6  ‐  ‐ 
rs735133  2  60842571  0.1552  C  A  0.0392745  4.67x10‐6  ‐  ‐ 
rs17163441  1  222882892  0.1436  C  A  ‐0.0509662  4.98x10‐6  Intronic  AIDA 
rs17548315  6  3114947  0.01824  A  G  0.0700267  5.06x10‐6  Exonic  RIPK1 
rs17163437  1  222878687  0.1439  A  C  ‐0.0507477  5.37x10‐6  Intronic  AIDA 
rs4364235  4  174635674  0.4482  A  G  ‐0.0319482  5.46x10‐6  ‐  ‐ 
rs3748631  1  222886588  0.144  A  G  ‐0.050744  5.52x10‐6  Intronic  BROX 
rs12058171  1  222913107  0.1439  G  A  ‐0.0505684  5.89x10‐6  Exonic  FAM177B 
rs6502321  17  13855742  0.07297  A  G  0.0520313  6.69x10‐6  ‐  ‐ 
rs9952353  18  19672632  0.07297  G  A  ‐0.0387656  9.29x10‐6  ‐  ‐ 
Joint effect 
rs12789145  11  94407736  0.08002  C  A  0.0005347  2.77x10‐8  ‐  ‐ 
rs11754507  6  116697130  0.01701  G  A  ‐0.021379  3.50x10‐7  Intronic  DSE 
rs9952353  18  19672632  0.07297  G  A  0.0388734  8.04x10‐7  ‐  ‐ 
rs1579282  5  155074865  0.3308  A  G  ‐0.03026209  1.03x10‐6  ‐  ‐ 
rs17070072  18  60205542  0.3437  A  C  ‐0.0123343  1.72x10‐6  Intronic  ZCCHC2 
rs10164188  18  11444650  0.02873  A  G  ‐0.08424123  1.86x10‐6  ‐  ‐ 
rs614123  13  34946870  0.291  A  G  ‐0.0266327  2.43x10‐6  ‐  ‐ 
rs12677170  8  85446567  0.1169  C  A  ‐0.0028139  3.66x10‐6  Intronic  RALYL 
rs17244735  13  73104490  0.04892  G  A  0.0995494  3.81x10‐6  ‐  ‐ 
rs7577053  2  49849708  0.2334  A  G  ‐0.02605342  4.96x10‐6  ‐  ‐ 
rs11663716  18  19704036  0.2645  G  A  0.03751  5.08x10‐6  ‐  ‐ 
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rs4409393  8  57214372  0.3665  A  G  ‐0.050243  5.31x10‐6  Intronic  SDR16C5 
rs2289841  3  124209438  0.3568  A  G  0.0506544  5.69x10‐6  Intronic  KALRN 
rs11259022  10  14385164  0.1712  A  G  0.06630978  6.01x10‐6  Intronic  FRMD4A(+12.3kb) 
rs4800108  18  19694044  0.3445  C  A  0.033282  7.39x10‐6  ‐  ‐ 
rs1010811  18  19677786  0.2512  G  A  0.0352367  7.82x10‐6  ‐  ‐ 
rs17548315  6  3114947  0.01824  A  G  0.0305173  8.18x10‐6  Exonic  RIPK1 
rs7736123  5  33039387  0.05975  A  G  0.0288125  8.68x10‐6  ‐  ‐ 
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Supplementary Table 9. Top DSLE GWEIS results in Generation Scotland (p<1x10‐5) ‐ Dependent SLE as exposure 
SNP  CHR  BP  MAF  A1  A2  BETA  p‐value  Location  Closest gene (<25kb) 
GxE effect 
rs17070072  18  60205542  0.3437  A  C  ‐0.0820149  1.46x10‐8  Intronic  ZCCHC2 
rs12000047  9  105728627  0.01119  A  G  ‐0.267122  5.08x10‐8  ‐  ‐ 
rs12005200  9  105708946  0.01119  G  A  ‐0.264636  5.77x10‐8  ‐  ‐ 
rs6502321  17  13855742  0.07297  A  G  0.118734  1.00x10‐7  ‐  ‐ 
rs4753426  11  92701596  0.4706  G  A  ‐0.0721806  4.07x10‐7  ‐  MTNR1B(‐1.192kb) 
rs12866867  13  45252171  0.2276  A  G  ‐0.0793227  1.34x10‐6  ‐  ‐ 
rs6483212  11  92725240  0.4884  A  G  0.0687848  1.76x10‐6  ‐  MTNR1B(+9.292kb) 
rs4753073  11  92717475  0.4876  G  A  0.0685863  1.89x10‐6  ‐  MTNR1B(+1.527kb) 
rs11754507  6  116697130  0.01701  G  A  0.251601  2.11x10‐6  Intronic  DSE 
rs9863500  3  112440948  0.4917  A  G  ‐0.0694618  4.07x10‐6  ‐  LOC101929694(‐14.35kb) 
rs11259593  10  15320660  0.01042  A  G  0.181618  5.35x10‐6  Intronic  FAM171A1 
rs9998501  4  30403871  0.0199  G  A  ‐0.157791  6.46x10‐6  ‐  ‐ 
rs6661803  1  117016646  0.01617  A  G  ‐0.263019  7.90x10‐6  ‐  ‐ 
rs7257519  19  57474120  0.4722  A  G  0.0670852  8.35x10‐6  ‐  ‐ 
rs17041322  4  110982272  0.01534  A  C  0.190737  8.40x10‐6  ‐  ELOVL6 
rs17126828  14  90969615  0.08638  A  G  ‐0.116789  9.69x10‐6  ‐  ‐ 
Joint effect 
rs17070072  18  60205542  0.3437  A  C  ‐0.07339185  1.96x10‐8  Intronic  ZCCHC2 
rs12000047  9  105728627  0.01119  A  G  ‐0.2313853  2.00x10‐8  ‐  ‐ 
rs12005200  9  105708946  0.01119  G  A  ‐0.2282324  2.09x10‐8  ‐  ‐ 
rs6502321  17  13855742  0.07297  A  G  0.0521247  3.26x10‐7  ‐  ‐ 
rs958033  18  1936530  0.1777  G  A  ‐0.0864242  1.29x10‐6  ‐  LINC00540(+18.03kb) 
rs8091041  18  1931566  0.1776  G  A  ‐0.086394  1.29x10‐6  ‐  ‐ 
rs4409393  8  57214372  0.3665  A  G  ‐0.0193113  1.62x10‐6  Intronic  SDR16C5 
rs4753426  11  92701596  0.4706  G  A  ‐0.055935  2.13x10‐6  ‐  MTNR1B(‐1.192kb) 
rs11754507  6  116697130  0.01701  G  A  0.14902  3.34x10‐6  Intronic  DSE 
rs7257519  19  57474120  0.4722  A  G  0.0238733  4.58x10‐6  ‐  ‐ 
rs11259022  10  14385164  0.1712  A  G  0.0448526  4.64x10‐6  ‐  FRMD4A(+12.3kb) 
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rs6483212  11  92725240  0.4884  A  G  0.0582159  5.52x10‐6  ‐  MTNR1B(+9.292kb) 
rs4753073  11  92717475  0.4876  G  A  0.0579492  6.03x10‐6  ‐  MTNR1B(+1.527kb) 
rs12866867  13  45252171  0.2276  A  G  ‐0.0564297  7.64x10‐6  ‐  ‐ 
rs10811635  9  21910698  0.1907  G  A  0.07892428  8.56x10‐6  ‐  ‐ 
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Supplementary Table 10. Top ISLE GWEIS results in Generation Scotland (p<1x10‐5) ‐ Independent SLE as exposure 
SNP  CHR  BP  MAF  A1  A2  BETA  p‐value  Location  Closest gene (<25kb) 
GxE effect 
rs2803589  10  88372958  0.1501  G  A  ‐0.0742497  1.56x10‐6 ‐ ‐
rs11628732  14  58514673  0.1513  G  A  0.0701941  1.80x10‐6  Intronic  C14orf37 
rs3825243  12  69750839  0.04063  A  G  0.109939  1.98x10‐6 ‐
LYZ(+2.826kb)|YEATS4(‐
2.692kb) 
rs12677170  8  85446567  0.1169  C  A  ‐0.074386  2.09x10‐6  Intronic  RALYL 
rs10250565  7  82370821  0.03151  A  G  ‐0.131706  2.50x10‐6 ‐ PCLO(‐12.5kb)
rs17548315  6  3114947  0.01824  A  G  0.141617  2.57x10‐6 Exonic RIPK1
rs800336  11  2473131  0.2504  G  A  0.0558322  4.40x10‐6  Intronic  KCNQ1 
rs2225291  14  57145062  0.3308  G  A  0.0511159  4.91x10‐6 ‐ ‐
rs8017903  14  57146809  0.3317  A  G  0.0509381  5.43x10‐6 ‐ ‐
rs12432233  14  57141318  0.3481  A  C  0.0497956  8.12x10‐6 ‐ ‐
rs716651  5  155087160  0.4005  A  G  ‐0.0465724  9.14x10‐6 ‐ ‐
rs1579282  5  155074865  0.3308  A  G  ‐0.0489933  9.68x10‐6 ‐ ‐
Joint effect 
rs1579282  5  155074865  0.3308  A  G  ‐0.04726137  1.94x10‐7 ‐ ‐
rs716651  5  155087160  0.4005  A  G  ‐0.04079837  6.97x10‐7 ‐ ‐
rs17244735  13  73104490  0.04892  G  A  0.1177909  8.04x10‐7 ‐ ‐
rs9879244  3  176614990  0.08416  A  G  ‐0.0781681  3.45x10‐6 ‐ ‐
rs17548315  6  3114947  0.01824  A  G  0.0764885  3.89x10‐6 Exonic RIPK1
rs2242223  5  121761461  0.2384  G  A  ‐0.0156052  5.08x10‐6  Intronic  SNCAIP 
rs12677170  8  85446567  0.1169  C  A  ‐0.0295941  5.27x10‐6  Intronic  RALYL 
rs2803589  10  88372958  0.1501  G  A  ‐0.0324028  5.69x10‐6 ‐ ‐
rs16870827  5  70976503  0.1787  G  A  0.0690271  5.88x10‐6  ‐  MCCC2(+21.97kb) 
rs2290987  5  121776301  0.2289  G  A  ‐0.0097764  9.23x10‐6  Intronic|Intronic  MGC32805|SNCAIP 






GeneSet  N  n  p‐value  adjusted p  genes 
GWAS catalog 
Post bronchodilator FEV1/FVC ratio  196  2  2.02x10‐5  1.45x10‐3  MDGA2, HSDL2 
GWEIS for joint effect 
GeneSet  N  n  p‐value  adjusted p  genes 
All Canonical Pathways 
biocarta gpcr pathway  34  2  1.80x10‐6  2.39x10‐3  CREB1, GNGT1 
reactome opioid signalling  77  2  2.16x10‐5  5.22x10‐3  CREB1, GNGT1 
reactome neurotransmitter receptor binding and downstream 
transmission in the postsynaptic cell  133  2  1.10x10‐4  5.37x10‐3  CREB1, GNGT1 
reactome transmission across chemical synapses  181  2  2.74x10‐4  6.07x10‐3  CREB1, GNGT1 
reactome gastrin creb signalling pathway via pkc and mapk  200  2  3.68x10‐4  6.78x10‐3  CREB1, GNGT1 
reactome neuronal system  273  2  9.10x10‐4  1.27x10‐2  CREB1, GNGT1 
GO biological processes  
bone morphogenesis  79  2  2.33x10‐5  2.68x10‐2  COL13A1, GLG1 
bone development  155  2  1.74x10‐4  2.79x10‐2  COL13A1, GLG1 
skeletal system morphogenesis  200  2  3.68x10‐4  3.86x10‐2  COL13A1, GLG1 
neuron projection guidance  204  2  3.90x10‐4  3.86x10‐2  KLF7, CREB1 
GO molecular functions 
transcription factor activity rna polymerase ii distal enhancer 
sequence specific binding  89  2  3.33x10‐5  1.07x10‐2  CREB1, PURA 
transcription factor activity protein binding  580  3  6.38x10‐4  2.55x10‐2  KLF7, CREB1, PHF2 
transcription coactivator activity  295  2  1.14x10‐3  3.77x10‐2  KLF7, PHF2 
GWAS catalog 
Migraine  76  2  2.08x10‐5  3.19x10‐3  AGBL1, IMMP2L 
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GeneSet  N  n  p‐value  Adjusted p  genes 
GO biological processes  
regulation of jun kinase activity  81  2  3.13x10‐5  3.40x10‐2  AIDA, RIPK1 
regulation of jnk cascade  159  2  2.33x10‐4  4.03x10‐2  AIDA, RIPK1 
endoplasmatic reticulum to golgi vesicle mediated transport  165  2  2.60x10‐4  4.15x10‐2  MIA3, TRAPPC3L 
GWAS catalog 
Age‐related macular degeneration  64  2  1.54x10‐5  5.22x10‐3  FRK, COL10A1 
Myopia  72  2  2.20x10‐5  5.22x10‐3  NT5DC1, COL10A1 
Urate levels  79  2  2.91x10‐5  5.22x10‐3  MIA3, FRK 
TSLE GWEIS  for  joint effect 
GeneSet  N  n  p‐value  adjusted p  genes 
GO biological processes  
protein autophosphorylation  192  2  3.26x10‐4  4.34x10‐2  RIPK1, FRK 
GWAS catalog 
Heschl's gyrus morphology  35  2  1.97x10‐6  2.12x10‐3  KALRN, DSE 
Age‐related macular degeneration  64  2  1.24x10‐5  3.68x10‐3  FRK, COL10A1 





GeneSet  N  n  p‐value  adjusted p  genes 
GWAS catalog 
Age‐related macular degeneration  64  2  2.89x10‐6  8.89x10‐4  FRK, COL10A1 
Myopia  72  2  4.13x10‐6  8.89x10‐4  NT5DC1, COL10A1 
DSLE GWEIS for joint effect 
GeneSet  N  n  p‐value  adjusted p  genes 
GO biological processes  
sulfur compound biosynthetic process  201  2  1.73x10‐4  2.24x10‐2  DSE, MTAP 
carboxylic acid biosynthetic process  264  2  3.86x10‐4  3.45x10‐2  DSE, MTAP 
organic acid biosynthetic process  264  2  3.86x10‐4  3.45x10‐2  DSE, MTAP 
GWAS catalog 
Age‐related macular degeneration  64  2  5.65x10‐6  1.34x10‐3  FRK, COL10A1 









GeneSet  N  n  p‐value  adjusted p  genes 
GO biological processes  
regulation of transporter activity  198  2  2.08x10‐5  3.46x10‐3  KCNQ1, RIPK1 
regulation of transmembrane transport  423  2  2.00x10‐4  1.24x10‐2  KCNQ1, RIPK1 
regulation of ion transport  588  2  5.27x10‐4  2.14x10‐2  KCNQ1, RIPK1 
regulation of secretion  694  2  8.56x10‐4  3.03x10‐2  KCNQ1, PCLO 
regulation of transport  1795  3  9.62x10‐4  3.22x10‐2  KCNQ1, RIPK1, PCLO 
regulation of defense response  755  2  1.09x10‐3  3.53x10‐2  KCNQ1, RIPK1 
cell cell signaling  757  2  1.10x10‐3  3.54x10‐2  KCNQ1, PCLO 
GO molecular functions 
phospholipid binding  355  2  1.19x10‐4  1.00x10‐2  KCNQ1, PCLO 
lipid binding  649  2  7.03x10‐4  3.11x10‐2  KCNQ1, PCLO 
GO cellular components 
membrane microdomain  286  2  6.25x10‐5  1.21x10‐2  KCNQ1, RIPK1 
plasma membrane protein complex  507  2  3.41x10‐4  3.31x10‐2  KCNQ1, RIPK1 
GWAS catalog 
Body mass index  335  2  1.00x10‐4  1.19x10‐2  KCNQ1, RALYL 
ISLE GWEIS for joint effect 
GeneSet  N  n  p‐value  adjusted p  genes 
GO molecular functions 
ubiquitin like protein ligase binding  263  2  2.46x10‐5  1.14x10‐2  SNCAIP, RIPK1 
















Phenotype  Summary.statistics  Threshold  Num_SNP  PRS.R2  Full.R2  Null.R2  Coefficient 
Standard 
Error  p‐value  Empirical‐p 
GHQ  PGC2‐MDD GWAS  0.3  42768  0.00779085  0.0326142  0.0248234  0.0479313  0.00763397  3.71x10‐10  1.00x10‐4 
GHQ  UKB GWAS  0.5  64419  0.00564066  0.030464  0.0248234  0.0403361  0.00755848  9.90x10‐8  1.00x10‐4 
GHQ 
UKB GWEIS ‐ GxE 
effect  0.03  7259  0.00153355  0.0263569  0.0248234  0.0211521  0.00761778  0.00551253  0.029897 
GHQ 
UKB GWEIS ‐ Joint 
effect  0.4  55348  0.00578933  0.0306127  0.0248234  4.11x10‐2  0.00760206  6.72x10‐8  1.00x10‐4 
Predicting in UK Biobank: 
Phenotype  Summary.statistics  Threshold  Num_SNP  PRS.R2  Full.R2  Null.R2  Coefficient 
Standard 
Error  p‐value  Empirical‐p 
PHQ  PGC2‐MDD GWAS  0.5  57356  0.0044533  0.0373778  0.0329245  0.0590839  0.00277599  2.69x10‐100  1.00x10‐4 
PHQ  GS GWAS  0.2  34755  0.000403055  0.0333276  0.0329245  0.0177551  0.00276299  1.32x10‐10  1.00x10‐4 
PHQ 
GS GWEIS using TSLE 
‐ GxE effect  0.001  526  2.60x10‐5  0.0329505  0.0329245  ‐0.00450364  0.00276207  0.102993  0.382062 
PHQ 
GS GWEIS using DSLE 




GxE effect  0.02  5440  1.18x10‐5  0.0329363  0.0329245  ‐0.0030395  0.00276926  0.272387  0.748225 
PHQ 
GS GWEIS using TSLE 
‐ Joint effect  1  94403  0.000322961  0.0332475  0.0329245  0.0158888  2.76x10‐3  8.85x10‐9  1.00x10‐4 
PHQ 
GS GWEIS using DSLE 
‐ Joint effect  0.5  65749  0.000119752  0.0330443  0.0329245  0.00969592  2.77x10‐3  4.62x10‐4  0.00429957 
PHQ 
GS GWEIS using ISLE ‐ 












































TSLE ‐ Joint effect  0.001  473  0.00257  0.01949  0.01692  0.10353  0.04421  0.01920  0.07029  0.34997 
Alzheimer 
(R) UKB GWAS 1  90832  0.00053  0.01745  0.01692  0.04718  0.04426  0.28638  0.74433  0.88963 
Alzheimer 





effect  1  91064  0.00058  0.01750  0.01692  0.04960  0.04449  0.26497  0.75393  0.89384 
Asthma  GS GWAS  0.001  342  0.00136  0.04156  0.04020  ‐0.07963  0.04772  0.09516  0.26637  0.62923 
Asthma 
GS GWEIS using 
DSLE ‐ GxE effect  0.2  35852  0.00043  0.04063  0.04020  0.04363  0.04647  0.34784  0.72433  0.88618 
Asthma 
GS GWEIS using 
DSLE ‐ Joint effect  0.05  12712  0.00119  0.04139  0.04020  0.07315  0.04671  0.11730  0.34207  0.69809 
Asthma 
GS GWEIS using 
ISLE ‐ GxE effect  0.005  1666  0.00273  0.04293  0.04020  ‐0.11483  0.04890  0.01886  0.06299  0.34997 
Asthma 
GS GWEIS using 
ISLE ‐ Joint effect  1  95515  0.00087  0.04107  0.04020  0.06372  0.04757  0.18038  0.47775  0.79064 
Asthma 
GS GWEIS using 
TSLE ‐ GxE effect  0.1  21099  0.00004  0.04024  0.04020  ‐0.01381  0.04800  0.77363  0.99890  0.99950 
Asthma 
GS GWEIS using 
TSLE ‐ Joint effect  0.1  21700  0.00048  0.04068  0.04020  0.04786  0.04831  0.32187  0.71963  0.88618 
Asthma  UKB GWAS  0.2  34864  0.00063  0.04083  0.04020  ‐0.05419  0.04766  0.25545  0.69863  0.88618 
Asthma  UKB GxE effect  0.1  19894  0.00077  0.04097  0.04020  0.06028  0.04810  0.21014  0.65753  0.87456 
Asthma 
UKB GxE Joint 
effect  0.005  1927  0.00067  0.04087  0.04020  0.05542  0.04742  0.24249  0.72903  0.88618 
Asthma (R)  GS GWAS  0.5  66423  0.00204  0.11480  0.11276  0.09352  0.04125  0.02338  0.07879  0.36366 
Asthma (R) 
GS GWEIS using 
DSLE ‐ GxE effect  0.005  1907  0.00031  0.11307  0.11276  ‐0.03599  0.04066  0.37613  0.76452  0.89384 
Asthma (R) 
GS GWEIS using 
DSLE ‐ Joint effect  1  95559  0.00116  0.11392  0.11276  0.06855  0.04025  0.08856  0.27707  0.63589 
Asthma (R) 
GS GWEIS using 
ISLE ‐ GxE effect  0.001  441  0.00065  0.11342  0.11276  0.05250  0.04085  0.19880  0.48355  0.79271 
Asthma (R) 
GS GWEIS using 
ISLE ‐ Joint effect  0.2  35677  0.00153  0.11429  0.11276  0.08069  0.04100  0.04905  0.16628  0.49819 
Asthma (R) 
GS GWEIS using 
TSLE ‐ GxE effect  0.005  1836  0.00100  0.11376  0.11276  0.06457  0.04065  0.11222  0.29517  0.64729 
Asthma (R) 
GS GWEIS using 
TSLE ‐ Joint effect  0.1  21704  0.00151  0.11427  0.11276  0.08102  0.04150  0.05089  0.16468  0.49819 
Asthma (R)  UKB GWAS  0.4  56075  0.00100  0.11376  0.11276  0.06493  0.04088  0.11218  0.38966  0.74458 
Asthma (R)  UKB GxE effect  0.1  19901  0.00100  0.11377  0.11276  0.06585  0.04142  0.11184  0.42846  0.76164 
Asthma (R) 
UKB GxE Joint 
effect  0.4  55274  0.00064  0.11340  0.11276  0.05209  0.04115  0.20565  0.64194  0.86748 
Bowel 

























TSLE ‐ Joint effect  0.4  57528  0.00074  0.01172  0.01099  0.05449  0.04328  0.20807  0.51985  0.82248 
Bowel 
cancer (R)  UKB GWAS  0.03  8341  0.00102  0.01200  0.01099  0.06476  0.04384  0.13964  0.46365  0.78144 
Bowel 




effect  0.5  63553  0.00092  0.01191  0.01099  ‐0.06209  0.04406  0.15873  0.54915  0.82248 
Breast 
























TSLE ‐ Joint effect  0.001  474  0.00355  0.20346  0.19991  ‐0.18852  0.11771  0.10925  0.32357  0.66959 
Breast 
cancer  UKB GWAS  0.4  56115  0.00861  0.20852  0.19991  ‐0.29322  0.11810  0.01303  0.06379  0.34997 
Breast 




effect  1  91009  0.00160  0.20151  0.19991  ‐0.12611  0.11707  0.28137  0.77982  0.90002 


























TSLE ‐ Joint effect  0.001  473  0.00240  0.01111  0.00871  ‐0.10277  0.04674  0.02788  0.09939  0.38304 
Breast 
cancer (R)  UKB GWAS  0.001  556  0.00224  0.01094  0.00871  ‐0.10028  0.04718  0.03356  0.14849  0.49819 
Breast 




effect  0.005  1930  0.00078  0.00949  0.00871  ‐0.05876  0.04678  0.20907  0.65603  0.87456 
COPD  GS GWAS  0.005  1543  0.00437  0.11993  0.11556  ‐0.21163  0.12635  0.09393  0.27457  0.63589 
COPD 
GS GWEIS using 
DSLE ‐ GxE effect  0.5  67087  0.00428  0.11984  0.11556  ‐0.19134  0.09598  0.04621  0.15828  0.49819 
COPD 
GS GWEIS using 
DSLE ‐ Joint effect  0.5  66455  0.00590  0.12146  0.11556  ‐0.23792  0.10671  0.02578  0.11549  0.43308 
COPD 
GS GWEIS using 
ISLE ‐ GxE effect  0.005  1669  0.00619  0.12175  0.11556  ‐0.24883  0.12404  0.04485  0.15399  0.49819 
COPD 
GS GWEIS using 
ISLE ‐ Joint effect  0.001  421  0.00470  0.12026  0.11556  ‐0.21220  0.12191  0.08176  0.25997  0.62394 
COPD 
GS GWEIS using 
TSLE ‐ GxE effect  0.3  47860  0.00590  0.12146  0.11556  ‐0.22583  0.10703  0.03486  0.13109  0.46795 
COPD 
GS GWEIS using 
TSLE ‐ Joint effect  0.001  473  0.00496  0.12053  0.11556  ‐0.21840  0.12205  0.07354  0.23688  0.59201 
COPD  UKB GWAS  0.005  2004  0.00548  0.12104  0.11556  0.22961  0.12200  0.05982  0.23618  0.59201 
COPD  UKB GxE effect  0.02  5183  0.00080  0.11636  0.11556  ‐0.08756  0.12170  0.47188  0.96220  0.99279 
COPD 
UKB GxE Joint 
effect  0.01  3375  0.00762  0.12318  0.11556  0.26858  0.12104  0.02649  0.13809  0.47616 
COPD (R)  GS GWAS  0.5  66477  0.00505  0.03944  0.03439  0.15006  0.04652  0.00126  0.00560  0.05249 





DSLE ‐ Joint effect  0.01  3433  0.00186  0.03625  0.03439  0.09176  0.04691  0.05047  0.16908  0.49819 
COPD (R) 
GS GWEIS using 
ISLE ‐ GxE effect  1  95337  0.00044  0.03483  0.03439  ‐0.04570  0.04865  0.34761  0.72663  0.88618 
COPD (R) 
GS GWEIS using 
ISLE ‐ Joint effect  0.005  1725  0.00450  0.03889  0.03439  0.14340  0.04726  0.00241  0.01010  0.08416 
COPD (R) 
GS GWEIS using 
TSLE ‐ GxE effect  0.001  531  0.00356  0.03795  0.03439  ‐0.12862  0.04790  0.00725  0.02780  0.19393 
COPD (R) 
GS GWEIS using 
TSLE ‐ Joint effect  0.01  3322  0.00709  0.04148  0.03439  0.17978  0.04721  0.00014  0.00080  0.01000 
COPD (R)  UKB GWAS  0.001  555  0.00053  0.03492  0.03439  ‐0.04974  0.04787  0.29872  0.77512  0.90002 
COPD (R)  UKB GxE effect  0.2  33863  0.00222  0.03661  0.03439  0.10221  0.04810  0.03361  0.16498  0.49819 
COPD (R) 
UKB GxE Joint 
effect  1  91066  0.00036  0.03475  0.03439  0.04107  0.04779  0.39012  0.90861  0.95980 
Depression  GS GWAS  0.1  20325  0.01066  0.07495  0.06428  0.23175  0.05000  0.00000  0.00010  0.00200 
Depression 
GS GWEIS using 
DSLE ‐ GxE effect  0.001  524  0.00037  0.06465  0.06428  0.04298  0.05042  0.39393  0.78102  0.90002 
Depression 
GS GWEIS using 
DSLE ‐ Joint effect  0.005  1912  0.00689  0.07117  0.06428  0.18269  0.04938  0.00022  0.00080  0.01000 
Depression 
GS GWEIS using 
ISLE ‐ GxE effect  0.005  1667  0.00393  0.06821  0.06428  ‐0.14306  0.05189  0.00584  0.02180  0.15856 
Depression 
GS GWEIS using 
ISLE ‐ Joint effect  0.2  35692  0.00821  0.07249  0.06428  0.20150  0.04956  0.00005  0.00030  0.00474 
Depression 
GS GWEIS using 
TSLE ‐ GxE effect  0.001  531  0.00113  0.06541  0.06428  ‐0.07536  0.05062  0.13657  0.35497  0.71952 
Depression 
GS GWEIS using 
TSLE ‐ Joint effect  0.2  36078  0.00781  0.07209  0.06428  0.20093  0.05070  0.00007  0.00040  0.00600 
Depression  UKB GWAS  0.01  3542  0.00629  0.07057  0.06428  0.17820  0.05077  0.00045  0.00280  0.02896 
Depression  UKB GxE effect  0.04  9348  0.00192  0.06620  0.06428  0.09922  0.05117  0.05249  0.23418  0.59201 
Depression 
UKB GxE Joint 
effect  0.05  12391  0.00284  0.06712  0.06428  0.12184  0.05165  0.01833  0.09939  0.38304 
Depression 

























TSLE ‐ Joint effect  0.005  1846  0.00222  0.08077  0.07855  0.09916  0.04375  0.02343  0.08569  0.36503 
Depression 
(R) UKB GWAS 0.005  2005  0.00307  0.08162  0.07855  0.11570  0.04350  0.00782  0.03590  0.23040 
Depression




effect 0.01  3372  0.00027  0.07882  0.07855  0.03434  0.04364  0.43137  0.93601  0.97501 
Diabetes  GS GWAS 0.04  9516  0.00130  0.08072  0.07942  0.09759  0.07736  0.20714  0.50595  0.82046 
Diabetes 
GS GWEIS using
DSLE ‐ GxE effect 0.005  1908  0.00070  0.08012  0.07942  ‐0.07403  0.08042  0.35729  0.73443  0.88618 
Diabetes 
GS GWEIS using
DSLE ‐ Joint effect 0.001  502  0.00164  0.08106  0.07942  0.10934  0.07778  0.15978  0.44366  0.77341 
Diabetes 
GS GWEIS using
ISLE ‐ GxE effect 0.02  5484  0.00129  0.08071  0.07942  ‐0.09902  0.08012  0.21649  0.51155  0.82248 
Diabetes 
GS GWEIS using
ISLE ‐ Joint effect 1  95519  0.00086  0.08028  0.07942  0.07923  0.07726  0.30511  0.70523  0.88618 
Diabetes 
GS GWEIS using
TSLE ‐ GxE effect 0.005  1837  0.00021  0.07963  0.07942  0.03889  0.07771  0.61677  0.96740  0.99391 
Diabetes 
GS GWEIS using
TSLE ‐ Joint effect 0.2  36074  0.00125  0.08067  0.07942  0.09542  0.07680  0.21404  0.54195  0.82248 
Diabetes  UKB GWAS 0.001  556  0.00613  0.08555  0.07942  0.21643  0.07996  0.00680  0.03610  0.23040 
Diabetes  UKB GxE effect 0.005  1458  0.00141  0.08083  0.07942  0.10012  0.07690  0.19294  0.63014  0.86475 
Diabetes 
UKB GxE Joint
effect 0.001  468  0.00159  0.08101  0.07942  0.10829  0.07831  0.16676  0.57154  0.82284 
Diabetes (R)  GS GWAS  1  95406  0.00018  0.02840  0.02822  0.02508  0.03695  0.49724  0.89401  0.95108 
Diabetes (R) 
GS GWEIS using 
DSLE ‐ GxE effect  0.005  1909  0.00052  0.02874  0.02822  ‐0.04229  0.03708  0.25401  0.58704  0.83863 
Diabetes (R) 
GS GWEIS using 
DSLE ‐ Joint effect  0.05  12705  0.00009  0.02831  0.02822  ‐0.01748  0.03697  0.63636  0.98440  0.99737 
Diabetes (R) 
GS GWEIS using 




ISLE ‐ Joint effect  0.1  21221  0.00022  0.02843  0.02822  0.02715  0.03692  0.46212  0.88451  0.94432 
Diabetes (R) 
GS GWEIS using 
TSLE ‐ GxE effect  0.001  530  0.00087  0.02909  0.02822  ‐0.05445  0.03704  0.14151  0.37126  0.72324 
Diabetes (R) 
GS GWEIS using 
TSLE ‐ Joint effect  0.005  1843  0.00076  0.02898  0.02822  0.05089  0.03695  0.16842  0.45376  0.77345 
Diabetes (R)  UKB GWAS  1  90858  0.00116  0.02937  0.02822  0.06290  0.03706  0.08964  0.32527  0.66959 
Diabetes (R)  UKB GxE effect  0.02  5172  0.00317  0.03139  0.02822  ‐0.10539  0.03748  0.00493  0.03000  0.20453 
Diabetes (R) 
UKB GxE Joint 
effect  0.01  3377  0.00065  0.02887  0.02822  0.04749  0.03715  0.20120  0.63204  0.86475 
Extraversion  GS GWAS  0.4  57527  0.00365  0.02915  0.02550  ‐0.21489  0.06011  0.00036  0.00130  0.01500 
Extraversion 
GS GWEIS using 
DSLE ‐ GxE effect  0.5  67060  0.00032  0.02582  0.02550  0.06396  0.06040  0.28969  0.63524  0.86475 
Extraversion 
GS GWEIS using 
DSLE ‐ Joint effect  0.4  57695  0.00152  0.02702  0.02550  ‐0.13873  0.06028  0.02142  0.08219  0.36393 
Extraversion 
GS GWEIS using 
ISLE ‐ GxE effect  0.03  7742  0.00089  0.02639  0.02550  0.10652  0.06035  0.07765  0.22118  0.58720 
Extraversion 
GS GWEIS using 
ISLE ‐ Joint effect  0.5  65950  0.00339  0.02889  0.02550  ‐0.20696  0.06013  0.00058  0.00340  0.03290 
Extraversion 
GS GWEIS using 
TSLE ‐ GxE effect  0.2  35569  0.00051  0.02601  0.02550  0.08034  0.06044  0.18381  0.44656  0.77341 
Extraversion 
GS GWEIS using 
TSLE ‐ Joint effect  1  95501  0.00425  0.02975  0.02550  ‐0.23166  0.06009  0.00012  0.00070  0.00954 
Extraversion  UKB GWAS  0.2  34868  0.00028  0.02578  0.02550  0.05994  0.06079  0.32414  0.81072  0.91092 
Extraversion  UKB GxE effect  0.03  7260  0.00095  0.02645  0.02550  0.11081  0.06103  0.06951  0.29717  0.64729 
Extraversion 
UKB GxE Joint 
effect  0.001  468  0.00102  0.02652  0.02550  0.11517  0.06112  0.05960  0.25577  0.62384 
Heart 
















ISLE ‐ Joint effect  0.005  1727  0.00059  0.16302  0.16242  ‐0.06737  0.07554  0.37248  0.79052  0.90002 






TSLE ‐ Joint effect  0.04  10597  0.00064  0.16306  0.16242  0.07048  0.07535  0.34959  0.75293  0.89384 
Heart 
disease  UKB GWAS  0.001  555  0.00134  0.16376  0.16242  ‐0.10223  0.07614  0.17938  0.55465  0.82248 
Heart 




effect  0.05  12389  0.00349  0.16591  0.16242  0.16191  0.07480  0.03041  0.14569  0.49665 
Heart 
























TSLE ‐ Joint effect  0.001  473  0.00213  0.02708  0.02494  0.08510  0.03707  0.02169  0.07269  0.34997 
Heart 
disease (R)  UKB GWAS  0.01  3552  0.00200  0.02694  0.02494  0.08342  0.03754  0.02628  0.12359  0.44670 
Heart 




effect  0.1  21009  0.00178  0.02673  0.02494  0.07885  0.03755  0.03575  0.17618  0.50822 
High BP  GS GWAS  0.4  57528  0.00129  0.16093  0.15964  0.07970  0.04470  0.07456  0.21638  0.58481 
High BP 
GS GWEIS using 
DSLE ‐ GxE effect  0.005  1912  0.00054  0.16017  0.15964  ‐0.05275  0.04600  0.25146  0.57294  0.82284 
High BP 
GS GWEIS using 
DSLE ‐ Joint effect  0.2  36247  0.00053  0.16017  0.15964  0.05341  0.04652  0.25093  0.61904  0.85978 
High BP 
GS GWEIS using 
ISLE ‐ GxE effect  0.01  2989  0.00017  0.15981  0.15964  0.02878  0.04403  0.51330  0.89811  0.95206 
High BP 
GS GWEIS using 




TSLE ‐ GxE effect  0.02  5887  0.00011  0.15974  0.15964  ‐0.02284  0.04493  0.61129  0.96300  0.99279 
High BP 
GS GWEIS using 
TSLE ‐ Joint effect  0.001  473  0.00080  0.16043  0.15964  0.06231  0.04457  0.16212  0.42906  0.76164 
High BP  UKB GWAS  0.02  6037  0.00052  0.16016  0.15964  0.04988  0.04422  0.25934  0.70373  0.88618 
High BP  UKB GxE effect  0.1  19873  0.00081  0.16045  0.15964  0.06368  0.04514  0.15832  0.53995  0.82248 
High BP 
UKB GxE Joint 
effect  0.005  1927  0.00054  0.16018  0.15964  0.05153  0.04482  0.25030  0.73553  0.88618 
High BP (R)  GS GWAS  0.005  1543  0.00072  0.07199  0.07126  0.04951  0.03576  0.16624  0.41986  0.75963 
High BP (R) 
GS GWEIS using 
DSLE ‐ GxE effect  0.03  8308  0.00053  0.07179  0.07126  ‐0.04279  0.03635  0.23905  0.55185  0.82248 
High BP (R) 
GS GWEIS using 
DSLE ‐ Joint effect  0.04  10658  0.00012  0.07139  0.07126  ‐0.02059  0.03584  0.56568  0.95141  0.98762 
High BP (R) 
GS GWEIS using 
ISLE ‐ GxE effect  0.01  2988  0.00075  0.07202  0.07126  0.05061  0.03589  0.15841  0.40086  0.74843 
High BP (R) 
GS GWEIS using 
ISLE ‐ Joint effect  0.01  3217  0.00061  0.07187  0.07126  0.04549  0.03575  0.20318  0.53305  0.82248 
High BP (R) 
GS GWEIS using 
TSLE ‐ GxE effect  0.005  1838  0.00022  0.07148  0.07126  0.02730  0.03579  0.44563  0.85012  0.92404 
High BP (R) 
GS GWEIS using 
TSLE ‐ Joint effect  0.02  5965  0.00038  0.07164  0.07126  0.03571  0.03570  0.31710  0.70453  0.88618 
High BP (R)  UKB GWAS  0.01  3547  0.00161  0.07288  0.07126  0.07503  0.03626  0.03852  0.15918  0.49819 
High BP (R)  UKB GxE effect  0.1  19904  0.00085  0.07212  0.07126  0.05481  0.03643  0.13241  0.47965  0.79064 
High BP (R) 
UKB GxE Joint 
effect  0.005  1927  0.00100  0.07226  0.07126  0.05882  0.03614  0.10359  0.39866  0.74843 
Hip fracture 




















TSLE ‐ GxE effect  0.001  531  0.00187  0.01830  0.01643  0.09615  0.05227  0.06583  0.19788  0.55480 




(R) UKB GWAS 0.01  3549  0.00033  0.01677  0.01643  ‐0.04101  0.05304  0.43936  0.92081  0.96927 
Hip fracture 




effect 0.05  12395  0.00078  0.01721  0.01643  ‐0.06314  0.05327  0.23591  0.70623  0.88618 
Lung cancer 
























TSLE ‐ Joint effect 0.005  1844  0.00232  0.02690  0.02458  0.09536  0.04144  0.02139  0.07349  0.34997 
Lung cancer 
(R) UKB GWAS 0.005  2003  0.00052  0.02510  0.02458  0.04522  0.04134  0.27405  0.72663  0.88618 
Lung cancer 




effect 0.001  469  0.00105  0.02563  0.02458  0.06419  0.04145  0.12144  0.45945  0.77874 
Mood 

























TSLE ‐ Joint effect  0.1  21683  0.01276  0.08702  0.07425  0.36820  0.06517  0.00000  0.00010  0.00200 
Mood 
disorder  UKB GWAS  0.03  8329  0.00226  0.07652  0.07425  0.15605  0.06596  0.01808  0.08629  0.36503 
Mood 




effect  0.1  20988  0.00281  0.07706  0.07425  0.17425  0.06607  0.00841  0.04900  0.29397 
Neuroticism  GS GWAS  1  95359  0.03538  0.09100  0.05562  0.60308  0.05244  0.00000  0.00010  0.00200 
Neuroticism 
GS GWEIS using 
DSLE ‐ GxE effect  0.3  47865  0.00137  0.05698  0.05562  ‐0.11900  0.05360  0.02649  0.09069  0.37270 
Neuroticism 
GS GWEIS using 
DSLE ‐ Joint effect  0.1  21776  0.01876  0.07437  0.05562  0.44034  0.05307  0.00000  0.00010  0.00200 
Neuroticism 
GS GWEIS using 
ISLE ‐ GxE effect  0.02  5485  0.00046  0.05608  0.05562  ‐0.06923  0.05362  0.19670  0.46815  0.78461 
Neuroticism 
GS GWEIS using 
ISLE ‐ Joint effect  1  95499  0.03105  0.08666  0.05562  0.56490  0.05257  0.00000  0.00010  0.00200 
Neuroticism 
GS GWEIS using 
TSLE ‐ GxE effect  0.3  47828  0.00129  0.05691  0.05562  ‐0.11563  0.05363  0.03114  0.10259  0.38958 
Neuroticism 
GS GWEIS using 
TSLE ‐ Joint effect  1  95507  0.03155  0.08716  0.05562  0.56936  0.05255  0.00000  0.00010  0.00200 
Neuroticism  UKB GWAS  1  90784  0.00557  0.06118  0.05562  0.24077  0.05364  0.00001  0.00020  0.00333 
Neuroticism  UKB GxE effect  0.001  327  0.00030  0.05592  0.05562  ‐0.05628  0.05377  0.29534  0.79282  0.90002 
Neuroticism 
UKB GxE Joint 
effect  0.2  34852  0.00370  0.05932  0.05562  0.19771  0.05407  0.00026  0.00160  0.01714 
Osteo 




















TSLE ‐ GxE effect  0.005  1838  0.00018  0.19167  0.19149  0.03402  0.05708  0.55122  0.92571  0.97102 




arthritis  UKB GWAS  0.02  6030  0.00044  0.19193  0.19149  ‐0.05180  0.05542  0.34995  0.83782  0.91911 
Osteo 




effect  0.5  63512  0.00057  0.19206  0.19149  ‐0.05992  0.05642  0.28816  0.78582  0.90002 
Osteo 
























TSLE ‐ Joint effect  0.02  5967  0.00515  0.05957  0.05443  0.13991  0.03944  0.00039  0.00160  0.01714 
Osteo 
arthritis (R)  UKB GWAS  1  90783  0.00110  0.05552  0.05443  0.06451  0.03939  0.10148  0.36476  0.72324 
Osteo 




effect  0.02  5946  0.00041  0.05484  0.05443  ‐0.03976  0.03972  0.31678  0.83532  0.91911 
Parkinson (R)  GS GWAS  0.05  11504  0.00364  0.02723  0.02359  0.14927  0.06623  0.02422  0.08249  0.36393 
Parkinson (R) 
GS GWEIS using 
DSLE ‐ GxE effect  0.02  5951  0.00044  0.02403  0.02359  ‐0.05306  0.06815  0.43616  0.82912  0.91784 
Parkinson (R) 
GS GWEIS using 
DSLE ‐ Joint effect  0.005  1909  0.00481  0.02839  0.02359  0.17088  0.06576  0.00936  0.04270  0.26140 
Parkinson (R) 
GS GWEIS using 
ISLE ‐ GxE effect  0.005  1667  0.00102  0.02461  0.02359  ‐0.08202  0.06994  0.24096  0.55654  0.82248 
Parkinson (R) 
GS GWEIS using 
ISLE ‐ Joint effect  0.3  47486  0.00388  0.02747  0.02359  0.15239  0.06513  0.01928  0.07659  0.35903 
Parkinson (R) 
GS GWEIS using 




TSLE ‐ Joint effect  0.03  8416  0.00362  0.02720  0.02359  0.14887  0.06654  0.02527  0.09369  0.37476 
Parkinson (R)  UKB GWAS  0.3  46449  0.00389  0.02748  0.02359  ‐0.15737  0.06852  0.02164  0.09959  0.38304 
Parkinson (R)  UKB GxE effect  0.03  7263  0.00152  0.02511  0.02359  ‐0.09921  0.06916  0.15142  0.52915  0.82248 
Parkinson (R) 
UKB GxE Joint 
effect  0.001  469  0.00449  0.02808  0.02359  0.16990  0.06888  0.01364  0.07279  0.34997 
Prostate 
























TSLE ‐ Joint effect  0.5  66141  0.00194  0.01263  0.01069  0.10204  0.05736  0.07524  0.23408  0.59201 
Prostate 
cancer (R)  UKB GWAS  0.03  8341  0.00122  0.01191  0.01069  0.08256  0.05913  0.16260  0.52415  0.82248 
Prostate 




effect  0.4  55274  0.00107  0.01176  0.01069  ‐0.07743  0.05911  0.19021  0.61904  0.85978 
Rheumatoid 

























TSLE ‐ Joint effect  0.04  10596  0.00263  0.08792  0.08529  0.15289  0.10546  0.14715  0.40566  0.75122 
Rheumatoid 
arthritis  UKB GWAS  1  90845  0.00497  0.09026  0.08529  0.20883  0.10711  0.05121  0.20968  0.57710 
Rheumatoid 




effect  0.05  12401  0.00267  0.08796  0.08529  0.15451  0.10801  0.15258  0.52905  0.82248 
Rheumatoid 
























TSLE ‐ Joint effect  0.001  473  0.00424  0.04173  0.03749  0.13073  0.04210  0.00190  0.00850  0.07727 
Rheumatoid 
arthritis (R)  UKB GWAS  0.4  56079  0.00372  0.04120  0.03749  0.12261  0.04221  0.00368  0.01940  0.14549 
Rheumatoid 




effect  1  91009  0.00412  0.04160  0.03749  0.12975  0.04245  0.00224  0.01580  0.12153 
Schizotypal 
















ISLE ‐ Joint effect  0.5  65965  0.02152  0.05611  0.03459  0.56781  0.07737  0.00000  0.00010  0.00200 






TSLE ‐ Joint effect  1  95511  0.01830  0.05289  0.03459  0.52391  0.07754  0.00000  0.00010  0.00200 
Schizotypal 
personality  UKB GWAS  0.3  46408  0.00800  0.04259  0.03459  0.34867  0.07846  0.00001  0.00020  0.00333 
Schizotypal 




effect  0.4  55262  0.00915  0.04374  0.03459  0.37512  0.07890  0.00000  0.00010  0.00200 
Stroke  GS GWAS  0.02  5283  0.00123  0.13099  0.12976  0.11224  0.11921  0.34642  0.72313  0.88618 
Stroke 
GS GWEIS using 
DSLE ‐ GxE effect  0.2  35891  0.00225  0.13201  0.12976  0.14540  0.10585  0.16954  0.42286  0.75963 
Stroke 
GS GWEIS using 
DSLE ‐ Joint effect  0.02  6098  0.00205  0.13181  0.12976  0.14446  0.11643  0.21471  0.55315  0.82248 
Stroke 
GS GWEIS using 
ISLE ‐ GxE effect  0.001  440  0.00268  0.13244  0.12976  ‐0.15737  0.11543  0.17279  0.44016  0.77341 
Stroke 
GS GWEIS using 
ISLE ‐ Joint effect  0.001  421  0.00220  0.13196  0.12976  ‐0.14525  0.11697  0.21431  0.55574  0.82248 
Stroke 
GS GWEIS using 
TSLE ‐ GxE effect  0.001  530  0.00884  0.13860  0.12976  ‐0.29457  0.11776  0.01237  0.06109  0.34997 
Stroke 
GS GWEIS using 
TSLE ‐ Joint effect  0.005  1844  0.00177  0.13153  0.12976  ‐0.13614  0.12270  0.26720  0.63704  0.86475 
Stroke  UKB GWAS  0.03  8340  0.00325  0.13301  0.12976  0.17140  0.11356  0.13122  0.44506  0.77341 
Stroke  UKB GxE effect  0.03  7261  0.00514  0.13490  0.12976  0.22327  0.11741  0.05722  0.25917  0.62394 
Stroke 
UKB GxE Joint 
effect  0.03  8269  0.00491  0.13467  0.12976  0.21603  0.11671  0.06417  0.27347  0.63589 
Stroke (R)  GS GWAS  0.04  9523  0.00096  0.01576  0.01480  0.05490  0.03510  0.11782  0.32437  0.66959 
Stroke (R) 
GS GWEIS using 
DSLE ‐ GxE effect  0.001  523  0.00008  0.01488  0.01480  ‐0.01596  0.03493  0.64775  0.97800  0.99519 
Stroke (R) 
GS GWEIS using 
DSLE ‐ Joint effect  0.001  503  0.00197  0.01677  0.01480  ‐0.07872  0.03508  0.02481  0.08849  0.36871 
Stroke (R) 
GS GWEIS using 
ISLE ‐ GxE effect  0.001  441  0.00222  0.01702  0.01480  ‐0.08363  0.03519  0.01748  0.05889  0.34644 
Stroke (R) 
GS GWEIS using 
ISLE ‐ Joint effect  1  95520  0.00034  0.01514  0.01480  0.03241  0.03499  0.35436  0.76572  0.89384 
Stroke (R) 
GS GWEIS using 
TSLE ‐ GxE effect  0.001  529  0.00025  0.01505  0.01480  0.02780  0.03497  0.42659  0.82122  0.91586 
Stroke (R)  GS GWEIS using  0.2  36063  0.00044  0.01524  0.01480  0.03725  0.03509  0.28851  0.65763  0.87456 
418
TSLE ‐ Joint effect 
Stroke (R)  UKB GWAS  0.04  10426  0.00137  0.01617  0.01480  ‐0.06593  0.03519  0.06101  0.23878  0.59201 
Stroke (R)  UKB GxE effect  0.001  328  0.00111  0.01591  0.01480  ‐0.05902  0.03508  0.09249  0.37406  0.72399 
Stroke (R) 
UKB GxE Joint 









DCC  is  a gene encoding  for  the netrin 1  receptor and  is  involved  in neuron 
projection  and  development  of  prefrontal  cortex  during  adolescence.  DCC 
mediates  axon  guidance  of  neuronal  growth  cones  towards  sources  of  its 
ligand, netrin 1. We have previously shown association between the Netrin‐
pathway and MDD1. DCC was significantly associated with a GWAS of mood 
instability  in UKB2 and  it  is essential  for NMDAR‐dependent LTP and certain 
forms  of  synaptic  plasticity3. DCC  expression  appears  altered  in  individuals 
with  psychiatric  disorders  and overexpressed  in  individuals who  committed 






6.51x10‐7  ACSS3  gene encodes  for  an  acyl‐coenzyme A  synthetase  involved  in  energy 
generation via lipid synthesi as part of fatty acid metabolism. ACSS3 has also 


















STAG1  encodes  for  a  cohesin  subunit.  STAG1  has  been  linked  to 








the  correct  development  of  language  and  speech12.  FOXP2  has  been 






KYNU  encodes  for  a  kynureninase.  KYNU  expression  is  regulated  by 
corticosteroids via  the glucocorticoid  receptor and kynurenine pathway has 
been suggested to be  involved  in stress/inflammation‐induced depression14. 






PHF2  encodes  for  a  histone  demethylase  (a  Lysine  demethylase  that  also 
demethylates non‐histone proteins) involved in epigenetic regulation of gene 












associated with  blood pressure,  cardiac  parameters,  fasting  plasma  glucose 
levels  and  T2D17‐20. MNTNR1B  is  targeted  by  the  neurohormone melatonin 
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Manhattan  plot  showing  gene‐based  association  of  PHQ  using  summary  statistics  for  the  additive  effect  derived  from  GWAS  in  UK 





Manhattan  plot  showing  gene‐based  association  of  GHQ  using  summary  statistics  for  the  additive  effect  derived  from  GWAS  in 
Generation Scotland (N = 4,919). The x‐axis is base‐paired chromosomal position and the y‐axis represents the significance (‐log10 p value) 
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Genome-wide by environment interaction
studies of depressive symptoms and
psychosocial stress in UK Biobank and
Generation Scotland
Aleix Arnau-Soler 1, Erin Macdonald-Dunlop2, Mark J. Adams 3, Toni-Kim Clarke3, Donald J. MacIntyre3,
Keith Milburn4, Lauren Navrady 3, Generation Scotland5, Major Depressive Disorder Working Group of the Psychiatric
Genomics Consortium, Caroline Hayward , Andrew M. McIntosh 3 and Pippa A. Thomson 1
Abstract
Stress is associated with poorer physical and mental health. To improve our understanding of this link, we performed
genome-wide association studies (GWAS) of depressive symptoms and genome-wide by environment interaction
studies (GWEIS) of depressive symptoms and stressful life events (SLE) in two UK population-based cohorts (Generation
Scotland and UK Biobank). No SNP was individually significant in either GWAS, but gene-based tests identified six
genes associated with depressive symptoms in UK Biobank (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; p < 2.77 ×
10−6). Two SNPs with genome-wide significant GxE effects were identified by GWEIS in Generation Scotland:
rs12789145 (53-kb downstream PIWIL4; p= 4.95 × 10−9; total SLE) and rs17070072 (intronic to ZCCHC2; p= 1.46 ×
10−8; dependent SLE). A third locus upstream CYLC2 (rs12000047 and rs12005200, p < 2.00 × 10−8; dependent SLE)
when the joint effect of the SNP main and GxE effects was considered. GWEIS gene-based tests identified: MTNR1B
with GxE effect with dependent SLE in Generation Scotland; and PHF2 with the joint effect in UK Biobank (p < 2.77 ×
10−6). Polygenic risk scores (PRSs) analyses incorporating GxE effects improved the prediction of depressive symptom
scores, when using weights derived from either the UK Biobank GWAS of depressive symptoms (p= 0.01) or the PGC
GWAS of major depressive disorder (p= 5.91 × 10−3). Using an independent sample, PRS derived using GWEIS GxE
effects provided evidence of shared aetiologies between depressive symptoms and schizotypal personality, heart
disease and COPD. Further such studies are required and may result in improved treatments for depression and other
stress-related conditions.
Introduction
Mental illness results from the interplay between genetic
susceptibility and environmental risk factors1,2. Previous
studies have shown that the effects of environmental factors
on traits may be partially heritable3 and moderated by
genetics4,5. Major depressive disorder (MDD) is the most
common psychiatric disorder with a lifetime prevalence of
approximately 14% globally6 and with a heritability of
approximately 37%7. There is strong evidence for the role of
stressful life events (SLEs) as risk factor and trigger for
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depression8–12. Genetic control of sensitivity to stress may
vary between individuals, resulting in individual differences
in the depressogenic effects of SLE, i.e., genotype-by-
environment interaction (GxE)4,13–16. Significant evidence
of GxE has been reported for common respiratory diseases
and some forms of cancer17–22, and GxE studies have
identified genetic risk variants not found by genome-wide
association studies (GWAS)23–27.
Interaction between polygenic risk of MDD and recent
SLE are reported to increase liability to depressive
symptoms4,16; validating the implementation of genome-
wide approaches to study GxE in depression. Most GxE
studies for MDD have been conducted on candidate
genes, or using polygenic approaches to a wide range of
environmental risk factors, with some contradictory
findings28–32. Incorporating knowledge about recent SLE
into GWAS may improve our ability to detect risk var-
iants in depression otherwise missed in GWAS33. To date,
three studies have performed genome-wide by environ-
ment interaction studies (GWEIS) of MDD and SLE34–36,
but this is the first study to perform GWEIS of depressive
symptoms using adult SLE in cohorts of relatively
homogeneous European ancestry.
Interpretation of GxE effects may be hindered by
gene–environment correlation. Gene–environment cor-
relation denotes a genetic mediation of associations
through genetic influences on exposure to, or reporting
of, environments2,37. Genetic factors predisposing to
MDD may contribute to exposure and/or reporting of
SLE38. To tackle this limitation, measures of SLE can be
broken down into SLE likely to be independent of a
respondent’s own behaviour and symptoms, or into
dependent SLE, in which participants may play an active
role exposure to SLE39,40. Different genetic influences,
including a higher heritability, are reported for dependent
SLE compared to independent SLE38,41–44, suggesting that
whereas GxE driven by independent SLE is likely to reflect
a genetic moderation of associations between SLE and
depression, GxE driven by dependent SLE may result
from a genetic mediation of the association through
genetically driven personality or behavioural traits. To test
this, we analysed dependent and independent SLE scores
separately in Generation Scotland (GS).
Stress contributes to many human conditions, with
evidence of genetic vulnerability to the effect of SLE45.
Therefore, genetic stress-response factors in MDD may
also underlie the aetiology of other stress-linked disorders
with which MDD is often comorbid46,47 (e.g., cardiovas-
cular diseases48, diabetes49, chronic pain50 and inflam-
mation51). We tested the hypothesis that pleiotropy and
shared aetiology between mental and physical health
conditions may be due in part to genetic variants under-
lying SLE effects in depression.
In this study, we conduct GWEIS of depressive symp-
toms incorporating data on SLE in two independent UK-
based cohorts. We aimed to: (i) identify loci associated
with depressive symptoms through genetic response to
SLE; (ii) study dependent and independent SLE to support
a contribution of genetically mediated exposure to stress;
(iii) assess whether GxE effects improve the proportion of
phenotypic variance in depressive symptoms explained by
genetic additive main effects alone; and (iv) test for a
significant overlap in the genetic aetiology of the response
to SLE and mental and physical stress-related phenotypes.
Materials and methods
The core workflow of this study is summarised in Fig. 1.
Cohort descriptions
GS
GS is a family-based population cohort representative of
the Scottish population52. At baseline, blood and salivary
DNA samples were collected, stored and genotyped at the
Wellcome Trust Clinical Research Facility, Edinburgh.
Genome-wide genotype data were generated using the
Illumina HumanOmniExpressExome-8 v1.0 DNA Analy-
sis BeadChip (San Diego, CA, USA) and Infinium chem-
istry53. The procedures and details for DNA extraction
and genotyping have been extensively described else-
where54,55. In total, 21,525 participants were re-contacted
to participate in a follow-up mental health study (Strati-
fying Resilience and Depression Longitudinally,
STRADL), of which 8541 participants responded provid-
ing updated measures in psychiatric symptoms and SLE
through self-reported mental health questionnaires56.
Samples were excluded if: they were duplicate samples,
had diagnoses of bipolar disorder, no SLE data
(non-respondents), were population outliers (mainly non-
Caucasians and Italian ancestry subgroup), had sex mis-
matches or were missing >2% of genotypes. Single
nucleotide polymorphisms (SNPs) were excluded if:
missing >2% of genotypes, Hardy–Weinberg equilibrium
test p < 1 × 10−6, or minor allele frequency <1%. Further
details of the GS and STRADL cohort are available else-
where52,56–58. All components of GS and STRADL
obtained ethical approval from the Tayside Committee on
Medical Research Ethics on behalf of the NHS (reference
05/s1401/89). After quality control, individuals were fil-
tered by degree of relatedness (pi-hat < 0.05), maximising
retention of those individuals reporting a higher number
of SLE. The final dataset comprised data on 4919 unre-
lated individuals (1929 men; 2990 women) and 560,351
SNPs.
Independent GS datasets
Additional datasets for a range of stress-linked medical
conditions and personality traits were created from GS (N
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= 21,525) excluding respondents and their relatives (N=
5724). Following the same quality control criteria detailed
above, we maximised unrelated non-respondents for
retention of cases, or proxy cases (see below), to maximise
the information available for each phenotype. This
resulted in independent datasets with unrelated indivi-
duals for each trait. Differences between respondents and
non-respondents are noted in the figure legend of Table 1.
UK Biobank (UKB)
This study used data from 99,057 unrelated individuals
(47,558 men; 51,499 women) from the initial release of
UKB genotyped data (released 2015; under UKB project
4844). Briefly, participants were removed based on UKB
genomic analysis exclusion, non-white British ancestry,
high missingness, genetic relatedness (kinship coefficient
> 0.0442), QC failure in UK BiLEVE study and gender
mismatch. GS participants and their relatives were
excluded and GS SNPs imputed to a reference set com-
bining the UK10K haplotype and 1000 Genomes Phase 3
reference panels59. After quality control, 1,009,208 SNPs
remained. UKB received ethical approval from the NHS
National Research Ethics Service North West (reference:
11/NW/0382). Further details on UKB cohort description,
genotyping, imputation and quality control are available
elsewhere60–62.
All participants provided informed consent.
Phenotype assessment
SLEs
GS participants reported SLE experienced over the
preceding 6 months through a self-reported brief life
events questionnaire based on the 12-item list of threa-
tening experiences39,63,64 (Supplementary Table 1a). The
total number of SLE reported (TSLE) consisted of the
number of ‘yes’ responses. TSLE were subdivided into SLE
Fig. 1 Study flowchart. Overview of the analyses conducted in this study: (i) identify loci associated with depressive symptoms through genetic
response to SLE; (ii) test whether results of studying dependent and independent SLE support a contribution of genetically mediated exposure to
stress; (iii) assess whether GxE effects improve the proportion of phenotypic variance in depressive symptoms explained by genetic additive main
effects alone and (iv) test whether there is significant overlap in the genetic aetiology of the response to SLE and mental and physical stress-related
phenotypes. Two core cohorts are used, Generation Scotland (GS) and UK Biobank (UKB). Summary statistics from genome-wide association studies
(GWAS) and genome-wide by environment interaction studies (GWEIS) are used to generate polygenic risk scores (PRSs). Summary statistics from
Psychiatric Genetic Consortium (PGC) Major Depressive Disorder (MDD) GWAS are also used to generate PRS (PRSMDD). PRS weighted by: additive
effects (PRSD and PRSMDD), GxE effects (PRSGxE) and joint effects (the combined additive and GxE effect; PRSJoint), are used for phenotypic prediction.
TSLE stands for total number of SLE reported. DSLE stands for SLE dependent on an individual’s own behaviour. Conversely, ISLE stands for
independent SLE. N stands for sample size. NnoGS stands for sample size with GS individuals removed. NnoUKB stands for sample size with UKB
individuals removed
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potentially dependent or secondary to an individual’s own
behaviour (DSLE, questions 6–11 in Supplementary Table
1a), and independent SLE (ISLE, questions 1–5 in
Supplementary Table 1a; pregnancy item removed) fol-
lowing Brugha et al.39,40. Thus, three SLE measures
(TSLE, DSLE and ISLE) were constructed for GS. UKB
Table 1 GS samples with stress-related phenotypes
Trait N Males/females N SNPs N Cases N Controls
Alzheimer (R) 3377 1475/1903 560,622 655 2722
Asthma 3390 1500/1890 560,569 555 2835
Asthma (R) 3375 1470/1905 560,432 910 2465
Bowel cancer (R) 3386 1495/1891 560,630 672 2714
Breast cancer 3388 1486/1902 560,611 83 3305
Breast cancer (R) 3386 1482/1904 560,579 564 2822
Chronic obstructive pulmonary disease 3387 1496/1891 560,591 73 3314
Chronic obstructive pulmonary disease (R) 3387 1474/1913 560,620 553 2834
Depression 3385 1495/1890 560,584 483 2902
Depression (R) 3382 1506/1876 560,514 731 2651
Diabetes 3388 1497/1891 560,469 185 3203
Diabetes (R) 3389 1481/1908 560,584 1144 2245
Heart disease 3392 1504/1888 560,526 212 3180
Heart disease (R) 3377 1483/1894 560,479 2254 1123
High blood pressure 3402 1501/1901 560,508 729 2673
High blood pressure (R) 3372 1464/1908 560,569 1901 1471
Hip fracture (R) 3388 1489/1899 560,572 421 2967
Lung cancer (R) 3379 1492/1887 560,600 798 2581
Osteoarthritis 3395 1486/1909 560,640 411 2984
Osteoarthritis (R) 3383 1466/1917 560,516 961 2422
Parkinson (R) 3388 1488/1900 560,590 236 3152
Prostate cancer (R) 3381 1495/1886 560,570 329 3052
Rheumatoid arthritis 3387 1490/1897 560,618 93 3294
Rheumatoid arthritis (R) 3380 1487/1893 560,543 765 2615
Stroke 3387 1492/1895 560,613 81 3306
Stroke (R) 3385 1463/1922 560,478 1506 1879
Neuroticisma 3421 1521/1900 560,484 - -
Extraversiona 3420 1520/1900 560,476 - -
Schizotypal personalitya 2386 1065/1321 560,369 - -
Mood disordera 2307 1040/1267 560,318 - -
Samples were maximised for retention of cases to maximise the information available for each trait. There was no preferential selection of relatives in pairs for
quantitative phenotypes, in order to retain the underlying distribution. All individuals involved in the datasets listed above were non-respondents to the GS follow-up
study. Compared with individuals included at GS GWEIS (respondents in GS follow-up), non-respondents were significantly: younger, from more socioeconomically
deprived areas, generally less healthier and wealthier. Non-respondents were more likely to smoke, and less likely to drink alcohol, although they consumed more
units per week, compared with respondents. At GS baseline, non-respondents experienced more psychological distress and reported higher scores in symptoms of
GHQ-depression and GHQ-anxiety than respondents56
The total target sample size (N), number of males and females in N, number of SNPs (N SNPs) in target sample size N: the number of SNPs used as predictors after
clumping step range between 90,650 and 91,000. The number of cases and controls in the independent target sample is indicated for binary phenotypes only.
Samples were mapping by proxy approach was used (i.e., where first-degree relatives of individuals with the disease were considered proxy cases and included into
the group of cases) are indicated by (R)
GS Generation Scotland, GWEIS genome-wide by environment interaction studies, GHQ General Health Questionnaire
aAssessed through self-reported questionnaires
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participants were screened for ‘illness, injury, bereave-
ment and stress’’ (Supplementary Table 1b) over the
previous 2 years using six items included in the UKB
Touchscreen questionnaire. A score reflecting SLE
reported in UKB (TSLEUKB) was constructed by summing
the number of ‘yes’ responses.
Psychological assessment
GS participants reported whether their current mental
state over the preceding 2 weeks differed from their
typical state using a self-administered 28-item scaled
version of the General Health Questionnaire (GHQ)65–67.
Participants rated the degree and severity of their current
symptoms with a four-point Likert scale (following
Goldberg et al.67). A final log-transformed GHQ was used
to detect altered psychopathology and thus, assess
depressive symptoms as results of SLE. In UKB partici-
pants, current depressive symptoms over the preceding
2 weeks were evaluated using four psychometric screening
items (Supplementary Table 2), including two validated
and reliable questions for screening depression68, from
the Patient Health Questionnaire (PHQ) validated to
screen mental illness69,70. Each question was rated in a
four-point Likert scale to assess impairment/severity of
symptoms. Due to its skewed distribution, a four-point
PHQ score was formed from PHQ (0= 0; 1= 1–2; 2=
3–5; 3= 6 or more) to create a more normal distribution.
Stress-related traits
Targeted GS stress-related phenotypes and sample sizes
are shown in Table 1 and detailed elsewhere52. These
conditions were selected from literature review based on
previous evidence of a link with stress45 (see also Sup-
plementary Material: third section). Furthermore, we
created additional independent samples using mapping by
proxy, where individuals with a self-reported first-degree
relative with a selected phenotype were included as proxy
cases. This approach provides greater power to detect
susceptibility variants in traits with low prevalence71.
Statistical analyses
SNP-heritability and genetic correlation
A restricted maximum likelihood approach was applied
to estimate SNP-heritability (h2SNP) of depressive symp-
toms and self-reported SLE measures, and within samples
bivariate genetic correlation between depressive symp-
toms and SLE measures using GCTA72.
GWAS analyses
GWAS were conducted in PLINK73. In GS, age, sex and
20 principal components (PCs) were fitted as covariates.
In UKB, age, sex and 15 PCs recommended by UKB were
fitted as covariates. The genome-wide significance
threshold was p= 5 × 10–8.
GWEIS analyses
GWEIS were conducted on GHQ (the dependent vari-
able) for TSLE, DSLE and ISLE in GS and on PHQ for
TSLEUKB in UKB fitting the same covariates
detailed above to reduce error variance. GWEIS were
conducted using an R plugin for PLINK73 developed by
Almli et al.74 (https://epstein-software.github.io/robust-
joint-interaction). This method implements a robust test
that jointly considers SNP and SNP–environment inter-
action effects from a full model (Y ~ β0+ βSNP+ βSLE+
βSNPxSLE+ βCovariates) against a null model where
both the SNP and SNP×SLE effects equal 0, to assess the
joint effect (the combined additive main and GxE genetic
effect at a SNP) using a nonlinear statistical approach that
applies Huber–White estimates of variance to correct
possible inflation due to heteroscedasticity (unequal var-
iances across exposure levels). This robust test should
reduce confounding due to differences in variance
induced by covariate interaction effects if present75.
Additional code was added (courtesy of Prof. Michael
Epstein;74 Supplementary Material) to generate beta-
coefficients and the p-value of the GxE term alone. In
UKB, correcting for 1,009,208 SNPs and one exposure, we
established a Bonferroni-adjusted threshold for sig-
nificance at p= 2.47 × 10–8 for both joint and GxE effects.
In GS, correcting for 560,351 SNPs and three measures of
SLE we established a genome-wide significance threshold
of p= 2.97 × 10–8.
Post-GWAS/GWEIS analyses
GWAS and GWEIS summary statistics were analysed
using FUMA76 including: gene-based tests, functional
annotation, gene prioritisation and pathway enrichment
(Supplementary Material).
Polygenic profiling and prediction
Polygenic risk scores (PRSs) weighting by GxE effects
(PRSGxE) were generated using PRSice-2
77 (Supplemen-
tary Material) in GS using GxE effects from UKB-GWEIS.
In UKB, PRSGxE were constructed using GxE effects from
all three GS-GWEIS (TSLE, DSLE and ISLE as exposures)
independently. PRS were also weighted in both samples
using either UKB-GWAS or GS-GWAS statistics (PRSD),
and summary statistics from Psychiatric Genetic Con-
sortium (PGC) MDD-GWAS (released 2016; PRSMDD)
that excluded GS and UKB individuals when required
(NnoGS= 155,866; NnoUKB= 138,884). Furthermore, we
calculated PRS weighted by the joint effects (the com-
bined additive main and GxE genetic effects; PRSJoint)
from either the UKB-GWEIS or GS-GWEIS. PRS pre-
dictions of depressive symptoms were permuted 10,000
times. Multiple regression models fitting PRSGxE and
PRSMDD, and both PRSGxE and PRSD were tested. All
models were adjusted by same covariates used in GWAS/
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GWEIS. Null models were estimated from the direct
effects of covariates alone. The predictive improvement of
combining PRSGxE and PRSMDD/PRSD effects over
PRSMDD/PRSD effects alone was tested for significance
using the likelihood ratio test (LRT).
Prediction of PRSD, PRSGxE and PRSJoint of stress-linked
traits were adjusted by age, sex and 20 PCs; and permuted
10,000 times. Empirical-p-values after permutations were
further adjusted by false discovery rate (FDR, conservative
threshold at Empirical-p= 6.16 × 10–3). The predictive
improvement of fitting PRSGxE combined with PRSD and
covariates over prediction of a phenotype using the PRSD
effect alone with covariates was assessed using LRT, and
LRT-p-values adjusted by FDR (conservative threshold at
LRT-p= 8.35 × 10–4).
Results
Phenotypic and genetic correlations
Depressive symptom scores and SLE measures were
positively correlated in both UKB (r2= 0.22, p < 2.2 ×
10–16) and GS (TSLE-r2= 0.21, p= 1.69 × 10−52; DSLE-r2
= 0.21, p= 8.59 × 10−51; ISLE-r2= 0.17, p= 2.33 ×
10−33). Significant bivariate genetic correlation between
depression and SLE scores was identified in UKB (rG=
0.72; p < 1 × 10−5, N= 50,000), but not in GS (rG= 1, p=
0.056, N= 4919; Supplementary Table 3a).
SNP-heritability (h2SNP)
In UKB, a significant h2SNP of PHQ was identified
(h2SNP= 0.090; p < 0.001; N= 99,057). This estimate
remained significant after adjusting by TSLEUKB effect
(h2SNP= 0.079; p < 0.001), suggesting a genetic contribu-
tion unique to depressive symptoms. The h2SNP of
TSLEUKB was also significant (h
2
SNP= 0.040, p < 0.001;
Supplementary Table 3b). In GS, h2SNP was not significant
for GHQ (h2SNP= 0.071, p= 0.165; N= 4919). However,
in an ad hoc estimation from the baseline sample of 6751
unrelated GS participants (details in Supplementary Table
3b) we detected a significant h2SNP for GHQ (h
2
SNP=
0.135; p < 5.15 × 10−3), suggesting that the power to esti-
mate h2SNP in GS may be limited by sample size. Estimates
were not significant for either TSLE (h2SNP= 0.061, p=
0.189; Supplementary Table 3b) or ISLE (h2SNP= 0.000, p
= 0.5), but h2SNP was significant for DSLE (h
2
SNP= 0.131,
p= 0.029), supporting a potential genetic mediation and
gene–environment correlation.
GWAS of depressive symptoms
No genome-wide significant SNPs were detected by
GWAS in either cohort. Top findings (p < 1 × 10−5)
are summarised in Supplementary Table 4. Manhattan
and QQ plots are shown in Supplementary Figures 1-4.
There was no evidence of genomic inflation
(all λ1000 < 1.01).
Post-GWAS analyses
Gene-based test identified six genes associated with
PHQ using the UKB-GWAS statistics at genome-wide
significance (Bonferroni-corrected p= 2.77 × 10−6; DCC,
p= 7.53 × 10−8; ACSS3, p= 6.51 × 10−7; DRD2, p=
6.55 × 10−7; STAG1, p= 1.63 × 10−6; FOXP2, p= 2.09 ×
10−6; KYNU, p= 2.24 × 10−6; Supplementary Figure 8).
Prioritised genes based on position, expression quantita-
tive trait loci (eQTL) and chromatin interaction mapping
are detailed in Supplementary Table 5. No genes were
detected in GS-GWAS gene-based test (Supplementary
Figures 9). No tissue-specific enrichment was detected
from GWAS in either cohort. Significant gene-sets and
GWAS catalogue associations for UKB-GWAS are
reported in Supplementary Table 6. These included the
biological process: positive regulation of long-term
synaptic potentiation, and GWAS catalogue associations:
brain structure, schizophrenia, response to ampheta-
mines, age-related cataracts (age at onset), fibrinogen,
acne (severe), fibrinogen levels and educational attain-
ment; all adjusted-p < 0.01. There was no significant gene-
set enrichment from GS-GWAS.
GWEIS of depressive symptoms
Manhattan and QQ plots are shown in Supplementary
Figures 1-4. There was no evidence of GWEIS inflation
for either UKB or GS (all λ1000 < 1.01). No genome-wide
significant GWEIS associations were detected for SLE in
UKB. GS-GWEIS using TSLE identified a significant GxE
effect (p < 2.97 × 10−8) at an intragenic SNP on chromo-
some 11 (rs12789145, p= 4.95 × 10−9, β= 0.06, closest
gene: PIWIL4; Supplementary Figure 5), and using DSLE
at an intronic SNP in ZCCHC2 on chromosome 18
(rs17070072, p= 1.46 × 10−8, β=−0.08; Supplementary
Figure 6). In their corresponding joint effect tests, both
rs12789145 (p= 2.77 × 10−8) and rs17070072 p= 1.96 ×
10−8) were significant. GWEIS for joint effect using DSLE
identified two further significant SNPs on chromosome 9
(rs12000047, p= 2.00 × 10−8, β=−0.23; rs12005200, p=
2.09 × 10−8, β=−0.23, LD r2 > 0.8, closest gene: CYLC2;
Supplementary Figure 7). None of these associations
replicated in UKB (p > 0.05), although the effect direction
was consistent between cohorts for the SNP close to
PIWL1 and SNPs at CYLC2. No SNP achieved genome-
wide significant association in the GS-GWEIS using ISLE
as exposure. Top GWEIS results (p < 1 × 10−5) are sum-
marised in Supplementary Tables 7-10.
Post-GWEIS analyses: gene-based tests
All results are shown in Supplementary Figures 10-17.
Two genes were associated with PHQ using the joint
effect from the UKB-GWEIS (ACSS3 p= 1.61 × 10−6;
PHF2, p= 2.28 × 10−6; Supplementary Figure 11). ACSS3
was previously identified using the additive main effects,
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whereas PHF2 was only significantly associated using the
joint effects. Gene-based tests identified MTNR1B as
significantly associated with GHQ on the GS-GWEIS
using DSLE in both GxE (p= 1.53 × 10−6) and joint
effects (p= 2.38 × 10−6; Supplementary Figures 14-15).
Post-GWEIS analyses: tissue enrichment
We prioritised genes based on position, eQTL and
chromatin interaction mapping in brain tissues and
regions. In UKB, prioritised genes using GxE effects were
enriched for upregulated differentially expressed genes
from adrenal gland (adjusted-p= 3.58 × 10−2). Using joint
effects, prioritised genes were enriched on upregulated
differentially expressed genes from artery tibial (adjusted-
p= 4.34 × 10−2). In GS, prioritised genes were enriched:
in upregulated differentially expressed genes from artery
coronary (adjusted-p= 4.55 × 10−2) using GxE effects
with DSLE; in downregulated differentially expressed
genes from artery aorta tissue (adjusted-p= 4.71 × 10−2)
using GxE effects with ISLE; in upregulated differentially
expressed genes from artery coronary (adjusted-p=
5.97 × 10−3, adjusted-p= 9.57 × 10−3) and artery tibial
(adjusted-p= 1.05 × 10−2, adjusted-p= 1.55 × 10−2) tis-
sues using joint effects with both TSLE and DSLE; and in
downregulated differentially expressed genes from lung
tissue (adjusted-p= 3.98 × 10−2) and in up- and down-
regulated differentially expressed genes from the spleen
(adjusted-p= 4.71 × 10−2) using joint effects with ISLE.
There was no enrichment using GxE effect with TSLE.
Post-GWEIS analyses: gene-sets enrichment
Significant gene-sets and GWAS catalogue hits from
GWEIS are detailed in Supplementary Tables 11-14,
including for UKB Biocarta: GPCR pathway; Reactome:
opioid signalling, neurotransmitter receptor binding and
downstream transmission in the postsynaptic cell, trans-
mission across chemical synapses, gastrin CREB signalling
pathway via PKC and MAPK; GWAS catalogue: post
bronchodilator FEV1/FVC ratio, migraine and body mass
index. In GS, enrichment was seen using TSLE and DLSE
for GWAS catalogue: age-related macular degeneration,
myopia, urate levels and Heschl’s gyrus morphology; and
using ISLE for biological process: regulation of transporter
activity. All adjusted-p < 0.01.
Cross-cohort prediction
In GS, PRSD weighted by the UKB-GWAS of PHQ
significantly explained 0.56% of GHQ variance (Empirical-
p < 1.10−4), similar to PRSMDD weighted by PGC MDD-
GWAS (R2= 0.78%, Empirical-p < 1.10−4). PRSGxE
weighted by the UKB-GWEIS GxE effects explained
0.15% of GHQ variance (Empirical-p= 0.03, Supplemen-
tary Table 15). PRSGxE fitted jointly with PRSMDD sig-
nificantly improved prediction of GHQ (R2= 0.93%,
model p= 6.12 × 10−11; predictive improvement of 19%,
LRT-p= 5.91 × 10−3) compared with PRSMDD alone.
Similar to PRSGxE with PRSD (R
2= 0.69%, model p=
2.72 × 10−8; predictive improvement of 23%, LRT-p=
0.01). PRSJoint weighted by the UKB-GWEIS also pre-
dicted GHQ (R2= 0.58%, Empirical-p < 1.10−4), although
Fig. 2 Prediction of depression scores by PRSGxE, PRSD, PRSMDD
and PRSJoint. Variance of depression score explained by PRSGxE PRSD,
PRSMDD and PRSJoint as single effect; and combining both PRSD and
PRSMDD with PRSGxE in single models. Prediction was conducted using
a Generation Scotland (GS) and b UK Biobank (UKB) as target sample.
PRSGxE were weighted by cross- sample genome-wide by
environment interaction studies (GWEIS) using GxE effect. PRSD were
weighted by cross-sample genome-wide association studies (GWAS)
of depressive symptoms effect. PRSMDD was weighted by Psychiatric
Genetic Consortium (PGC) Major Depressive Disorder (MDD)-GWAS
summary statistics. PRSJoint were weighted by cross-sample GWEIS
using joint effect. A nominally significant gain in variance explained of
General Health Questionnaire (GHQ) of about 23% was seen in GS
when PRSGxE was incorporated into a multiple regression model along
with PRSD; and of about 19% when PRSGxE was incorporated into a
multiple regression model along with PRSMDD. Such a gain was not
seen in UKB, but it must be noted that both PRSD and PRSMDD also
explains much less variance of PHQ in UKB than of GHQ in GS. Also
note, a noticeably reduction of variance explained by PRSJoint
compared with combined polygenic risk scores (PRS)/effects
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the variance explained was significantly reduced com-
pared with the model fitting PRSGxE and PRSD together
(LRT-p= 4.69 × 10−7), suggesting that additive and GxE
effects should be modelled independently for polygenic
approaches (Fig. 2a).
In UKB (Fig. 2b), both PRSD weighted by the GS-GWAS
of GHQ and PRSMDD significantly explained 0.04 and
0.45% of PHQ variance, respectively (both Empirical-p <
1.10−4; Supplementary Table 15). PRSGxE derived from
the GS-GWEIS GxE effect did not significantly predicted
PHQ (TSLE-PRSGxE Empirical-p= 0.382; DSLE-PRSGxE
Empirical-p= 0.642; ISLE-PRSGxE Empirical-p= 0.748).
Predictive improvements using the PRSGxE effect fitted
jointly with PRSMDD or PRSD were not significant (all
LRT-p > 0.08). PRSJoint significantly predicted PHQ
(TSLE-PRSJoint: R
2= 0.032%, Empirical-p < 1.10−4; DSLE-
PRSJoint: R
2= 0.012%, Empirical-p= 4.3 × 10−3; ISLE-
PRSJoint: R
2= 0.032%, Empirical-p < 1.10−4), although
the variance explained was significantly reduced com-
pared with the models fitting PRSGxE and PRSD together
(all LRT-p < 1.48 × 10−3).
Prediction of stress-related traits
Prediction of stress-related traits in independent sam-
ples using PRSD, PRSGxE and PRSJoint are summarised in
Fig. 3a and Supplementary Table 16. Significant trait
prediction after FDR adjustment (Empirical-p < 6.16 ×
10−3, FDR-adjusted Empirical-p < 0.05) using both UKB
and GS PRSD was seen for: depression status, neuroticism
and schizotypal personality. PRSGxE weighted by the GS-
GWEIS GxE effect using ISLE significantly predicted
depression status mapped by proxy (Empirical-p= 7.00 ×
10−4, FDR-adjusted Empirical-p= 9.54 × 10−3).
Nominally significant predictive improvements (LRT-p
< 0.05) of fitting PRSGxE, over the PRSD effect alone, using
summary statistics generated from both UKB and GS
were detected for schizotypal personality, heart diseases
and chronic obstructive pulmonary disease (COPD) by
proxy (Fig. 3b). PRSGxE weighted by GS-GWEIS GxE
effect using ISLE significantly improved prediction over
PRSD effect alone of depression status mapped by proxy
after FDR adjustment (LRT-p= 1.96 × 10−4, FDR-
adjusted LRT-p= 2.35 × 10−2).
Discussion
This study performs GWAS and incorporates data on
recent adult SLEs into GWEIS of depressive symptoms,
identifies new loci and candidate genes for the modulation
of genetic response to SLE; and provides insights to help
disentangle the underlying aetiological mechanisms
increasing the genetic liability through SLE to both
depressive symptoms and stress-related traits.
SNP-heritability of depressive symptoms (h2SNP=
9–13%), were slightly higher than previous estimates from
African-American populations34, and over a third larger
than estimates in MDD from European samples78. h2SNP
for PHQ in UKB (9.0%) remained significant after
adjusting for SLE (7.9%). Thus, although some genetic
contributions may be partially shared between depressive
symptoms and reporting of SLE, there is still a relatively
large genetic contribution unique to depressive symp-
toms. Significant h2SNP of DSLE in GS (13%) and TSLEUKB
in UKB (4%), which is mainly composed of dependent SLE
items, were detected similar to previous studies (8 and
29%)34,42. Conversely, there was no evidence for herit-
ability of independent SLE. A significant bivariate genetic
correlation between depressive symptoms and SLE (rG=
0.72) was detected in UKB after adjusting for covariates,
suggesting that there are shared common variants
underlying self-reported depressive symptoms and SLE.
This bivariate genetic correlation was smaller than that
estimated from African-American populations (rG= 0.97;
p= 0.04; N= 7179)34. Genetic correlations between SLE
measures and GHQ were not significant in GS (N= 4919;
rG= 1; all p > 0.056), perhaps due to a lack of power in
this smaller sample.
Post-GWAS gene-based tests detected six genes sig-
nificantly associated with PHQ (DCC, ACSS3, DRD2,
STAG1, FOXP2 and KYNU). Previous studies have
implicated these genes in liability to depression (see
Supplementary Table 17), and three of them are genome-
wide significant in gene-based tests from the latest meta-
analysis of major depression that includes UKB (DCC, p
= 2.57 × 10−14; DRD2, p= 5.35 × 10−14; and KYNU, p=
2.38 × 10−6; N= 807,553)79. This supports the imple-
mentation of quantitative measures such as PHQ to detect
genes underlying lifetime depression status80. For exam-
ple, significant gene ontology analysis of the UKB-GWAS
identified enrichment for positive regulation of long-term
synaptic potentiation, and for previous GWAS findings of
brain structure81, schizophrenia82 and response to
amphetamines83.
The key element of this study was to conduct GWEIS of
depressive symptoms and recent SLE. We identified two
loci with significant GxE effect in GS. However, none of
these associations replicated in UKB (p > 0.05). The
strongest association was using TSLE at 53-kb down-
stream of PIWIL4 (rs12789145). PIWIL4 is brain expres-
sed and involved in chromatin modification84, suggesting
it may moderate the effects of stress on depression. It
encodes HIWI2, a protein thought to regulate OTX2, that
is critical for the development of forebrain and for coor-
dinating critical periods of plasticity disrupting the inte-
gration of cortical circuits85,86. Indeed, an intronic SNP in
PIWIL4 was identified as the strongest GxE signal in
attention deficit hyperactivity disorder using mother’s
warmth as environmental exposure87. The other sig-
nificant GxE identified in our study was in ZCCHC2 using
Arnau-Soler et al. Translational Psychiatry            (2019) 9:14 Page 8 of 13
DSLE. This zinc-finger protein is expressed in blood CD4
+ T cells and is downregulated in individuals with MDD88
and in those resistant to treatment with citalopram89. No
GxE effect was seen using ISLE as exposure.
No significant locus or gene with GxE effect was
detected in the UKB-GWEIS. Nevertheless, joint effects
(the combined additive main and GxE genetic effects)
identified two genes significantly associated with PHQ
(ACSS3 and PHF2; see Supplementary Table 17). PHF2
was recently detected as genome-wide significant at the
latest meta-analysis of depression79. Notably, PHF2
paralogs have previously been linked with MDD through
stress-response in three other studies90–92. Joint effects
analyses in GS also detected an additional significant
association upstream CYLC2, a gene nominally associated
(p < 1 × 10−5) with obsessive-compulsive disorder
and Tourette’s syndrome93. Gene-based test from the
GS-GWEIS identified a significant association with
Fig. 3 Polygenic risk score (PRS) prediction in independent Generation Scotland (GS) datasets. a Heatmap illustrating PRS prediction of a wide
range of traits from GS listed in the x axis (Table 1). (R) refers to traits using mapping by proxy approach (i.e., where first-degree relatives of individuals
with the disease are considered proxy cases and included into the group of cases). Y axis shows the discovery sample and the effect used to weight
PRS. Numbers in cells indicate the % of variance explained, also represented by colour scale. Significance is represented by asterixes according to the
following significance codes: **p < 0.01; *p < 0.05; in grey Empirical-p-values after permutation (10,000 times) and in yellow FDR-adjusted Empirical-p-
values. b Predictive improvement by GxE effect in independent GS datasets. Heatmap illustrating the predictive improvement as a result of
incorporating PRSGxE into a multiple model along with PRSD and covariates (full model), over a model fitting PRSD alone with covariates (null model);
predicting a wide range of traits from GS listed in the x axis (Table 1). Covariates: age, sex and 20 PCs. (R) refers to traits using mapping by proxy
approach (i.e., where first-degree relatives of individuals with the disease are consider proxy cases and included into the group of cases). PRSGxE are
weighted by genome-wide by environment interaction studies (GWEIS) using GxE effects. PRSD were weighted by the genome-wide association
studies (GWAS) of depressive symptoms additive main effects. The y axis shows the discovery sample used to weight PRS. Numbers in cells indicate
the % of variance explained by the PRSGxE, also represented by colour scale. Notice that those correspond to the PRSGxE predictions in Fig. 3a when
PRSGxE are weighted by GxE effects. Significance was tested by likelihood ratio tests (LRT): full model including PRSD+ PRSGxE vs. null model with
PRSD alone (covariates adjusted). Significance is represented by asterixes according to the following significance codes: ***p < 0.001; **p < 0.01; *p <
0.05; in grey LRT-p-values and in yellow FDR-adjusted LRT-p-values
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MTNR1B, a melatonin receptor gene, using DSLE (both
GxE and joint effect; Supplementary Table 17). Genes
prioritised using GxE effects were enriched in differen-
tially expressed genes from several tissues including the
adrenal gland, which releases cortisol into the blood-
stream in response to stress, thus playing a key role in the
stress-response system, reinforcing a potential role of GxE
in stress-related conditions.
The different instruments and sample sizes available
make it hard to compare results between cohorts.
Whereas GS contains deeper phenotyping measurements
of stress and depressive symptoms than UKB, the sample
size is much smaller, which may be reflected in the sta-
tistical power required to reliably detect GxE effects.
Furthermore, the presence and size of GxE effects are
dependent on their parameterisation (i.e., the measure-
ment, scale and distribution of the instruments used to
test such interaction)94. Thus, GxE may be incomparable
across GWEIS due to differences in both phenotype
assessment and stressors tested. Although our results
suggest that both depressive symptom measures are cor-
related with lifetime depression status, different influences
on depressive symptoms from the SLE covered across
studies may contribute to lack of stronger replication.
Instruments in GS cover a wider range of SLE and are
more likely to capture changes in depressive symptoms as
consequence of their short-term effects. Conversely, UKB
could capture more marked long-term effects, as SLE
were captured over 2 years compared with the 6 months
in GS. New mental health questionnaires covering a wide
range of psychiatric symptoms and SLE in the latest
release of UKB data provides the opportunity to create
similar measures to GS in the near future. Further repli-
cation in independent studies with equivalent instruments
is required to validate our GWEIS findings. Despite these
limitations and a lack of overlap in the individual genes
prioritised from the two GWEIS, replication was seen in
the predictive improvement of using PRSGxE derived from
the GWEIS GxE effects to predict stress-related
phenotypes.
The third aim of this study was to test whether mod-
elling GxE effects could improve predictive genetic
models, and thus help to explain deviation from additive
models and missing heritability for MDD95. Multiple
regression models suggested that inclusion of PRSGxE
weighted by GxE effects could improve prediction of an
individual’s depressive symptoms over use of PRSMDD or
PRSD weighted by additive effects alone. In GS, we
detected a predictive gain of 19% over PRSMDD weighted
by PGC MDD-GWAS, and a gain of 23% over PRSD
weighted by UKB-GWAS (Fig. 2a). However, these find-
ings did not surpass stringent Bonferroni correction and
could not be validated in UKB. This may reflect in the
poor predictive power of the PRS generated from the
much smaller GS discovery sample. The results show a
noticeably reduced prediction using PRSJoint weighted by
joint effects, which suggests that the genetic architecture
of stress-response is at least partially independent and
differs from genetic additive main effects. Overall, our
results from multiple regression models suggest that for
polygenic approaches main and GxE effects should be
modelled independently.
SLE effects are not limited to mental illness45. Our final
aim was to investigate shared aetiology between GxE for
depressive symptoms and stress-related traits. Despite the
differences between the respondents and non-
respondents (Table 1 legend), a significant improvement
was seen in predicting depressive status when mapping by
proxy cases using GxE effect from GS-GWEIS with
independent SLE (FDR-adjusted LRT-p= 0.013), but not
with dependent SLE. GxE effects using statistics generated
from both discovery samples, despite the differences in
measures, nominally improved the phenotypic prediction
of schizotypal personality, heart disease and the proxy of
COPD (LRT-p < 0.05). Other studies have also found
evidence supporting a link between stress and depression
in these phenotypes (see Supplementary Material for
extended review) and suggest, for instance, potential
pleiotropy between schizotypal personality and stress-
response. Our findings point to a potential genetic com-
ponent underlying a stress-response-depression-
comorbidities link due, at least in part, to shared stress-
response mechanisms. A relationship between SLE,
depression and coping strategies such as smoking sug-
gests that genetic stress-response may modulate adaptive
behaviours such as smoking, fatty diet intake, alcohol
consumption and substance abuse. This is discussed fur-
ther in the Supplementary Material.
In this study, evidence for SNPs with significant GxE
effects came primarily from the analyses of dependent
SLE and not from independent SLE. This supports a
genetic effect on probability of exposure to, or reporting
of SLE, endorsing a gene–environment correlation.
Chronic stress may influence cognition, decision making
and behaviour eventually leading to higher risk taking96.
These conditions may also increase sensitivity to stress
among vulnerable individuals, including those with
depression, who also have a higher propensity to report
SLE, particularly dependent SLE38. A potential reporting
bias in dependent SLE may be mediated as well by heri-
table behavioural, anxiety or psychological traits such as
risk taking42,97. Furthermore, individuals vulnerable to
MDD may behave in a manner that exposes them more
frequently to high risk and stressful environments14. This
complex interplay, reflected in the form of a
gene–environment correlation effect, would hinder the
interpretation of GxE effects from GWEIS as pure inter-
actions. A mediation of associations between SLE and
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depressive symptoms, through genetically driven sensi-
tivity to stress, personality or behavioural traits would
support the possibility of subtle genotype-by-genotype
(GxG) interactions, or genotype-by-genotype-by-envir-
onment (GxGxE) interactions, contributing to depres-
sion98,99. In contrast, PRS prediction of the stress-related
traits: schizotypal personality, heart disease and COPD,
was primarily from derived weights using independent
SLE, suggesting that a common set of variants moderate
the effects of SLE across stress-related traits and that
larger sample sizes will be required to detect the indivi-
dual SNPs contributing to this. Thus, our findings support
the inclusion of environmental information into GWAS
to enhance the detection of relevant genes. The results of
studying dependent and independent SLE support a
contribution of genetically mediated exposure to and/or
reporting of SLE, perhaps through sensitivity to stress as
mediator.
This study emphasises the relevance of GxE in depres-
sion and human health in general and provides the basis
for future lines of research.
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